Translational research in tuberculosis: crossing barriers between molecular and clinical pharmacology by Brake, L.H.M. te
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/161372
 
 
 
Please be advised that this information was generated on 2018-07-08 and may be subject to
change.

Translational research in tuberculosis:
crossing barriers 
between molecular and 
clinical pharmacology
Lindsey te Brake
About the cover
On the migration of birds: the seasonal journeys to and from a given area - a flight from 
one place to another, not limited by human or natural barriers - wings as a mode of 
transportation - a journey of life, a journey of discovery
Translational research in tuberculosis: 
crossing barriers between molecular and clinical pharmacology
Thesis, Radboud University, Nijmegen, The Netherlands
ISBN
978-94-028-0435-5
Cover and chapter design
Annouk Goselink
Lay-out
Lindsey te Brake
Print
Ipskamp Printing, Enschede
Publication of this thesis was financially supported by the KNCV Tuberculosis Foundation, 
and the Department of Pharmacy of the Radboud university medical center.
Copyright 2016, Lindsey H.M. te Brake
All rights are reserved. No part of this book may be reproduced, distributed, stored in a retrievel system, or 
transmitted in any form or by any means, without prior permission of the author or from the publishers holding 
the copyright of the published articles.
Translational research in tuberculosis:
crossing barriers 
between molecular and 
clinical pharmacology
Proefschrift
ter verkrijging van de graad van doctor
aan de Radboud Universiteit Nijmegen
op gezag van de rector magnificus prof. dr. J.H.J.M. van Krieken,
volgens besluit van het college van decanen
in het openbaar te verdedigen
op donderdag 22 december 2016 
om 12.30 precies 
door
Lindsey Hendrika Maria te Brake
geboren op 21 april 1987
te Winterswijk
Promotoren:
Prof. dr. D.M. Burger
Prof. dr. F.G.M. Russel
Copromotoren:
Dr. R.E. Aarnoutse
Dr. ir. J.B. Koenderink
Manuscriptcommissie:
Prof. dr. M.G. Netea
Prof. dr. R. Masereeuw (Universiteit Utrecht)
Dr. J.W.C. Alffenaar (Universitair Medisch Centrum Groningen)
Voor mijn ouders
6Contents
  Introduction
Chapter 1 General introduction     9
Chapter 2 The role of efflux pumps in TB treatment and their   25
  promise as a target in drug development: unraveling 
  the black box
  Accepted for review by Annual Review of Pharmacology and Toxicology
Part 1   Molecular pharmacology
Chapter 3 Identification of a Mycobacterium tuberculosis   89
  ATP-binding cassette transporter potentially involved 
  in antibiotic resistance
  In preparation
Chapter 4 Inhibitory potential of tuberculosis drugs on    107
  ATP-binding cassette drug transporters
  Tuberculosis. 2016 Jan; 96: 150-157
Chapter 5 Moxifloxacin is a potent in vitro inhibitor of OCT- and   133
  MATE-mediated transport of metformin and ethambutol
  Accepted for publication in Antimicrobial Agents and Chemotherapy
Part 2   Animal studies
Chapter 6 Human pharmacokinetic equivalent dose and dried   159
  blood spot analyses of linezolid in BALB/c mice
  Submitted
Chapter 7  Dried blood spot analysis and human pharmacokinetic  171
  equivalent dose of moxifloxacin in mice
  Submitted
7Part 3   Clinical pharmacology
Chapter 8 Exposure to total and protein-unbound rifampicin is   185
  not affected by malnutrition in Indonesian tuberculosis 
  patients
  Antimicrobial Agents and Chemotherapy. 2015 Jun; 59 (7): 3233-3239
Chapter 9 Rifampicin increases metformin exposure in    205
  Indonesian patients with tuberculosis and diabetes
  In preparation
Chapter 10 Pharmacokinetic-pharmacodynamic analysis of an   227 
  intensified regimen containing rifampicin and 
  moxifloxacin for tuberculous meningitis
  International Journal of Antimicrobial Agents. 2015 May; 45 (5): 496-503
Chapter 11 General discussion     247
Chapter 12 Epilogue      285
  Summary      287
  Samenvatting      295
  List of publications     303
  Curriculum vitae      305
  RIMLS portfolio      306
  Dankwoord      309

General introduction
10
Chapter 1
Tuberculosis as a major public health problem
The disease burden of tuberculosis (TB) remains one of the world’s biggest threats. 
Globally, 10.4 million new TB cases arose in 2015, and a total of 1.8 million TB patients 
died (1). A third of the world’s population is latently infected with the causative bacterium 
Mycobacterium tuberculosis (M. tuberculosis), forming an enormous reservoir that 
serves as the seedbed for new cases of active TB (2). Irrespective of these numbers, 
efforts to combat TB have made substantial progress in the last decades. Advanced 
screening, effective diagnosis and treatment improvements resulted in the savior of 
approximately 43 million lives between 2000 and 2014 and a drop in the mortality of 
47% since 1990. With the implementation of the ‘End TB Strategy’, the World Health 
Organization (WHO) aims to further reduce the number of new cases by 80% and the 
number of deaths by 90% in 2030 (1).
Historical perspective of TB treatment
Mankind has been confronted with TB since ancient times. Modern strains of M. 
tuberculosis seem to have originated from a common ancestor about 15,000-20,000 
years ago (3). Archaeological evidence of early TB has been found in for example 
Egyptian and Peruvian mummies, and was already described in classical Greece as 
phthisis. In 19th century Western Europe, TB reached mortality as high as 1000 deaths 
per 100,000 people (3). In the same century the first sanatoria were opened, where 
open-air treatment, rest, and nourishing food were used to “cure” TB patients. Also 
thoracic surgeries were performed to control TB at that time (4). 
Antibiotic treatment against TB became successful for the first time in 1944 with the 
discovery of streptomycin (Figure 1) (5, 6). This drug revolutionized TB treatment, 
being the first bactericidal agent against M. tuberculosis. Use of this agent alone led 
to resistance, which is still a major problem associated with antibiotic treatment. The 
concomitant use of streptomycin and para-aminosalicylic acid (PAS) was found to 
prevent the development of drug resistance (3, 7). Thereafter, more effective drugs 
followed, such as isoniazid in the 1950s and rifampicin in the 1960s (Figure 1). In the 1970s, 
the addition of rifampicin to the regimen of streptomycin, isoniazid, and ethambutol 
allowed a shortening of treatment to 9-12 months. In the 1980s, the replacement of 
streptomycin with pyrazinamide yielded more rapid sterilization, allowing a shortening 
of treatment to 6-8 months (5, 8). 
TB management became so successful by the late 1980s that the US Department of 
Health and Human Services predicted TB would be eradicated from the country by 
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2010 (7). However, in Africa TB became a major public health issue again due to the rise 
of HIV infection, which is the strongest risk factor for active TB. The incidence of TB in 
eastern and southern Africa more than tripled in the 1990s, because of the overlapping 
epidemics of HIV and TB infection (7, 9). Furthermore, TB resurged in the former Soviet 
Union after several decades of decline, due to deteriorating living standards and the 
general failure of health-care systems since 1991 (9). The TB incidence rate increased 
on average by 7.5% per year in the 1990s. High incidence of drug resistance further 
complicated TB treatment in this region (7, 9, 10). 
Current TB treatment and its challenges
Standard minimum treatment for TB, as recommended by the WHO, still includes 
a combination of isoniazid, rifampicin, pyrazinamide, and ethambutol for 2 months 
(intensive phase), followed by 4 months of isoniazid and rifampicin (continuation 
phase) (12). 
Several major problems remain associated with this long-standing TB regimen (14). 
First, the duration and complexity of treatment is known to result in non-adherence. 
Such non-adherence, together with inter-individual variability in exposure to TB drugs, 
results in low TB drug concentrations, suboptimal response (failure and relapse), the 
emergence of resistance, and continuous spread of the disease. Second, the increasing 
incidence of multidrug-resistant TB (MDR-TB; resistance to at least rifampicin and 
Figure 1. TB drug development over time (8, 11-13). 
TB drug group classification according to WHO guidelines is displayed between parentheses in roman 
numerals (12). Group I drugs are first-line agents and considered the most potent and best tolerated. 
Group II drugs contain injectable agents used against multidrug-resistant TB (MDR-TB), including 
kanamycin and amikacin. Group III includes fluoroquinolones, such as higher generation members 
levofloxacin and moxifloxacin. Group IV drugs are mostly oral bacteriostatic second-line agents. Group 
V drugs are agents not recommended by the WHO for routine use in MDR-TB treatment because of 
limited data available. Not all TB drugs are depicted.
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isoniazid) and extensively drug-resistant TB (XDR-TB; MDR resistance plus resistance 
to a fluoroquinolone and an aminoglycoside of the second-line regimen) has become 
a major problem on its own. For MDR-TB, a range of second-line TB drugs are in 
use (groups II-V, Figure 1), which are administered for longer periods, generally have 
less potency and are associated with more toxicity than the first-line TB drugs (15). 
Third, the presence of TB-associated co-morbidities, such as HIV infection and diabetes 
mellitus, fuel the TB epidemic, increase the risks of treatment failure, and complicate 
optimal drug treatment with unwanted drug-drug interactions (DDIs). Finally, the 
high prevalence of adverse drug reactions to TB drugs contributes to the problem of 
non-adherence and premature cessation of TB treatment. 
The identification and development of novel drug combinations could potentially 
improve TB treatment outcomes and address the aforementioned issues. Unfortunately 
development of new TB drugs is hampered by several obstacles, such as an expectation 
by the pharmaceutical industry of insufficient profit opportunities, difficulty to identify 
new compounds with activity against M. tuberculosis, and time-consuming phase 3 
clinical trials (14). As a result, TB drug research has been aiming at redevelopment of 
existing first-line TB drugs (high dose rifamycins and pyrazinamide) and repurposing 
of available antibiotics (e.g. moxifloxacin, linezolid and clofazimine (8)), alongside the 
development of new compounds (e.g. bedaquiline, delamanid and pretomanid). The 
advantage of repurposing and redeveloping existing antibiotics is that results can 
be obtained rapidly and there is already safety data available (16). This is especially 
interesting for the slow progression of TB drug development in the last decades, in 
which only a few new agents have reached the market (11, 15).
Improving TB treatment with available drugs: success 
stories and their limitations
Redeveloped and repurposed drugs are currently in various phases of (pre)clinical 
development. The overall aim is to develop safe and effective optimized dosing 
schedules that can serve as building blocks for new TB combination regimens. Here, we 
will elaborate on the development of three promising building blocks for treatment of 
drug-sensitive (high-dose rifampicin and moxifloxacin) and drug-resistant TB (linezolid). 
The first-line TB drug rifampicin is a good example of effective redevelopment of an 
existing TB drug. Rifampicin was initially approved for the treatment of TB by the Food 
and Drug Administration (FDA) in 1971, after a range of trials and case series had 
demonstrated the efficacy of rifampicin-containing regimens in a dose of 600 mg daily 
(17). Currently, the 600 mg dose is being re-evaluated, and higher doses of rifampicin 
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have been tested in patients with pulmonary TB as well as TB meningitis. A randomized 
comparison of higher-dose intravenous rifampicin (approximately 13 mg/kg per day) 
versus a standard oral dose (10 mg/kg per day) in 60 Indonesian TB meningitis patients 
demonstrated a drop in mortality of 50% in the higher dose group (18). In contrast, 
in another study in Vietnamese TB meningitis patients, intensified oral treatment 
(containing higher-dose rifampicin (15 mg/kg per day) and levofloxacin (20 mg/kg 
per day)) was not associated with a higher rate of survival (19). Very recently, much 
higher oral doses of rifampicin, up to 35 mg/kg daily, have been administered safely in 
African pulmonary TB patients, resulting in strongly increased plasma exposures (20) 
and a reduced time to culture conversion (21). Overall, available literature suggests that 
further dose optimizations are required to deduce the optimal dose of rifampicin in 
different populations and TB manifestations. 
The fluoroquinolone moxifloxacin was one of the first drugs to be repurposed for TB 
treatment. This broad-spectrum antibiotic was previously used to treat a wide range 
of infections, including community-acquired pneumonia. Moxifloxacin was repurposed 
as a TB drug after identification of its good early bactericidal activity (EBA) (22, 23). 
EBA is used as a measure for the ability to kill metabolically active bacteria in the early 
stage of TB treatment and is represented by the fall in viable colony-forming units 
of M. tuberculosis in sputum early in therapy (24). Meanwhile, fluoroquinolones have 
become the cornerstone of treatment of MDR-TB (25, 26). More recently, moxifloxacin 
has been investigated in multiple phase 3 clinical trials as one of few promising drugs 
for shortening of treatment of drug-sensitive TB (27-29). Results were disappointing, as 
moxifloxacin substitutions were unfavorable in comparison with the standard regimen 
(16, 29). So far moxifloxacin has been applied in a common dose (400 mg once daily) 
that has not been optimized for treatment of TB. This is especially striking when 
considering that the TB drug rifampicin reduces moxifloxacin plasma concentrations 
substantially (30). Higher doses of moxifloxacin may be required for optimal response 
against M. tuberculosis. Moreover, high-dose moxifloxacin (800 mg) during the first 2 
weeks in patients with TB meningitis was found to be safe (18).
Linezolid is a synthetic drug belonging to the oxazolidinone class of antibiotics. In 2000, 
it was introduced for the treatment of serious Gram-positive infections (31). Linezolid 
was used “off-label” before reliable data from multicenter observational studies were 
available. Later on it became a repurposed agent in the treatment of fluoroquino-
lone-resistant MDR-TB, with good evidence for activity against drug resistant strains in 
preclinical studies (32, 33), and growing evidence for its efficacy in MDR-TB and XDR-TB 
patients (34). At the moment linezolid is still classified as a group 5 TB drug: agents 
that are undergoing additional investigation to better define their safety, tolerability 
14
Chapter 1
and efficacy against MDR-TB (8). The application of linezolid for drug-sensitive TB is 
limited by its modest EBA (35), high costs, and adverse effects (e.g. hematologic toxicity 
and peripheral neuropathy) associated with long-term use. Additional studies are 
necessary to assess the optimal dose and adequate duration of treatment of linezolid 
for various types of drug-sensitive TB infection. Analogues of linezolid (e.g. sutezolid) 
are in development. 
Overall, knowledge on the appropriate dose, resulting plasma exposure, and eventual 
anti-mycobacterial efficacy are key components for adequate redevelopment and 
repurposing of TB drugs and optimization of TB therapy. In short, we must better 
understand the pharmacology of the drugs under consideration. 
Pharmacology of TB drugs
Pharmacology is the science that studies the effect of drugs on biological systems. 
Traditionally there are two major principles that describe the relation between dose, 
drug exposure, and clinical response: the pharmacokinetics and pharmacodynamics of 
a drug. Drug pharmacokinetics is known as “what the body does to the drug”, meaning 
it includes the study of the absorption, distribution, metabolism, and excretion of 
an administered drug. On the other hand, drug pharmacodynamics involves “what 
the drug does to the body”, referring to the study of the relationship between drug 
concentration and its therapeutic response or toxicity. 
Figure 2 gives a schematic overview of TB pharmacology, ranging from prescription 
on the one side, to drug response on the other side. The ‘drug concentration’ is 
the connecting link in-between. Firstly, drug adherence, co-medication, and patient 
characteristics, including gender, co-morbidity (HIV/AIDS, diabetes mellitus), genetics, 
and malnutrition, affect the drug concentration reached and thus drug pharmacokinetics 
(36-41). Secondly, pharmacodynamic variables from the host as well as the bacterium 
can modify the concentration-effect relationship, such as metabolic and physiological 
adaptations in response to drug exposure and lesion specific characteristics (42). 
Generally, suboptimal drug concentrations can lead to unfavorable TB treatment 
outcomes and/or stimulate drug resistance (low concentrations), or contribute to 
toxicity (high concentrations) (43, 44). For concentration-response or pharmacoki-
netic-pharmacodynamic (PK-PD) analyses, free rather than total drug concentrations 
should be evaluated (45), as only protein-unbound drugs are pharmacologically active 
(46, 47). For this reason the free drug concentration was assigned a central role in 
Figure 2. 
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Today, the most common PK-PD measures used to describe the dose-effect relationship 
of TB drugs are the ratio of the area under the concentration-time curve relative to the 
minimum inhibitory concentration of M. tuberculosis (AUC0-24h/MIC) and the ratio of the 
peak drug concentration relative to the MIC (Cmax/MIC) (48-51). The relation between 
inadequate exposure and suboptimal clinical response has been relatively well described 
for TB drugs (36, 51-55) and PK-PD indices are used in both clinical and research 
settings to predict the outcome of TB treatment. Nonetheless, this association has not 
been demonstrated in all studies (56-58) and it is known that plasma concentrations 
cannot explain all of the variability in patient responses to TB treatment, as well as 
that it cannot guarantee patient outcomes (50). Furthermore, the relationship between 
plasma concentrations and toxicity has not been well established, with exception of 
pyrazinamide, ethambutol, cycloserine, and linezolid (50, 59). 
Figure 2. Schematic overview of the relationship between the prescribed dose and the eventual 
effect, with the drug concentration as intermediate link.
PK-PD, pharmacokinetic-pharmacodynamic; TB, tuberculosis
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The place of pharmacology in TB drug development and 
drug optimization
Before new medicines reach the market, they generally have to go through the complete 
drug development pipeline. According to present-day standards, this involves various 
phases that can broadly be grouped into three stages: discovery, preclinical, and clinical 
(phase 1, 2 and 3) studies. After discovery of a lead compound, a range of in vitro and 
animal tests will be performed. In general, they contain toxicology studies and tests that 
examine drug pharmacokinetics (absorption, distribution, metabolism and excretion) 
and pharmacodynamics. These data aid in deducing a safe starting dose for the clinical 
phase in humans. After the preclinical phase, the optimal clinical dose of a TB drug can 
be derived from the study of multiple doses and their relationships with drug exposure 
and efficacy/toxicity profiles in phase 1 and 2 clinical studies, followed by pivotal phase 
3 efficacy studies of drug regimens in larger patient populations (17). 
The modern paradigm of PK-PD that underlie the aforementioned study sequence 
had not yet been established at the time most currently used TB drugs were brought 
onto the market (Figure 1). With hindsight, the historical pharmacokinetic, toxicity, and 
cost arguments that formed the basis of our current TB regimen seem short-sighted, 
meaning that there is a lot of leeway for drug dosing improvements (6). Optimum 
drug dosages, substantiated by the pharmacological and PK-PD characteristics of a 
drug has the potential to greatly maximize efficacy of current TB medication (6). As 
mentioned earlier, application of the redeveloped drug rifampicin and the repurposed 
drugs moxifloxacin and linezolid may greatly benefit from such evidence-based dose 
and exposure optimization, more specifically:
1. In vitro studies: molecular pharmacology
Modern mechanistic understanding of basic pharmacological principles on 
for example metabolizing enzymes, drug transporters, genotypic variations, 
and available in vitro assays, provide valuable input for understanding TB 
drug pharmacology. Such data can aid in explaining unresolved toxicity/DDI 
profiles, predicting DDIs for new drug combinations, and implementing dose 
individualization. DDIs play a central role here, as many TB patients also suffer 
from co-morbidities, such as HIV infection and diabetes mellitus, which require 
the combined use of antimycobacterial, antiviral and antidiabetic agents. 
Furthermore, current TB research has shown increasing notion that insight into 
drug transport mechanisms is extremely relevant to the efficacious treatment of 
TB and that transport of drugs across human and mycobacterial membranes 
is related to major problems in TB treatment. These research topics can be 
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investigated with current in vitro techniques, but were unknown at the time 
most TB drugs were developed.
2. Animal studies
Before the contribution of single TB drugs to (novel MDR-)TB regimens can be 
investigated in patients, studies have to be performed in appropriate preclinical 
models, such as the TB mouse model. Pharmacokinetic data are indispensable 
in these studies, as exposure is considered predictive for treatment outcome 
and adverse effects. To improve clinical predictability from animal efficacy 
studies, it is important to test a dose that is pharmacokinetically equivalent (i.e 
yields similar exposures) to the dose used in TB patients. This rationale is essential 
in appropriate drug efficacy testing in animals and extrapolation from animals to 
humans and vice versa.
3. Human studies: clinical pharmacology
Reaching effective systemic concentrations, but also locally (e.g. lung tissue 
in pulmonary TB and brain tissue/cerebrospinal fluid (CSF) in TB meningitis) 
are key to therapeutic success and therefore are an interesting focus of clinical 
research. For accurate concentration-response evaluations in clinical studies, 
the free plasma drug concentration should be measured, as this is the active 
concentration, which can diffuse or be actively transported into tissues and to 
the sites of action. 
Outline of the thesis
The overall objective of the studies in this thesis is to contribute to exposure optimization 
of drugs used in TB treatment and associated co-morbidities. The central principle 
underlying these studies is that the efficacy and toxicity of these drugs is related to 
their plasma concentrations (Figure 2). We pay special attention to the role of drug 
transporters, as they are a key determinant for (systemic and intracellular) free drug 
concentrations (Figure 2).
All studies in this thesis are thus interconnected by their shared aim to reach/maintain 
effective TB drug concentrations (Figure 2). They can be divided into three parts, which 
represent all stages of drug development: in vitro, animal, and human pharmacological 
studies. The combined studies form a translational approach (‘crossing barriers’) to 
optimize TB drug treatment. The first part consists of molecular pharmacological 
research, containing in vitro investigations of drug-target interactions. These studies 
aim to improve the mechanistic understanding of TB drug pharmacology, including 
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drug resistance and transporter-mediated DDIs. The second part comprises animal 
research, with a specific focus on the application of pharmacokinetically optimized 
doses. The final part includes clinical pharmacokinetic studies that investigate predictors 
for drug exposure, concentration-effect relationships, and DDIs; results that can directly 
be implemented in clinical practice. In the first part of the thesis, all TB drugs (first- and 
second-line) are studied, while in the second and third part we focus on the TB drugs 
rifampicin, moxifloxacin and linezolid. 
Introduction: review of the literature
To further elaborate on the importance of drug concentrations for TB drug efficacy, 
chapter 2 reviews the role of drug transport mechanisms across human and 
mycobacterial membranes in reaching optimal systemic and local drug concentrations 
and efficacious treatment of TB. 
Part 1: Molecular pharmacology 
In chapter 3 we address the transport of drug out of the mycobacterium or (in 
relation to this) transporter-mediated drug resistance. Traditionally, mycobacterial drug 
resistance has been ascribed to spontaneous genetic mutations, altering drug targets, 
or prodrug-activating enzymes. However, resistance or adaptation cannot always be 
explained by classic gene mutations. Therefore, in this chapter we will describe our 
efforts to identify mycobacterial ATP-binding cassette (ABC) transporters that mediate 
TB drug resistance via a transporter-related mechanism, using in vitro overexpression 
techniques. In chapters 4 and 5 we assess the interaction of human transporters in 
TB drug pharmacokinetics and DDIs in in vitro transporter-overexpression models. 
Multiple-drug therapy for TB and TB-associated co-morbidity increase the likelihood 
of DDIs to occur. Inhibition of membrane transporters is an important mechanism 
underlying DDIs. Therefore, chapter 4 assesses the in vitro inhibitory potential of 
currently used first- and second-line TB drugs, as well as of proposed mycobacterial 
efflux pump inhibitors (EPIs) (chapter 2) on the human ABC transporters most relevant to 
drug transport. Subsequently, chapter 5 specifically focuses on DDIs to be expected in 
TB patients with concurrent diabetes mellitus (DM). Currently, there is scanty evidence on 
the need for dose adjustments if metformin (first choice antidiabetic) is co-administered 
with TB drugs. This study evaluates the in vitro inhibitory effects of TB drugs on 
metformin transport. Furthermore, we identify TB drugs that, similarly to metformin, 
are transporter substrates and thus can become a victim of transporter-mediated DDIs.
Part 2: Animal studies 
In chapters 6 and 7 we aim to identify the human pharmacokinetic equivalent dose of 
linezolid (chapter 6) and moxifloxacin (chapter 7), as well as to evaluate ‘dried blood 
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spot’ (DBS) analyses for measuring DBS concentrations in mouse blood spots. Both 
drugs are promising agents for future drug-sensitive and/or MDR-TB regimens, to be 
evaluated in combination with existing and new TB drugs in the TB mouse model. 
To improve clinical predictability from animal efficacy studies, it is important to test a 
dose that is pharmacokinetically equivalent to the dose used in patients. Furthermore, 
pharmacokinetic analyses in mice would benefit from measurement of analytes in 
small blood volumes using the DBS technique, because it allows for the assessment of 
multiple drug concentrations over time within a single mouse. 
Part 3: Clinical pharmacology
Firstly, in chapter 8 we investigate the impact of nutritional status on the steady-state 
pharmacokinetics of total and protein-unbound (free, active) concentrations of 
rifampicin. Malnutrition is a key feature of TB, which was called ‘consumption’ in the 
past, an old term for wasting away of the body. Malnutrition and associated low 
concentrations of drug-binding plasma proteins may cause a change in the equilibrium 
between unbound and bound concentrations, rendering total drug concentrations 
misleading. As a secondary objective, we evaluate the interindividual variability in 
exposure to protein-unbound rifampicin, as this may provide relevant information to 
understand exposure-response relationships for this pivotal TB drug. In chapter 9 we 
focus again on TB patients with concurrent DM and transporter-mediated DDIs. Until 
now, the impact of rifampicin on metformin pharmacokinetics in TB-DM patients and 
on the clinical response to the drug had been unclear. Transporters largely mediate 
the oral absorption, hepatic uptake, and renal excretion of metformin. Rifampicin is 
a known inducer of transporters, which may cause alterations in metformin exposure 
and efficacy. Therefore, this study aims to assess the effect of chronic rifampicin use 
on the steady-state pharmacokinetics of metformin. Alongside, the glucose-lowering 
activity of metformin is evaluated to determine the clinical relevance of the identified 
pharmacokinetic interaction. The final chapter of part 3, chapter 10, examines the 
concentration-response relationship, systemically and locally (CSF), for rifampicin 
and moxifloxacin in TB meningitis patients. The chapter aims to deduce minimum 
target values for drug exposure that can aid in TB treatment, but also in the design of 
pharmacokinetically optimized dosing regimens in other populations. 
General discussion
Finally, the main findings of this thesis are summarized and discussed in chapter 11. 
Remaining knowledge gaps will be identified and a framework for future research is 
brought forward.
20
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Abstract
Current tuberculosis (TB) research has shown increasing notion that insight into drug 
transport mechanisms is highly relevant to the efficacious treatment of TB and that 
transport of drugs across human and mycobacterial membranes is related to major 
problems in TB treatment. Firstly, efflux transporters located in the intestines, liver and 
kidneys all determine the pharmacokinetics of TB drugs, with a high risk of drug-drug 
interactions in case of concurrent use of antimycobacterial, antiretroviral and antidiabetic 
agents. Secondly, human efflux transporters limit the penetration of TB drugs into the 
brain and cerebrospinal fluid, which is especially important in the treatment of TB 
meningitis. Finally, efflux transporters located in the macrophage and Mycobacterium 
tuberculosis membrane play a pivotal role in the emergence of phenotypic tolerance 
and drug resistance, respectively. We review the role of efflux transporters in TB drug 
handling, and also evaluate the promise of efflux pump inhibition from a novel holistic 
perspective. 
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Introduction
Tuberculosis (TB) remains a leading cause of morbidity and mortality worldwide. In 
2014 an estimated 9.0 million people developed active TB and approximately 1.5 million 
patients died (1). Even though the global incidence of TB is declining, several key 
challenges persist, including the duration and complexity of the currently available TB 
treatment, the high incidence of adverse events in response to TB drugs, the presence 
and growth of diseases that fuel the TB epidemic (e.g. HIV infection and diabetes 
mellitus), the emergence of drug-resistant TB, and the devastating effect of severe 
forms of TB, such as TB meningitis. 
The introduction of new drugs and novel regimens could potentially improve TB 
treatment outcomes. Unfortunately the development of new compounds (bedaquiline, 
pretomanid and delamanid) has been very slow and only a few new TB drugs have 
reached the market the last decades (2, 3). Drug development has been hampered 
by multiple obstacles, such as insufficient profit opportunities for the pharmaceutical 
industry, difficulty to identify new compounds with activity against Mycobacterium 
tuberculosis (M. tuberculosis) and time-consuming phase III clinical trials (4). As a result, 
TB drug research is currently aiming at repurposing available TB drugs (clofazimine and 
moxifloxacin) and redevelopment of existing first-line TB drugs (high dose rifamycins). 
The past decade has shown considerable research interest into mechanisms of drug 
transport in and out of human and bacterial cells. There is increasing notion that insight 
into drug transport mechanisms is highly relevant to the efficacious treatment of TB 
and that transport of drugs across human and mycobacterial membranes is related to 
major problems in TB treatment. In this light, administration of drug transport inhibitors 
alongside available TB drugs may be an efficient strategy to improve current antibiotic 
efficacy by circumventing the development of new antibiotics. In general, transport 
proteins can be subdivided in influx (or uptake) transporters that mediate the entry 
of drugs and other compounds into cells; and efflux transporters that are involved 
in removal of drugs out of cells. In the specific case of TB patients, administered TB 
drugs encounter many human, but also mycobacterial transporters (Figure 1), which all 
determine the fate and effectiveness of these agents.  
After oral administration, the first transporters TB drugs encounter are at the site of the 
intestines, liver and kidneys, all affecting the pharmacokinetics of the drug (Figure 1). 
These transporters often work together with drug metabolizing enzymes in handling 
drugs. In case of concurrent use of antimycobacterial, antiretroviral and antidiabetic 
drugs, there is a high risk of drug-drug interactions (DDIs) at this level, which are 
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clinically very relevant (5, 6). Transporter proteins may be involved in these interactions, 
as they can be inhibited or induced by other drugs, similar to metabolic enzymes. 
Therefore, it is important to establish if newly developed TB drugs are a substrate, 
inhibitor or inducer of transporters. 
Besides their vital role in the disposition of drugs, human efflux transporters also protect 
sanctuary sites such as the brain against entry of xenobiotics. This is especially important 
in the treatment of TB meningitis, the most severe manifestation of M. tuberculosis 
infection (7), where penetration of TB drugs into the brain and cerebrospinal fluid (CSF) 
is affected by transporters (Figure 1). One way to improve the outcome of TB meningitis 
may be to enhance the penetration of TB drugs into the brain and CSF by intervening 
with efflux mechanisms located at the blood-brain barrier (BBB) and blood-CSF barrier 
(BCSFB) (8). 
The final human barrier that TB drugs need to cross before gaining access to the 
site of infection, is formed by the macrophage membrane (Figure 1). In contrast to 
normal bacterial infections, M. tuberculosis can survive and reside within macrophages. 
These cells can therefore be considered as a pharmacological sanctuary site, forming 
an additional barrier between TB drugs and their mycobacterial targets. Crossing will 
depend on the physiochemical properties of the drugs, but also on the presence of 
efflux transporters expressed on the macrophage outer membrane. Beneficial effects 
could be anticipated from inhibition of these transporters, which cause decreased and 
suboptimal intracellular drug concentrations (9).
After passing the macrophage membrane, the final barrier is encountered, which is 
formed by the M. tuberculosis cell wall and the underlying plasma membrane (Figure 
1). It has been increasingly recognized that mycobacterial efflux transporters may play 
a pivotal role in the emergence of resistance to TB drugs. As treatment options are 
running out, new drugs and more effective regimens are urgently needed to improve 
the outcomes of TB patients. Accordingly, inhibition of mycobacterial drug efflux 
mechanisms has been proposed as a novel adjuvant treatment strategy to increase 
intramycobacterial concentrations of TB drugs, which may even reverse M. tuberculosis 
efflux pump induced resistance (10-12). 
In short, membrane transporters are important in the TB drug pharmacokinetic-phar-
macodynamic (PK-PD) relation and can influence TB treatment at multiple levels (Figure 
1). This review will assess the promises and pitfalls of inhibition of efflux transporters 
as an advantageous adjuvant TB treatment strategy. Firstly, we will evaluate available 
data on the role of transporters in TB drug pharmacokinetics and on possible relevant 
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transporter-mediated drug-drug interactions (DDIs). Secondly, we will assess the 
contribution of human efflux transporters to limiting TB drug penetration into sanctuary 
sites, such as brain and CSF, and evaluate enhancing local drug exposure via efflux 
inhibition. Thirdly, we will review the role of macrophage and M. tuberculosis efflux 
transporters in the emergence of drug tolerance and resistance. Finally, we will form a 
holistic perspective and put forward key knowledge gaps to come to a conclusion on 
the feasibility of efflux pump inhibition as an adjunctive treatment strategy for TB. 
ABC transporters and drug-drug interactions in TB 
patients
More than 400 membrane transporters in the ATP-binding cassette (ABC) and the 
solute carrier (SLC) protein superfamilies have been annotated in the human genome 
(13). These transporters can be categorized as influx or efflux transporters, depending 
on the direction of substrate translocation across the membrane. While the SLC family 
contains both importers and exporters, the ABC superfamily is unidirectional and only 
consists of exporters (14). Because we are mainly interested in efflux pumps in this 
review, we will focus on human ABC transporters.
ABC proteins are solely primary active transporters, meaning that they mediate the 
translocation of substrates at the expense of ATP hydrolysis. The human genome carries 
49 ABC genes, classified into seven subfamilies, designated A to G (15). High sequence 
homology in the ATP-binding domains, called nucleotide-binding domains (NBDs)), 
allows identification and classification of members of the ABC transporter family. The 
subfamilies are involved in many cellular processes, including efflux of endogenous 
and xenobiotic substrates. ABC transporters that are involved in drug transport can 
be found in the ABCB, ABCC, and ABCG families (16). Interaction of a drug with one 
of these transporters could alter the systemic or local disposition of compounds 
that are substrates of the same transporter (victim drugs) (17). Consequently, drug 
concentrations of the victim drug can be increased or decreased, and the safety and 
efficacy of this drug may be at risk (17, 18). 
In the following paragraphs we will first discuss ABC transporters known to be involved 
in drug efflux, after which we will evaluate the contribution of these transporters to TB 
drug pharmacokinetics and transporter-mediated DDIs, and highlight knowledge gaps 
herein. 
 
 
30
Chapter 2
Figure 1. Schematic overview of human and mycobacterial transporters that are relevant in TB 
treatment. 
Firstly, transporters at the site of the intestines (absorption) (A), liver (metabolism and excretion) 
(B) and kidneys (excretion) (C) are important for drug pharmacokinetics and transporter-mediated 
drug-drug interactions. Secondly, transporters located at the BBB and BCSFB (D) influence the entry 
of TB drugs into the brain and CSF, respectively, which is especially relevant in the treatment of TB 
meningitis. Finally, transporters in the bacterial and macrophage membrane (E and F) determine local 
TB drug concentrations.
A
D
B
C
E
F
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ABC transporter proteins
Multidrug resistance protein 1 (MDR1) or p-glycoprotein (P-gp) (gene: ABCB1) is 
probably the best-known ABC transporter. It has an unusually broad substrate specificity 
and is expressed in the epithelia of many tissues, including intestine, kidney, liver, brain, 
and placenta (13, 19). A large number of P-gp substrates are large-molecular-weight 
(>500 Da), lipophilic or amphiphilic, polyvalent organic cations (14, 20-23). P-gp can 
also act as an effective gatekeeper of the central nervous system (CNS), which is why 
drug development will be aimed at either minimizing or maximizing P-gp efflux activity, 
depending on whether the drug has a CNS or non-CNS target (13, 22). Among its 
substrates are the antibiotics clarithromycin, erythromycin, rifampicin, tetracycline and 
multiple fluoroquinolones; the glucocorticoids hydrocortisone and dexamethasone; 
and antiretrovirals including lopinavir, ritonavir, darunavir and atazanavir (14, 19). 
Similar to P-gp, breast cancer resistance protein (BCRP, gene: ABCG2) functions 
as a high capacity drug transporter with a broad substrate specificity, including 
mostly lipophilic compounds. BCRP is highly expressed in tissue barriers such as the 
intestine, BBB, placenta, testis, kidney and liver (24, 25). Its substrates include different 
chemotherapeutic agents, drugs (e.g. prazosin, glyburide, cimetidine, sulfasalazine, 
rosuvastatin, nitrofurantoin and pantoprazole) and endogenous substances (e.g. 
estrone-3-sulfate, 17β-estradiol 17-(β-D-glucuronide) and uric acid) (26). 
The bile salt export pump (BSEP; gene: ABCB11) is exclusively expressed in the apical 
membrane of hepatocytes. BSEP is involved in transport of bile salts into the bile, but 
also transports pravastatin (27). Inhibition of this transporter can result in accumulation 
of bile salts and drug-induced cholestatic liver injury (28). 
Finally, multidrug resistance associated proteins (MRPs) (gene: ABCC) primarily mediate 
the extrusion of organic anions, such as drugs conjugated to glutathione, sulphate 
or glucuronate. Some MRP members also transport endogenous compounds (29). 
For example, MRP1 effluxes both hydrophobic compounds and organic anions, 
including conjugated drugs, but also uncharged compounds in cotransport with 
glutathione (30, 31). MRP2 is dominantly expressed in the apical membranes of liver, 
kidney and gut epithelium, where it can mediate the efflux of bilirubin glucuronides 
and other organic anions, playing a role in the detoxification of many endogenous and 
xenobiotic compounds (32). Both MRP1 and MRP2 can also mediate the cotransport 
of unconjugated compounds together with glutathione, as well as glutathione itself 
(30, 31). MRP3 mostly transports glucuronidated compounds (33) and, finally, MRP4 
and MRP5 are organic anion transporters that can also mediate the efflux of several 
nucleoside analogs, including reverse transcriptase inhibitors acting against HIV (31, 
34, 35).
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TB drugs interacting with ABC transporter proteins
To assess the importance of transporter-mediated DDIs in TB treatment, we first need 
to establish if TB drugs are substrates (victim drugs) or inhibitors/inducers (perpetrator 
drugs) of transporters. Of the first- and second-line TB drugs, we know that rifampicin, 
moxifloxacin and possibly ethambutol are P-gp substrates, and thus can become a 
victim and perpetrator (competitive inhibition) of DDIs (9, 36). With respect to the 
inhibitory potential, we recently reported that rifampicin inhibits P-gp, BCRP, BSEP and 
MRP1-5 (37). Indeed BSEP inhibition by rifampicin has previously been proposed as 
an explanation for rifampicin-associated cholestasis (38). Of the second-line TB drugs, 
clofazimine is a known inhibitor of P-gp, BCRP and MRP1 (37). Because clofazimine 
is not in widespread clinical use and no interaction studies have been undertaken, 
the occurrence of DDIs mediated via transporter inhibition is relatively unknown (39). 
Finally, we know that rifampicin is a potent inducer of P-gp expression (40, 41), but also 
of other ABC transporters, including BCRP and MRP2 (42, 43). Upregulation occurs by 
activation of pregnane X receptor (PXR), which acts as a ligand-activated transcription 
factor that can also increase cytochrome P450 (CYP) levels (44, 45). Rifampicin-induced 
P-gp expression is known to decrease bioavailability of, for example, concomitantly 
administered HIV drugs (46).
Co-administration of inhibitor (TB) drugs with the respective transporter substrates 
could lead to DDIs by elevating substrate concentrations (decreased extrusion), either 
systemically or intracellularly. Because transporters often work together with drug 
metabolizing enzymes in handling drugs, decreased cellular elimination of victim 
drugs may in turn affect the amount of intracellular metabolism. The interplay between 
transporter induction, inhibition and metabolism can be difficult to interpret. For 
example, repeated dosing of rifampicin will induce P-gp. This will mostly reduce plasma 
concentrations of P-gp substrates by decreasing the bioavailability of transporter 
substrate drugs (45). However, rifampicin can also act as a clinically relevant P-gp 
inhibitor, but only when it is administered in temporal proximity with the victim drug 
and not separated in time (47-49). Rifampicin’s inhibitory effect may be studied isolated 
from its inductive effect by single-dose administration. 
Transporter mediated drug-drug interactions: knowledge gaps
For most TB drugs it is unknown whether they are substrates of ABC transporters. Because 
transporter proteins may be involved in DDIs between TB drugs and co-administered 
transporter inhibitors or substrates, it is important to know if newly developed and 
available TB drugs are a substrate, inhibitor or inducer of these transporters. For many 
of the currently used TB drugs this information is lacking, probably because most of 
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them were discovered in the 1950s and 1960s (50). At that time the role of transporters 
in drug disposition was largely unknown, and their molecular identity and cellular 
distribution was yet to be discovered (13) . Further research is necessary to fill these 
knowledge gaps. Finally, information on TB drug transporter substrates and inhibition 
kinetics could provide input for a physiologically-based pharmacokinetic (PBPK) model 
to enable quantitative pharmacokinetic predictions. Such a model may aid dose finding 
for pharmacokinetic studies and help design and prioritize interaction studies by 
providing a mechanistic basis. 
Efflux pump inhibition at the blood-brain barrier in 
tuberculous meningitis
TB mostly affects the lungs, but may occur anywhere in the human body. Hematogenous 
seeding occurs most frequently in regions of the body that are highly oxygenated, 
including the brain (51). Cerebral tuberculosis manifests itself as meningitis and brain 
abcesses or tuberculomas, which can be up to several centimeters large (51-53). 
Tuberculous (TB) meningitis, the most severe manifestation of M. tuberculosis infection, 
results in death or neurological disability in up to 50% of patients affected (1, 7). The 
same TB drugs and dosing guidelines are applied as for pulmonary TB patients (54), 
even though it is known that the penetration of some first-line anti-tuberculosis drugs, 
especially rifampicin, into cerebrospinal fluid (CSF) is limited (55).
When considering the pathology, it seems eminent that optimal drug concentrations 
should be reached in the brain tissue and its interstitial fluid (ISF) as well as in the 
surrounding CSF and meninges. In this section we therefore elaborate on the role 
of efflux transporters in the penetration of TB drugs into the brain and CSF and 
contemplate on the possibilities of targeted efflux pump inhibition in reaching higher 
and more efficacious drug concentrations locally (8). In the following paragraphs 
we will first describe physiology and function of the CNS barriers, after which we 
will discuss specific CNS penetration characteristics of TB drugs and the use of CSF 
as exposure marker. Finally, we will evaluate the possibilities for enhancing local TB 
drug concentrations by efflux inhibition and identify knowledge gaps that should be 
addressed before this concept can be applied in practice. 
The blood-brain-barrier and blood-CSF-barrier 
The BBB and the BCSFB separate the extracellular CNS fluid compartment, the ISF and 
the CSF, from the blood compartment, thereby protecting the CNS from the free entry 
of (neuro)toxic substances (8, 56). In the case of TB meningitis, the BBB and the BCSFB 
will have an increased permeability and the degree of inflammation and affection of CSF 
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flow will influence the amount of drug penetration (57). Figure 2 provides an overview 
of the relation between the BBB, consisting of brain endothelial cells, and the BCSFB, 
consisting of choroid plexus epithelial cells, plus their most relevant drug transporters. 
The endothelial and epithelial cells that form the barriers are kept together with tight 
junctions that block the paracellular diffusion of polar solutes (58-60). The BCSFB is 
more “leaky” than the BBB, which is consistent with its principal function, namely the 
formation and secretion of CSF (22, 56, 61). The diffusional barrier between the brain ISF 
and the CSF consists of the ependymal lining of the cerebral ventricles (Figure 2) and 
is considered relatively leaky across a large surface area  (57, 62). Thus, solutes can be 
distributed from the ISF to CSF via diffusion or convection.
Physicochemical and drug properties such as molecular size, lipophilicity and plasma 
protein binding determine BBB and BCSFB penetration (57). Especially the lipid solubility 
of a drug correlates well with the degree of permeation (8, 57, 59, 66). Polar solutes can 
enter the brain or CSF by specific inwardly-directed transport mechanisms, such as the 
organic anion-transporting polypeptide (OATP) member of the SLC superfamily (8, 65, 
66). In contrast, entry of lipophilic solutes is limited by (active) transport mediated by ABC 
proteins (59). P-gp was the first exporter to be associated with the BBB, and together 
with BCRP it is the most abundant transporter (63, 64). Both transporters are located 
at the apical side of the BBB and BCSFB, meaning that they excrete their substrates in 
the blood and in the CSF, respectively (22).  Expression and localization of MRPs is less 
clear (56, 67). At least MRP4 has been detected at the BBB in quantifiable levels with 
the use of proteomic analyses in multiple studies (22, 63, 64), and MRP1 seems more 
abundantly expressed than P-gp at the BCSFB (68). During TB treatment the expression 
Figure 2. Overview of the relation between the blood-brain barrier (BBB), made up by brain 
endothelial cells, and the blood-CSF barrier (BCSFB), made up by choroid plexus epithelial cells. 
The ependymal lining of the cerebral ventricles form the barrier between brain and CSF. The ABC 
transporters (exporters) and solute carrier transporters (SLCs, importers) most relevant in drug 
transport are colored blue and purple, respectively (13, 22, 56, 58, 63-65).
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of P-gp and BCRP in the brain is induced via PXR transcription factor activation caused 
by rifampicin, potentially augmenting the function of these transporters at the BBB and 
the BCSFB (42, 69, 70). Nonetheless, the clinical role of PXR at the BBB remains rather 
unclear (49, 69).
TB drugs and their CNS penetration characteristics
Most data available on CNS TB drug entry are based on measurements in the CSF 
compartment, sampled from lumbar punctures. Of the first-line TB drugs, isoniazid and 
pyrazinamide (low protein binding and uncharged at physiological pH) reach the CSF 
best, with peak concentrations (Cmax) comparable to those in blood (55). In contrast, 
rifampicin CSF concentrations rarely exceed the minimum inhibitory concentration (MIC) 
of M. tuberculosis. Penetration is poor, probably due to the high plasma protein binding 
(± 80%), high molecular weight (800 Da) and the negative charge at physiological 
pH (55, 57). Streptomycin and ethambutol also demonstrate poor CSF penetration 
(both charged at physiological pH), especially when meningeal inflammation is less 
pronounced (55, 57). Finally, of the second-line TB drugs, ethionamide, cycloserine and 
the fluoroquinolones reach the CSF relatively well (all uncharged at physiological pH) 
(55, 57). In general, CSF exposure is considered a relevant parameter in the assessment 
of PK-PD relationships in CNS infections (66), also in case of TB meningitis (55, 71). 
However, little is known about how well these lumbar CSF concentrations correlate with 
intracranial CSF, ISF and brain tissue concentrations (60).
When using CSF as an exposure marker, one should consider that under normal 
conditions the CSF-to-unbound plasma concentration ratio reflects the balance between 
drug permeability across the blood-CNS barriers and the sink action of CSF relative to 
the ISF. The sink action is established by the higher rate of CSF turnover compared 
to ISF and the leaky ependymal barrier in between, causing drug concentrations to 
be almost equal or lower compared to the ISF (60, 72). This blood-ISF-CSF relation is 
compromised when efficient efflux occurs, either at the site of the BBB (decreasing ISF 
concentration relative to CSF), or at the site of the BCSFB (decreasing CSF concentration 
relative to the ISF). These processes hamper the interpretation of CSF as a surrogate of 
unbound brain concentrations for efflux pump substrates. For example, penetration of 
rifampicin and moxifloxacin into the CNS is limited at the BBB by their efflux via P-gp. 
However, P-gp located at the BCSFB may export these drugs directly into the CSF 
(Figure 2). Indeed, our group recently demonstrated that in Indonesian TB meningitis 
patients with increasing rifampicin and moxifloxacin plasma concentrations, relatively 
less drug enters the CSF, possibly indicating saturation of P-gp transport (71). Thus, 
with P-gp acting as an importer into the CSF, CSF levels may actually be overestimating 
brain concentrations in case of P-gp substrates. This underlines the caution that should 
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be taken when interpreting CSF drug concentrations, especially when dealing with TB 
drugs that are transporter substrates. 
Enhancing drug penetration via efflux inhibition 
Various strategies are available to circumvent the brain and CSF barrier, for example 
physicochemical property modification, intracerebral injection, olfactory route delivery, 
tight-junction modulation e.g. by osmotic opening, liposome or nanoparticle-mediated 
permeation and, finally, inhibition of efflux mechanisms (8, 73, 74). In case of TB meningitis 
the applicability of many of these strategies is limited, especially when considering that 
TB occurs mostly in low and middle income countries. Furthermore, adequate drug 
modification is challenging, as underlined by the fact that in the last decades only a 
few new drugs were proven clinically effective and reached the market. However, efflux 
pump inhibition may provide a relatively easy way to enhance CNS drug exposure of 
currently available drugs. 
In the past, multiple competitive and non-competitive P-gp, BCRP and MRP inhibitors 
have been tested, of which P-gp inhibition has been successfully applied to enhance 
penetration into the human and/or rodent brain of classic substrate drugs, including 
verapamil, morphine, loperamide, digoxin, nelfinavir and paclitaxel (8, 22). The first 
P-gp inhibitor was discovered in 1981 by Tsuruo et al., who demonstrated that the 
calcium channel blocker verapamil inhibits P-gp-mediated drug efflux in resistant 
tumor cells (75). Later on, valspodar (PSC833) and various third generation P-gp 
inhibitors (elacridar (GF120918), tariquidar (XR9576), and zosuquidar (LY335979)) were 
found to increase paclitaxel brain concentrations and reduce tumor size in mice (59, 
76, 77). Numerous preclinical studies underline the potential of P-gp inhibition at the 
BBB; increases in CNS exposure of P-gp substrates have been found in the order of 
2- to 100-fold (22). Nonetheless, it has been argued that the large increases observed 
in rodent studies, either by transporter knock-out or chemical inhibition, have not yet 
been observed in humans. Inter-species differences in substrate affinity, transporter 
abundance and transporter capacity hamper the extrapolation from animals to humans 
(78-80). Furthermore, effective dosing of efflux pump inhibitors at safe concentrations 
in humans has been proven difficult (22, 81).
BBB efflux pump inhibition: knowledge gaps
Before we can assess the applicability of targeted efflux pump inhibition at the BBB in 
TB meningitis treatment, we should understand the relation between TB drug systemic 
exposure, brain/ISF concentration, and CSF flow and concentration. Most data on CNS 
entry of TB drugs involve measurements in the CSF compartment obtained from lumbar 
punctures. However, little is known about how well these CSF concentrations correlate 
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with concentrations in other CNS regions. Inferences on exposure assessments from 
CSF should especially be made cautiously in case of transporter substrates, because 
of differences in transporter location and function in the BBB compared to the BCSFB. 
We know that rifampicin and moxifloxacin are P-gp substrates, but other relevant TB 
drug-exporter interactions have not yet been reported and still need to be assessed.
Most data on BBB transport inhibition originate from animal studies, which have been 
associated with difficulties in inter-species extrapolation. Positron emission tomography 
(PET) imaging in humans with radiolabeled P-gp substrates may circumvent this problem 
by enabling the direct study of transporter-mediated interactions. PET allows the 
monitoring of the whole-body distribution and pharmacokinetics of radiolabeled drugs 
and thereby enables a simultaneous assessment of the impact of transporter inhibition 
on the exposure of multiple organs, including kidney, liver, and brain. Furthermore, 
PET imaging results can be used to correlate CSF concentrations with brain exposure, 
which can give valuable information for the clinical use of CSF measurements from 
lumbar punctures and provide scaling factors for extrapolation of rodent data to 
humans. Recently a promising PET study in five healthy volunteers investigated the 
effect of continuous infusion of tariquidar on (R)-[11C]verapamil brain distribution and 
concluded that substantial and safe inhibition of P-gp (273 ± 78% relative to baseline 
scans without tariquidar) could be achieved (82).
Modulating transport activity at the macrophage level 
The macrophage membrane forms the final human barrier that TB drugs need to 
cross before reaching the site of infection, thereby posing an important drug target 
itself as well. In the following paragraphs we will first evaluate M. tuberculosis as an 
intracellular pathogen, after which we will elaborate on the expression of important 
macrophage drug exporters and their potential to counteract macrophage-induced 
tolerance. Finally, knowledge gaps will be identified that currently limit the mechanistic 
understanding of the use of macrophage-targeted efflux inhibition.
Intracellular Mycobacterium tuberculosis and drug tolerance
M. tuberculosis is an intracellular pathogen which primarily infects macrophages and 
can parasitize and modulate macrophage cell function. After uptake by macrophages, 
M. tuberculosis can arrest the normal progression of the phagosome by intervening 
with its acidification and hydrolytical activity, and help in avoiding a local productive 
immune response (83). Furthermore, M. tuberculosis can slow down its own metabolism 
and replication, rendering itself extremely resistant to host defense and drug treatment 
(84). This state of dormancy is thought to be evoked by the hypoxic and low nutrient 
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conditions intracellularly (84). According to this paradigm, bacterial dormancy causes 
drug tolerance during infection, i.e. poor bacterial killing with an unchanged MIC or 
‘phenotypic drug resistance’ (84-87). However, drug tolerance has also been reported 
in the presence of non-quiescent intracellular bacteria (88). Irrespective of the 
mechanisms underlying various types of dormancy and/or tolerance, inhibition of efflux 
mechanisms located on the macrophage membrane may enhance intracellular drug 
concentrations and thereby stimulate intracellular killing  (9).
Expression of drug transporters on the macrophage plasma membrane
The capacity of drugs to penetrate the macrophage membrane will depend on their 
physiochemical properties as well as the expression of influx and efflux transporters. As 
influx transporters are beyond the scope of this review, we will focus on expression of 
drug exporters. Primary human macrophages generated from blood monocytes display 
high MRP1 and MRP3 expression, and medium MRP4 and BCRP mRNA expression (89). 
P-gp is expressed at low levels or not at all (89). In contrast, in human macrophage-like 
cell lines P-gp could be detected (9, 90-92). Figure 3 shows the expression profiles 
of ABC transporters in blood monocytes and neutrophils from TB patients before 
treatment and from healthy controls (93). From this figure we can conclude that at the 
mRNA level mostly MRPs are expressed by the monocyte. 
Functional multi-drug transporters may reduce intracellular TB drug concentrations by 
transporting drug substrates out of the macrophage, a process that may be counteracted 
by adding efflux pump inhibitors. Indeed in J774 murine macrophages verapamil and 
cyclosporin (P-gp inhibitors) increased the accumulation of the antibiotics azithromycin, 
erythromycin and telithromycin (P-gp substrates) (91), whereas in the same model 
gemfibrozil (MRP inhibitor) was able to increase the accumulation of ciprofloxacin 
(MRP substrate) (94). Furthermore, in ciprofloxacin-resistant J774 macrophages 
overexpressing MRP4, ciprofloxacin accumulation was significantly reduced compared 
to wild-type, but was markedly increased by ATP depletion (95). These data indicate 
that efflux pump-mediated drug transport in the macrophage may indeed be relevant. 
Targeting macrophage transporters to overcome drug tolerance 
It remains unclear if drug transporters leading to alterations in macrophage drug 
concentrations also affect pharmacodynamics of treatment. Literature reports that 
macrophage-induced tolerance can be developed to most TB drugs, which can be 
reversed upon exposure to verapamil in case of rifampicin, isoniazid, moxifloxacine and 
bedaquiline (12). In another in vitro cell model, the P-gp inhibitor tariquidar significantly 
increased intramacrophage killing of M. tuberculosis by ethambutol and rifampicin (9). 
This was explained as P-gp-mediated, as this transporter was found to be expressed 
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on the macropage-like cell line and rifampicin was demonstrated to be a substrate of 
P-gp (9). Furthermore, upon phagocytosis of M. tuberculosis, promonocytic U1 cells 
(chronically infected with HIV, but with negligible virus levels) accumulated significantly 
less intracellular isoniazid (10%), with verapamil increasing the intracellular accumulation 
of isoniazid as well as the sensitivity of M. tuberculosis towards isoniazid (92). This finding 
was ascribed to the expression of P-gp, even though, to our knowledge, isoniazid is not 
a substrate of P-gp. These findings underline the fact that more research is necessary 
to clarify the relation between drug substrates, macrophage efflux transporters, and 
targeted efflux pump inhibition. 
Macrophage drug transporters: knowledge gaps
Significant knowledge gaps exist in our understanding of the relation between 
increased intracellular TB drug accumulation and enhanced bacterial killing. In this light, 
conclusions on enhanced antibiotic activity should be made cautiously. For example, 
from literature we know that larger intramacrophage drug concentrations can lead to 
no or little changes in (active) free drug concentrations or do not necessarily correlate 
with larger drug concentrations at the cellular compartment of interest. In J774 cells 
highly accumulated gemifloxacin was equipotent to moxifloxacin and ciprofloxacin 
against Listeria monocytogenes and Staphylococcus aureus, possibly indicating binding 
to cellular constituents such as soluble proteins (95). In another study, the MRP inhibitor 
Figure 3. Expression profiles of ABC transporters in blood monocytes and neutrophils from TB 
patients before treatment and healthy controls. 
Data on transporter expression were obtained from the Gene Expression Omnibus (GEO) database 
(www.ncbi.nlm.nih.gov/geo), containing genome-wide transcriptional profiles by Berry et al. (2010) 
(93). Individual data points are presented, together with their median. Significance analysis was 
performed by comparing differences in controls (n=4) versus patients (n=7) within each transporter 
gene with students t-tests, not corrected for multiple comparisons. Only MRP5 was significantly 
downregulated in patient neutrophils.
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gemfibrozil increased the total accumulation of MRP substrate ciprofloxacin in J774 
macrophages by approximately 2.5-fold. The excess was mainly found in the cytosol, 
which increased activity almost 2.5-fold against the cytosolic Listeria monocytogenes, 
but not against the phagolysosomal Staphylococcus aureus (94). In the same study, 
verapamil (P-gp inhibitor) increased the cellular accumulation of P-gp substrate 
azithromycin by approximately 2.5-fold without modifying its subcellular distribution, 
causing a similar bacteriostatic effect against L. monocytogenes and bactericidal effect 
against S. aureus at 7-fold lower extracellular concentrations (94). To summarize, 
before making inferences on enhanced antibiotic activity of TB drugs combined with 
targeted macrophage efflux pump inhibitors, we should assess if increased free TB 
drug concentrations can be obtained in the mycobacterial subcellular compartment 
of interest.
Adding to the complexity, bacterial and human transporters potentially share overlap 
in substrate and inhibitor specificities. With current knowledge and techniques it is hard 
to differentiate between the contributions of human and bacterial transporters, further 
complicating the substrate-(macrophage)transporter-tolerance relation. In addition, 
upon macrophage infection, many factors affecting drug susceptibility are altered, as 
cells respond to environmental changes by altering gene expression in order to restore 
homeostasis and cell survival. At the bacterial site, macrophage residence can induce 
efflux pumps and their regulators (88, 96, 97) and at the host site, drug exposure can 
modulate the expression of multiple multidrug efflux transporters. For example, in J774 
murine macrophages exposed to moxifloxacin, the transporter proteins P-gp, MRP2 and 
BCRP were upregulated and MRP4 protein expression was downregulated (98), while in 
J774 macrophages made resistant to ciprofloxacin, the ciprofloxacin efflux transporter 
MRP4 was the most upregulated protein (99, 100). This dynamic environment makes it 
hard to assign changes in tolerance to either the mycobacterium or the host immune 
cell, as both influence drug accumulation and resistance. Even when resistance and/
or uptake studies are performed in both extracellular and intracellular infection models 
in parallel (90, 101), it is difficult to control for all the environmental changes upon 
infection and make accurate inferences on the balance between cooperation and/or 
antagonism of the efflux pumps in the different test settings. 
Overall it seems that inhibition of efflux pumps may be a useful strategy to improve 
antibiotic efficacy against intracellular bacteria by increasing accumulation of free (active) 
drug in the M. tuberculosis compartment of interest. Furthermore, intracellular TB drug 
exposure may potentially form a good predictor of TB outcome, but only after unraveling 
transporter expression and function in the infected host cell, the substrate specificity of 
these transporters, and the intracellular drug compartmentalization characteristics. In 
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an azithromycin hollow-fiber model of disseminated and intracellular Mycobacterium 
avium infection, intramacrophage concentrations were used for the dose-response 
analysis, as both microbial kill and resistance emergence were more closely linked to 
the within-macrophage area under the concentration-time curve (AUC)/MIC ratio than 
extracellular concentrations (102). Such a new pharmacokinetic parameter may come 
with additive information when combined with the PK-PD parameters used currently to 
predict outcome, such as the AUC-to-MIC ratio for rifampicin’s microbial killing (103).
 
Efflux pump-induced Mycobacterium tuberculosis 
resistance 
From literature it is evident that bacterial efflux pumps play an important role in many 
cellular processes, such as physiological homeostasis, resistance to stress conditions, 
lipid transport, cell wall maintenance and virulence (104-112). Very similar to humans, 
bacteria also use efflux systems for their protection by eliminating exogenous 
toxins, such as antibiotics (11, 113). In the following paragraphs we will identify the 
role of efflux systems in drug resistance and address the feasibility of counteracting 
transporter-mediated resistance by mycobacterial efflux pump inhibition. Finally, we will 
highlight the gaps in our understanding of efflux pump inhibition at the bacterial level. 
Mycobacterium tuberculosis efflux systems and drug resistance 
Traditionally mycobacterial drug resistance has been ascribed to spontaneous 
chromosomal mutations, altering drug targets or prodrug-activating enzymes (11, 114). 
Drug resistant mutant bacteria are selected following exposure to monotherapy or 
low antibiotic doses due to inadequate prescription, poor patient compliance, and 
interpatient pharmacokinetic variability (115, 116). However, resistance or adaptation 
cannot always be explained by classic gene mutations (117). For example, approximately 
20-30% of resistant isolates to the first-line drug isoniazid do not have mutations in any 
of the genes associated with isoniazid resistance (118). Alternative resistance mechanisms 
also include decreased cell wall permeability, the production of drug-modifying and 
drug-inactivating enzymes (119, 120) and bacterial upregulation of drug efflux systems 
located in the cytoplasmic membrane (113).
Efflux pumps are thought to extrude TB drugs, thereby decreasing intramycobacterial 
drug concentrations to sub-inhibitory levels and contributing to TB resistance (11, 102, 
119, 121, 122). Enhanced efflux pump activity may explain multiple aspects of drug 
resistance in tuberculosis: (1) intrinsic resistance, (2) acquired multidrug resistance, 
and (3) antibiotic induced tolerance (88). For example, under conditions of suboptimal 
exposure to antibiotics and increased mycobacterial efflux pump expression, bacteria 
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may have greater chances of acquiring and accumulating chromosomal mutations, 
conferring to higher levels of drug resistance and even multidrug resistance (MDR) (121, 
123-125). Furthermore, drug-induced efflux pumps may have overlapping substrate 
specificities with other TB drugs, explaining cross-resistance to multiple drugs (121).
Mycobacterial efflux systems can be classified into two classes, depending upon the 
energy source they use to facilitate transport. Primary transporters that belong to the 
ATP binding cassette (ABC) superfamily extrude their substrates at the expense of ATP 
(126). Secondary transporters utilize a proton gradient for drug expulsion (120, 127) and 
can be subdivided in the Multidrug and Toxic compound Extrusion (MATE) family, the 
Major Facilitator Superfamily (MFS) (128), the Small Multidrug Resistance (SMR) family, 
and the Resistance Nodulation Division (RND) superfamily. 
After systematically reviewing the available literature for the role of M. tuberculosis 
efflux pumps in transported-mediated TB drug resistance (Box 1), we found that a 
large part of the literature comprises studies reporting transporter expression analyses 
of drug-resistant clinical isolates and/or laboratory strains (118, 124, 129-145), which 
provides only indirect evidence for efflux pump-mediated resistance. Preclinical 
studies focusing on the mechanism of interaction between transporters and drug 
resistance, mainly overexpress the M. tuberculosis transporters of interest in bacteria, 
i.e. Escherichia coli (129, 146, 147), M. smegmatis (128, 147-153), M. bovis BCG (154-156) 
or M. tuberculosis (157-159), or knock-out/mutate the tuberculosis transporter of 
interest (88, 154, 156, 157, 159-164). These genetically modified organisms are generally 
subjected to drug sensitivity studies in order to come to a conclusion on the unwanted 
protective effect of the transporter of interest. Table 1 provides an overview of the most 
relevant M. tuberculosis drug efflux transporters reported in literature, together with the 
available evidence that associates them with TB drug resistance.
Mycobacterial efflux pump inhibition as adjuvant TB therapy
To combat resistance, preferably new antibiotics need to be developed. However, as 
discussed earlier, very few new TB drugs have reached the market the last decades. 
Inhibitors of resistance mechanisms can be used as an adjuvant to current TB regimens, 
which may circumvent the necessity to develop new antibiotics. Table 1 shows the 
effect of efflux pump inhibitors (EPIs) on specific M. tuberculosis efflux pumps and their 
transporter activity and/or alleged transporter-mediated resistance. The selection 
of EPIs by these studies often occurred based on previous evidence of mammalian 
efflux pump inhibition (11, 165). According to Table 1, verapamil, tariquidar, reserpine, 
thioridazine, piperine (inhibitors of mammalian ABC transporters (37, 166)) and 
cyanide-m-chlorophenylhydrazone (CCCP, protonophore that uncouples the proton 
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gradient (167)) can be identified as inhibitors of M. tuberculosis efflux systems. Many of 
these are broad-spectrum inhibitors (167), of which at least CCCP is considered highly 
toxic to humans. This emphasizes the need for optimization studies to determine safe 
and effective concentrations, before these drugs can be applied in humans.
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Sequence similarity of M. tuberculosis transporters with human drug transporters could 
provide a compelling start to unraveling M. tuberculosis ABC transporter function 
and indicate suitable inhibition strategies. In an effort to relate M. tuberculosis and 
human ABC transporters, we constructed a phylogenetic tree of the highly conserved 
human and M. tuberculosis ATP-binding units of the intracellular nucleotide binding 
domains (NBDs) (Box 2 and Figure 4). Membrane spanning domains (MSDs) were 
not included because of their highly variable composition. The phylogenetic tree 
gives a graphic representation of the evolutionary distance between human and M. 
tuberculosis ABC transporter subfamilies and enabled us to group the M. tuberculosis 
ABC transporters with the human ABC subfamilies according to sequence similarity 
(15, 168). Results seem congruent with findings of Xiong et al. (2015) who showed that 
the seven eukaryote ABC transporter families (A-G) fall into three adjacent groups: 
Figure 4. Simplified representation of the phylogenetic tree of the highly conserved ATP-binding 
units of human and TB ABC transporters, based on maximum likelihood, Bayesian and neighbour 
joining methods.
M. tuberculosis gene names are depicted at the corresponding branches and, where possible, were 
grouped within a colored clade containing one of the human ABC subfamilies.
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A&G, B,C&D and E&F group (169). Because human ABCB (ABCB1 (P-gp) and ABCB11 
(BSEP)), ABCG (ABCG2 or BCRP) and ABCC (MRP1-5) subfamily members are involved 
in drug transport, the M. tuberculosis ABC transporters allocated to these clades would 
be most promising to investigate for their role in drug resistance and targeted efflux 
pump inhibition. Accordingly, from Figure 4, Rv0194 (ABCB), Rv1273c/Rv1272c (ABCB), 
Rv1348/Rv1349 (ABCB), CydC/CydD (ABCC) and Rv1747 (ABCG) would be interesting 
targets for further research. Their protein organization indeed suggests that these 
M. tuberculosis transporters are congruent to their human counterparts, namely full 
transporters (ABCB1 or P-gp and ABCC members; MSD-NBD-MSD-NBD) or (reverse) 
half transporters (ABCG2 or BCRP; NBD-MSD) (15, 126, 168) (Box 2). After verification of 
functional similarities, we hypothesize that subfamily specific inhibitors could be used 
to modulate the corresponding M. tuberculosis transporter activity, for example, for 
example verapamil for a functional ABCB subfamily member and probenecid for an 
ABCC member.
Mycobacterial transporters: knowledge gaps
So far, research into mycobacterial efflux mechanisms, using clinical strains, 
overexpression models or mutated bacteria, has provided promising hypotheses, 
but the contribution of specific efflux pumps in clinical resistance remains unclear. To 
tackle drug resistance, it is essential to understand the molecular mechanisms by which 
bacteria acquire drug resistance. In this context, four knowledge gaps can be identified. 
Firstly, there is limited knowledge on the pathways involved in drug transporter 
upregulation. Most available data only offer phenotypic evidence and do not provide 
a mechanistic explanation of the specific environmental stimuli and cellular pathways 
involved. The interpretation of such comparative expression studies is complicated by 
the presence of transporters with overlapping triggers and substrate specificities. Studies 
often report upregulation of a panel of transporter genes after single or combined 
drug stimulation (118, 124, 130, 131, 140, 144, 170, 171), but an obvious pattern seems to 
be lacking or remains yet to be discovered. For instance single genes of an operon can 
be differentially expressed, while encoding a single transporter (130, 170). Furthermore, 
only a few transcriptional regulators, such as Lsr2 (172), whiB7 (144, 173, 174), MmpLR5 
(Rv0687) (163, 175), Rv0302 (176) and possibly NapM (177), have been related to efflux 
pump expression, but knowledge on their environmental triggers, signaling network 
and role in efflux pump-mediated resistance remains limited. In general, the function of 
antibiotic-induced transcriptional changes is poorly understood.
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Table 1. Overview of M. tuberculosis efflux pumps associated with TB drug resistance.
Genes 
Family 
(126-128)
Bacterium Evidence type Efflux Inhibitor
Rv0194 ABC
M. 
smegmatis
Overexpression of Rv0194 increased the 
MICs of ampicillin, vancomycin, novobiocin, 
and erythromycin for M. smegmatis. 
Expression also reduced ethidium bromide 
accumulation, which reached WT levels 
again with RES. Ethidium bromide-induced 
growth reduction in WT was not observed 
in Rv0194 bacteria, which was also reversed 
by RES (148) 
Ethidium 
bromide 
uptake 
RES
M. tb
Was upregulated significantly (>2-fold) after 
exposure to STM at 1/3 and 1/4MIC, and to 
ETH at 1/4MIC (140)
NA NA
Rv0933 
(PstB)
ABC
M. tb Was upregulated in RIF monoresistant 
strains without a rpoB mutation (129)
NA NA
M. tb
Was upregulated significantly in 2/4 
MDR-TB strains following RIF exposure. 
Susceptibility could be partially restored of 
all 15 RIF resistant strains by adding RES and 
VPM (170)
NA RES and 
VPM
M. tb
Rv0933 was significantly upregulated in 
high-level FQ resistant strains. For 2 isolates 
with high-level pstB transcripts CCCP 
reduced levofloxacin resistance (146)
NA CCCP
E. coli
E. coli with pstB increased MIC from <0.125 
to 2 µg/mL, which was reduced by CCCP 
to 0.25 µg/mL. PstB may either pump out 
FQ or it may create better conditions by 
importing phosphate (146), as it is classified 
as an ABC importer (126)
Rv1218-
Rv1217
ABC
M. tb
66.7 % (n=16) and 62.5 % (n=5) of MDR-TB 
isolates had upregulated Rv1217c and 
Rv1218c, while drug sensitive isolates did 
not (n=12). Increased expression of both 
Rv1217c and Rv1218c correlated with 
slightly higher MIC of RIF, while increased 
expression of only Rv1218c correlated with 
slightly higher MICs of INH (132) 
NA NA
M. tb
KO of Rv1218 decreased the MIC for RIF and 
CLF by 2-fold. VPM and PAβN decreased 
the MICs for CLF by 4- to 8-fold for the WT 
and 4-fold for the KO mutants, indicating a 
role for other efflux systems. Finally, there 
was a decreased susceptibility for KAN 
when Rv1218 was overexpressed in both 
WT and KO (160)
NA VPM, 
PAβN
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Genes 
Family 
(126-128)
Bacterium Evidence type Efflux Inhibitor
Rv1218-
Rv1217
ABC
M. tb
Rv1217 and Rv1218 were >2-fold 
upregulated in 2/7 and 1/7 MDR/XDR-TB 
strains, respectively, following exposure 
to INH compared to not exposed. MDR 
and XDR strains showed higher levels 
of ethidium bromide accumulation in 
presence of inhibitors compared to INH 
monoresistant strains. (144)
Ethidium 
bromide 
accumu-
lation
VPM, 
thiori-
dazine, 
chlorpro-
mazine, 
flu-
penthixol
M. tb
β-lactams exhibited increased potency 
against all four efflux pump KOs tested 
compared to WT. KO of Rv1218 resulted in 
a 4-fold decreased MIC for penicillin, and a 
2- to 4-fold decreased MIC for ampicillin. 
MIC for INH was unchanged (164)
NA NA
M. tb
Rv1218 and Rv1217 were upregulated (both 
>4-fold) after 12 hours of RIF exposure in 
an micro-array analysis. Results could not 
be confirmed with qRT-PCR (145)
NA NA
Rv1273-
Rv1272
ABC
M. tb
Was upregulated significantly (>2-fold) 
after exposure to INH at 1/2MIC, to STM 
at 1/4MIC, and to ETH also at 1/4MIC (140)
NA NA
M. tb
Expression levels of all tested efflux pumps 
were significantly higher, including Rv1273 
>2-fold, in clinical (drug sensitive and 
MDR-TB) strains compared to reference 
strains, with also a lower sensitivity to  STM 
and RIF (139)
NA NA
Rv1456-
Rv1457-
Rv1458
ABC
M. tb
Expression levels of Rv1456c, Rv1457c, and 
Rv1458c increased significantly (3.4-, 4.6-, 
and 5.4-fold, respectively) in drug-resistant 
strains when comparing to susceptible 
group (133)
NA NA
M. tb Was upregulated only in 1/4 MDR-TB strains 
following RIF exposure (170)
NA NA
Rv1473 ABC M. tb
whiB7 was induced by subinhibitory 
concentrations of antibiotics (erythromycin, 
tetracycline, and streptomycin). whiB7 was 
the only gene induced initially, indicating it 
is a primary regulator. The expression profile 
of Rv1473 appeared to be influenced by 
antibiotic exposure and the activity of whiB7 
(174)
NA NA
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Genes 
Family 
(126-128)
Bacterium Evidence type Efflux Inhibitor
Rv1621-
Rv1620 
(CydD-
CydC)
ABC M. tb 
Disruption of cydC accelerated bacterial 
clearance in INH-treated mice without 
affecting growth or survival in untreated 
mice. Mutants responded normally to INH 
when grown in macrophages ex vivo or in 
vitro. Complementation of the cydC mutant 
reversed the persistence in the lungs and 
spleens of INH-treated mice, although not 
to WT levels (194)
NA NA
Rv1687 ABC M. tb
Expression levels of all tested efflux pumps 
were significantly higher, including Rv1687 
>2-fold, in clinical (drug sensitive and 
MDR-TB) strains compared to reference 
strains, with also a lower sensitivity to  STM 
and RIF (139)
NA NA
Rv1747 ABC M. tb
Rv1747 was upregulated significantly in 
2/4 MDR-TB strains following RIF exposure. 
Susceptibility could be partially restored of 
all 15 RIF resistant strains by adding RES and 
VPM (170)
NA RES and 
VPM
Rv1819 ABC
M. tb
Was upregulated significantly (>2-fold) after 
exposure to INH at 1/2 and 1/3MIC, and to 
RIF at 1/3 and 1/4MIC (140)
NA NA
M. tb
Rv1819 was upregulated >2-fold after RIF 
and INH stress in 2/5 and 4/5 MDR-TB 
isolates, respectively (131)
NA NA
Rv2477 ABC M. tb Was upregulated >2-fold after ofloxacin 
stress in 4/5 MDR-TB isolates (131)
NA NA
Rv2688-
Rv2787-
Rv2686
ABC
M. tb Rv2688 was upregulated 2-fold after STM 
stress in 5/5 MDR-TB isolates (131)
NA NA
M. tb
Rv2688 was upregulated significantly in 2/4 
MDR-TB isolates, Rv2687 in 0/4 isolates and 
Rv2686 in 1/4 strains after RIF exposure. 
Susceptibility of all 15 tested RIF resistant 
strains could be partially restored by RES 
and VPM, respectively (170)
NA RES and 
VPM
M. 
smegmatis
Cells expressing the operon had >8- fold 
higher MIC for ciprofloxacin than WT. 
The MICs of norfloxacin, moxifloxacin 
and sparfloxacin were all doubled. 
Susceptibilities to RIF, INH, STM, ETH, 
ofloxacin and levofloxacin were not affected. 
RES, VPM and CCCP reduced ciprofloxacin 
resistance to the same level as the control. 
Accumulation of ciprofloxacin was ±60% 
lower in cells expressing the operon. RES 
increased the uptake almost to that of the 
control (150)
Cipro-
floxacin 
accumu-
lation
RES, VPM 
and CCCP
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Bacterium Evidence type Efflux Inhibitor
Rv2936-
Rv2937-
Rv2938
(drrA-
drrB-
drrC)
ABC
M. tb
drrA and drrB were upregulated under INH 
stress (9/9 tested MDR isolates) and drrB 
under RIF stress (2/9 isolates). Some of these 
isolates were increasingly sensitive toward 
INH (6/9) or RIF (2/2) when combined with 
CCCP or RES (130)
NA CCCP and RES
M. tb Was upregulated in RIF monoresistant 
strains without a rpoB mutation (129)
NA NA
E. coli Rv2936 expression increased the E. coli MIC 
for RIF from 8 to 32 μg/ml (129)
M. tb
Rv2938 was upregulated >2-fold after STM 
and ETH stress in 5/5 and 4/5 MDR-TB 
isolates, respectively (131)
NA NA
M. tb Only drrB was upregulated in 1/4 MDR-TB 
strains following exposure to RIF (170)
NA NA
E. coli
Radiolabeled doxorubicin uptake was 
significantly lower (±2.5-fold) in E.coli 
expressing DrrAB, which was counteracted 
by RES. (147)
Radio-
labeled
doxo-
rubicin, 
& BCECF 
uptake
RES
M. 
smegmatis
Doxorubicin uptake was significantly lower 
(±3-fold) in M. smegmatis induced to 
express DrrAB, which was counteracted by 
RES. Resistance was conferred to a broad 
range of antibiotics, including ETH, STM and 
norfloxacin (147)
M. tb
Rv2938 was significantly upregulated in the 
high-level FQ-resistant strains as compared 
to low-level resistant strains (146)
NA NA
M. tb
Expression levels of all tested efflux pumps 
were significantly higher, including drrA and 
drrB >2-fold, in clinical (drug sensitive and 
MDR-TB) strains compared to reference 
strains, with also a lower sensitivity to  STM 
and RIF (139)
NA NA
Rv0037 MFS M. tb
Expression levels of all tested efflux pumps 
were significantly higher, including Rv0037 
>2-fold, in clinical (drug sensitive and 
MDR-TB) strains compared to reference 
strains, with also a lower sensitivity to  STM 
and RIF (139)
NA NA
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Bacterium Evidence type Efflux Inhibitor
Rv0783 
(emrB)
MFS
M. tb
Rv0783 was upregulated in RIF 
monoresistant strains without a rpoB 
mutation (129) NA NA
E. coli Rv0783 expression increased the E. coli MIC 
for RIF from 8 to 16 μg/ml (129)
M. tb Rv0783 was upregulated in only 1/4 
MDR-TB isolates after RIF exposure (170)
NA NA
M. tb
Expression levels of all tested efflux pumps 
were significantly higher, including Rv0783 
>2-fold, in clinical (drug sensitive and 
MDR-TB) strains to reference strains, with 
also a lower sensitivity to  STM and RIF (139)
NA NA
Rv0849 MFS
M. tb
KO of Rv0849 decreased the MIC for RIF, CLF 
and AMK 2-fold. VPM and PAβN decreased 
the MIC for CLF 4- to 8-fold for the WT 
and 4-fold to none, respectively, for the KO, 
indicating that more efflux mechanism are 
involved. MICs for KAN and AMK increased 
with Rv0849 overexpression in WT and KO 
(160)
NA VPM, 
PAβN
M. tb
Was upregulated under INH stress (1/9 
tested MDR isolates), but not under RIF 
stress (0/9 isolates) (130)
NA NA
M. tb
β-lactams exhibited increased potency 
against all four efflux pump KOs tested 
compared to WT. KO of Rv0849 resulted in 
a 2-fold decreased MIC for penicillin, and a 
2- to 4-fold decreased MIC for ampicillin. 
MIC for INH was unchanged (164)
NA NA
Rv1250 MFS
M. tb
Was upregulated under INH stress (1/9 
tested MDR isolates), but not under RIF 
stress (0/9 isolates) (130)
NA NA
M. tb Was upregulated significantly (>2-fold) after 
exposure to INH at 1/2MIC (140)
NA NA
M. tb
Expression levels of all tested efflux pumps 
were significantly higher, including Rv1250 
>2-fold, in clinical (drug sensitive and 
MDR-TB) strains compared to reference 
strains, with also a lower sensitivity to  STM 
and RIF (139)
NA NA
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Rv1258 
(Tap)
MFS
M. tb
After 96 hr of macrophage residence, two 
Rv1258 mutants retained INH, but lost RIF 
tolerance and became hypersusceptible 
to RIF. The mutants were compromised 
for intramacrophage growth, suggesting 
that this efflux pump is required for both 
intracellular growth and RIF tolerance. 
VPM treatment phenocopied the Rv1258c 
mutation (88)
NA VPM
M. tb
Was upregulated (>3-fold) in 3/3 INH 
induced M. tb strains. VPM promoted at 
least a 4-fold reduction of the INH MIC in 
the induced strains. Moreover, it caused 
the reversal of resistance to INH to a level 
similar as the WT (118) 
NA VPM
M. tb
RIF exposure upregulated Rv1258c in a 
RIF resistant M. tb strain. The MICs of RIF 
and ethidium bromide was reduced in the 
presence of piperine (8- fold  and >32- fold, 
respectively) and VPM (2-fold and >8- fold, 
respectively) (134)
NA Piperine 
and VPM
M. tb
Was upregulated after RIF (3.5-fold) and 
INH (5-fold) exposure in a single MDR-TB 
strain containing also classic resistance 
mutations (135)
NA NA
M. tb
Rv1258c was upregulated 10- and 6- 
fold after exposing a MDR-TB isolate to 
subinhibitory levels (1/4MIC) of RIF and 
ofloxacin, respectively (136)
NA NA
M. tb
Rv1258 was upregulated significantly in 
3/4 MDR-TB isolates after RIF exposure. 
Susceptibility could be partially restored of 
all 15 tested RIF resistant strains by adding 
RES and VPM, respectively. Furthermore, 
VPM reduced the bacilli load and, therefore, 
restored susceptibility to first-line TB drugs 
in MDR-TB infected Balb/c mice (170)
NA RES and 
VPM
M. 
smegmatis
Expression of Rv1258 conferred low level 
resistance to tetracycline, but not to any of 
the TB drugs tested, such as INH, RIF, PYR, 
STM, aminoglycosides and FQs. The MIC 
was reduced by CCCP. The overexpression 
strain accumulated more tetracycline, 
however, accumulation did not change by 
preincubation with CCCP (151)
Tetra-
cycline 
accumu-
lation
CCCP
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Bacterium Evidence type Efflux Inhibitor
Rv1258 
(Tap)
MFS
M. 
smegmatis
M. smegmatis expressing Rv1258 conferred 
resistance to tetracycline, STM and 
gentamicin. Tetracycline accumulation was 
reduced with 10–15% (128)
Tetra-
cycline 
accumu-
lation
NA
M. tb
KO of Rv1258 reduced RIF, CLF, AMK, 
gentamicin and spectinomycin MICs. This 
was (partially) restored for gentamycin and 
spectionomycin upon complementation 
with Rv1258. Expression of Rv1258 increased 
the MIC for AMK and KAN compared to 
the WT. Finally, VPM and PAβN decreased 
CLF MICs only 2-fold for the Rv1258 KO, 
resulting in a similar MIC (VPM) or double 
the MIC (PAβN) to that of the WT with 
inhibitor, suggesting involvement of other 
efflux pumps (160)
NA VPM, 
PAβN
M. tb 
Among the synthesized VPM analogues, 
one analogue with a benzyl substituent for 
a nitrogen demonstrated a 4-fold reduction 
in the MIC99 of RIF, comparable to VPM. The 
analogue had more favorable interactions 
with the binding sites of  Rv1258c than 
VPM, RES and piperine (178)
NA VPM ana-logues
M. tb
Low level KAN resistant M. tb strains 
contained 8 independent mutations in the 
5’ untranslated region of the transcriptional 
activator whiB7, leading to 23- to 145-fold 
increased whiB7 transcripts and 30- to 
175-fold increased expression of Rv1258c. 
The loss of whiB7 lead to a 15-fold reduction 
in Tap mRNA. Mutations in the 5’UTR of 
whiB7 also conferred resistance to STM. 
Deletion of Tap decreased the MIC for STM 
5-fold, becoming more susceptible, but not 
for KAN (163)
NA NA
M. tb
Was >2-fold upregulated in 1/7 MDR/
XDR-TB strains following exposure to INH 
compared to not exposed. Upregulation 
also occurred inside macrophages upon 
exposure to INH. MDR and XDR strains 
showed higher levels of ethidium bromide 
accumulation in presence of inhibitors 
compared to INH monoresistant strains. 
(144)
Ethidium 
bromide 
accumu-
lation
VPM, 
thio-
ridazine, 
chlorpro-
mazine, 
flupen-
thixol
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Bacterium Evidence type Efflux Inhibitor
Rv1258 
(Tap)
MFS
M. tb
Rv1258 was upregulated (>2-fold) in an 
ofloxacin/RIF/INH resistant strain, but 
only after exposure to ofloxacin and not 
to RIF or INH. This strain was increased 
in susceptibility (16- to 32-fold) after 
combining RIF (and not INH or ofloxacin) 
with EPIs, such as VPM, thioridazine or 
chlorpromazine. Expression of Rv1258 was 
also upregulated (>20-fold) in an other 
INH/RIF resistant strain after exposure to 
INH or RIF. Susceptibility of this strain could 
be increased 2- to 4-fold after combining 
RIF (and not INH) with VPM, thioridazine 
or chlorpromazine. Ethidium bromide 
accumulation in both MDR-TB strains could 
be reduced by addition of VPM  (171)
Ethidium 
bromide 
accumu-
lation
VPM
M. tb
The Rv1258c KO appeared more susceptible 
for spectinamide-derivatives than WT. 
Complementation of the KO with Rv1258c 
restored the MICs for these compounds 
to wild-type levels, thus confirming the 
role of Rv1258c in their efflux. Synthetic 
modifications avoided pump-mediated 
efflux (162) 
NA NA
M. tb
Expression levels of all tested efflux pumps 
were significantly higher, including Rv1258 
>2-fold, in clinical (drug sensitive and 
MDR-TB) strains compared to reference 
strains, with also a lower sensitivity to  STM 
and RIF (139)
NA NA
M. tb
β-lactams exhibited increased potency 
against all four efflux pump KOs tested 
compared to WT. KO of Rv1258 resulted in 
a 2-fold decreased MIC for penicillin, and a 
2- to 4-fold decreased MIC for ampicillin. 
MIC for INH was unchanged (164)
NA NA
M. tb
whiB7 was induced by subinhibitory 
concentrations of antibiotics (erythromycin, 
tetracycline, and streptomycin). whiB7 was 
the only gene induced initially, indicating it 
is a primary regulator. The expression profile 
of Rv1258 appeared to be influenced by 
antibiotic exposure and the activity of whiB7 
(174)
NA NA
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Bacterium Evidence type Efflux Inhibitor
Rv1410 
(p55)
MFS
M. tb
p55 was upregulated after in vitro induced 
INH resistance. Strains demonstrated higher 
efflux capacity, as measured by ethidium 
bromide accumulation. Effects were 
counteracted by EPIs (124)
Ethidium 
bromide 
uptake 
Thiori-
dazine, 
chlorpro-
mazine, 
VPM
M. tb
Was upregulated after RIF (3.5-fold) and 
INH (6-fold) exposure in a single MDR-TB 
strain containing also classic resistance 
mutations (135) 
NA NA
M. 
smegmatis
p55 expressed in M. smegmatis conferred 
resistance to aminoglycosides, tetracycline 
and STM and accumulated less tetracycline. 
Resistance to STM and tetracycline was 
inhibited by CCCP, VPM and RES (152)
Tetra-
cycline 
accumu-
lation
CCCP, 
VPM and 
RES
M. bovis
BCG
Deletion of p55 made the strain more 
susceptible to, amongst others, RIF and 
CLF, which was restored by the introduction 
of the wild-type genes. The MIC for RIF 
decreased by adding CCCP and valinomycin 
for the wild type (154)
NA CCCP
M. tb
Of the P27-P55 operon, P55 encodes an 
efflux pump. KO of P27 and P55 did not 
affect resistance to RIF, while the KO of 
P27 became (slightly) more susceptible 
to both INH and ETH. Resistance to INH 
and ETH was reversed when a copy of the 
whole operon was introduced, indicating 
that both genes are implicated. Finally, 
KO of P27 showed much higher sensitivity 
to ethidium bromide than WT, and only 
complementation with P55 provided partial 
resistance. In the presence of RES, all strains 
were sensitive to ethidium bromide (159)
NA RES
M. tb
Was >2-fold upregulated in 2/7 MDR/
XDR-TB strains following exposure to INH 
compared to not exposed. Was upregulated 
>2-fold in 4/5 MDR/XDR-TB strains after 
exposure to RIF. Upregulation also occurred 
inside macrophages upon exposure to 
INH. MDR and XDR strains showed higher 
levels of ethidium bromide accumulation 
in presence of inhibitors compared to INH 
monoresistant strains. (144)
Ethidium 
bromide 
accumu-
lation
VPM, 
thio-
ridazine, 
chlorpro-
mazine, 
flupen-
thixol
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Bacterium Evidence type Efflux Inhibitor
Rv1410 
(p55)
MFS
M. tb
p55 was upregulated (>4-fold) in an 
ofloxacin/RIF/INH resistant strain, but 
only after exposure to ofloxacin and not 
to RIF or INH. This strain was increased 
in susceptibility (16- to 32-fold) after 
combining RIF (and not INH or ofloxacin) 
with EPIs, such as VPM, thioridazine or 
chlorpromazine. Expression of p55 was also 
upregulated (>20-fold) in another INH/
RIF resistant strain after exposure to INH 
or RIF. Susceptibility of this strain could 
be increased 2- to 4-fold after combining 
RIF (and not INH) with VPM, thioridazine 
or chlorpromazine. Ethidium bromide 
accumulation in both MDR-TB strains could 
be reduced by addition of VPM  (171)
Ethidium 
bromide 
accumu-
lation
VPM
M. tb
Was upregulated (>3-fold) in 3/3 INH 
induced M. tb strains. VPM promoted at 
least a 4-fold reduction of the INH MIC in 
the induced strains. Moreover, it caused 
the reversal of resistance to INH to a level 
similar as the WT (118) 
NA VPM
Rv1634 MFS
M. tb
In a range of MDR isolates (n=9) Rv1643 
was upregulated under INH (n=1) and RIF 
(n=1) stress. The isolates overexpressing 
Rv1634 were found to increase in sensitivity 
toward INH and RIF when combined with 
CCCP and RES (130)
NA CCCP and RES
M. tb
After RIF exposure, Rv1634 was significantly 
upregulated in 3/4 MDR-TB isolates. 
Susceptibility could be partially restored 
of all 15 RIF resistant strains by adding 
RES and VPM, respectively. Finally, VPM 
reduced the bacilli load and, therefore, 
restored susceptibility to first-line TB drugs 
in MDR-TB infected  Balb/c mice (170)
NA RES and 
VPM
M. 
smegmatis
M. smegmatis expressing Rv1634 conferred 
2- tot 4-fold resistance to FQs and uptake 
of norfloxacin was approximately 25% less 
(128)
Nor-
floxacin 
accumu-
lation
NA
M. tb
Expression levels of all tested efflux pumps 
were significantly higher, including Rv1634 
>2-fold, in clinical (drug sensitive and 
MDR-TB) strains compared to reference 
strains, with also a lower sensitivity to  STM 
and RIF (139)
NA NA
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Bacterium Evidence type Efflux Inhibitor
Rv1877 MFS
M. tb
Was upregulated significantly (>2-fold) after 
exposure to STM at 1/4MIC and to RIF at 
1/3 and 1/4MIC (140)
NA NA
M. tb
Was upregulated significantly in 2/4 
MDR-TB strains following RIF exposure. 
Susceptibility could be partially restored of 
all 15 RIF resistant strains by adding RES and 
VPM (170)
NA RES and 
VPM
Rv2333 MFS
M. tb
Following RIF exposure, Rv2333 was 
upregulated significantly in 2/4 MDR-TB 
isolates. Susceptibility could be partially 
restored of all 15 RIF resistant strains by RES 
and VPM. (170)
NA RES and 
VPM
M. bovis
BCG
M. bovis 2361c KO (identical to Rv2333) 
was 2- and 4-fold more susceptible to 
spectinomycin and tetracycline, respectively. 
The MICs for M. bovis expressing Rv2333 
were 2-fold higher than of controls. There 
were no significant changes in the MICs of 
other drugs. KO of the Rv2333 homologue 
accumulated ±25% more [3H]tetracycline, 
while expression of Rv2333 accumulated 
±25% less tetracycline (155)
Tetra-
cycline 
accumu-
lation
NA
M. tb
Expression levels of all tested efflux pumps 
were significantly higher, including Rv2333 
>2-fold, in clinical (drug sensitive and 
MDR-TB) strains compared to reference 
strains, with also a lower sensitivity to  STM 
and RIF (139)
NA NA
Rv2459 
( jefA)
MFS
M. tb
Was upregulated under INH stress (6/9 
tested MDR isolates) and all isolates 
increased in INH sensitivity when combined 
with an EPI (CCCP/RES) (130)
NA CCCP and RES
M. tb
Rv2459 was upregulated after in 
vitro induced INH resistance. Strains 
demonstrated higher efflux capacity, 
as measured by ethidium bromide 
accumulation. Effects were counteracted by 
EPIs (124) 
Ethidium 
bromide 
uptake 
Thiori-
dazine, 
chlorpro-
mazine, 
VPM
M. tb
Was upregulated in MDR-TB isolates after 
INH, ETH and STM stress. In 6/60 isolates, 
ETH and INH combination resistance levels 
were decreased by CCCP (131)
NA CCCP
M. tb Was upregulated in only 1/4 MDR-TB 
isolates after RIF exposure (170)
NA NA
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Bacterium Evidence type Efflux Inhibitor
Rv2459 
( jefA)
MFS
M. tb
Overexpression in M. tb led to an increased 
MIC of ETH (16-fold), INH (64-fold) and 
STM (8-fold), but not of RIF, ofloxacin and 
norfloxacin. MICs were only partly lowered 
by CCCP and/or VPM (158) 
NA CCCP, 
VPM
M. tb
Rv2459 was upregulated (>2-fold) in an 
ofloxacin/RIF/INH resistant strain, but 
only after exposure to ofloxacin and not 
to RIF or INH. This strain was increased 
in susceptibility (16- to 32-fold) after 
combining RIF (and not INH or ofloxacin) 
with EPIs, such as VPM, thioridazine or 
chlorpromazine. Expression of Rv2459 was 
also upregulated (16-fold) in another INH/
RIF resistant strain after exposure to RIF, but 
not to INH (171)
Ethidium 
bromide 
accumu-
lation
VPM
Rv2846 
(efpA)
MFS
M. tb
Rv2846 was upregulated (5/9 tested MDR 
isolates) under INH stress and all these 
isolates had increased INH sensitivity when 
combined with CCCP or RES (130)
NA CCCP and RES
M. tb
efpA was upregulated after in vitro 
induced INH resistance. The increased 
resistance could be reduced by adding 
EPIs. Strains demonstrated higher efflux 
capacity, as measured by ethidium bromide 
accumulation. Effects were counteracted by 
EPIs (124)
Ethidium 
bromide 
uptake 
Thiori-
dazine, 
chlorpro-
mazine, 
VPM
M. tb
Rv2846 was upregulated 4-fold after 
INH stress in 5/5 MDR-TB isolates. In 
6/60 isolates, ETH and INH combination 
resistance levels were decreased by CCCP 
(131)
NA CCCP
M. tb Was upregulated in only 1/4 MDR-TB 
isolates after RIF exposure (170)
NA NA
M. tb Was upregulated in M. tb upon INH 
exposure (122, 141)
NA NA
M. tb
Overexpression of lsr2, a histon-like 
transcriptional regulator, repressed 
INH-mediated induction of efpA compared 
to the H37Rv control (172)
NA NA
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Bacterium Evidence type Efflux Inhibitor
Rv2846 
(efpA
MFS
M. tb
Was >2-fold upregulated in 1/7 MDR/
XDR-TB strains following exposure to INH or 
RIF compared to not exposed. Upregulation 
also occurred inside macrophages upon 
exposure to INH. MDR and XDR strains 
showed higher levels of ethidium bromide 
accumulation in presence of inhibitors 
compared to INH monoresistant strains. 
(144)
Ethidium 
bromide 
accumu-
lation
VPM, 
thiori-
dazine, 
chlorpro-
mazine, 
flupen-
thixol
M. tb
Was upregulated in fast-growing bacilli, 
but not in slow growing cells, during INH 
exposure. (143)
NA NA
M. tb
efpA was upregulated (>4-fold) in an 
ofloxacin/RIF/INH resistant strain, but 
only after exposure to ofloxacin and not 
to RIF or INH. This strain was increased 
in susceptibility (16- to 32-fold) after 
combining RIF (and not INH or ofloxacin) 
with EPIs, such as VPM, thioridazine or 
chlorpromazine. Expression of efpA was 
also upregulated (>10-fold) in another 
INH/RIF resistant strain after exposure to 
INH or RIF. Susceptibility of this strain could 
be increased 2- to 4-fold after combining 
RIF (and not INH) with VPM, thioridazine 
or chlorpromazine. Ethidium bromide 
accumulation in both MDR-TB strains could 
be reduced by addition of VPM  (171)
Ethidium 
bromide 
accumu-
lation
VPM
M. tb
Was upregulated (>3-fold) in 3/3 INH 
induced M. tb strains. VPM promoted at 
least a 4-fold reduction of the INH MIC in 
the induced strains. Moreover, it caused 
the reversal of resistance to INH to a level 
similar as the WT (118) 
NA VPM
Rv2994 MFS
M. tb
Was upregulated significantly in 2/4 
MDR-TB strains following RIF exposure. 
Susceptibility could be partially restored of 
all 15 RIF resistant strains by adding RES and 
VPM (170)
NA RES and 
VPM
M. tb Was upregulated after STM stress in 5/5 
MDR-TB isolates (131)
NA NA
Rv3239 MFS M. tb
Rv3239 was upregulated significantly in 
4/4 MDR-TB isolates after RIF exposure. 
Susceptibility could be partially restored of 
all 15 tested RIF resistant strains by adding 
RES and VPM, respectively. Furthermore, 
VPM reduced the bacilli load and, therefore, 
restored susceptibility to first-line TB drugs 
in MDR-TB infected Balb/c mice (170)
NA RES and 
VPM
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Bacterium Evidence type Efflux Inhibitor
Rv3728 MFS
M. tb Was upregulated in only 1/4 MDR-TB 
isolates after RIF exposure (170)
NA NA
M. tb
Rv3728 was upregulated >2-fold after 
RIF, INH and ETH stress in 3/5, 5/5 and 
2/5 MDR-TB isolates, respectively. In 
6/60 isolates, ETH and INH combination 
resistance levels were decreased by CCCP 
(131)
NA CCCP
Rv3065 
(mmr)
SMR
M. tb
mmr was upregulated under INH stress in 
1/9 MDR isolates. This isolate was not found 
to increase in sensitivity toward INH when 
combined with EPIs (130)
NA None
M. tb
mmr was upregulated after in vitro induced 
INH resistance. Strains demonstrated higher 
efflux capacity, as measured by ethidium 
bromide accumulation. Effects were 
counteracted by EPIs (124)
Ethidium 
bromide 
uptake 
Thiori-
dazine, 
chlorpro-
mazine, 
VPM
M. tb
Rv3065 was upregulated after INH and 
ETH stress in 2/5 and 3/5 MDR-TB isolates, 
respectively. In 6/60 isolates, ETH and INH 
combination resistance was decreased by 
CCCP (131)
NA CCCP
M. tb
The mmr KO became more susceptible 
to ethidium bromide, but not to INH. 
Overexpression of mmr decreased 
susceptibility to ethidium bromide, but 
not to INH. Effects were counteracted by 
VPM and CCCP. Ethidium bromide efflux 
decreased in the KO and increased in the 
overexpression strain, and was inhibited by 
VPM (157)
Ethidium 
bromide 
accumu-
lation
VPM and 
CCCP
M. tb
The MIC of CLF decreased 2- to 4-fold and 
that of AMK 2-fold in the Rv3065 mutant. 
VPM and PAβN decreased CLF MICs 4- to 
8-fold for the WT and 4-to 2-fold for the 
KO mutant, respectively. This suggests a role 
for additional efflux pumps. The KO and 
WT supplemented with Rv3065 exhibited 
an 8-to16-fold increase in the MICs for 
ethidium bromide and KAN (160)
NA VPM and 
PAβN
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Bacterium Evidence type Efflux Inhibitor
Rv3065 
(mmr)
SMR
M. 
smegmatis
Expression of mmr in M. smegmatis 
conferred resistance to, amongst 
others, tetraphenylphosphonium (TPP), 
erythromycin and ethidium bromide, which 
was reduced by CCCP. Susceptibility to e.g. 
STM and RIF was not affected. M. smegmatis 
cells expressing mmr accumulated less than 
20% TPP compared to the vector-only 
control, which was counteracted by CCCP 
(153)
TPP 
accu-
mulation
CCCP
M. tb
Was >2-fold upregulated in 2/7 MDR/
XDR-TB strains following exposure to INH 
compared to not exposed. Was upregulated 
>2-fold in 1/5 MDR/XDR-TB strains after 
exposure to RIF. Upregulation also occurred 
inside macrophages upon exposure to 
INH. MDR and XDR strains showed higher 
levels of ethidium bromide accumulation 
in presence of inhibitors compared to INH 
monoresistant strains (144)
Ethidium 
bromide 
accumu-
lation
VPM, 
thiori-
dazine, 
chlorpro-
mazine, 
flupen-
thixol
M. tb Was upregulated in both slow and fast 
growing bacilli after INH exposure. (143)
NA NA
M. tb
mmr was upregulated (>2-fold) in an 
ofloxacin/RIF/INH resistant strain, but 
only after exposure to ofloxacin and not 
to RIF or INH. This strain was increased 
in susceptibility (16- to 32-fold) after 
combining RIF (and not INH or ofloxacin) 
with EPIs, such as VPM, thioridazine or 
chlorpromazine. Expression of mmr was 
also upregulated (>135-fold) in another 
INH/RIF resistant strain after exposure to 
INH or RIF. Susceptibility of this strain could 
be increased 2- to 4-fold after combining 
RIF (and not INH) with VPM, thioridazine 
or chlorpromazine. Ethidium bromide 
accumulation in both MDR-TB strains could 
be reduced by addition of VPM (171)
Ethidium 
bromide 
accumu-
lation
VPM
M. tb
β-lactams exhibited increased potency 
against all four efflux pump KOs tested 
compared to WT. KO of Rv3065 resulted in 
a 4-fold decreased MIC for penicillin, and a 
2- to 4-fold decreased MIC for ampicillin. 
MIC for INH was unchanged (164)
NA NA
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Genes 
Family 
(126-128)
Bacterium Evidence type Efflux Inhibitor
Rv3065 
(mmr)
SMR M. tb
Was upregulated (>3-fold) in 3/3 INH 
induced M. tb strains. VPM promoted at 
least a 4-fold reduction of the INH MIC in 
the induced strains. Moreover, it caused 
the reversal of resistance to INH to a level 
similar as the WT (118) 
NA VPM
Rv0341-
Rv0342-
Rv0343
(iniB-
iniA-
iniC)
M. tb
iniA was upregulated by both INH and ETH, 
but not by RIF or STM (agents that do not 
act on the cell wall) (142, 156)
NA NA
M. tb
Rv0341 was upregulated significantly after 
RIF exposure in 2/4 MDR-TB isolates, 
Rv0342 in 2/4 and Rv0343 in 1/4 MDR 
isolates. Susceptibility could be partially 
restored of all 15 tested RIF resistant strains 
by RES and VPM (170)
NA RES and 
VPM
M. bovis 
BCG
BCG strains overexpressing M. tb iniA 
became tolerant to both INH and EMB, as 
overexpressing strains grew and survived 
longer. RES reversed tolerance to INH and 
resistance to ethidium bromide in BCG, 
although iniA did not appear to directly 
transport INH from the cell (156) Ethidium 
bromide 
accumu-
lation
RES
M. tb
M. tb strains lacking iniA were more 
susceptible to INH than controls. KO of 
iniA resulted in increased accumulation 
of ethidium bromide. Overexpression of 
iniA did not increase antibiotic tolerance 
to either INH or EMB, suggesting that 
induction of endogenous iniA by INH or 
EMB produces a maximal tolerance (156)
M. tb
Overexpression of lsr2, a histon-like 
transcriptional regulator, repressed 
INH-mediated induction of M. tb iniBAC 
genes compared to the H37Rv control (172)
NA NA
M. 
smegmatis
M. smegmatis lsr2 mutants had increased 
expression of M. tb iniBAC, which were more 
resistant to EMB than controls, indicating 
that lsr2 participates in repression of the 
iniBAC operon. Complementation of lsr2 
restored expression and EMB susceptibility 
to the level of the control (172)
M. tb
Was >2-fold upregulated in 2/5 MDR/
XDR-TB strains following exposure to RIF 
(but not INH) compared to not exposed. 
MDR and XDR strains showed higher 
levels of ethidium bromide accumulation 
in presence of inhibitors compared to INH 
monoresistant strains (144)
Ethidium 
bromide 
accumu-
lation
VPM, 
thiori-
dazine, 
chlorpro-
mazine, 
flupen-
thixol
63
The promise of efflux pump inhibition in TB treatment: unraveling the black box
Genes 
Family 
(126-128)
Bacterium Evidence type Efflux Inhibitor
Rv0341-
Rv0342-
Rv0343
(iniB-
iniA-
iniC)
M. tb
In serial XDR M. tb isolates a pattern of 
differential gene expression was identified 
that could explain observed systemic 
adaptation to challenge by multiple 
compounds, including an up-regulation of 
the iniBAC operon over time. Concomitantly, 
a slight down-regulation of lsr2 (a negative 
regulator of iniBAC expression) was 
observed (117)
NA NA
M. tb
Expression levels of all tested efflux pumps 
were significantly higher, including iniA 
>2-fold, in clinical (drug sensitive and 
MDR-TB) strains compared to reference 
strains, with also a lower sensitivity to  STM 
and RIF (139)
NA NA
Rv0450 
(mmpL4)
M. tb
Expression levels of all tested efflux pumps 
were significantly higher, including mmpL4 
>2-fold, in clinical (drug sensitive and 
MDR-TB) strains compared to reference 
strains, with also a lower sensitivity to  STM 
and RIF (139)
NA NA
M. tb
mmpL4 was upregulated (>3-fold) after 
12 hours of RIF exposure in an micro-array 
analysis. Results could not be confirmed 
with qRT-PCR (145)
NA NA
Rv0676 
(mmpL5)
M. tb
Authors argue that non-target (atpE) based 
resistance to BDQ, and cross-resistance to 
CFZ (182), is due to mutations in Rv0678, a 
transcriptional repressor of MmpS5-MmpL5, 
leading indeed to enhanced protein 
expression of this pump. Mutant Rv0678 
correlated with BDQ MIC increases (8-fold) 
in vitro and were cross-resistant to CFZ, with 
similar MIC increases as for BDQ. The EPIs 
VPM and RES reduced the MICs of both 
BDQ and CFZ. BDQ and CFZ MICs of the 
MmpS5-MmpL5 overexpression strain were 
increased by 4-fold and 2-fold, respectively, 
which was decreased by VPM. VPM failed 
to increase the bactericidal effect of BDQ in 
mice and was unable to reverse resistance 
in vivo (175).
NA VPM and RES
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Genes 
Family 
(126-128)
Bacterium Evidence type Efflux Inhibitor
Rv0676 
(mmpL5)
M. tb
In vitro CLF-resistant M. tb were found to be 
cross-resistant to BDQ. Bacteria contained 
mutations in transcription regulator 
Rv0678, which resulted in 11.6- and 
11.2-fold-increased expression of mmpL5 
and rv0678, respectively. Expression of 
Rv0678 in H37Rv lead to partial resistance 
to both clofazimine and BDQ (173) 
NA NA
M. tb
Was upregulated significantly (>2-fold) 
after exposure to STM at 1/3 and 1/4MIC 
(140)
NA NA
M. tb
mmpL5 was upregulated (>10-fold) after 
12 hours of RIF exposure in an micro-array 
analysis. Results could not be confirmed 
with qRT-PCR (145)
NA NA
Rv2942 
(mmpL7) 
M. tb
mmpL7 was upregulated after in 
vitro induced INH resistance. Strains 
demonstrated higher efflux capacity, 
as measured by ethidium bromide 
accumulation. Effects were counteracted by 
EPIs (124)
Ethidium 
bromide 
uptake 
Thiori-
dazine, 
chlorpro-
mazine, 
VPM
M. tb
Following exposure to RIF, mmpL7 was 
upregulated in only 1/4 MDR-TB isolates 
(170)
NA NA
M. 
smegmatis
mmpL7 overexpression increased the MIC 
for INH and ethionamide >16- fold and 
4-fold, respectively. Susceptibilities to RIF, 
ETH, ofloxacin, ciprofloxacin, tetracycline, 
ethidium bromide and doxorubicin were 
unaffected. RES and CCCP reduced INH 
resistance. Accumulation of radio-labeled 
INH was approximately 65% lower in cells 
expressing mmpL7, which was counteracted 
by RES (149)
Radio-
labeled 
isoniazid 
accumu-
lation
RES and 
CCCP
M. tb
Drug susceptibilities of the mmpL 7 mutant, 
plus of the 10 other mmpL mutants, to a 
broad spectrum of agents, such as INH, 
ETH, RIF, PYR and STM were unaltered. 
Inactivation of MmpL7, but also MmpL4, 
MmpL8 and MmpL11 increased C57BL/6 
mice survival. However, only mmpL4 
and mmpL7 were essential for normal 
replication during the active growth phase 
of the murine tuberculosis model (149, 161) 
NA NA
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Genes 
Family 
(126-128)
Bacterium Evidence type Efflux Inhibitor
Rv2942 
(mmpL7)
M. tb
Was >2-fold upregulated in 3/7 MDR/
XDR-TB strains following exposure to INH 
compared to not exposed. Was upregulated 
>2-fold in 1/5 MDR/XDR-TB strains after 
exposure to RIF. Upregulation also occurred 
inside macrophages upon exposure to 
INH. MDR and XDR strains showed higher 
levels of ethidium bromide accumulation 
in presence of inhibitors compared to INH 
monoresistant strains. (144)
Ethidium 
bromide 
accumu-
lation
VPM, 
thiori-
dazine, 
chlorpro-
mazine, 
flupen-
thixol
M. tb
mmpL7 was upregulated (>4-fold) in a 
RIF/INH/ofloxacin resistant strain, but only 
after exposure to ofloxacin and not to RIF 
or INH. The same strain was increased 
in susceptibility (16- to 32-fold) after 
combining RIF (and not INH or ofloxacin) 
with EPIs, such as VPM, thioridazine or 
chlorpromazine. Expression of mmpL7 was 
also upregulated (>90-fold) in another 
INH/RIF resistant strain after exposure to 
INH or RIF. Susceptibility of this strain could 
be increased 2- to 4-fold after combining 
RIF (and not INH) with VPM, thioridazine 
or chlorpromazine. Ethidium bromide 
accumulation in both MDR-TB strains could 
be reduced by addition of VPM  (171)
Ethidium 
bromide 
accumu-
lation
VPM
M. tb
Expression levels of all tested efflux pumps 
were significantly higher, including mmpL7 
>2-fold, in clinical (drug sensitive and 
MDR-TB) strains compared to reference 
strains, with also a lower sensitivity to  STM 
and RIF (139)
NA NA
M. tb
Was upregulated (>3-fold) in 3/3 INH 
induced M. tb strains. VPM promoted at 
least a 4-fold reduction of the INH MIC in 
the induced strains. Moreover, it caused 
the reversal of resistance to INH to a level 
similar as the WT (118) 
NA VPM
ABC, ATP-binding cassette; AMK, amikacin; BDQ, bedaquiline; CCCP, cyanide-m-chlorophenyl-
hydrazone; CLF, clofazimine; EPI, efflux pump inhibitor; ETH, ethambutol; FQ, fluoroquinolone; INH, 
isoniazid; KAN, kanamycin; KO, knock-out; M. tb, Mycobacterium tuberculosis; MDR, multi-drug 
resistant; MFS, Major Facilitator Superfamily; MIC, minimum inhibitory concentration; PAβN, 
Phenylalanine-Arginine Beta-Naphthylamide; PYR, pyrazinamide; RIF, rifampicin; STM, streptomycin; 
TPP, tetraphenylphosphonium; WT, wild type
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Secondly, from Table 1 it is evident that limited mechanistic evidence is available to 
support the clinical promise of targeted efflux pump inhibition of M. tuberculosis 
transporters. In general, many studies researching efflux pump inhibition consist of in 
vitro screening for synergistic antimycobacterial activity of EPIs combined with novel, 
first- or second-line TB drugs (118, 130, 131, 134, 146, 152, 156-160, 170, 171, 175, 178-191) 
against M. tuberculosis bacterial isolates that are either wild type, antibiotic resistant, 
knock-outs or overexpressing transporters. These studies report generic effects on drug 
susceptibility or efflux pump model substrate uptake. However, reported changes in 
antibiotic susceptibility and compound accumulation may also be caused by alterations 
in cell wall permeability, toxicity caused by exposure to a second drug and changes in 
efflux pump-associated bacterial homeostasis. There appears to be a missing causal 
link between transporter upregulation, elevated antibiotic efflux and evidence of 
increased cellular drug concentrations due to EPIs. Striking examples are presented 
in Table 1: EPIs have often been applied without considering its target, i.e. classic ABC 
transporter inhibitors were used to inhibit secondary transporters, and vice versa. 
Furthermore, only a limited number of studies showed reduced antibiotic resistance 
together with increased drug concentrations after adding EPIs, and all these studies 
were performed in M. smegmatis (128, 147, 149-152), M. bovis (155) or Escherichia coli 
(147) overexpressing TB transporter genes. The few studies that did report intracellular 
drug concentrations in M. tuberculosis in the presence and absence of efflux inhibitors 
failed to detect differences in drug accumulation (86) or could not clearly correlate 
increased drug accumulation in the presence of EPIs with enhanced drug susceptibility 
(185). 
Thirdly, to our knowledge no substrates of M. tuberculosis efflux pumps have been 
identified according to the standards set for human transporter substrates, as defined by 
Giacomini et al. (2010) (13), with validated overexpression models and transport studies. 
Such experimental data is hard to gather, considering that uptake by slow-growing 
mycobacteria is time-consuming (192) and/or functional substrate uptake studies 
have not been reported for M. tuberculosis. Furthermore, the interpretation of uptake 
experiments is complicated by a high degree of surface-adsorption, especially in case 
of antibiotics, the alleged substrates of bacterial efflux pumps (148). Therefore, transport 
capacity is often modeled in M. tuberculosis with the use of eukaryotic ABC transporter 
model substrates that are fluorescent and easy to track, such as ethidium bromide 
(118, 124, 134, 144, 148, 156, 157, 171, 184, 189). Only after identifying M. tuberculosis 
transporter (drug) substrates, the next step can be to add specific EPIs and assess the 
effects on actual drug transport. Such data would directly support the hypothesis that 
EPIs can enhance drug activity by increasing intracellular drug accumulation and would 
underline their clinical promise.
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Fourthly, only few in vitro data have been verified in murine efficacy models (161, 170, 
193-198), even though it has been demonstrated that drug-treated mice can display 
a very distinct phenotype due to host-pathogen specific interactions (194). A final 
challenge is the extrapolation of rodent studies to humans, considering the differences 
in substrate affinity, transporter abundance and capacity (78, 79) and the lack of 
mechanistic information a rodent model provides.
Overall, we conclude that the balance between transporter upregulation, cellular drug 
transport, transporter inhibition and the effects on drug resistance is not yet clearly 
understood, and further studies are required to elucidate the mechanistic interactions 
involved. For now the clinical importance of mycobacterial efflux pump-induced 
resistance and the possible role of highly specific EPIs remains unresolved. Further 
research is necessary to assess the intramycobacterial concentration-response relation, 
which will aid in drawing conclusions on the role of efflux pumps in conferring resistance. 
Finally, only after having addressed the potential problems caused by the overlap in 
(interspecies) pump and/or inhibitor substrate specificities, we can draw conclusions on 
the feasibility of efflux mechanisms as a therapeutic target.
Concluding remarks
In this review we evaluated the role of efflux pumps in TB pharmacology. The transporters 
of interest are located at pharmacokinetic barriers (intestines, liver and kidney), at 
pharmacological sanctuary sites (brain and CSF) and at the infection site itself, namely 
M. tuberculosis residing within macrophages. We conclude that membrane transporters 
are important in the TB drug PK-PD relation and can negatively influence TB treatment 
by reducing exposure to suboptimal concentrations at multiple levels (Figure 1).  
Several limitations to efflux pump inhibition as a treatment strategy can be brought 
forward. Firstly, drug transport can not be modulated specifically. For example, 
inhibition at the BBB may also allow other (toxic) transporter substrates to enter the 
brain. In addition, transporters will not only be inhibited at the site of interest, but also 
at other tissues that express the same transporter, resulting in an increased risk of 
transporter-mediated DDIs. Furthermore, currently available EPIs cannot target drug 
transporters in a specific fashion. For example, cyclosporine A inhibits P-gp, but also 
BCRP, MRP1 and MRP 2 (199-201), and while tariquidar was developed as a specific P-gp 
inhibitor, it is also a substrate and inhibitor of BCRP, though at higher concentrations 
(202). In addition, when considering the phylogenetic tree (Figure 4), we anticipate that 
inhibitors of M. tuberculosis transporters interact with human transporters, and vice 
versa. 
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Another challenge is presented by the difficulty of dosing EPIs to reach full inhibition 
at effective, but safe concentrations (22, 81). For example, cyclosporine A caused only 
small changes in [11C]verapamil brain entry, but the use of higher doses is limited by 
safety concerns. In contrast, tariquidar seems relatively well tolerated at doses required 
to inhibit P-gp at the BBB (82). Even though these limitations seem significant, one 
should also consider that patients suffering from TB meningitis or MDR-TB face a high 
mortality rate with the current treatment options, making treatment side-effects more 
acceptable. The slow development of novel TB drugs in the last few decades further 
underline the promise of efflux pump inhibition, as this forms an enhancement of 
already available treatment.
Overall, efflux pump inhibition may provide a valuable tool to enhance the effectiveness 
of currently available drugs. However, some key knowledge gaps need to be addressed 
before EPIs can be applied in TB treatment. Firstly, at the pharmacokinetic level it is 
largely unknown for which transporters TB drugs are substrates. This information is 
indispensable for 1) predicting or explaining unresolved transporter-mediated DDIs; 2) 
enhancing TB drug exposure in macrophages sheltering M. tuberculosis; or 3) increasing 
drug penetration in the brains of TB meningitis patients. In this regard, the influence 
of transporter single nucleotide polymorphisms (SNPs) should also be investigated, as 
genetic variation in transporters may potentially explain part of the high interindividual 
variation observed in TB drug pharmacokinetics (116, 203-205). Secondly, for the use of 
EPIs at the M. tuberculosis level, more data is necessary to support the relation between 
transporter upregulation and transporter-mediated resistance; next to identification 
of transporter substrates according to the standards set for human substrates, with 
validated overexpression models and transport studies (13).  Only after addressing 
these matters, issues such as overlap in pump and/or inhibitor substrate specificities can 
be assessed with a solid mechanistic understanding in animal and/or clinical studies. 
With current knowledge, adding EPIs to murine TB efficacy models still equals adding 
drugs to a black box of which it is unknown how it will handle the compounds, how 
it may explain the observed outcome and, most importantly, how it can be translated 
to the human situation. Finally, a combination of in vivo, in vitro and clinical data can 
form valuable input for a TB-specific PBPK model. Such a model would allow for the 
integration of transporter data at multiple levels and enable quantitative pharmacokinetic 
predictions in the relevant compartments involved, such as M. tuberculosis, infected 
macrophages, the brain and/or CSF and various other organs. 
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Abstract
Introduction 
Inhibitors of transporter-mediated resistance mechanisms are currently under 
investigation for their use as adjuvant to current TB regimens, which would circumvent 
the necessity to develop new antibiotics. In this study, we aimed to characterize 
ATP-binding cassette (ABC) transporters that confer antibiotic resistance to M. 
tuberculosis and to establish an in vitro system to screen for effective mycobacterial 
efflux pump inhibitors (EPIs). We selected Rv1747, Rv0194 and Rv1819c as candidate 
transporter genes, because they are not organized in operons, and have different 
protein organization, probably representing different classes of ABC transporter activity 
and function.
Methods
M. tuberculosis candidate pumps were cloned using Gateway technology for expression 
in BL21-AI E. coli and in Human Embryonic Kidney 293 (HEK293) cells. Membrane 
vesicles were isolated from transporter-overexpressing cells and vesicular transport 
assays were performed to measure ATP-dependent uptake of ABC transporter probe 
substrates and to screen for EPIs. 
Results 
All three candidate efflux pumps were successfully expressed in E. coli, while only 
Rv0194 and Rv1819c could be expressed in HEK293 cells. Although expression levels 
seemed lower in HEK293-derived membrane vesicles, we found that the fluorescent 
molecule ‘Fluo_P-gp’, a novel human P-glycoprotein (P-gp) substrate, was associated 
with increased ATP-dependent transport by Rv0194 in HEK293 vesicles (p=0.079, 
n=3). This transport was reduced by the known P-gp inhibitors verapamil, SQ109 and 
thioridazine, but not by the MRP inhibitor probenecid. We were not able to detect 
functional activity for any of the transporters in BL21-AI vesicles.
Discussion
We identified Rv0194 as a potential drug efflux pump in M. tuberculosis. For future 
research we propose to optimize protein expression in the HEK293 cell model to 
further characterize Rv0194 transport kinetics, study transport of TB drugs, and evaluate 
specific EPIs. 
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Introduction
Traditionally, mycobacterial drug resistance has been ascribed to spontaneous 
genetic mutations, altering drug targets or prodrug-activating enzymes. This includes 
resistance to most routine tuberculosis (TB) drugs, such as rifampicin (substitutions 
in the drug target RNA polymerase β subunit (rpoB)), isoniazid (substitutions in the 
isoniazid activating enzyme catalase-peroxidase (katG), and the drug target acyl carrier 
protein reductase (inhA)), and streptomycin (substitutions in drug targets ribosomal 
S12 protein (rspL), and 16S rRNA (rrs)) (1-4). Mutant bacteria can be further selected by 
exposure to monotherapy, low antibiotic doses due to inadequate prescription, poor 
patient compliance, and interpatient pharmacokinetic variability (5, 6). 
However, resistance or adaptation cannot always be explained by classic gene mutations 
(7). For example, while over 90% of rifampicin-resistant Mycobacterium tuberculosis (M. 
tuberculosis) isolates have at least one mutation in rpoB, approximately 5% of which 
have no mutation and are believed to acquire resistance by alternative mechanisms 
(3, 8). In addition, 20-30% of isoniazid resistant isolates do not bear mutations in 
any of the genes associated with resistance (9). Alternative resistance mechanisms 
include upregulation of drug efflux systems located in the cytoplasmic membrane (10), 
decreased cell wall permeability and induction of drug-modifying and drug-inactivating 
enzymes (3, 11). 
From literature it is evident that bacterial efflux pumps play an important role in vital 
processes, such as homeostasis, response to stress conditions, lipid transport, cell wall 
maintenance and virulence (12-20). Bacteria also use efflux systems for their protection 
against potentially toxic compounds, such as antibiotics (2, 10). It is hypothesized 
that efflux pumps extrude TB drugs, thereby decreasing drug concentrations in the 
mycobacterium to sub-inhibitory levels and contributing to TB resistance (2, 3, 21-23). 
Enhanced efflux pump activity may explain different aspects of drug resistance 
in tuberculosis: (1) intrinsic resistance, (2) acquired multidrug resistance, and (3) 
antibiotic-induced tolerance (24). For example, conditions of suboptimal exposure 
to antibiotics and increased mycobacterial efflux pump expression enhance the 
chances of acquiring and accumulating genetic mutations, conferring to higher levels 
of drug resistance and even multidrug resistance (MDR) (21, 25-27). Furthermore, 
drug-induced efflux pumps may have overlapping substrate specificities with other 
TB drugs, explaining cross-resistance to multiple drugs (21). Recent in vitro and in 
vivo studies have explored strategies to reverse efflux pump-mediated resistance by 
co-administration of efflux pump inhibitors (EPIs), which could partially restore drug 
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susceptibility (chapter 2). This may have significant clinical implications, especially 
in management of multidrug-resistant TB (MDR-TB), where treatment options are 
extremely limited.
ATP-binding cassette (ABC) transporters are known to be involved in drug efflux in 
many species. In eukaryotes and prokaryotes ABC proteins consist of two hydrophobic 
membrane spanning domains (MSD) associated with two cytoplasmic nucleotide 
binding domains (NBD) (28). While eukaryotic ABC transporters are usually composed 
of a large multi-domain protein encoded by a single gene (28), M. tuberculosis expresses 
the transporter domains as independent polypeptides encoded by genes organized in 
operon(s) or clustered in one DNA region. Rv1747, Rv0194 and Rv1819c are the only 
three ABC transporter genes in M. tuberculosis that are not located in operons, and are 
considered ‘unclustered’ (28).
ABC transporters extrude their substrates at the expense of ATP. High sequence 
homology in the ATP-binding domains (located in the NBDs), allows identification and 
classification of members of the ABC transporter family. In the previous chapter we 
classified human ABC transporters together with M. tuberculosis ABC transporters, 
according to their common evolutionary origin that was based on sequence similarity 
(chapter2, Figure 4). Because human ABCB (ABCB1 or P-glycoprotein (P-gp), and 
ABCB11 or BSEP), ABCG (ABCG2 or BCRP) and ABCC (MRP1-5) family members are 
mostly involved in drug transport, the M. tuberculosis ABC transporters allocated to 
these clades would be most promising to investigate for their role in drug resistance 
and targeted efflux pump inhibition (29). 
Interestingly, the unclustered genes Rv1747, Rv0194, and Rv1819c display different 
protein organizations. Rv0194 encodes two NBDs and two MSDs fused together, a 
so-called full transporter. Rv1819c and rv1747 encode half transporters, containing 
one MSD fused to one NBD. Both are probably dimeric exporters, i.e. a functional 
complex consisting of two protein molecules. The shared common evolutionary 
origin with specific human ABC transporter families, allows these transporters to be 
classified as ABCB (Rv0194), ABCD (Rv1819c) and ABCG (Rv1747) family members. 
Their protein organization indeed suggests that these M. tuberculosis transporters 
are congruent to their human counterparts, namely full transporters (ABCB1 or P-gp; 
MSD-NBD-MSD-NBD), half transporters (ABCD; MSD-NBD) or reverse half transporters 
(ABCG2 or BCRP; NBD-MSD) (28, 30-32) (Figure 1). 
Inhibitors of M. tuberculosis drug efflux pumps and transporter-mediated resistance 
may be used as adjuvant to current TB regimens, which would circumvent the necessity 
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to develop new antibiotics. In this study, we aimed to identify ABC transporter proteins 
that confer antibiotic resistance to M. tuberculosis and to establish an in vitro system, 
based on expression in Escherichia coli (E. coli) and in Human Embryonic Kidney 
293 (HEK293) cells, that enables screening for effective efflux pump inhibitors. We 
selected Rv1747, Rv0194 and Rv1819c as candidate pumps for expression in E. coli and 
HEK293 cells, because cloning and expression of unclustered genes are practically less 
challenging, and because the three genes have different protein organization and 
probably represent different classes of ABC transporter activity and function.
Figure 1. Schematic overview of the different structures of selected M. tuberculosis ABC 
transporters.
Full structure represents the ABC transporter gene that encodes two TMDs and two NBDs; Half 
structure represents the ABC transporter gene that encodes one TMD and one NBD (28, 32).
MSD, membrane spanning domain; NBD, nucleotide binding domain
Methods
Materials
Genomic M. tuberculosis DNA (H37Rv laboratory strain) was kindly provided by the 
department of Medical Microbiology (Radboudumc, Nijmegen, the Netherlands). All 
primers were produced by Biolegio (Nijmegen, The Netherlands). The Bac-to-Bac 
Gateway system was purchased from Invitrogen (Breda, The Netherlands). Adenosine 
monophosphate (AMP), adenosine triphosphate (ATP), magnesium chloride (MgCl2), 
probenecid, and verapamil were purchased from Sigma-Aldrich. SQ109 was kindly 
provided by Sequella Inc. (Rockville, MD, USA). MultiScreenHTS-vacuum manifold 
filtration device and MultiscreenHTS 96-wells glass fiber filter plates were obtained from 
Millipore (Etten-Leur, The Netherlands). 
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Amplification and cloning of M. tuberculosis ABC transporters
PCR was performed on genomic DNA (H37Rv) to create attB-flanked PCR products 
for Gateway cloning (Table 1). For expression in HEK293, the forward primer was 
also designed to contain a Kozak sequence (ribosomal binding site for translation 
initiation in eukaryotes) and a hexahistidine tag (His-tag for protein detection). In 
the PCR reaction, PfuUltra II fusion HS DNA polymerase (Agilent technologies, Santa 
Clara, CA, United States) with the supplied reaction buffer, and dNTP mix (12.5 mM) 
(Invitrogen, Breda, the Netherlands), each completed to 50 µL end volume, were used. 
PCR amplification consisted of initial denaturation at 95°C (2 minutes); followed by 40 
cycles of denaturation at 95°C (20 seconds), annealing at 54-55 °C (Rv0194) or 58-59°C 
(Rv1747 and Rv1819c) (20 seconds), and elongation at 72°C (2 minutes); and ending 
with a final elongation step at 72 °C (5 minutes). 
Table 1. Primer pairs used to amplify ABC transporters of M. tuberculosis for expression in E. coli 
and HEK293.
Name Sequence (5→3) Tm 
Rv1747-BL21AI-FW
5- GGGGACAAGTTTGTACAAAAAAGCAGGCTTC|
ATGCCGATGAGCCAACCAGC -3 62.5 ᵒC
Rv1747-HEK-FW
5- GGGGACAAGTTTGTACAAAAAAGCAGGCTTC|GCCACC|
ATGCATCACCATCACCATCAC|GGAGGAGGA|
GTGCCGATGAGCCAACCAGC -3
64.6 ᵒC
Rv1747-RV
5- GGGGACCACTTTGTACAAGAAAGCTGGGTA|
CTAGCACGCCTTGAGGCGAATC -3
65.8 ᵒC
Rv0194-BL21AI-FW
5- GGGGACAAGTTTGTACAAAAAAGCAGGCTTC|
ATGCGCACGAATTGCTGG -3 56.3 ᵒC
Rv0194-HEK-FW
5- GGGGACAAGTTTGTACAAAAAAGCAGGCTTC|GCCACC|
ATGCATCACCATCACCATCAC|GGAGGAGGA|
ATGCGCACGAATTGCTGG -3
56.3 ᵒC
Rv0194-RV
5- GGGGACCACTTTGTACAAGAAAGCTGGGTA|
CTATGCGTCAATACATTGAAGCTG -3
62.0 ᵒC
Rv1819c-BL21AI-FW
5- GGGGACAAGTTTGTACAAAAAAGCAGGCTTC|
TTGGGCCCGAAATTGTTTAAGC -3 60.1 ᵒC
Rv1819c-HEK-FW
5- GGGGACAAGTTTGTACAAAAAAGCAGGCTTC|GCCACC|
ATGCATCACCATCACCATCAC|GGAGGAGGA|
TTGGGCCCGAAATTGTTTAAGC -3
60.1 ᵒC
Rv1819c-RV
5- GGGGACCACTTTGTACAAGAAAGCTGGGTA|
TTACACTTCGGCGGGCGC -3
60.8 ᵒC
BL21-AI forward primer sequence: attB1 | gene-specific nucleotides
HEK293 forward primer sequence: attB1 | Kozak | hexameric His-tag | linker | gene-specific nucleotides 
Transcript translation is initiated in HEK293 with the His-tag ATG start codon, depicted in italic. 
Reverse primers: attB2 | gene-specific nucleotides
FW, forward primer; RV, reverse primer; Tm, melting temperature for the gene specific nucleotides 
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PCR products were cloned into pDONR-221 donor vectors using Gateway BP 
clonase (Invitrogen). Subsequently, vector DNA was amplified in competent DH5α 
E. coli (Invitrogen) and isolated with GenElute plasmid mini prep kit (Zwijndrecht, the 
Netherlands). Entry clones were sequenced at the Radboud University Medical Center 
Sequencing Facility (Nijmegen, the Netherlands) using a 3730(XL) DNA sequencer. 
Genes of interest were transferred from selected entry clones with the gateway LR 
reaction (Invitrogen) into pDEST17 destination vectors (Invitrogen) behind an inducible 
T7 promotor and an N-terminal fusion His-tag (expression in E. coli), or into a VSV-G 
improved pFastBacDual vector for mammalian cell transduction containing a CMV 
promotor for expression in HEK293 (33).
Heterologous expression in BL21-AI and HEK293 and vesicle preparation
For expression in bacteria, pDEST17 constructs containing transporter genes and 
enhanced yellow fluorescent protein (EYFP) (cytosolic protein, negative control) were 
transformed in BL21-AI One Shot Chemically Competent E. coli (Invitrogen), designed 
for tight regulation and strong expression of toxic proteins. Transformed bacteria 
were cultured to an OD600 of 0.4-0.6 in the presence of ampicillin (selection marker) 
and glucose (0.1%), after which they were induced for protein expression with 1 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) and 0.2% arabinose. High shear passage 
through a 100-μm opening under 1000 bar pressure was used to prepare membrane 
vesicles.
For expression in HEK293, baculoviruses containing the transporter genes of interest 
and Enhanced Yellow Fluorescent Protein (EYFP, negative control) were produced as 
described in the Bac-to-Bac manual. HEK293 cells were transduced with baculoviruses 
as reported previously (33), with slight modifications: cells were cultured in 875-cm2 
flasks until 40% confluency, after which baculovirus (diluted seven times in culture 
medium) and sodium butyrate (2 mM final concentration) were added immediately. 
Membrane vesicles were prepared from the transporter overexpressing HEK293 cells 
by high-shear passage through a 100-μm opening (under 200 bar pressure). 
The 100,000 g membrane fraction of crude lysates was homogenized in ice-cold TS buffer 
(10 mM Tris-HEPES and 250 mM sucrose, pH 7.4). Protein concentration of BL21-AI and 
HEK293 vesicles was determined using the Bio-Rad protein assay (Bio-Rad laboratories 
Inc, Veenendaal, the Netherlands). Vesicles were aliquoted at concentrations of 2.5 mg/
mL, snap-frozen in liquid nitrogen, and stored at -80°C. 
Protein expression was verified by Western blotting. Membrane vesicle preparations 
of M. tuberculosis transporters (15 µg total protein of BL21-AI vesicles and 50 µg 
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protein of HEK293 vesicles), were solubilized in SDS sample buffer and separated on 
SDS gels containing 7.5% acrylamide according to Laemmli (1970) (34), followed by 
blotting on nitrocellulose membrane using the iBlot dry blotting system (Invitrogen). 
Mouse monoclonal anti-His-tag antibody (Abcam, Cambridge, United Kingdom) was 
used to detect His-tagged transporters. As a secondary antibody, the fluorescent 
goat-anti-mouse IRDye TM 800 (Rockland inc, Limerick, PA, United States) was applied. 
Signals were visualized using Odyssey infrared imaging system (LI-COR, Bad homburg, 
Germany).
Screening for transporter substrates and inhibitors 
A panel of 40 ABC transporter fluorescent probe substrates was tested to assess 
transport activity in HEK293 vesicles. Probe substrates were provided by the Centre for 
Drug Research, Faculty of Pharmacy, University of Helsinki (Finland) and were substrates 
for human MRP or MDR family members (data not shown). Screening for transport 
activity was performed with transport assays as follows: 17.5 µg of membrane vesicle 
protein in TS buffer (10 mM Tris-HEPES and 250 mM sucrose, pH 7.4) were incubated 
for 10 minutes at 37 ᵒC with reaction mixtures containing probe substrates (5 or 10 
µM), 4 mM AMP (negative control) or ATP and 10 mM MgCl2, in a total volume of 30 
µL per well. EYFP vesicles (cytosolic protein) were included as extra negative control, 
to correct for active background transport by endogenously expressed transporters. 
The vesicle reaction mixtures were transferred onto glass fiber 96-wells filter plates that 
had been preincubated with TS buffer. To separate the vesicles from the incubation 
solution, samples were filtered using a vacuum manifold device, after which the filters 
were washed twice with 200 µL TS buffer. Vesicles were extracted by incubation with 
100 µL 0.1 M NaOH for 10 minutes. Depending on the probe substrate tested, mixtures 
were not acidified prior fluorescence detection, or acidified using 100 or 200 µL 0.1 M 
HCl to enhance fluorescence. Fluorescence was quantified with the Victor X3 multilabel 
platereader (Perkin-Elmer, Groningen, The Netherlands) or in single cuvettes (500 µL 
total volume supplemented by Milli-Q) with an UV-Vis spectrophotometer (Shimadzu, 
‘s Hertogenbosch, Netherlands).
To assess the effect of efflux pump inhibitors (EPIs) on transport function, uptake 
experiments were performed as described (substrate concentration 13 µM), with addition 
of verapamil (P-gp inhibitor(35)), SQ109 and thioridazine (broad range inhibitors (36), 
of which SQ109 is also a novel TB drug candidate (37)) and probenecid (MRP inhibitor 
(35)) to a final concentration of 140 µM. Fluorescence was quantified after acidification 
(100 µL of 0.1 M HCl) in single cuvettes using UV-Vis spectrophotometry.
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Data analysis
After subtraction of aspecific background fluorescence in the presence of AMP, mean 
values of ATP-dependent transport vesicular transport were expressed as fluorescent 
arbitrary unit (AU) per mg protein per minute. For the inhibition studies, mean values of 
ATP-dependent transport in presence of EPIs were expressed as percentage transport 
relative to that of Rv0194 expressing vesicles in solvent, namely milli-Q (probenecid, 
thioridazine and verapamil), and DMSO (1%) (SQ109). 
All data are presented as mean ± standard error of the mean (SEM). Differences in 
transport were tested using a one-way analysis of variance (ANOVA), followed by 
Dunnett’s multiple comparison test using GraphPad Prism version 5.03 (GraphPad 
Software Inc., San Diego, CA, USA).
Results
Heterologous expression in BL21-AI and HEK293 cells
All three candidate transporter genes were successfully cloned into the E. coli expression 
vector pDEST17, but only two ABC transporters (Rv0194 and Rv1819c) could be cloned 
into the mammalian baculovirus expression vector. Western blot analysis of membrane 
vesicles prepared from BL21 AI and HEK293 cells overexpressing these transporters 
showed seemingly higher expression levels in BL21-AI (Figure 2). Interestingly, RV1819c 
was higher expressed than Rv0194 in HEK293, while this was the opposite in BL21-AI 
(Figure 2). Finally, the His-tag specific protein bands appeared at somewhat lower sizes 
in HEK293 compared to BL21-AI.
Screening for transporter substrates 
Transporter activity of membrane vesicles obtained from HEK293 cells overexpressing 
Rv0194 and Rv1819c was tested for forty fluorescent probe substrates of human ABC 
transporters. The six probe substrates resulting in the largest differences in uptake 
between AMP vs ATP conditions were further investigated with another independent 
vesicle batch (new transduction, new virus). This procedure resulted in one lead 
substrate, which we named Fluo_P-gp, as this fluorescent molecule also demonstrated 
to be a substrate of human P-gp (data not shown). The molecule is a positively charged 
organic compound, like most of the P-gp substrates that are lipophilic or amphiphilic 
(polyvalent) organic cations (38, 39). Figure 3 shows the results of Fluo_P-gp uptake 
into membrane vesicles. Although the ATP-dependent fluorescent signal was definitely 
higher for Rv0194 (but not for Rv1819c) containing vesicles, the results did not reach 
statistical significance as compared to the EYFP control (p=0.079). 
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We were not able to detect functional activity for any of the transporters in BL21-AI 
vesicles (data not shown).
Figure 2. Western blot analysis of membrane vesicle batches obtained from BL21-AI (E. coli) and 
HEK293 cells, overexpressing Rv1747-His (15 µg of protein loaded), Rv0194-His (15 and 50 µg 
loaded, respectively), and Rv1819c-His (15 and 50 µg loaded, respectively). 
Predicted protein band sizes are 92 kDa, 129 kDa and 71 kDa according to http://tuberculist.epfl.
ch, respectively. Bands of overexpressed transporters are indicated by arrows. Of the His-positive 
controls, P-gp (50 µg loaded) and MRP4 (12 and 15 µg loaded, respectively) predicted band sizes are 
141 kDa and 150 kDa, respectively.
Figure 3. ATP-dependent transport of Fluo_P-gp into membrane vesicles overexpressing Rv1819c 
and Rv0194 in comparison to control vesicles (EYFP).
After subtraction of background fluorescence in the presence of AMP, mean values of ATP-dependent 
transport were expressed as fluorescent arbitrary unit (AU) per mg protein per minute and presented as 
mean ± SEM. Differences with EYFP control were evaluated with one-way ANOVA, post-hoc Dunnett’s 
test (p-value <0.05). Data were pooled from three independent experiments and vesicle batches, each 
performed in duplicate.
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Screening for efflux pump inhibitors 
To assess the effect of EPIs on Rv0194 function, transport studies were performed with 
Fluo_P-gp alongside verapamil, SQ109, thioridazine, and probenecid. Figure 4 shows 
that indeed the model P-gp inhibitors reduced ATP-dependent transport in Rv0194 
vesicles. In addition, they also decreased ATP-dependent transport in Rv1819c vesicles 
(negative transport control), thus inhibiting transport by endogenously expressed 
transporters. The model MRP inhibitor probenecid did not affect ATP-dependent 
uptake into Rv0194 vesicles. 
Figure 4. Effect of efflux pump inhibitors (EPIs) (100 µM) on the ATP-dependent transport of 
Fluo_P-gp into membrane vesicles overexpressing Rv0194.
The inhibitory effect of EPIs (100 µM) on (AMP-corrected) transport of Rv0194 was assessed. Transport 
was expressed in % of the solvent and presented as mean ± SEM. Rv1819c (no Fluo_P-gp transport) 
served as control for Rv0194 transport. All normalized data points from two independent experiments 
and vesicle batches (performed in triplicate) were pooled. 
MQ, Milli-Q; PBC, probenecid; TRD, thioridazine; VPM, verapamil; SQ, SQ109 
Discussion
This study aimed to identify ABC proteins involved in transporter-mediated drug 
resistance and to develop an in vitro screen that can test the potency of mycobacterial 
efflux pump inhibitors (EPIs). After having identified Rv1747, Rv0194 and Rv1819c as 
candidate transporter genes, all three were cloned and expressed in BL21-AI E. coli, 
while only Rv0194 and Rv1819c could be successfully cloned and expressed in HEK293. 
By screening a panel of human ABC transporter probe substrates we identified 
Fluo_P-gp as a substrate of Rv0194 in membrane vesicles derived from HEK293 cells, 
and transport activity was reduced by known P-gp inhibitors (verapamil, SQ109 and 
thioridazine), but not by the MRP inhibitor probenecid. 
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To our knowledge no substrates of M. tuberculosis efflux pumps have been identified 
according to the standards set for human transporter substrates, as defined by 
Giacomini et al. (2010) (40). HEK293 cells expressing membrane transporters and 
inside-out membrane vesicles prepared from these cells have been extensively used 
as an eukaryotic expression tool for recombinant proteins (41). Furthermore, it is one 
of the recommended techniques for the identification of transporter substrates and 
inhibitors (40), which is why we selected this expression system for our study. Data on 
expression of prokaryotic proteins in mammalian systems are limited (42, 43), and we 
are unaware of any publication concerning heterologous expression of M. tuberculosis 
proteins in mammalian or human cell lines. 
Expression levels of M. tuberculosis transporters in HEK293 cells were relatively low in 
our study. Recombinant protein expression in bacteria, such as E. coli, is considered 
the most successful strategy for high protein yields. Furthermore, one may expect that 
expression of a mycobacterial transporter in a prokaryotic host is the best match to 
ensure protein with the proper post-translational modifications. Eukaryotic translation 
deviations (protein synthesis, post-translational modifications, protein cleavage 
and splicing, and/or differences in molecule charges due to changes in amino acid 
composition) may explain the lower than expected protein band sizes observed in 
HEK293 membrane vesicles. Irrespective of these theoretical considerations, we were 
not able to detect specific transport activity in BL21-AI membrane vesicles (data not 
shown), possibly because the applied vesicular transport is not optimized for transport 
studies in E. coli-derived membrane vesicles. 
The Rv0194 transporter protein, consisting of two NBDs and two MSDs, possesses the 
four typical domains of an ABC transporter, fused and expressed in one single protein, 
an arrangement mostly encountered in ABC transporters from higher eukaryotes (28), 
and more specifically in human P-gp (32). Danilchanka et al. (2008) reported previously 
that overexpression of Rv0194 in M. smegmatis (a surrogate in vitro model for M. 
tuberculosis) increased the minimum inhibitory concentration (MIC) for ampicillin, 
vancomycin, novobiocin, and erythromycin. Expression also reduced ethidium bromide 
accumulation, which reached wild-type levels again upon addition of the EPI reserpine. 
Furthermore, ethidium bromide-induced growth reduction in wild-type M. smegmatis 
was not observed in Rv0194-overexpressing bacteria (44). Finally, studies investigating 
the M. tuberculosis genome identified mutations in the Rv0194 gene in TB clinical 
isolates exhibiting extensive drug-resistance (45, 46). These results support the role 
of Rv0194 as possible drug efflux pump in M. tuberculosis and underline its promise as 
target for efflux pump inhibition and adjuvant TB therapy.
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Off-target human transporter inhibition by EPIs presents a significant limitation to the 
application of inhibition of mycobacterial efflux mechanisms as adjuvant to TB therapy. 
Via this pathway EPIs may cause unwanted drug-drug interactions (DDIs) when 
co-administered with drug substrates of human transporters. Many currently available 
EPIs are known to target more than one transporter. For example, cyclosporine 
A inhibits P-gp, but also BCRP, MRP1 and MRP 2 (47-49), and while tariquidar was 
developed as a specific P-gp inhibitor, it is also a substrate and inhibitor of BCRP, though 
at higher concentrations (50). In the following chapter (chapter 4) we will show the 
results of a study in which we assessed the in vitro inhibitory potential of currently used 
first- and second-line TB drugs and of proposed EPIs on the major human ABC drug 
transporters, namely P-gp, BCRP, BSEP and MRP1-5 (36). We also investigated the EPI 
SQ109 in chapter 4, which is of special interest considering its status as a new TB drug 
candidate (37) and known inhibitor of MmpL3, a M. tuberculosis transporter involved 
in cell wall assembly (51).
All proteins in this study were expressed with a His-tag fused to the N-terminal side. We 
cannot exclude that the observed deviations in protein band sizes are due to His-tag 
detection of smaller parts of the protein or protein breakdown. Furthermore, the tag 
might also have interfered with transport activity, although protein activity is rarely 
affected because of the relatively small size and charge of the His-tag (52, 53). To 
overcome these issues we will also overexpress the transporters without fusion tag and 
may develop antibodies for transporter protein specific targeting, which is however a 
more time-consuming approach. 
Next to ABC transporters, other relevant transporter superfamilies have been identified 
in M. tuberculosis. Members from the Multidrug and Toxic compound Extrusion (MATE) 
family, the Major Facilitator Superfamily (MFS), the Small Multidrug Resistance (SMR) 
family, and the Resistance Nodulation Division (RND) superfamily (54) may contain 
interesting targets to be investigated in cellular and/or vesicular transport assays, as 
presented in this chapter.
To summarize, we identified Rv0194 as a potential drug efflux pump in M. tuberculosis. 
We were able to express Rv0194 in human HEK293 membrane vesicles and this was 
associated with increased ATP-dependent transport of a fluorescent P-gp probe 
substrate. Transport activity could be inhibited by known P-gp inhibitors (verapamil, 
SQ109 and thioridazine). Future research should be directed at optimizing protein 
expression in the HEK293 cell model to further characterize transport kinetics of Rv0194, 
and test transport of TB drugs that are known P-gp substrates, such as rifampicin 
and moxifloxacin (55, 56). These data would allow for better comparison of Rv0194 
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with human P-gp. Eventually, overexpression or knock-out of Rv0194 in M. tuberculosis 
itself may answer the question whether inhibition of Rv0194 results in increased drug 
accumulation and enhanced bacterial killing. Such functional substrate transport 
studies have not yet been reported for M. tuberculosis (chapter 2). 
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Abstract
Introduction 
Multiple-drug therapy for tuberculosis (TB) and TB-associated co-morbidity increase 
the likelihood of drug-drug interactions (DDIs). Inhibition of membrane transporters 
is an important mechanism underlying DDIs. In this study, we assessed the in vitro 
inhibitory potential of currently used first- and second-line TB drugs and of proposed 
mycobacterial efflux pump inhibitors (EPIs) on the major ABC transporters relevant to 
drug transport, namely P-gp, BCRP, BSEP and MRP1-5.
Methods 
Membrane vesicles isolated from transporter-overexpressing HEK293 cells were used 
to study the inhibitory action of TB drugs and EPIs on the transport of model substrates 
[3H]-NMQ (P-gp); [3H]-E1S (BCRP); [
3H]-TCA (BSEP); [3H]-E217βG (MRP1, 3 and 4) and 
[3H]-MTX (MRP2 and 5).
Results 
A strong inhibition (IC50 value <15 µM) was observed for clofazimine (P-gp, BCRP and 
MRP1), thioridazine (BCRP), timcodar (P-gp, BSEP and MRP1) and SQ109 (P-gp and 
BCRP). Rifampicin inhibited all transporters, but less potently. 
Conclusions 
Co-administration of clofazimine, thioridazine, timcodar, SQ109 and possibly rifampicin 
with drugs that are substrates for the inhibited transporters may lead to DDIs. The 
mycobacterial EPIs potently inhibited a wider range of human ABC transporters than 
previously reported. These vesicular transport data are especially valuable considering 
the current emphasis on development of TB drug regimens. 
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Introduction
Tuberculosis (TB) remains a prevalent global health problem. In 2013, an estimated 9.0 
million people developed active TB and 1.5 million died from the disease (1). Treatment 
of TB requires long and intensive combination drug therapy. The first-line regimen for 
drug-sensitive TB contains four drugs, namely rifampicin, isoniazid, pyrazinamide and 
ethambutol (2) (Table 1). For multidrug-resistant TB (MDR-TB), a range of second-line 
TB drugs are in use (Table 1), which are administered for longer periods, generally have 
less potency and are associated with more toxicity (3). In recent years, novel TB drugs 
have been developed (bedaquiline and delamanid) and available TB drugs are being 
repurposed or optimized as first-line TB drugs (e.g. high dose rifamycins, moxifloxacin 
and clofazimine). In addition, various new compounds are still being evaluated for 
treatment of both drug-sensitive and resistant TB (3, 4). Overall, in TB drug development 
the focus is on development of regimens rather than just single new TB drugs, and in 
this context, drug-drug interactions (DDIs) between available and (potential) new TB 
drugs need to be assessed.
Because TB is increasingly associated with co-morbidities, drug therapy is becoming 
even more complex. An estimated 1.1 million (13%) of the people who developed 
TB in 2013 were HIV-positive (1). In addition, the relative burden of type 2 diabetes 
mellitus (DM) to the TB epidemic is increasing, as the incidence of DM is rapidly rising 
in countries where TB is endemic and DM is a prominent risk factor for active TB (5). 
The concurrent use of antimycobacterial, antiretroviral, and antidiabetic drugs further 
increases the likelihood of DDIs to occur in this patient population (6). 
Inhibition of membrane transporter activity is one of the mechanisms known to result 
in relevant DDIs. In general, drugs need to cross multiple cellular barriers in order to 
reach their sites of action. Uptake and efflux via membrane transporters play a vital 
role in the passage across these barriers and, therefore, in the absorption, distribution 
and excretion of drugs. Efflux transporters also protect sanctuary sites such as brain 
and placenta against xenobiotics and increase their elimination via liver and kidney. 
Many transporters of the ATP binding cassette (ABC) transporter protein family are 
involved in the cellular efflux of drugs (7). ABC proteins are primary active transporters 
that mediate the translocation of substrates across the membrane at the expense of 
ATP hydrolysis. Interaction of a drug with such a transporter could alter the systemic or 
local disposition of other compounds that are substrates of the same transporter (8). 
Consequently, drug concentrations of the other substrate drug can be increased or 
decreased and the safety and efficacy of this drug may be at risk (8, 9). As an example for 
an interaction affecting systemic exposure, the antimycobacterial drug clarithromycin 
110
Chapter 4
(classified as a group V TB drug) has demonstrated to increase the oral bioavailability 
and reduce the nonglomerular renal clearance of digoxin, a P-glycoprotein (P-gp) 
substrate, probably by inhibiting intestinal and renal P-gp (10). This inhibitory effect 
has also been demonstrated in an in vitro model (11) and may form a reasonable 
explanation for the reports of clarithromycin induced digoxin intoxication (12). 
Considering the likelihood of DDIs to occur in TB treatment, we aimed to clarify the 
in vitro interaction potential of available TB drugs with the major ABC transporters 
relevant to drug transport, namely P-gp, BCRP, BSEP and MRP1-5 (13). For this purpose, 
we used membrane vesicles isolated from transporter-overexpressing HEK293 cells. In 
drug development, inside-out membrane vesicles are recognized as an appropriate 
in vitro model to assess whether a drug is an in vivo transporter substrate or inhibitor 
(13). This model has as a major advantage that drugs can be directly applied to the 
cytoplasmic compartment, and influx rather than efflux, is measured. In the field of 
TB treatment, vesicular transport data are especially valuable, because of the limited 
knowledge on interactions of TB drugs with ABC transporters and the current emphasis 
on development of TB drug regimens. Next to first- and second-line TB drugs, we 
assessed the inhibitory potential of three so-called mycobacterial efflux pump inhibitors 
(EPIs) (14), i.e. thioridazine, timcodar and SQ109 (Table 1). EPIs are proposed to work 
as co-adjuvant drugs to increase intramycobacterial concentrations of TB drugs, which 
may even reverse Mycobacterium tuberculosis (M. tuberculosis) efflux pump induced 
resistance (14-20). 
Table 1. Overview of first-line and second-line drugs and EPIs1,2.
Group Drugs
Group I: first-line oral agents rifampicin, rifabutin, isoniazid, pyrazinamide and ethambutol
Group II: injectable agents amikacin, kanamycin, capreomycin and streptomycin 
Group III: fluoroquinolones levofloxacin, moxifloxacin and ofloxacin
Group IV: oral bacteriostatic 
second-line agents
para-aminosalicylic acid (PAS), cycloserine, terizidone, ethionamide 
and protionamide
Group V: agents with unclear role in 
treatment of DR-TB
clofazimine, linezolid, amoxicillin/clavulanate, thioacetazone, 
imipenem/cilastatin, high-dose isoniazid and clarithromycin
Other: Adjuvant drugs proposed 
to be mycobacterial efflux pump 
inhibitors (EPIs) (15-17, 19, 20)
e.g. SQ109, thioridazine, timcodar and verapamil
1 Adapted from Table 7.1 of the WHO guideline: Treatment of Tuberculosis: Guidelines for National 
Programmes (2009) (2). 2 The underlined TB drugs were evaluated in this study 
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Methods
Chemicals
The following TB drugs were purchased from Sigma-Aldrich (Zwijndrecht, the 
Netherlands): rifampicin, isoniazid, pyrazinamide, ethambutol, amikacin, moxifloxacin 
hydrochloride, cycloserin, ethionamide, 4-aminosalicylic acid (PAS), amoxicillin, 
clofazimine, linezolid and thioridazine hydrochloride. SQ109 was kindly provided 
by Sequella Inc. (Rockville, MD, USA) and timcodar by Vertex Pharmaceuticals Inc. 
(Boston, MA, USA), respectively. P-gp substrate [3H]-N-methyl quinidine ([3H]-NMQ) 
and unlabeled NMQ were obtained from Solvo Biotechnology (Szeged, Hungary). 
Substrates [3H]-estrone sulfate ([3H]-E1S), [
3H]-taurocholic acid ([3H]-TCA) and 
[3H]-estradiol 17β-glucuronide ([3H]-E217βG) were purchased from Perkin Elmer Life 
Sciences (Waltham, MA, USA). [3H]-methotrexate ([3H]-MTX) was purchased from 
Moravek Biochemicals (Brea, CA, USA). Adenosine 5’-triphosphate disodium salt 
(ATP) (from bacterial source) was purchased from Sigma-Aldrich (Zwijndrecht, the 
Netherlands). 
Membrane vesicles preparation 
Membrane vesicles were obtained from PharmTox (Nijmegen, the Netherlands, http://
www.pharmtox.nl). They were prepared from Human Embryonic Kidney 293 (HEK293) 
cells overexpressing P-gp, BCRP, BSEP, MRP1-5 or the cytosolic enhanced Yellow 
Fluorescent Protein (EYFP) (21). In short, human P-gp, BCRP, BSEP and MRP1-5 were 
cloned behind a CMV promotor into a Baculovirus. HEK293 cells were transduced with 
these viruses and harvested by centrifugation. The 100,000 g membrane fraction was 
homogenized in ice-cold TS buffer (10 mM Tris-HEPES and 250 mM sucrose, pH 7.4) and 
high shear passage through a 100 μm opening was used to prepare membrane vesicles. 
Protein concentration of these vesicles was determined using the Bio-Rad protein assay 
(Bio-Rad laboratories Inc, Veenendaal, the Netherlands). Vesicles were snap-frozen in 
liquid nitrogen and stored at -80°C. Functional activity of the investigated transporters 
with respect to their model substrates is presented in Supplementary file 1.
Screening for ABC transporter activity inhibition
A rapid filtration technique was applied to study the inhibitory action of 200 µM TB 
drugs and EPIs on the transport of model substrates into inside-out membrane vesicles. 
This was performed as follows; 7.5 µg of membrane vesicle protein in TS buffer (10 
mM Tris-HEPES and 250 mM sucrose, pH 7.4) was supplemented with ATP containing 
reaction mixtures, which included a specific radio-labeled model substrate, 10 mM 
MgCl2, 4 mM ATP and 200 µM TB drug or EPI (or solvent control, 1%), in a total volume 
of 30 µL. TB/EPI drug stocks (20 mM) were prepared in either Milli-Q water (isoniazid, 
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pyrazinamide, ethambutol, amikacin, moxifloxacin hydrochloride, cycloserine and 
thioridazine hydrochloride) or DMSO (rifampicin, ethionamide, amoxicillin, clofazimine, 
linezolid, SQ109 and timcodar). Membrane vesicles overexpressing P-gp were incubated 
with model substrate [3H]-NMQ (0.1 µM/0.015 µCi) and BCRP vesicles with [3H]-E1S (0.1 
µM/0.1 µCi) for 1 minute at 37°C. BSEP vesicles were incubated with [3H]-TCA (0.1 µM/0.15 
µCi) for 5 minutes at 37°C. MRP1, MRP3 and MRP4 were incubated with [3H]-E217βG (0.1 
µM/0.15 µCi) for 5 minutes at 37°C and, finally, MRP2 and MRP5 vesicles were incubated 
with [3H]-MTX (0.4 µM/0.15 µCi) for 10 minutes. Incubation was stopped on ice and by 
adding 150 µL ice cold TS buffer. The vesicle reaction mixtures were transferred onto 
MultiScreenHTS 96-wells filter plates from Millipore (Etten-Leur, the Netherlands) that 
had been preincubated with TS buffer. To separate the vesicles from the incubation 
solution, the samples were filtered using a MultiScreenHTS-vacuum manifold filtration 
device from Millipore, after which the filters were washed twice with 200 µL TS buffer. 
The filter plates contained either filters from glass fiber to filter the substrates [3H]-NMQ 
and [3H]-E1S or filters from PVDF to filter the substrates [
3H]-E217βG), [3H]-TCA and 
[3H]-MTX. After adding 2 mL of Opti-fluor scintillation fluid (PerkinElmer, Waltham, MA, 
USA), samples were counted using a liquid scintillation counter. Control uptake was 
quantified by measuring transport into membrane vesicles isolated form HEK293 cells 
overexpressing the cytosolic EYFP. Experiments were performed in duplicate for at least 
three independent batches of vesicles. 
Concentration-dependent inhibition of ABC transporter activity
TB drugs and EPIs resulting in a decreased transporter substrate uptake of more 
than 70% at a concentration of 200 µM were selected to further determine 
concentration-dependent inhibition and assess 50% inhibitory concentrations (IC50). 
Transport studies were performed as described, using the following drug concentration 
range: 0.1, 0.3, 1, 3, 10, 30, 100 and 300 µM. In case of clofazimine the maximum 
concentration tested was 30 µM, due to its limited solubility beyond this concentration. 
For each concentration, at least duplicate data points were recorded for at least two 
independent transporter vesicle batches. 
Data Analysis
After subtraction of EYFP background transport (control), mean values of substrate 
specific transport were expressed as percentages of the solvent control. Negative 
calculated values were set to 0% transport. All individual data points per drug-transporter 
interaction were pooled. Transport data were expressed as mean ± standard error of the 
mean (SEM). Differences in percentages of the solvent control between drug-transporter 
combinations were tested using an one-way analysis of variance (ANOVA) followed by 
Dunnett’s multiple comparison test. Curve fitting of concentration-dependent inhibition 
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of transport and subsequent calculation of IC50 values was established by nonlinear 
regression analysis (with the top constrained to 100% transport) using GraphPad Prism 
version 5.03 (GraphPad Software Inc., San Diego, CA, USA). 
Results
Screening for ABC transporter activity inhibition
Membrane vesicles isolated from transporter-overexpressing HEK293 cells were used to 
study the inhibitory action of TB drugs and EPIs on the transport of model radio-labeled 
substrates [3H]-NMQ (P-gp); [3H]-E1S (BCRP); [
3H]-TCA (BSEP); [3H]-E217βG; (MRP1, 
3 and 4) and [3H]-MTX (MRP2 and 5). Figure 1 shows the results of screening for 
the inhibitory potency of TB drugs and EPIs at a concentration of 200 µM against 
ATP-dependent uptake of the model substrates. Of all transporters, P-gp-mediated 
[3H]-NMQ uptake was inhibited for more than 70% by the most TB/EPI drugs (Figure 
1A), namely by rifampicin, clofazimine, thioridazine, SQ109 and timcodar. All resulting 
in <15% of solvent control transporter activity (p<0.0001). BCRP-mediated [3H]-E1S 
transport was >70% inhibited by rifampicin, clofazimine, thioridazine and SQ109 (Figure 
1B), of which all resulted in <15% of solvent control transporter activity (p<0.0001). 
Above 70% inhibition of [3H]-TCA transport by BSEP was only observed for rifampicin 
and timcodar (Figure 1C), with uptake reduced to <15% compared to solvent control 
(p<0.0001). Of the MRP family, MRP1-mediated [3H]-E217βG transport was inhibited 
>70% by rifampicin, clofazimine, SQ109 and timcodar (Figure 1D), of which the latter 
three resulted in <15% uptake of solvent control (p<0.0001). MRP2-5 were all inhibited 
by rifampicin and SQ109 (Figure 1E-H), though this did not amount to >70% inhibition 
in the case of MRP3 by rifampicin, and MRP5 by both rifampicin and SQ109. Of the 
interactions with MRP2-5, only MRP4-mediated [3H]-E217βG transport was reduced 
by SQ109 to <15% of the transporter activity of the solvent control (p<0.0001) (Figure 
1G). Finally, in some cases stimulation of transport was observed (Figure 1). This is 
probably caused by allosteric interactions, which are substrate dependent and more 
often observed for ABC transporters.
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Figure 1. Effect of TB drugs (200 µM) on the ATP-dependent uptake of radio-labeled substrates 
into membrane vesicles overexpressing P-gp (A), BCRP (B), BSEP (C) and MRP1-5 (D-H).  
The inhibitory effect of TB drugs and EPIs (200 µM) on ABC transporter activity was assessed. Data 
were pooled from experiments performed in duplicate for three independent batches of vesicles. TB 
drugs are displayed per group of TB drugs in roman numerals, as proposed by the WHO guideline 
(2). Transport is expressed in % of the solvent controls and is presented as mean ± SEM. Inhibition 
larger than 70% is indicated by the gray bars. These drugs were selected to further determine 
concentration-dependent inhibition. 
* Statistically significant difference from vehicle control with one-way ANOVA, post-hoc Dunnett’s test 
(p-value <0.05). AMK, amikacin; AMX, amoxicillin; CLF, clofazimine; CS, cycloserin; EMB, ethambutol; 
ETO, ethionamide; INH, isoniazid; LZD, linezolid; MQ, Milli-Q; MXF, moxifloxacin; PZA, pyrazinamide; 
RIF, rifampicin; PAS, 4-aminosalicylic acid; TIM, timcodar; TRD, thioridazine.
Concentration-dependent inhibition of ABC transporter activity
Concentration-dependent inhibition of ABC transporter activity was determined for 
each transporter and TB/EPI drug that resulted in an inhibition of at least 70% at the 
screening concentration of 200 µM. IC50 curves of these interactions were constructed 
(Figure 2) and the results are displayed in Table 2. Overall, P-gp, BCRP and MRP1 (Figure 
2A, B and D) were most potently inhibited, as indicated by the bold red colors in Table 
2. IC50 values for P-gp, arranged from lowest to highest, were 1.0 µM (95% CI 0.8-1.1 
µM) for timcodar, 1.8 µM (95% CI 1.4-2.2 µM) for clofazimine, 11 µM (95% CI 4.5-25 µM) 
for SQ109, 23 µM (95% CI 18-29 µM) for thioridazine and 29 µM (95% CI 17-49 µM) for 
rifampicin. IC50 values of BCRP amounted to 3.2 µM (95% CI 2.2-4.6 µM) for clofazimine, 
5.5 µM (95% CI 2.0-16 µM) for SQ109, 6.6 µM (95% CI 4.4-10 µM) for thioridazine and 
56 µM (95% CI 36-87 µM) for rifampicin. BSEP inhibition by timcodar resulted in an IC50 
curve with a steep slope (Figure 2C) and a relatively low IC50 value of 3.0 µM. BSEP was 
less potently inhibited by rifampicin with an IC50 of 25 µM (95% CI 20-31 µM). Similarly 
to BCRP and P-gp, MRP1 was potently inhibited by various TB drugs; IC50 values were 
4.3 µM (95% CI 3.5-5.4 µM) for timcodar, 6.8 µM (95% CI 5.5-8.3 µM) for clofazimine, 
32 µM (95% CI 20-52 µM) for rifampicin and 85 µM (95% CI 68-106 µM) for SQ109. In 
case of clofazimine, MRP1 could not be maximally inhibited, due to its limited solubility 
beyond 30 µM (Figure 2D). In contrast to MRP1, the other MRPs were less inhibited, 
with IC50 values >15 µM (Table 2). Of note, rifampicin interacted in different degrees with 
all the transporters tested, but interactions did not result in IC50 values <15 µM (Table 2).
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Figure 2. Concentration-dependent inhibition of the ATP-dependent transport of radio-labeled 
substrates by P-gp (A), BCRP (B), BSEP (C) and MRP1 (D).
For TB drugs or EPIs with an inhibitory potential of >70% during screening, concentration-dependent 
inhibition was determined. The effect of 0.1, 0.3, 1, 3, 10, 30, 100 and 300 µM of various TB drugs 
and EPIs on uptake of radio-labeled substrates was assessed. For each concentration, data were 
pooled from at least duplicate data points per two independent transporter vesicle batches. Transport 
is expressed in % of the solvent controls and is presented as mean ± SEM for each data point.
A
P-gp P-gp
P-gp P-gp
P-gp
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Figure 2 continued. Concentration-dependent inhibition of the ATP-dependent transport of 
radio-labeled substrates by P-gp (A), BCRP (B), BSEP (C) and MRP1 (D).
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Figure 2 continued. Concentration-dependent inhibition of the ATP-dependent transport of 
radio-labeled substrates by P-gp (A), BCRP (B), BSEP (C) and MRP1 (D).
Discussion 
We assessed the in vitro inhibitory potential of a range of currently used TB drugs and 
novel EPIs on various ABC transporters that are important in drug transport, namely 
P-gp, BCRP, BSEP and MRP1-5. Inhibition of these membrane transporters may be 
an important mechanism underlying clinically relevant drug-drug interactions (DDIs). 
Overall, we demonstrated a strong inhibition (IC50 <15 µM) of P-gp, BCRP and MRP1 
by clofazimine; P-gp and BCRP by SQ109; BCRP by thioridazine and inhibition of P-gp, 
BSEP and MRP1 by timcodar. Rifampicin inhibited all tested transporters, but with lower 
potency (IC50 >15 µM). Co-administration of these TB drugs or EPIs with compounds 
that are substrates for either P-gp, BCRP, BSEP or MRP1 could lead to DDIs in the clinical 
setting (Supplementary file 2). All other first- and second-line TB drugs did not show 
inhibition. Results of our study can provide further insight in explaining and predicting 
DDIs for TB drug- and EPI-drug combinations and, moreover, aid in prioritizing and 
designing in vivo DDI-studies. 
D
MRP1 MRP1
MRP1 MRP1
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Table 2. Overview of average TB drug concentrations (µM) resulting in 50% inhibition (IC50) of the 
ATP-dependent uptake of radio-labeled substrates by P-gp, BCRP, BSEP and MRP1-5.
P-gp BCRP BSEP MRP1 MRP2 MRP3 MRP4 MRP5
rifampicin
isoniazid
pyrazinamide
ethambutol
amikacin
moxifloxacin
cycloserin
PAS
ethionamide
amoxicillin
clofazimin
linezolid
SQ109
thioridazine
timcodar
Concentration-dependent inhibition was determined for TB drugs and EPIs with an inhibitory potential 
of >70% at a concentration of 200 µM. Curve fitting and subsequent calculation of IC50 values was 
established by nonlinear regression analysis. IC50 values are displayed in µM and the corresponding 
95% confidence intervals can be found in the results section. The bold red colors indicate a high 
inhibitory potential, whereas the bold green colors indicate a relatively low inhibitory potential. 
1 In screening (200 µM) between 40% and 70% transport activity (Figure 1). 2 In screening (200 µM) 
between 30-40% transport activity (Figure 1).
The antibiotic rifampicin forms the cornerstone of TB therapy. Although rifampicin 
inhibited the widest range of transporters in this study, reported IC50 values may at 
first sight seem clinically less relevant, as the lowest IC50 (~25 µM) corresponds to 
a protein-unbound concentration of ca. 22 mg/L. This is ten times above average 
protein-unbound peak plasma concentrations of 1.5-2 mg/L with current dosing. 
However, comparisons between IC50 values and plasma concentrations should be 
made cautiously, since the studied efflux transporters are usually inhibited from the 
inside of the cell. Accumulation of rifampicin beyond the central compartment cannot 
be excluded and intracellular concentrations exposed to the transporter can be much 
higher. For example, high concentrations in the intestinal lumen, portal vein and 
Strong inhibition Weak inhibition
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hepatocyte may potentially produce profound inhibition of ABC transporter activity. In 
line with this, reports are available that following repeated administration rifampicin can 
increase the AUC and Cmax of digoxin when taken simultaneously and not staggered. This 
indicates the presence of an interaction mechanism other than induction of intestinal/
hepatic P-gp (22, 23) and demonstrates the possible relevance of the inhibitory effects 
of rifampicin. In addition, in vitro BSEP inhibition (in our study an IC50 of ~25 µM) has 
previously been posed as a possible explanation for rifampicin-associated cholestasis 
(24). Impaired BSEP activity results in accumulation of bile acids within hepatocytes, 
which can cause cholestatic liver injury. 
Clofazimine is an antibiotic mainly used in the treatment of leprosy. Initially clofazimine 
was studied for use in TB, but after signs of inconsistent therapeutic activity clofazimine 
was sidetracked. Today, the drug is a group V TB drug, i.e. an agent with unclear efficacy, 
for the treatment of MDR TB (25, 26). Interest in clofazimine has recently increased due 
to the promising efficacy of clofazimine in a mouse model for TB (27, 28) and as part 
of highly efficacious TB regimens for MDR TB (4, 29). In the present study, clofazimine 
demonstrated to be a potent inhibitor of P-gp, BCRP and MRP1, with IC50 values 
translating into 0.9, 1.5 and 3.2 mg/L, respectively. The P-gp IC50 value is lower than 
the P-gp IC50 of >10 µM reported by Horita and Doi (2014) (30), which was measured 
in P-gp-expressing MDCK cells. The IC50 values found in our study seem within the 
therapeutic range, as daily oral administration of 100, 300 or 400 mg in leprosy patients 
resulted in average total (free plus protein-bound) plasma concentrations of 0.7, 1.0 and 
1.41 mg/L, respectively (31). Of note, IC50 values represent free drug concentrations and 
because the in vivo protein binding of clofazimine is unknown, comparison between IC50 
values and plasma concentrations should be made carefully. Adding to the complexity, 
beyond the central compartment accumulation of clofazimine occurs due to its high 
lipophilicity, making it likely that intracellular concentrations at the transporter site are 
higher than in the central compartment. Because clofazimine is not in widespread 
clinical use and no interaction studies have been undertaken, the occurrence of DDIs 
mediated via transporter inhibition is relatively unknown (31). However, there is a case 
report available that clofazimine may reduce phenytoin concentrations (32). Phenytoin 
is an approved anti-convulsant drug, but can also be used in case of TB meningitis with 
convulsions and by people with AIDS to relieve the pain associated with peripheral 
neuropathy. Phenytoin is a substrate of P-gp (33). In rats, the P-gp inhibitor verapamil 
was able to influence phenytoin pharmacokinetics. The observed effect depended on 
the level of expression of efflux transporters and hepatic enzymes, resulting in either 
decreased intestinal clearance or increased total clearance of phenytoin (34). Such data 
make it plausible that DDIs mediated by clofazimine-induced transporter inhibition 
could be clinically relevant in TB treatment, where polypharmacy and co-morbidity play 
an important role. 
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Finally, we demonstrated a strong inhibitory effect (IC50 value <15 µM) of the EPIs SQ109 
(IC50 values of 3.5 mg/L for P-gp and 1.8 mg/L for BCRP inhibition), thioridazine (IC50 
of 2.7 mg/L for BCRP) and timcodar (IC50 of 0.7 mg/L for P-gp, 3.2 mg/L for MRP1 and 
2.2 mg/L for BSEP). These EPIs are proposed to inhibit bacterial efflux transporters 
and, in this way, cause increased intramycobacterial concentrations of TB drugs (14). 
In this study, we demonstrated that they potently inhibit a wide range of human ABC 
transporters as well. To our knowledge more so than previously reported or anticipated 
(35). Based on the results of this study, it can be expected that EPIs may cause DDIs 
when co-administered with drug substrates of the inhibited transporters, or possibly 
result in bile salt accumulation and drug induced cholestatic liver injury in case of 
BSEP inhibition by timcodar. Because SQ109 and timcodar are not in clinical use yet, 
the clinical importance of DDIs mediated by transporter inhibition is unknown and 
should be further investigated in vivo. In contrast, thioridazine has previously been 
used as a neuroleptic agent and is known for its small therapeutic window. Therapeutic 
antipsychotic thioridazine plasma concentrations range from 0.5 to 1.0 mg/L (36). An 
IC50 of 2.7 mg/L for BCRP inhibition may seem high in this context, however, it has been 
demonstrated that thioridazine can be concentrated by human macrophages (37) and 
accumulate in the brain (38).
The current study was initiated to provide a perspective on possible DDIs caused 
by TB drugs and EPIs due to inhibition of ABC transporters. Although the proposed 
inhibitory effects can indeed have undesirable or unforeseen effects on other TB 
drugs or co-administered drugs, it is important to note that beneficial effects may 
also be anticipated. For example, transport inhibition at the macrophage level or at 
the blood-brain barrier may cause increased drug concentrations and thus more 
extensive mycobacterial killing locally. M. tuberculosis bacilli can survive and grow 
within macrophages, in which they are protected from the human immune system. 
Drugs that are substrates for efflux transporters expressed on the macrophage outer 
membrane, such as P-gp, will show increased intracellular accumulation once they 
are combined with inhibitors of efflux transporters (7). In an in vitro cell model, the 
P-gp inhibitor tariquidar significantly increased intracellular killing of M. tuberculosis 
by ethambutol and rifampicin (39). A similar beneficial effect of efflux inhibition may 
occur at the blood-brain and blood-CSF barriers, where efflux pump inhibition may 
increase the penetration of TB drugs into the brain tissue and CSF, relevant to the 
treatment of TB meningitis (40). Further research is necessary to elucidate the impact 
of macrophage transporters in TB treatment and the clinical importance of blood-brain 
barrier transport inhibition.
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A few limitations on the interpretation of this study should be put forward here. Firstly, 
the observed inhibitory interactions may be substrate dependent. Translation of these 
results to other transporter-substrate combinations should therefore be taken with 
some precautions. Another limitation is that the current set-up of the vesicular transport 
assay will not provide information on the inhibitory kinetics of transporter-substrate 
interactions and whether the perpetrator TB/EPI drugs are substrates of the transporters 
themselves. A final limitation is that the used membrane vesicles do not display cellular 
transporter regulation. Rifampicin is known to upregulate the expression of P-gp and 
other ABC transporters in vivo by activation of pregnane X receptor (PXR) (41), which is 
an important mechanism in rifampicin induced DDIs.
To summarize, we assessed the in vitro inhibitory potential of a large number of first-line 
and second-line TB drugs and EPIs on ABC transporters that are important in drug 
transport, namely P-gp, BCRP, BSEP and MRP1-5. Of the TB drugs, we demonstrated 
that clofazimine causes a relatively strong inhibition of P-gp, BCRP and MRP1 and that 
rifampicin inhibits all tested transporters, but less potently. Co-administration of these 
TB drugs with drugs that are substrates for either P-gp, BCRP or MRP1 could lead to 
DDIs. Furthermore, we have showed that the broad non-specific inhibitory potential 
of EPIs, which are meant to be mycobacterial efflux pump inhibitors, should be taken 
into consideration in the process of drug development and implementation of these 
compounds. 
Clearly, the membrane vesicular transport assay forms a useful tool to evaluate the 
potential of drugs to cause DDIs by inhibition of efflux transporters. We propose that 
this in vitro tool will be applied as part of the development of new TB drug candidates, 
along with other preclinical screens to assess the potential of drugs to inhibit or induce 
metabolic enzymes. Furthermore, we would like to remark that our data can serve 
as input for physiologically based pharmacokinetic (PBPK) modeling. With a PBPK 
model, quantitative pharmacokinetic predictions can be performed and the effects of 
intrinsic (e.g. co-morbidity, age, genetics) and extrinsic (e.g. drug-drug interactions) 
factors on drug exposure can be evaluated. Such a model would be highly valuable 
in the context of TB drug development, because it would provide clinical DDI/PK 
studies with a mechanistic basis and help in the study design. Overall, considering 
the emphasis on development of TB drug regimens rather than single drugs and 
TB-associated polypharmacy, more preclinical pharmacological information would 
be highly relevant. Such data, as presented here, can assist in prioritizing interaction 
studies and performing dose optimization studies and safety/tolerability studies for 
specific TB drugs or combinations of drugs during early clinical development.
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Supplementary file 1. 
Functional activity of investigated ABC transporters with respect to the uptake of model substrate. 
Substrate
AMP 
(pmol/mg/min)
ATP 
(pmol/mg/min)
AMP/ATP Ratio
Background NMQ 24 ± 1 29 ± 2 1
P-gp NMQ 25 ± 2 125 ± 8 5
Background E1S 0.78 ± 0.03 0.94 ± 0.01 1
BCRP E1S 1.24 ± 0.15 13.08 ± 1.42 11
Background TCA 0.34 ± 0.10 0.65 ± 0.52 2
BSEP TCA 0.42 ± 0.08 8.10 ± 0.08 19
Background E217βG 0.10 ± 0.01 0.11 ± 0.01 1
MRP1 E217βG 0.23 ± 0.02 1.08 ± 0.06 5
MRP3 E217βG 0.17 ± 0.02 4.47 ± 0.11 26
MRP4 E217βG 0.19 ± 0.02 1.04 ± 0.08 5
Background MTX 0.02 ± 0.01 0.03 ± 0.01 1
MRP2 MTX 0.03 ± 0.01 0.11 ± 0.01 4
MRP5 MTX 0.05 ± 0.01 0.46 ± 0.02 9
Functional activity of tested transporters and their background values. Background uptake was 
quantified by measuring transport into membrane vesicles isolated form HEK293 cells overexpressing 
the cytosolic EYFP. Results are for one representative vesicle batch and are presented in pmol/mg 
protein/min as well as the associated AMP/ATP ratios of transported model substrate. Values are 
expressed as mean ± SEM.
Background: EYFP, enhanced Yellow Fluorescent Protein (negative control); E217βG, estradiol 
17-β-D-glucuronide; E1S, estrone sulfate; MTX, methotrexate; NMQ, N-methyl-quinidine; TCA, 
taurocholic acid.
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Supplementary file 2. 
An overview of the tested ABC transporters, their location, possible relevant substrates and a 
comparison between the in vitro IC50 values and human maximum plasma drug concentrations (Cmax). 
Location Substrates ¥
IC50 value of 
tested inhibitor
Cmax plasma (µM) & 
protein binding (%)
P-gp 
(1-3)
Intestines
Liver
Kidney
Brain 
endothelia
Placenta
Lympho-
cytes
N-methyl-quinidine 
Antibiotics
   erythromycin, 
   levofloxacin, ofloxacin,
   rifampicin 
Chemotherapeutic agents
   actinomycin D,
   anthracyclines, 
anthracenes,
   etoposide, irinotecan,
   imatinib, paclitaxel, taxanes,
   vinblastine, vincristine
HIV protease inhibitors
   amprenavir, indinavir,
   lopinavir, nelfinavir, ritonavir,
   saquinavir
Other drugs
   amitryptiline, atorvastatin,
   berberine, cimetidine,
   colchicine, cyclosporine,
   dexamethasone,
   domperidone, digoxin,
   fexofenadine, itraconazole,
   hydrocortisone,
   lansoprazole, loperamide,
   morphine, phenytoin,
   quinidine, reserpine,
   talinolol, verapamil
Rifampicin (29 µM)
Clofazimine (1.8 µM)
SQ109 (11 µM)
Thioridazine (23 µM)
Timcodar (1.0 µM)
Cmax of 7.5-20.2 µM  after 600 
mg (4), of which ~90% may 
be plasma protein bound (5)
Cmax of 1.1-4.2 µM following 
100 mg (4)
Cmax of 47.5-442 µM (6) after 
300 mg, of which ~18-24% 
may be protein bound (in 
vitro at 7.5 µM) (7)
Cmax of 6.6-362 µM after 50 
mg single dose, of which 
~95%  may be protein bound 
(8)
Unpublished for humans §
BCRP 
(3, 9, 
10)
Intestines
Liver
Kidney
Brain 
endothelia
Placenta
Testes 
Mammary 
glands
Estrone sulphate
Antibiotics
   fluoroquinolones,
   nitrofurantoin
Antivirals
   abacavir, acyclovir,
   lamivudine, zidovudine
Chemotherapeutic agents
   anthracyclines, imatinib,
   methotrexate, topetecan
Other drugs
   cimetidine, glyburide,
   pantoprazole, prazosin,
   statins, sulfasalazine
Endogenous substrates
   estradiol-17β-D-glucuro
   nide, estrone-3-sulfate,
   uric acid
Rifampicin (56 µM)
Clofazimine (3.2 µM)
SQ109 (5.5 µM)
Thioridazine (6.6 µM)
Timcodar (100-150 
µM)
Cmax of 7.5-20.2 µM  after 600 
mg (4), of which ~90% may 
be plasma protein bound (5)
Cmax of 1.1-4.2 µM following 
100 mg (4)
Cmax of 47.5-442 µM (6) after 
300 mg, of which ~18-24% 
may be protein bound (in 
vitro at 7.5 µM) (7)
Cmax of 6.6-362 µM after 50 
mg single dose, of which 
~95%  may be protein bound 
(8)
Unpublished for humans §
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Location Substrates ¥
IC50 value of 
tested inhibitor
Cmax plasma (µM) & 
protein binding (%)
BSEP 
(11, 12)
Liver
Taurocholic acid
Drugs
   pravastatin
Endogenous substrates
   bile salts
Rifampicin (25 µM)
Timcodar (3.0 µM)
Cmax of 7.5-20.2 µM  after 600 
mg (4), of which ~90% may 
be plasma protein bound (5)
Unpublished for humans §
MRP1 
(2, 13)
Intestines 
Liver
Kidney 
Testes
Placenta
Lung
Macro-
phages
Skeletal 
& heart 
muscle
Estradiol 17-β-D-glucuronide
Antivirals 
   adefovir, indinavir
Chemotherapeutic agents
   anthracyclines, etoposide,
   topotecan, vinblastine,
   vincristine
Many glutathione, 
glucuronide or sulphate 
conjugated (organic anion) 
drugs and endogenous 
substrates
Rifampicin (32 µM)
Clofazimine (6.8 µM)
SQ109 (85 µM)
Timcodar (4.3 µM)
Cmax of 7.5-20.2 µM  after 600 
mg (4), of which ~90% may 
be plasma protein bound (5)
Cmax of 1.1-4.2 µM following 
100 mg (4)
Cmax of 47.5-442 µM (6) after 
300 mg, of which ~18-24% 
may be protein bound (in 
vitro at 7.5 µM) (7)
Unpublished for humans §
MRP2 
(2, 3, 
14)
Intestines 
Liver 
Kidney
Placenta 
Methotrexate
Antivirals 
   indinavir
Chemotherapeutic agents
   anthracyclines, cisplatin,
   etoposide, mitoxantrone,
   vincristine, vinblastine 
Other drugs
   valsartan
Endogenous substrates
   bile salts 
Many glutathione and 
glucuronide conjugated 
(organic anion) drugs and 
endogenous substrates
Rifampicin (27 µM)
SQ109 (92 µM)
Cmax of 7.5-20.2 µM  after 600 
mg (4), of which ~90% may 
be plasma protein bound (5)
Cmax of 47.5-442 µM (6) after 
300 mg, of which ~18-24% 
may be protein bound (in 
vitro at 7.5 µM) (7)
MRP3 
(3, 15)
Intestines
Liver
Kidney
Adrenal 
glands
Pancreas
Spleen
Estradiol 17-β-D-glucuronide
Chemotherapeutic agents
   etoposide, metothrexate,
   teniposide
Endogenous substrates
   bile salts 
Many mainly glucuronide 
conjugated (organic anion) 
drugs and endogenous 
substrates 
Rifampicin (97 µM)
SQ109 (59 µM)
Cmax of 7.5-20.2 µM  after 600 
mg (4), of which ~90% may 
be plasma protein bound (5)
Cmax of 47.5-442 µM (6) after 
300 mg, of which ~18-24% 
may be protein bound (in 
vitro at 7.5 µM) (7)
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Location Substrates ¥
IC50 value of 
tested inhibitor
Cmax plasma (µM) & 
protein binding (%)
MRP4 
(3, 
16-19)
Liver
Kidney
Brain 
endothelia
Prostate
Pancreas 
Estradiol 17-β-D-glucuronide
Antiretrovirals
   tenofovir, nucleoside
   analogs i.e. PMEA, AZT,
   6-mercaptopurine
Other drugs
   Statins
Endogenous substrates
   bile salts, cAMP, cGMP,
   glutathione
Rifampicin (88 µM)
Timcodar (100-150 
µM)
Cmax of 7.5-20.2 µM  after 
600 mg (4), of which ~90% 
may be plasma protein 
bound (5)
Unpublished for humans §
MRP5 
(3, 18, 
20)
Urethra
Heart
Placenta
Brain 
endothelia
Methotrexate
Antiretrovirals
   nucleoside analogs i.e.
   PMEA
Other drugs
   Statins
Endogenous substrates
   cAMP, cGMP
SQ109 (100-150 µM)
Cmax of 47.5-442 µM (6) after 
300 mg, of which ~18-24% 
may be protein bound (in 
vitro at 7.5 µM) (7)
The model substrates tested in this study are underlined
§ The only pharmacokinetic data available for timcodar is in mice. 200 mg single dose resulted in a 
maximum plasma drug concentration (Cmax) of 20 µM (21). Plasma protein binding was not reported. 
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Abstract
Introduction
It is largely unknown if simultaneous administration of tuberculosis (TB) drugs and 
metformin leads to drug-drug interactions (DDIs). Disposition of metformin is 
determined by organic cation transporters (OCTs) and multidrug and toxin extrusion 
proteins (MATEs). Thus any DDIs would primarily be mediated via these transporters. 
This study aimed to assess the in vitro inhibitory effects of TB drugs (rifampicin, isoniazid, 
pyrazinamide, ethambutol, amikacin, moxifloxacin and linezolid) on metformin 
transport, and whether TB drugs are also substrates themselves of OCTs and MATEs. 
Methods
HEK293 cells overexpressing OCT1, OCT2, OCT3, MATE1 and MATE2K were used to 
study TB drug-mediated inhibition of [14C]metformin uptake and to test if TB drugs are 
transporter substrates. Metformin uptake was determined by quantifying [14C]metformin 
radioactivity and TB drug uptake was analyzed using LC-MS/MS. DDI-indices were 
calculated (plasma Cmax/IC50), and based on literature a cut-off of >0.1 was assumed to 
warrant further in vivo investigation.
Results
Moxifloxacin was the only TB drug identified as a potent inhibitor (DDI-index>0.1) of 
MATE1- and MATE2K-mediated metformin transport (IC50 of 12 µM (95% CI 5.1-29 
µM) and 7.6 µM (95% CI 0.2-242 µM), respectively). Of all TB drugs, only ethambutol 
appeared to be a substrate of OCT1, OCT2, OCT3, MATE1 and MATE2K. MATE1-mediated 
ethambutol uptake was inhibited strongly (DDI-index >0.1) by moxifloxacin (IC50 12 µM 
(95% CI 3.4-43 µM)). 
Conclusions
Our findings provide a mechanistic basis for DDI-predictions concerning ethambutol. 
According to international guidelines, an in vivo interaction study is warranted for the 
observed in vitro interaction between ethambutol and moxifloxacin. 
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Introduction
Tuberculosis (TB) remains a leading cause of morbidity and mortality in developing 
countries, claiming over a million lives annually (1). Treatment of TB requires long and 
intensive combination drug therapy, which can be complicated by the presence of 
concurrent diseases. The non-communicable disease diabetes mellitus (DM) impacts 
TB with increasing magnitude (2, 3). At the moment, an estimated 15% of TB cases can 
be attributed to DM (3). 
Patients with DM have three times the risk of developing active TB compared to 
non-diabetics (3, 4), probably by impairing host defences. In addition, patients with 
TB and DM show a worse response to TB treatment than patients with TB alone and 
thus face a higher risk of TB treatment failure, relapse after cure, and death (5). The 
impact of DM will only increase further due to the rising prevalence of DM, especially in 
countries where TB is endemic. The other way around, DM management is hampered 
by TB treatment. The TB drug rifampicin possibly affects blood glucose itself and 
induces hyperglycemia by augmenting intestinal absorption of glucose or reducing 
insulin sensitivity (6, 7). 
Metformin is the first choice antihyperglycemic drug to treat diabetes mellitus type 2. 
It is affordable and may be advantageous when combined with rifampicin, as it is not 
metabolized. Metformin lowers both basal and postprandial plasma glucose (8) by 
inhibiting the production of hepatic glucose, reducing intestinal glucose absorption, 
and improving glucose uptake and utilization (9). Interestingly, recent data show 
that metformin also inhibits the intracellular growth of Mycobacterium tuberculosis 
(M. tuberculosis), restricts disease immunopathology and augments the efficacy of 
conventional TB drugs. It has even been suggested as a possible adjunctive to standard 
TB treatment in non-diabetic TB patients (10). 
Metformin is eliminated unchanged into the urine with a half-life of approximately 5 
h (11). Over a range of renal function, the mean renal clearance in the population is 
approximately 4 times greater than that of creatinine, indicating that tubular secretion 
is the most important route of elimination (11). The oral absorption, hepatic uptake and 
renal excretion of metformin are largely mediated by membrane transporters of the 
solute carrier (SLC) family, namely organic cation transporter 1, 2 and 3 (OCT1, OCT2 
and OCT3) and multidrug and toxin extrusion protein 1 and 2K (MATE1 and MATE2K) 
(Figure 1) (11, 12). Genetic polymorphisms in these transporter genes explain at least 
some of the variability observed in metformin pharmacokinetics and drug responses 
(11). Furthermore, from studies in humans and in mice we know that inhibitors of OCTs 
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and MATEs can alter the disposition of concomitantly administered organic cations, 
increasing drug concentrations in the systemic or intracellular compartment depending 
on the preferential inhibition of OCTs or MATEs (Figure 1) (13-15).
There is scanty evidence on the degree to which metformin and TB drugs can be 
administered simultaneously, without any anticipated drug-drug interactions (DDIs) 
and corresponding dose adjustments to retain optimal TB and DM treatment. Because 
metformin is not metabolized in the body and its disposition is largely dependent 
on OCTs and MATEs, any expected DDIs would be primarily mediated via these 
membrane transporters (Figure 1). Accordingly, this study sought to assess the in 
vitro inhibitory effects of TB drugs (rifampicin, isoniazid, pyrazinamide, ethambutol, 
amikacin, moxifloxacin and linezolid) on transport of metformin by OCT1, OCT2, OCT3, 
MATE1 and MATE2K.  Furthermore, we investigated whether the tested TB drugs are 
substrates of OCT1, OCT2, OCT3, MATE1 and MATE2K and therefore can become a 
victim themselves of transporter-mediated DDIs. 
Figure 1.  Schematic overview of the most important transporters involved in the absorption, 
hepatic uptake and excretion of metformin (11, 15, 40-43). The physiological significance of the 
transporters depicted in gray are still unclear (11). 
PMAT is mostly responsible for the uptake of metformin from the gastrointestinal tract, being far more 
abundant than OCT3. OCT1 and OCT3 together mediate the uptake of metformin in the liver, which is 
the most important site of action of metformin. The biliary excretion of metformin from the hepatocyte 
via MATE1 seems negligible in man, and OCT1 and OCT3 probably also transport their substrates from 
the hepatocyte back into the blood. In the kidneys, OCT2 mediates the uptake of metformin into the 
proximal tubular cells, and MATE1 and MATE2K are responsible for the excretion of metformin into the 
urine. In the present study we did not assess any interaction mediated via PMAT. 
MATE, multidrug and toxin extrusion protein; OCT, organic cation transporter; PMAT, plasma membrane 
monoamine transporter
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Methods
Chemicals and materials
The following drugs were purchased from Sigma-Aldrich (Zwijndrecht, the Netherlands): 
rifampicin, isoniazid, pyrazinamide, ethambutol dihydrochloride, amikacin, moxifloxacin 
hydrochloride, linezolid and metformin hydrochloride. [14C] metformin hydrochloride 
was obtained from Moravek (Brea, CA, USA). Stock solutions of the TB drugs were 
made in DMSO (rifampicin and linezolid) or Milli-Q water (isoniazid, pyrazinamide, 
ethambutol, amikacin and moxifloxacin hydrochloride). Stock solutions of metformin 
were made in Milli-Q water. Hanks’ balanced salt solution (HBSS), GlutaMAX 
high-glucose Dulbecco’s modified Eagle medium (DMEM) and foetal calf serum were 
provided by Life Technologies (Bleiswijk, The Netherlands). Bovine serum albumin (BSA) 
was obtained from Roche Diagnostics GmbH (Mannheim, Germany). Sodium butyrate 
and HEPES were both purchased from Sigma-Aldrich (Zwijndrecht, the Netherlands). 
BD Biocoat poly-D-lysine-coated 24-well tissue-culture plates were ordered from 
VWR (Leuven, Belgium). HPLC grade methanol was purchased from Lab Scan (Dublin, 
Ireland) and NaOH from Merck (Darmstadt, Germany). Protein concentrations were 
determined with an assay kit from Bio-Rad laboratories (Veenendaal, The Netherlands). 
Cell line maintenance and transduction
Human embryonic kidney cells (HEK) 293 were maintained at 37°C with 5% CO2 in 
DMEM containing 10% foetal calf serum (FCS). After growing cells to 70% confluency, 
cells were diluted 4-5x in the DMEM culture medium and seeded in poly-D-lysine-coated 
24-well plates in a volume of 375 µl per well. 24 hours after seeding, HEK293 cells were 
transduced with 30 µL recombinant baculovirus to express the transporter of interest 
(OCT1 (amino acid sequence same as accession no. BC126364.1), OCT2 (accession no. 
NM_003058.2), OCT3 (accession no. NM_021977.2), MATE1 (accession no. NM_018242.2), 
MATE2K (accession no. NM_001099646.1), as well as the vector control (background) 
expressing enhanced yellow fluorescent protein (EYFP). To produce the recombinant 
Baculovirus, genes of interest had been cloned downstream a cytomegalovirus CMV 
promotor into a Baculovirus for protein expression in mammalian cells, as described 
previously (16). Of note, such a overexpression set-up does not allow for the assessment 
of DDIs caused by induction of transporter proteins. To enhance protein expression, 195 
µl DMEM (10% FCS) containing 6 mM sodium butyrate was added to each well (2 mM 
final concentration). Uptake experiments with the cell monolayers were performed 2 or 
3 days post-transduction. 
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Inhibition of OCT1-, OCT2-, OCT3-, MATE1- and MATE2K-mediated metformin 
uptake by TB drugs
On the day of the transport experiment, the culture medium was removed and cells 
were firstly washed in order to equilibrate them to serum-free conditions with 400 µl 
buffer (HBSS + 10 mM HEPES, pH 7.4), prewarmed to 37°C. Uptake was initiated by 
replacing this solution with 150 µl of fresh transport buffer (HBSS-HEPES pH 7.4, pH 8.5 
in case of MATE2K; kept at 37°C) supplemented with the TB drug(s) of interest, incubated 
at 37°C for either 5 minutes (MATE1 and MATE2K) or 10 minutes (OCTs). Similarly to 
the OCTs, MATE1 and MATE2K activity were measured in the uptake direction, even 
though in the kidney and liver the MATEs export organic cations into the urine and bile, 
respectively. MATE2K import was further stimulated by increasing the proton gradient 
(alkaline transport buffer, pH 8.5) (17). 
To enable screening for metformin uptake inhibition, the transport buffer contained 
6 µM [14C]metformin (equaling plasma maximum concentrations (Cmax) of 10 µM (18)) 
and 200 µM TB drug (rifampicin, isoniazid, pyrazinamide, ethambutol, moxifloxacin 
hydrochloride, amikacin or linezolid). TB drugs were selected to represent the range of 
available first- and second-line TB drugs according to the WHO (19); rifampicin, isoniazid, 
pyrazinamide, ethambutol (group I first-line oral agents); amikacin (group II injectable 
aminoglycosides); moxifloxacin (group III fluoroquinolones) and linezolid (group V TB 
drugs with unclear efficacy). Screening occurred at 200 µM of TB drug, because this 
was assumed to be a maximum physiologically relevant concentration. Following the 
results of these experiments, the concentration-dependent inhibition of moxifloxacin 
on MATE1- and MATE2K-mediated metformin transport was determined. Cells were 
co-incubated with increasing concentrations of moxifloxacin (0.1, 0.3, 3, 30, 100, 300 
and 1000 µM) to enable determination of an IC50 value. For all experiments, compound 
solvents (Milli-Q or DMSO (1%)) were used as positive control. Uptake was stopped at 5 
or 10 min as indicated above by removing the transport buffer and immediately rinsing 
the monolayers with 400 µl of ice-cold HBSS-HEPES buffer containing 0.5% BSA (pH 
7.4), followed by washing with 400 µl of ice-cold HBSS-HEPES buffer (pH 7.4). 
To measure intracellular [14C] metformin concentrations, cells were solubilized in 200 
µl of 1 M NaOH and the radioactivity was determined in aliquots of the lysate after 
adding 4 ml Opti-fluor scintillation fluid (PerkinElmer, Waltham, MA, USA). Radioactivity 
was measured using a Packard Tri-Carb liquid scintillation counter (Ramsey, MN, USA). 
In all experiments, transporter-dependent uptake was calculated by subtracting the 
background (vector control cells containing EYFP) from the corresponding values 
measured in the HEK-transporter cells and expressed relative to the vehicle (positive) 
control.
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Identification of OCT1, OCT2, OCT3, MATE1 and MATE2K TB drug substrates 
To determine whether TB drugs are substrates of OCT1, OCT2, OCT3, MATE1 and 
MATE2K, the uptake of rifampicin, pyrazinamide, ethambutol, amikacin, moxifloxacin 
and linezolid was determined in HEK cells transiently expressing the respective 
transporters as well as EYFP. Intracellular isoniazid could not be quantified under 
current test conditions. The cells were incubated with HBSS-HEPES (HBSS-HEPES pH 
7.4; pH 8.5 in case of MATE2K) containing 10 µM (rifampicin and moxifloxacin) or 100 
µM (isoniazid, pyrazinamide, ethambutol, amikacin, and linezolid) TB drugs at 37°C for 
10 minutes. After the washing steps with ice-cold HBSS-HEPES, cells were solubilized in 
200 µL of 50% Methanol/0.1% formic acid mixture. 
Aliquots were analyzed using LC-MS/MS, consisting of a UPLC (Acquity® I-Class, 
Waters, Milford, MA, USA) coupled to a triple quadrupole mass spectrometer (MS) 
(TQ-S micro®, Waters, Milford, MA, USA). Separation was performed with Liquid 
Chromatography (LC) at 40 °C using a HSS T3 analytical column (1.8 μm; 100 × 2.1 
mm, Acquity UPLC®, Waters, Ireland) coupled with a VanGuard® HSS T3 pre-column 
(1.8 µm; 5 × 2.1 mm, Acquity UPLC®, Waters, Ireland). The mobile phase consisted of 
solvent A (0.1% (v/v) formic acid (HCOOH) in water) and solvent B (0.1% (v/v) formic 
acid (HCOOH) in acetonitrile) at a flow rate of 0.25 mL/minute, using the following 
gradient: 0-4 minutes solvent A (100%), 4-6 minutes solvent A (10%) + solvent B (90%) 
and 6-12 minutes solvent A (100%). The TQ-S micro MS detector was used to assess the 
transitions of five selected reaction monitoring mass pairs for the quantitative analysis of 
all TB drugs. TB drug concentrations were recalculated into intracellular accumulation, 
which was expressed as picomoles per milligram of protein per minute. 
Further kinetic characterization of the proposed substrate ethambutol occurred by 
determining time-dependent and concentration-dependent transport. Time-dependent 
uptake of ethambutol (100 µM) was assessed by performing transport assays at various 
incubation times, namely 1, 5, 10 and 15 minutes. Concentrations-dependent uptake 
was determined by performing uptake assays at a concentration range (0.03, 0.1, 0.3, 1 
and 3 mM) after 1 minute incubation at 37°C.
Follow-up experiments: inhibition of  OCT1-, OCT2-, OCT3-, MATE1- and 
MATE2K-mediated ethambutol uptake
To assess the inhibitory potential of metformin (via competitive inhibition) and 
moxifloxacin on OCT1, OCT2, OCT3, MATE1 and MATE2K-mediated ethambutol uptake, 
10 µM of ethambutol (equaling plasma Cmax of 10 µM (20)) was combined with 200 µM 
of metformin or moxifloxacin in the transport buffer. Cells were incubated for 5 minutes 
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at 37°C. Intracellular ethambutol accumulation was again assessed with LC-MS/MS. 
Finally, we assessed moxifloxacin concentration-dependent inhibition (0.3, 3, 30, 100, 
300 and 1000 µM) of OCT3 and MATE1-mediated ethambutol transport. For these 
transporter inhibition experiments, uptake was again corrected for background (EYFP 
cells) and expressed relative to the vehicle (positive) control.
Data analysis
Data were expressed as mean ± standard error of the mean (SEM) of three independent 
experiments. In each transporter assay, the average amount of cellular protein per 
transporter transduction was determined as a measure for amount of cells per well. 
This estimation of cell death was used to correct for the effects of each transporter 
transduction. Cells for protein concentration determination were solubilized in 200 µL 1 
M NaOH and stored at -20 °C upon analysis. Protein concentrations were determined 
using the Bio-Rad protein assay kit with BSA as a standard. 
Statistically significant differences in uptake (p<0.05) due to transport inhibition were 
assessed using one-way analysis of variance (ANOVA) followed by Dunnett’s post hoc 
multiple comparisons. Curve fitting of concentration-dependent inhibition of transport 
and estimation of IC50 values were established by nonlinear regression analysis using 
GraphPad Prism software version 5.03 (GraphPad Software Inc., San Diego, CA, USA). 
Drug-drug-interaction (DDI) indices, or ratios, were calculated by dividing the maximal 
inhibitor concentration in plasma (unbound and total Cmax) by the transporter-specific 
in vitro IC50 value. Based on international guidelines, a cut-off of >0.1 can be assumed 
to warrant further prospective in vivo investigation (21). Substantial pharmacokinetic 
alterations can be expected for a DDI-index >1 (21). 
One-sample t tests were performed to test if drug uptake ratios of transporter 
expressing cells versus control cells were statistically greater than 1. To estimate 
maximum transport velocity (Vmax) and the substrate concentration at which half of 
this speed is obtained (Km), concentration-dependent uptake data were fitted to the 
Michaelis-Menten equation using GraphPad Prism.
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Results
Inhibition of OCT1-, OCT2-, OCT3-, MATE1- and MATE2K-mediated metformin 
uptake 
HEK293 cells expressing OCT1, OCT2, OCT3, MATE1 and MATE2K were used to study 
the inhibitory action of TB drugs on metformin transport. Figure 2 shows the results of 
screening for inhibition at a TB drug concentration of 200 µM. Firstly, it can be observed 
that metformin uptake by OCT1 and OCT3 was significantly inhibited by moxifloxacin 
to 52 ± 9% and 39 ± 9% (p<0.05) of the control conditions, respectively (Figure 2A 
and 2C). Uptake remained around 50% of that of the control, indicating that the IC50 
values of moxifloxacin were around the tested concentration of 200 µM. Secondly, for 
OCT2-mediated metformin transport both inhibition and stimulation were observed, 
although these did not reach significant levels (Figure 2B). Finally, Figure 2D and 2E 
show that metformin uptake by MATE1 and MATE2K was also significantly inhibited 
by moxifloxacin. This time almost complete inhibition compared to the vehicle control 
was obtained, namely 12 ± 1% (p<0.001) and 16 ± 2% (p<0.01), respectively. Therefore, 
moxifloxacin was selected to determine concentration-dependent inhibition of the 
MATEs. Figure 3A and 3B show these IC50 curves for inhibition of metformin uptake by 
MATE1 and MATE2K, corresponding to IC50 values of 12 µM (95% CI 5.1-29 µM) and 7.6 
µM moxifloxacin (95% CI 0.2-242 µM) (Table 1).
Identification of OCT1, OCT2, OCT3, MATE1 and MATE2K substrates 
HEK293 cells expressing OCT1, OCT2, OCT3, MATE1 and MATE2K were used to 
determine whether TB drugs are substrates of these transporters. Figure 4A-E show 
the results of screening for the uptake of TB drugs. No differences between background 
uptake (cells expressing EYFP) and uptake by transporter-expressing cells were 
observed for rifampicin, pyrazinamide, moxifloxacin and linezolid. Amikacin transport 
ratios (mean ± SEM) for OCT3 and MATE2K relative to control were 2.5 ± 1.5x and 
2.6 ± 0.5x, respectively, but ratios were not statistically significant (p=0.4 and p=0.07, 
respectively). In short, under current test conditions we could not identify rifampicin, 
pyrazinamide, moxifloxacin, amikacin or linezolid as transporter substrates. In contrast, 
ethambutol displayed increased uptake by all transporter expressing cells. Transport 
ratios amounted to 3.0 ± 0.4x for OCT1 (p<0.05), 3.3 ± 0.5x for OCT2 (p=0.05), 2.4 
± 0.09x for OCT3 (p<0.01), 3.5 ± 0.8x for MATE1 (p=0.09) and 1.6 ± 0.2x for MATE2K 
(p=0.05). Of note, we observed higher ethambutol uptake in control cells exposed 
to the transport buffer with pH 8.5 (Figure 4E), explaining the smaller transport ratio 
for MATE2K. Possibly there is enhanced contribution of endogenously expressed 
transporters under these conditions. 
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Figure 2. Effect of TB drugs (200 µM) on the uptake of metformin into HEK293 cells overexpressing 
OCT1 (A), OCT2 (B), OCT3 (C), MATE1 (D) and MATE2K (E).  
Transport is expressed in % of solvent controls and is presented as mean ± SEM. Inhibition larger 
than 70% is indicated by the gray bars. This drug (moxifloxacin) was selected to further determine 
concentration-dependent inhibition. Data were pooled from three independent experiments. 
* Statistically significant difference from control with one-way ANOVA, post-hoc Dunnett’s (p<0.05). 
AMK, amikacin; EMB, ethambutol; INH, isoniazid; LZD, linezolid; MQ, Milli-Q; MXF, moxifloxacin; PZA, 
pyrazinamide; RIF, rifampicin
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Figure 3. Moxifloxacin concentration-dependent inhibition of metformin uptake by MATE1 (A) 
and MATE2K (B).
For moxifloxacin, the TB drug with an inhibitory potential of >70% during screening, 
concentration-dependent inhibition of metformin was determined. Transport is expressed in % of 
solvent controls and is presented as mean ± SEM for each data point. Data were pooled from three 
independent experiments.
Table 1. In vitro inhibitory potency, expressed as a DDI-index, of moxifloxacin on 
transporter-mediated uptake of metformin and ethambutol.
Substrate
Moxifloxacin 
inhibition 
parameter
OCT1 OCT3 MATE1 MATE2K
Metformin 
IC50 (µM) ~200 ~200 12 7.6
Cmax/IC50 0.08 0.08 1.3 2.0
Cmax,free/IC50 0.04 0.04 0.6 1.0
Ethambutol
IC50 (µM) ~200 154 12 ~200
Cmax/IC50 0.08 0.1 1.3 0.08
Cmax,free/IC50 0.04 0.05 0.6 0.04
Moxifloxacin Cmax and derived Cmax,free were obtained from literature; Cmax was set at 6.0 mg/L (15 µM) 
(44) and protein binding at 50% (45). The DDI-index was calculated by dividing Cmax by IC50 and Cmax,free 
by IC50. DDI-indices exceeding the 0.1 cut-off value are in bold, and those >1 are also underlined (21). 
Cmax, maximum plasma concentration; Cmax,free maximum unbound plasma concentration 
After testing an incubation time range (1, 5, 10 and 15 minutes), it became evident that 
ethambutol (100 µM) uptake occurred linearly only for a very short time frame, namely 
from 0 until <1 minute for OCT1 and OCT2, and from 0 to approximately 1 minute for OCT3, 
MATE1 and MATE2K (Supplementary file). This information is important when deriving 
Michaelis-Menten curves and equations, as accurate concentration-dependency can 
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only be established within the linear phase of transport, and not at saturated transport 
conditions. Nonetheless, all Km-Vmax curves were performed with a 1 minute incubation 
time, because it was technically not possible to perform transport assays below 1 
minute. Thus we cannot exclude that Km values for OCT1 and OCT2 were obtained at 
saturated transport conditions and are therefore less reliable
.
Figure 4. Uptake of TB drugs into HEK293 cells overexpressing OCT1 (A), OCT2 (B), OCT3 (C), 
MATE1 (D) and MATE2K (E) relative to uptake in the control cell line expressing EYFP.
Uptake of TB drugs (10 µM of rifampicin and moxifloxacin or 100 µM of isoniazid, pyrazinamide, 
ethambutol, amikacin and linezolid) was assessed. Transport is expressed as pmol/mg/min and 
presented as mean ± SEM. Data were pooled from three or four independent experiments.
¥ Could only be performed in duplicate due to measurements below limit of detection
Figure 5A-E demonstrate the Michaelis-Menten curves of ethambutol for OCT1, OCT2, 
OCT3, MATE1 and MATE2K, respectively. The affinity of ethambutol, as quantified by 
A B
C D
E
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Km, amounted to 686 µM (95% CI 0-1521 µM) for OCT1, 314 µM (95% CI 0-646 µM) 
for OCT2, 1356 µM (95% CI 0-3584 µM) for OCT3, 2164 µM (95% CI 0-4838 µM) for 
MATE1 and 819 µM (95% CI 0-2660 µM) for MATE2K. To enable the determination of 
reliable affinity constants, substrate concentrations in the Michaelis-Menten plot should 
increase until 3-5 times the Km value, which was not the case for OCT3 and MATE1 
(Figure 5). However, testing at higher ethambutol concentrations (>3 mM) was deemed 
physiologically irrelevant. 
Figure 5. Michaelis–Menten kinetic curves showing the relation between ethambutol concentration 
and transport velocity of OCT1 (A), OCT2 (B), OCT3 (C), MATE1 (D) and MATE2K (E).
Transport is expressed in pmol/mg/min and presented as mean ± SEM for each data point. Data were 
pooled from three or four independent experiments. 
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Figure 6. Effect of metformin and moxifloxacin (200 µM) on the uptake of ethambutol into HEK293 
cells overexpressing OCT1 (A), OCT2 (B), OCT3 (C), MATE1 (D) and MATE2K (E).
Transport is expressed in % of solvent controls and is presented as mean ± SEM. Inhibition larger 
than 70% is indicated by the gray bars. This drug (moxifloxacin) was selected to further determine 
concentration-dependent inhibition. Data were pooled from three independent experiments.
* Statistically significant difference from control with one-way ANOVA, post-hoc Dunnett’s (p<0.05) 
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Inhibition of  OCT1-, OCT2-, OCT3-, MATE1- and MATE2K-mediated ethambu-
tol uptake
Figure 6 shows the results of screening for the inhibitory effect of metformin and 
moxifloxacin (200 µM) on ethambutol uptake by OCT1 (A), OCT2 (B), OCT3 (C), 
MATE1 (D) and MATE2K (E). Metformin only inhibited MATE2K-mediated ethambutol 
uptake significantly, but activity was not reduced to <30% of the control. Moxifloxacin 
significantly inhibited ethambutol transport by OCT1, OCT3 and MATE1. In case of OCT3 
and MATE1 inhibition was reduced >70%, namely 25 ± 5% (p<0.01) and 10 ± 1% (p<0.05) 
of the control, respectively (Figure 6C and 6D). Moxifloxacin concentration-dependent 
inhibition was further determined for OCT3 and MATE1 (Figure 7A and 7B). IC50 values 
corresponded to 154 µM (95% CI 60-393 µM) for OCT3 and 12 µM (95% CI 3.4-43 µM) 
for MATE1 (Table 1). 
Figure 7. Moxifloxacin concentration-dependent inhibition of ethambutol uptake by OCT3 (A) and 
MATE1 (B).
For moxifloxacin, the TB drug with an inhibitory potential of >70% during screening, 
concentration-dependent inhibition of ethambutol was determined. Transport is expressed in % of 
solvent controls and is presented as mean ± SEM for each data point. Data were pooled from three 
independent experiments.
Discussion
This study assessed the in vitro inhibitory effects of TB drugs (rifampicin, isoniazid, 
pyrazinamide, ethambutol, amikacin, moxifloxacin and linezolid) on the transport of 
metformin by OCT1, OCT2, OCT3, MATE1 and MATE2K. We found that moxifloxacin 
potently inhibited (DDI-index >0.1) MATE1- and MATE2K-mediated metformin transport 
(IC50 values of 12 µM (95% CI 5.1-29 µM) and 7.6 µM (95% CI 0.2-242 µM), respectively), 
but is not a substrate for these transporters itself. We did identify ethambutol as a 
substrate of OCT1, OCT2, OCT3, MATE1 and MATE2K, even though it did not have a 
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strong (competitive) inhibitory effect on metformin transport. Finally, we demonstrated 
that MATE1-mediated ethambutol uptake was also inhibited strongly (DDI-index >0.1) 
by moxifloxacin (12 µM (95% CI 3.4-43 µM)), but not by metformin. TB drugs other 
than moxifloxacin did not inhibit OCT- and MATE-mediated transport of metformin, 
and ethambutol was the only substrate to these transporters amongst the TB drugs 
investigated.   
This study identified moxifloxacin as a potent MATE1 (metformin and ethambutol 
uptake) and MATE2K (metformin uptake) inhibitor. The relatively weaker inhibition of 
OCT1 and OCT3 (metformin and ethambutol uptake) do not exceed the proposed 
DDI-index threshold of 0.1 (Table 1), but may still be relevant at the site of the intestinal 
lumen where drug exposure is expected to be higher than in plasma. However, the 
contribution of OCTs to intestinal uptake remain rather unclear, as they are far less 
abundant than PMAT (Figure 1). Our findings with respect to MATE inhibition by 
moxifloxacin complement the results published by Morrissey et al. (2016) recently, who 
reported that moxifloxacin inhibits MATE1- and MATE2K-mediated metformin transport 
with IC50 values of 5 and 1 µM, respectively (22). From literature we know that inhibitors 
of OCT and MATE can have a clinically relevant impact on the pharmacokinetics of 
concomitantly administered organic cations through reduction in their renal clearance 
(14, 15, 23). Known inhibitors are cimetidine for OCT2 (IC50 of 110 µM (24)) and MATE1/
MATE2K (Ki of 7 and 1 µM, respectively (25)); and pyrimethamine for OCT2 (Ki of 10 
µM (15)) and MATE1/MATE2K (Ki values of 93 and 59 nM, respectively (15)). Both 
inhibitors also increase plasma concentrations of metformin, even though the IC50 
value of cimetidine for the basolaterally located OCT2 does not seem clinically relevant 
(DDI-index 0.07 (26)). In contrast to cimetidine, the selective MATE2K inhibitor nizatidine 
did not significantly reduce renal clearance of metformin in twelve healthy volunteers, 
but it did increase the apparent volume of distribution, half-life and hypoglycaemic 
activity of metformin, possibly indicating increased metformin accumulation and 
subsequent glucose handling in renal cells, with continued renal filtration as well as 
secretory clearance via MATE1(22). 
When comparing cimetidine IC50 values for MATE1 and MATE2K (DDI-index of 1.1 and 
7.9, respectively) with those of moxifloxacin in this study (DDI-index of 1.3 and 2.0, 
respectively), the indices can be considered relatively similar and, therefore, a clinical 
significant interaction may be anticipated for moxifloxacin co-administered with MATE 
substrates such as metformin. DDI-indices for MATEs may even be underestimated, 
as these are based on (unbound) plasma concentrations, while MATE exporters 
are inhibited from the inside of the cell. Because moxifloxacin has a high volume of 
distribution (~3 L/kg (27)), is lipophilic, and has low protein binding (50%), it is likely that 
beyond the central compartment intracellular accumulation occurs.
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Reported findings for moxifloxacin may also have implications for the co-administration 
of levofloxacin (another group III fluoroquinolone TB drug) with cations, such as 
metformin. Previously, levofloxacin demonstrated to inhibit human MATE1 (IC50 value 
38 µM) and human MATE2K (IC50 value 82 µM) (28). IC50 values were reported for 
the model MATE substrate tetraethylammonium (TEA), but effects may be different for 
other substrates. Further research should assess the inhibitory potential of levofloxacin 
on transport of metformin and ethambutol to draw more firm conclusion with respect 
to its DDI potential.
Although metformin is known to have a very favorable safety profile, including a 
minimal risk of hypoglycaemia, decreased elimination of metformin might pose a 
higher risk for adverse effects, such as lactic acidosis (11, 29). However, lactic acidosis 
occurs only very rarely. On the other hand, MATE inhibition could also strengthen the 
glucose-lowering effect of metformin, either via the liver due to increased plasma and 
hepatocyte exposure or via the kidneys due to local metformin accumulation. Kidneys 
are known to have a minor but significant role in glucose uptake, gluconeogenesis and 
glucose utilization (30, 31). Overall, with current in vitro data it is hard to predict the 
effect of moxifloxacin-induced inhibition of renal excretion on accumulation in renal 
tubular cells, increased plasma concentrations and pharmacodynamic endpoints. These 
processes should also be considered when building and refining a physiologically-based 
pharmacokinetic (PBPK) model to predict pharmacokinetic DDIs in the kidneys based 
on in vitro data. 
To our knowledge, our study is the first to demonstrate that ethambutol is a substrate 
of cation transporters, such as the OCTs and the MATEs. This finding provides a 
mechanistic basis for DDI-predictions concerning ethambutol. For example, available 
data suggest that the combination of ethambutol with inhibitors of OCTs and MATEs, 
such as moxifloxacin, may have pharmacokinetic implications. Ethambutol is part of the 
first-line TB treatment regimen together with isoniazid, rifampicin and pyrazinamide, 
as recommended by the World Health Organization (WHO) (19), even though it is 
considered to have limited bactericidal activity. Similarly to metformin, ethambutol has 
a positive charge at physiologic pH and has low lipophilicity with a negative logP of 
-0.14 (32). Renal elimination is its major clearance mechanism, with approximately 50 to 
70% of oral doses and 70 to 84% of intravenous doses being recovered unchanged in 
the urine of subjects with normal renal function (33, 34). The renal clearance rate (~417 
ml/min) indicates that both active net tubular secretion and glomerular filtration (120 
ml/min) are involved (35). We previously did not know to what degree transporters 
are involved in the disposition of ethambutol. Only the study by Pan et al. (2013) had 
demonstrated an inhibitory potential of ethambutol on OCTs, but IC50 values were in 
the higher micromolar range (36). 
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There are no interaction studies available that have assessed the effect of moxifloxacin 
as an inhibitor on ethambutol pharmacokinetics. Current efforts to incorporate 
moxifloxacin in the first line TB treatment regimen mainly focus at replacing ethambutol 
(37, 38). For future regimens containing both ethambutol and moxifloxacin it could 
be of interest to perform an in vivo interaction study. Such studies are indispensable 
to assess the contribution of inhibition of single or multiple transporters expressed in 
various organs throughout the human body, and evaluate the clinical relevance of an 
observed pharmacokinetic interaction. An in vivo interaction study is not warranted for 
the interaction between metformin and ethambutol (Table 1). Possibly SLC transporters 
are less likely to be saturated by competition of two substrates, which is supported by 
the high Km values of both metformin and ethambutol (high micromolar and millimolar 
range) (39) and the high IC50 values on the function of OCTs in the study by Pan et al. 
(2013) (36).
In summary, we found moxifloxacin to be a potent inhibitor of MATE1- and 
MATE2K-mediated metformin transport and identified ethambutol as a substrate 
of OCT1, OCT2, OCT3, MATE1 and MATE2K. Furthermore, we demonstrated that 
MATE1-mediated ethambutol uptake was also inhibited by moxifloxacin, but not so 
by metformin. According to international guidelines, our results warrant further in vivo 
interaction studies. The data could also serve as valuable input for PBPK modeling to 
predict intracellular and plasma drug concentrations of metformin and ethambutol and 
simulate clinical DDIs with these drugs.
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Supplementary file. 
Ethambutol time curves showing the relation between incubation time in minutes and total uptake for 
OCT1, OCT2, OCT3, MATE1, and MATE2K. Transport is expressed in pmol/mg and is presented as 
mean ± SEM of three independent experiments.
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Abstract
Linezolid is a promising agent for future multi-drug resistant tuberculosis (MDR-TB) 
regimens. Efficacy of novel and experimental regimens is generally first evaluated in 
the TB mouse model. To improve clinical predictability from animal efficacy studies, 
it is important to test a linezolid dose that results in systemic drug exposures similar 
to those in MDR-TB patients. Furthermore, pharmacokinetic analyses in mice would 
benefit from measurement of analytes in small blood volumes using the ‘dried blood 
spot’ (DBS) technique, because it allows for the assessment of drug concentrations over 
time within a single mouse. This study aimed to identify the human pharmacokinetic 
equivalent dose of linezolid in mice, as well as to validate DBS analysis for measuring 
linezolid concentrations in mouse blood spots as an estimate of plasma concentrations. 
Pharmacokinetic studies were performed in 64 mice after oral administration of single 
doses (12.5, 25, 50 and 100 mg/kg) of linezolid. Linezolid total and unbound plasma 
concentrations and DBS concentrations were analyzed by validated high-performance 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) assays. Nonlinear 
kinetics of linezolid were observed, which complicated deriving an exact human 
pharmacokinetic equivalent dose. We identified 50 mg/kg oral linezolid (AUC0-∞ 78 
mg/L*h) in BALB/c mice as the pharmacokinetic equivalent of a dose between 300 
and 600 mg in humans. We recommend this dose for future MDR-TB regimen efficacy 
testing. Concentrations in mouse DBS spots were slightly lower than in plasma: 
Passing-Bablok regression demonstrated a significant proportional bias with a slope 
of 0.81 (95% CI 0.79-0.84). To compensate for the differences in mouse plasma and 
DBS, we propose a conversion factor of 1.2 to predict plasma concentrations from 
DBS. Measurement of drug concentrations in mouse DBS may significantly reduce the 
number of animals needed for future pharmacokinetic-pharmacodynamic (PK-PD) 
assessments of linezolid.
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Introduction
Globally, an estimated 480,000 tuberculosis (TB) patients suffer from multi-drug 
resistant TB (MDR-TB), a level that has changed little in recent years (1). Only 50% of 
MDR-TB patients were successfully treated in 2014 (1), indicating that MDR-TB treatment 
remains far from adequate. The oxazolidinone linezolid, a group 5 TB drug in the World 
Health Organization (WHO) treatment guideline, has shown good activity against drug 
resistant strains in preclinical studies (2, 3), with growing evidence for its efficacy in 
patients suffering from MDR-TB and extensively drug resistant TB (XDR-TB) (4, 5).
Before the contribution of linezolid to novel MDR-TB regimens can be investigated 
in patients, this first has to be tested in appropriate preclinical models, such as the TB 
mouse model. Pharmacokinetic data are indispensable in these studies, as linezolid 
exposure is considered predictive for treatment outcome and adverse effects such as 
hematologic toxicity and peripheral neuropathy (6-8). The linezolid pharmacokinet-
ic-pharmacodynamic (PK-PD) parameters of interest are the (protein-unbound) area 
under the concentration versus time curve (AUC) to minimum inhibitory concentration 
(MIC) ratio, and time above MIC (7, 9) .
To improve clinical predictability from animal efficacy studies, it is important to test 
a linezolid dose that is pharmacokinetically equivalent to the dose used in MDR-TB 
patients. Furthermore, pharmacokinetic analyses in mice would benefit from 
measurement of analytes in small blood volumes using the ‘dried blood spot’ (DBS) 
technique (10), because it allows for the assessment of drug concentrations over time 
within a single mouse. This could significantly reduce the number of animals needed for 
pharmacokinetic assessment, as conventionally one animal is euthanized for collection 
of a single blood sample to ensure sufficient quantities of analytical sample. 
To optimize linezolid efficacy testing in mice, the aim of this study was to identify the 
linezolid dose resulting in exposures equivalent to those found in humans, as well as to 
validate DBS analysis for measuring linezolid concentrations in mouse blood spots as 
an estimate of plasma concentrations.  
Methods
Animals
Specified-pathogen-free female BALB/c mice were obtained from Charles River (Les 
Oncins, France). Experimental protocols adhered to the rules specified in the Dutch 
Animal Experimentation Act (1977) and the published Guidelines on the Protection of 
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Experimental Animals by the Council of the EC (1986). The Institutional Animal Care 
and Use Committee of the Erasmus MC Rotterdam approved the protocol [117-12-14, 
EMC2888].
Experimental set-up
Pharmacokinetic studies were performed in 64 mice after oral administration of single 
doses of linezolid (Sigma-Aldrich, Zwijndrecht, the Netherlands). Mice were treated with 
a linezolid dosage range (12.5, 25, 50 and 100 mg/kg dissolved in phosphate-buffered 
saline (PBS)) and samples were taken at 0.25, 0.5, 0.75, 1, 1.5, 3, 5 and 10 h after the dose. 
Two animals were euthanized for each dosage and sampling time point. Blood was 
collected via cardiac puncture, after which DBS samples were obtained by pipetting 40 
µl of blood onto Whatman DMPK-C cards (Whatman, Kent, UK). The remaining blood 
was centrifuged to obtain plasma, which was stored at -80 °C until further analysis.
Analysis of plasma and DBS linezolid concentrations
Linezolid concentrations in plasma were analyzed by a validated high-performance 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay at the University 
Medical Center Groningen, the Netherlands (11). The assay accuracy was 96.3-108.5%, 
the within-run CV ranged from 2.5-7.1% and the lower limit of quantitation (LLOQ) 
was 0.05 mg/L. Cross-validation between human and mouse plasma matrices 
was performed by comparing responses of three Quality Control (QC) linezolid 
concentrations (0.5, 15 and 30 mg/L in 5-fold) in human plasma with those in mouse 
plasma. The accuracy of mouse relative to human plasma measurements was between 
101-114%, with a within-run CV of 1.7-2.6%. Protein-unbound concentrations of linezolid 
were measured in all samples and were obtained following ultrafiltration of plasma, to 
separate bound from unbound linezolid, using Centrifree YM-T 30 kDa ultrafiltration 
tubes (Merck-Millipore, Amsterdam, the Netherlands). Clear ultrafiltrate was analyzed 
via LC-MS/MS. 
To quantify mouse DBS samples a validated method for human samples was used 
(12). The DBS assay accuracy was within 98.7-106.3%, the overall precision (coefficient 
of variation, CV) ranged from 5.3-17.2%, and the lower limit of quantification (LLOQ) 
was 0.05 mg/L. Cross-validation between human and mouse DBS was performed by 
comparing responses of three quality control (QC) linezolid concentrations (0.5, 15 and 
30 mg/L in 5-fold) in human DBS with those in mouse DBS (40 µL blood spots). The 
accuracy of mouse relative to human DBS measurements was between 111-140% (mean 
bias 123%), with a within-run CV of 2.1-2.7%. The bias may be explained by measured 
differences in hematocrit concentrations in human and mice, 35% versus 55% (95% 
CI 44-67%), respectively. DBS sampling is hampered by variation in hematocrit due to 
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differences in blood viscosity values, yielding a proportional analytical bias. Therefore, 
we corrected all mouse DBS concentrations with a factor 0.82 (1/mean bias).
Pharmacokinetic evaluation
Pharmacokinetic parameters were assessed using standard noncompartmental 
methods in Phoenix WinNonlin version 6.4 (Pharsight Corporation) (13). To determine 
the human pharmacokinetic equivalent dose, AUC from time point 0 to infinity for 
single dose (AUC0-∞) in mice were compared to clinically relevant linezolid exposures in 
humans at steady state, namely AUC within the dosing interval (AUC0-τ). By definition, 
AUC0-∞ after single dose equals c after multiple doses (14). In literature, median AUC0-12h 
in TB patients taking 300 mg twice daily was 58 mg/L*h (15). For 600 mg twice daily, 
AUC0-12h amounted to 140-146 mg/L*h (15, 16). Single oral doses of 375 and 625 mg in 
healthy adults resulted in an AUC0-∞ of 66 and 102 mg/L*h, respectively (17). 
Agreement analysis of plasma and DBS linezolid concentrations
The level of agreement between the DBS and the plasma method was analyzed 
by comparing linezolid concentrations in DBS samples with those in plasma using 
Passing-Bablok regression and Bland-Altman analysis with Analyze-it version 2.20 
(Analyze-it Software, Ltd.) (18). Only DBS concentrations were included that were below 
the highest QC cross-validated (<30 mg/L).
Results
Pharmacokinetic evaluation
Plasma concentration-time profiles and pharmacokinetic parameters of linezolid 
dosages are shown in Figure 1 and Table 1, respectively. Pharmacokinetics appeared 
to be nonlinear, as increases in exposure were not proportional to increases in 
dosage. The highest dose of 100 mg/kg was an exception to this (Table 1). The mean 
percentage unbound linezolid across all samples was 57 ± 9% (mean ± sd), which 
seems comparable, though somewhat lower, than the free fraction found in humans 
(70%) (9). Considering the exposures in Table 1, and the relatively comparable protein 
binding in humans, 50 mg/kg in BALB/c mice (AUC0-∞ of 78 mg/L*h) would approximate 
free linezolid exposures of a dose between 300 and 600 mg in humans (or between 58 
and 140 mg/L*h). 
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Figure 1. Linezolid plasma concentration-time profiles following single oral doses of 12.5 mg/kg 
(diamonds), 25 mg/kg (open circles), 50 mg/kg (circles) and 100 mg/kg (triangles) in BALB/c mice. 
Plasma concentrations are plotted as mean and minimum-maximum of two mice per dosage and time 
point (n=64). LZD, linezolid
Table 1. Pharmacokinetic parameters of linezolid in plasma following single oral doses of 12.5 
mg/kg, 25 mg/kg, 50 mg/kg and 100 mg/kg in BALB/c mice. 
Dose  
(mg/kg)
AUC0-∞ 
(mg/l*h)
Cmax 
(mg/l)
CL/F  
(l/h)
Vd/F  
(l)
t½  
(h)
12.5 8.3 6.3 0.033 0.054 1.1
25 28 18 0.020 0.038 1.3
50 78 40 0.014 0.030 1.4
100a 141 63 0.016 0.054 2.4
Pharmacokinetic parameters are based on the mean concentration of two sacrificed mice (n=64) 
AUC0-∞ after single dose equals AUC0-τ for a dosing interval at steady state (14)
a Dosage was at the limit of solubility, homogeneity of suspension was strived for by vortexing just prior 
to administration. 
AUC0-∞, area under the plasma concentration-time curve from time point 0 to infinity for single dose; CL, 
clearance; Cmax, maximum plasma concentration; F, bioavailability; Vd, volume of distribution
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Figure 2. Assessment of the level of agreement between linezolid concentrations measured in 
plasma and in DBS using Passing-Bablok regression (A) and Bland-Altman analysis (B).
In the scatter plot with Passing-Bablok fit, linezolid concentrations in DBS are plotted against their 
concentration in plasma (a). The line of identity is presented in solid gray and the Passing-Bablok 
regression line is dashed. The regression line has a slope of 0.81 (95% CI 0.79-0.84) and an intercept 
of -0.015 (95% CI -0.064-0.041). Bland-Altman analysis plots the linezolid DBS/plasma concentration 
ratio versus the average concentration in DBS and plasma (b). The line representing the mean ratio is 
solid, while the lines depicting the 95% Limits of Agreement (LoA), containing 95% of the data points, 
are dashed. The mean ratio is 0.90 (95% CI 0.79-0.82). 
A
B
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Agreement between plasma and DBS concentrations
Figure 2 displays the assessment of the level of agreement between measurement of 
linezolid in mouse plasma and DBS samples (n=46 data points <30 mg/L). A significant 
proportional bias was observed in the Passing-Bablok analysis with a slope of 0.81 (95% 
CI 0.79-0.84) (Figure 2a). The Bland-Altman analysis showed that the lower (0.71 (95% 
CI 0.69-0.73)) and upper (0.90 (95% CI 0.87-0.92)) 95% Limits of Agreement (LoA) 
were relatively narrow around the mean DBS/plasma linezolid concentration ratio of 
0.80 (95% CI 0.79-0.82)) (Figure 2b). A 20% difference in exposure is often used as a 
clinically relevant difference in pharmacokinetic data-analysis. The lower and upper 
LoA are within this accepted range of variation. From a linear regression analysis with 
plasma concentration as dependent and DBS concentrations as independent variable, 
we derived a conversion factor of 1.23 to predict mouse plasma concentrations from 
DBS levels (R2 = 0.995, p<0.001). 
Discussion 
In this study, we found that a linezolid dose of 50 mg/kg resulted in an AUC0-∞ of 78 
mg/L*h in BALB/c mice, which approximates free linezolid exposures of a dose between 
300 and 600 mg in humans. We recommend this dose for future MDR-TB regimen 
efficacy testing. In literature there has been an ongoing debate on the optimal linezolid 
dose or concentrations associated with treatment efficacy in humans. Initial treatment 
of MDR-TB with 600 mg of linezolid twice daily has been limited by adverse effects 
(15, 19). Lower doses mostly seemed to retain effectiveness and limit toxicity (7, 15, 
19). Therefore, linezolid doses ≥100 mg/kg tested in mice previously, probably by far 
exceed clinically useable doses and exposures (20, 21).
Nonlinear kinetics of linezolid were observed. Exposure increases approximately 
3-fold after a 2-fold increase in dose, which complicated deriving an exact human 
pharmacokinetic equivalent dose. Of note, the 100 mg/kg dose shows a very distinct 
dose-exposure relation, i.e. a 2-fold increase in the higher dose range (from 50 to 100 
mg/kg) results in only a 1.8-fold increase in exposure (from 78 to 141 mg/l*h). Also 
peak exposures increased over 2-fold in the highest dosage group. This phenomenon 
may be explained by decreased solubility of higher concentrations of linezolid in the 
vehicle, possibly resulting in relatively less drug being available for absorption from 
the intestinal lumen. Another explanation may be formed by the limited absorption 
of large(r) amounts of drug in the gut lumen. Nonlinearity has been demonstrated 
in mice previously at lower oral linezolid doses (0.625-40 mg/kg) (22), but not after 
intraperitoneal or subcutaneous administration (23, 24). This underlines the importance 
of route of administration as well as pharmacokinetic confirmation of drug exposures 
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in drug efficacy studies. Nonlinearity has also been shown before in humans, but to 
different extends (9, 15, 17, 25). In a population pharmacokinetic analysis linezolid 
nonlinearity could not be explained by enzyme kinetics and was thought to be related 
to mitochondrial function (25) .
With respect to the analysis of linezolid in mouse DBS, we showed that concentrations in 
blood are slightly lower than in plasma, as we found a significant proportional bias with 
a slope of 0.81 (95% CI 0.79-0.84). To compensate for the differences in mouse plasma 
and blood, we propose a conversion factor of 1.2 to predict plasma concentrations 
from DBS levels. Bland-Altman analysis showed that the lower and upper 95% LoA 
are relatively narrow around the average linezolid DBS/plasma concentration ratio, 
namely 0.71-0.90, meaning that the DBS/plasma ratio can be estimated with rather 
good precision. 
Current findings are in contrast with the higher linezolid levels found in human DBS 
compared to human plasma previously (12), which may be explained by interspecies 
differences in (binding to) blood components. Furthermore, less spread is observed 
in mice plasma/DBS ratios compared to human ratios (12), probably due to the larger 
heterogeneity in human blood/hematocrit composition. To our knowledge, no studies 
measuring linezolid (or any other TB drug) in mouse DBS have been reported, even 
though the general feasibility of serial sampling in mice with the DBS technique has been 
published before (26, 27). Compound specific validation in DBS matrix is indispensible, 
as factors such as blood/plasma partition ratios and the impact of hematocrit may be 
very drug specific, and can greatly complicate the comparison with plasma samples 
(28).
Overall, this study provides very practical considerations and techniques for linezolid 
drug efficacy studies in mice, with linezolid as part of a future MDR-TB regimen. 
Furthermore, the applied measurement of drug concentrations in mouse DBS may 
significantly reduce the number of animals needed for these future PK-PD assessments. 
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Abstract
The use of dried blood spot (DBS) analysis for the quantification of drug concentrations 
can reduce the number of animals used in preclinical drug development. In order to 
evaluate the use of DBS analysis we conducted a pharmacokinetic study in healthy 
mice to compare moxifloxacin concentrations in plasma with mouse blood spots. We 
also determined the pharmacokinetic parameters to define a human equivalent dose of 
moxifloxacin. A Passing-Bablok plot showed a small positive bias for DBS versus plasma 
measurements, and Bland-Altman analysis showed a small range around the mean 
DBS/plasma moxifloxacin concentration ratio. This indicates that DBS concentrations can 
predict plasma concentrations with acceptable precision. Analyses of pharmacokinetic 
parameters showed that a 200 mg/kg dose of moxifloxacin in mice would approximate 
a human equivalent exposure, based on AUC values. These results suggest that DBS 
analysis can be used to predict moxifloxacin concentrations in plasma in preclinical 
mouse models.
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Introduction
Despite the failure of moxifloxacin to effectively shorten treatment duration of drug 
susceptible tuberculosis (TB) in recent trials (1), it remains a strong companion drug 
within novel TB drug combinations for susceptible TB (2). In addition, it is still of great 
value for multidrug-resistant TB (MDR-TB) treatment. MDR-TB requires a prolonged 
treatment time, drug treatment is expensive and yields successful response in only 
50% of MDR-TB patients (3). Several preclinical studies presented promising results of 
moxifloxacin as part of novel regimens against drug resistant Mycobacterium tuberculosis 
(M. tuberculosis) (4, 5) and, as a result of these preclinical studies, moxifloxacin is being 
evaluated as part of a universal regimen for susceptible and MDR-TB (6).
The use of moxifloxacin in preclinical studies as well as its subsequent evaluation in novel 
treatment regimens in TB patients requires a clear understanding of its dose-response 
relationships. Pharmacokinetic confirmation and optimum dose finding in preclinical 
models may prevent suboptimal exposures in efficacy studies and avoid inaccurate 
comparisons between regimen potencies (7). 
In these preclinical studies, moxifloxacin is ideally measured in small sample volumes 
allowing repeated sampling within one animal. This would allow for a significant decrease 
in the number of animals used for preclinical pharmacokinetic studies, which is of ethical 
importance. Dried blood spots (DBS) analysis in combination with high-performance 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis may permit 
these novel sampling strategies, which could possibly replace conventional sampling.
The objectives of our study were to evaluate the use of DBS analysis for measuring 
moxifloxacin concentrations in mouse blood spots, as well as to identify the human 
equivalent dose of moxifloxacin.
Methods
Animals 
Specified pathogen-free female BALB/c mice were obtained from Charles River (Les 
Oncins, France). At the day of the experiments, animals were 13-15 weeks old and 
weighed 20-25 gram. Experimental protocols adhered to the rules specified in the 
Dutch Animal Experimentation Act and are in concordance with the EU animal directive 
2010/63/EU. The Institutional Animal Care and Use Committee of the Erasmus MC 
approved the present protocols (117-12-14). 
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Experimental set-up 
A single-dose pharmacokinetic study was performed in healthy mice given oral doses 
of moxifloxacin (Sigma-Aldrich, Zwijndrecht, the Netherlands) dissolved in sterile water 
(50, 100, 200 and 400 mg/kg). Blood samples were obtained via cardiac puncture (n=2 
mice/dose/time point) at 0.25, 0.50, 0.75, 1, 1.5, 3, 5 and 10 h after dosing. Samples were 
collected in microcentrifuge tubes with EDTA. Before centrifugation, 40 µl of blood was 
spotted onto Whatman FTA/DMPK-C cards (Whatman, Kent, UK). Cards were allowed 
to dry for 3 hours. Remaining blood was centrifuged at 10.000 x g for 5 minutes to 
obtain plasma. Cards and plasma were frozen at -80°C.  
Analysis of plasma and DBS moxifloxacin concentrations 
Moxifloxacin concentrations in plasma were analyzed with a LC-MS/MS assay, validated 
for human plasma, at the University Medical Center Groningen, the Netherlands (8). 
Cross-validation of the assay for human plasma to mouse plasma was performed by 
comparing responses of 5-fold measurements of Quality Control (QC) moxifloxacin 
samples (concentrations 0.5, 2.5 and 5.0 mg/L) in human plasma with those in mouse 
plasma after analysis of all samples with the LC-MS/MS assay for human plasma. The 
accuracy of measurement of mouse samples with the assay for human samples was 
between 88-97% and the within-run CV amounted to 4.0-6.2%. 
Protein-unbound (free, active) concentrations of moxifloxacin were measured in all 
samples and were obtained following ultrafiltration of plasma, to separate unbound from 
bound moxifloxacin, using Centrifree YM-T 30 kDa ultrafiltration tubes (Merck-Millipore, 
Amsterdam, the Netherlands). Clear ultrafiltrate was analysed via LC-MS/MS. 
To quantify DBS samples, a validated extraction method was used (9). Extracts were 
analyzed using the same LC-MS/MS analysis method as for plasma. Cross-validation of 
the assay for human to mouse DBS samples was performed by comparing responses 
of 5-fold measurements of QC moxifloxacin DBS samples (concentrations 0.5, 2.5 and 5 
mg/L) in human blood with those in mouse blood (40 µL blood spots) after analysis of all 
samples with the LC-MS/MS assay for human DBS samples. Accuracy of measurement 
of mouse DBS samples with the assay for human DBS samples was between 123-125% 
and the within-run CV amounted to 2.0-3.6%. The positive bias of 23-25% may be 
explained by differences in hematocrit concentrations in humans and mice, i.e circa 
35% versus measured hematocrit of 55% (95% CI 44-67%), respectively. DBS sampling 
is known to be hampered by variation in hematocrit, resulting in differences in blood 
viscosity values and sample volumes, yielding a proportional analytical bias. Therefore, 
we corrected all mouse DBS concentrations with a factor 0.81 (1/mean bias).
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Pharmacokinetic evaluation
Pharmacokinetic parameters were assessed using standard noncompartmental 
methods in Phoenix WinNonlin version 6.4 (Pharsight Corporation), as described 
previously (10). To determine exposure equivalence with human moxifloxacin exposures, 
areas under the plasma concentration-time curve up to infinity (AUC0-∞) and peak (Cmax) 
values after a single dose in mice were compared to clinically relevant AUC0-τ and Cmax 
steady state moxifloxacin exposures in humans, considering that AUC0-∞ after a single 
dose is equivalent to AUC0-τ in a dosing interval t at steady-state.
Agreement analysis of moxifloxacin concentrations in plasma and DBS 
The level of agreement between the DBS method and the plasma method was analyzed 
by comparing the moxifloxacin concentrations in DBS samples with the concentrations 
in plasma using Passing-Bablok regression and Bland-Altman analysis with Analyze-it 
version 2.20 (Analyze-it Software, Ltd.) (11). Only DBS concentrations were included that 
were below the highest QC that was cross-validated, namely 5 mg/L.
Results
Comparison of moxifloxacin concentrations in plasma and DBS 
The level of agreement between moxifloxacin measured in mouse plasma and with 
DBS was determined using Passing-Bablok regression and Bland-Altman analysis and 
is shown in Figure 1. The Passing-Bablok analysis (Figure 1A) showed a high level of 
similarity between both methods with an intercept of 0.022 (95% CI -0.018-0.047) mg/L 
and a slope of 1.07 (95% CI 1.03-1.14), indicating an average 7% positive proportional 
bias for DBS versus plasma measurements of moxifloxacin in mice. 
Bland-Altman analysis (Figure 1B) showed a mean DBS/plasma concentration ratio of 
1.13 with a 95% CI of 1.09-1.16, with a lower limit of agreement (LoA) of 0.89 (95% CI 
0.83-0.96) and an upper LoA of 1.36 (95% CI 1.29-1.42), which means that 95% of the 
data points is within 0.89 and 1.36 concentration ratios.
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Figure 1. Assessment of the level of agreement between moxifloxacin concentrations measured 
in plasma and in DBS using Passing-Bablok regression (A) and Bland-Altman analysis (B).
In the scatter plot with Passing-Bablok fit (A), moxifloxacin concentrations in DBS are plotted against 
their concentration in plasma. The line of identity is presented in solid grey and in black (dashed) the 
Passing-Bablok regression line, y=0.02155+1.072x. Bland-Altman analysis plots (B) the moxifloxacin 
DBS/plasma concentration ratio versus the average concentration in DBS and plasma. The line 
representing the mean ratio is solid gray, while the lines depicting the 95% Limits of Agreement (LoA), 
containing 95% of the data points, are dashed.
A
B
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Pharmacokinetic evaluation 
Figure 2 displays the plasma concentration-time profiles and Table 1 the main 
pharmacokinetic parameters of single doses of moxifloxacin in uninfected mice. After 
oral administration of moxifloxacin in mice, the AUC0-∞ values were 4.5, 11, 24 and 76 
mg/L*h for 50, 100, 200 and 400 mg/kg, respectively. Pharmacokinetics appeared to 
be dose linear with increasing concentrations, except for the increase from the 200 to 
400 mg/kg dose, where multiplying the dose by two resulted in a 3-fold increase in 
exposure. The Cmax values were 2.8, 6.7, 12 and 18 mg/L for 50, 100, 200 and 400 mg/
kg, respectively. The mean percentage unbound moxifloxacin in all samples was 55% 
(42-76%) and seems comparable, but somewhat higher compared to the unbound 
fraction in humans (39-50%) (12, 13). 
Figure 2. Plasma profiles in plasma of healthy BALB/c mice following single oral doses of 50 
mg/kg (diamonds), 100 mg/kg (open circles), 200 mg/kg (circles) and 400 mg/kg (triangles) of 
moxifloxacin. 
Plasma concentrations are plotted as median with ranges of two mice per dosage and time point. 
MXF, moxifloxacin
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Table 1. Pharmacokinetic parameters of moxifloxacin in plasma following single dose of 50, 100, 
200 and 400 mg/kg in BALB/c mice. 
Dose  
(mg/kg)
AUC0-∞ 
(mg/l*h)
Cmax 
(mg/l)
CL/F  
(l/h)
Vd/F  
(l)
t½  
(h)
50 4.5 2.8 0.25 1.2 3.2
100 11 6.7 0.19 0.67 2.4
200 24 12 0.19 1.1 4.1
400 76 18 0.12 1.5 8.8
Pharmacokinetic parameters are based on the average concentration of two sacrificed mice per 
dosage and time point (n=64) AUC0-∞ after single dose equals AUC0-τ for a dosing interval at steady 
state (14)
AUC0-∞, area under the plasma concentration-time curve from time point 0 to infinity for single dose; CL, 
clearance; Cmax, maximum plasma concentration; F, bioavailability; Vd, volume of distribution
Discussion
Moxifloxacin is a promising building block in novel TB regimens for drug susceptible 
and resistant TB and remains an essential drug in the battle against MDR-TB. Therefore 
a clear understanding of its pharmacokinetics and pharmacodynamics in preclinical 
models is pivotal. In the present study we validate the use of DBS sampling by 
comparing concentrations in whole blood with concentrations in plasma, obtained from 
uninfected female BALB/c mice. When comparing DBS with plasma, the Passing-Bablok 
plot showed a positive bias with an acceptable level, demonstrating that data obtained 
with both methods are in concordance. Bland-Altman analysis showed a lower (0.89) 
and upper (1.36) 95% LoA indicating that DBS values can predict plasma concentrations 
with acceptable precision. 
Vu et al. found significantly higher moxifloxacin concentrations in DBS compared 
to plasma samples from actual TB-patients (14). This discrepancy between DBS and 
plasma concentrations is higher than found in the current study in mice. This might 
be explained by interspecies differences in the distribution of moxifloxacin between 
plasma and blood cells caused by a difference in binding capacity to plasma proteins 
and blood cells(15).
Based on these results we conclude that DBS can be used in preclinical drug 
development models to assess moxifloxacin pharmacokinetics. By using DBS in further 
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studies, small volumes can be analyzed and therefore repeated sampling within mice 
can be performed. This significantly decreases the number of mice necessary as well as 
the costs of the experiments. A limitation of the DBS technique, however, is that protein 
unbound drug concentrations cannot be assessed. 
Before performing efficacy studies with moxifloxacin in mice it is of great importance 
to use a human equivalent dose. In the present study, the pharmacokinetics of 
moxifloxacin were studied to determine the human equivalent dose in mice that can 
be used for further drug efficacy testing in TB infected mice. The AUC relative to the 
minimal inhibitory concentration has been suggested as the best parameter to predict 
in vivo efficacy against M. tuberculosis (16). Based on the protein binding which seems 
slightly higher in mice compared to humans and the AUC0-∞ calculated in the current 
study, a single dose of 200 mg/kg moxifloxacin in mice would approximate a human 
equivalent free drug exposure (AUC0-24 24.8 mg/L*h / fAUC0-24 17.3 mg*h/L(17)), which 
can be used in efficacy studies. This suggested 200 mg/kg dose complements the data 
from Poissy et al. who found AUC values close to those found in humans when a similar 
dose was used as well as the highest decline in CFU with this dose (18). 
The Cmax of moxifloxacin in humans after the standard dose of 400 mg is 2.5-3.3 mg/L 
(17, 19). The Cmax in mice obtained with the 100, 200 and 400 mg/kg dose was higher, 
where 50 mg/kg resulted in a Cmax of 2.8 mg/L which is in the Cmax range found in TB 
patients (17, 19). The median half-life of moxifloxacin in mice is 3.65 h compared to 
8.3-15.6 in humans (12, 19).
Our results are in contrast with AUC0-∞ and Cmax data presented by Rosenthal et al. 
who found higher AUC0-∞ and Cmax values in mice after a single dose of moxifloxacin 
(100, 200 and 400 mg/kg), except for the AUC0-∞ after a 400 mg/kg dose which is 
higher in the current study (20). 
In summary, we showed that DBS can be used to perform further moxifloxacin studies 
in mouse models to study pharmacokinetics and pharmacokinetic-pharmacodynamic 
relationships. Furthermore, we identified that 200 mg/kg moxifloxacin is an appropriate 
dose to perform efficacy studies in a TB mouse model.
Funding
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Abstract
Introduction
Nutritional status may have a profound impact on the pharmacokinetics of drugs, 
yet only few data are available for tuberculosis (TB) drugs. As malnutrition occurs 
frequently among TB patients, we assessed the effect of malnutrition on the steady-state 
pharmacokinetics of total and protein-unbound rifampicin during the intensive phase 
of TB  treatment. 
Methods
In a descriptive pharmacokinetic study in Bandung, Indonesia, patients received a 
fixed standard rifampicin dose of 450 mg once daily during the intensive phase of 
TB treatment. A full pharmacokinetic curve for rifampicin was recorded and total 
and unbound concentrations of rifampicin were analyzed in all samples. Rifampicin 
pharmacokinetic parameters were compared between severely malnourished (BMI 
<16.0 kg/m2), malnourished (BMI <18.5 kg/m2) and well-nourished (BMI ≥18.5 kg/m2) 
individuals. 
Results
No difference in total and protein-unbound pharmacokinetic parameters between 
severely malnourished (n=7), malnourished (n=11) and well-nourished patients (n=25) 
could be demonstrated. In addition, no significant correlation between BMI and 
exposure (AUC0-24h and Cmax) was found. Females had significantly higher total AUC0-24h 
(geometric mean 59.2 versus 48.2 mg/L*h; p=0.02) and higher unbound AUC0-24h 
(geometric mean 6.2 versus 4.8 mg/L*h; p=0.02) compared to males. Overall, a marked 
2-fold interindividual variation in the free fraction was observed (7.6-15.0%; N=36). 
Conclusion 
Nutritional status and BMI do not appear to have a major effect on total and 
protein-unbound pharmacokinetic parameters of rifampicin in Indonesian subjects. 
The large inter-individual variability in the free fraction of rifampicin suggests that 
protein-unbound rather than total rifampicin concentrations should preferably be used 
to study exposure-response relationships.  
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Introduction 
Inadequate exposure to rifampicin and other anti-tuberculosis (TB) drugs may 
contribute to a suboptimal clinical response in TB treatment. This follows from a recent 
study performed in a preclinical model, showing that pharmacokinetic variability is 
an important factor in the emergence of multidrug-resistant TB (1). Furthermore, a 
meta-analysis of clinical studies showed that pharmacokinetic variability to a single drug 
(isoniazid) in multi-drug TB regimens is associated with therapy failure and acquired 
drug resistance (2). A number of clinical studies have also reported associations between 
low concentrations of TB drugs and poor treatment response (3-8), but this association 
was not found in other studies (9, 10), including one of our studies on rifampicin plasma 
concentrations in Indonesian TB patients (11).
For rifampicin and other TB drugs, pharmacokinetic variability and low exposure may 
be affected by various factors, including gender, co-morbidity (HIV/AIDS, diabetes 
mellitus), genetics, drug formulation and malnutrition (3, 12-16). Malnutrition occurs 
frequently among TB patients. A case (n=121)-control (n=371) study in Indonesia 
documented malnutrition in 87% and 33% of cases and controls, respectively (17). A 
bidirectional interaction exists between malnutrition and TB (18, 19). On the one hand, 
malnutrition impairs immune function and increases the susceptibility for development 
of active TB. At the same time, TB leads to severe abnormalities in protein metabolism, 
loss of lean tissues and fat reserves. It is known that nutritional status can have a 
profound impact on the pharmacokinetics of drugs (20, 21), yet few data are available 
for TB drugs, and we are aware of only one publication on the effect of malnutrition on 
the exposure to rifampicin (12). 
In pharmacokinetic studies, measurement of rifampicin concentrations in plasma 
or serum usually relates to the total (protein-unbound plus bound) concentration 
of a drug. An equilibrium between total and protein-unbound concentrations is 
commonly assumed, yet free rather than total drug concentrations are preferably 
used in concentration-response evaluations (22), as only protein-unbound drugs are 
pharmacologically active and diffuse or are being actively transported into tissues and 
to the sites of action (23, 24). In a previous study among Indonesian TB patients (11), we 
confined to measurement of total concentrations of rifampicin and this may be one of 
several possible explanations for the absence of a concentration-response relationship in 
that study. Importantly, malnutrition and associated low concentrations of drug-binding 
plasma proteins may cause a change in the equilibrium between protein-unbound and 
bound concentrations, which renders the total drug concentrations misleading (24-26). 
This means that both total as well as protein-unbound plasma concentrations should 
be evaluated when studying the effects of malnutrition on drug pharmacokinetics.
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The primary objective of this study was to assess the effect of malnutrition on the 
steady-state  pharmacokinetics of total and protein-unbound rifampicin during the 
intensive phase of TB  treatment in Indonesian TB patients. As a secondary objective 
we evaluated the interindividual variability in exposure to protein-unbound rifampicin, 
as we feel this may provide relevant information to understand exposure-response 
relationships for this pivotal TB drug.  
Methods
Subjects
Study subjects were Indonesian patients with pulmonary TB in the intensive phase of 
treatment. Diagnosis of pulmonary TB was based on clinical symptoms and chest X-ray 
examination, confirmed by microscopic detection of acid-fast bacilli. Patients were 
excluded if they had a body weight above 55 kg, were below 18 and above 55 years of 
age, were pregnant or lactating, used any type of co-medication that may influence the 
pharmacokinetics of TB drugs, had liver or kidney abnormalities (including abnormal 
liver or renal function parameters) or any known history or medical condition that 
might affect the pharmacokinetics of TB drugs, such as diabetes mellitus, HIV infection, 
diarrhea and vomiting. 
Study design 
This was a descriptive pharmacokinetic study conducted in an urban outpatient 
tuberculosis clinic in Bandung, Indonesia. Patients were prospectively and consecutively 
recruited from the control arm of an intervention study on nutritional supplementation 
in TB patients. Subsequently the cohort was completed with data from patients who 
participated in a clinical trial on high dose rifampicin and who fulfilled the inclusion and 
exclusion criteria (27). During the intensive phase of TB treatment, all eligible patients 
received a fixed standard rifampicin dose of 450 mg once daily, roughly corresponding 
to 10 mg/kg in Indonesian people (for people below 55 kg), combined with once daily 
isoniazid (300 mg), pyrazinamide (1,500 mg), and ethambutol (750 mg). All patients 
received TB drugs from the same manufacturer (PT Kimia Farma, Bandung, Indonesia), 
formulated in separate tablets. The bioequivalence of the rifampicin tablets and an 
international reference standard has been established before (28). 
A full pharmacokinetic curve for rifampicin was recorded between 2 and 6 weeks after 
start of TB treatment, when steady-state for the TB drugs can be expected (29). Body 
weight, height (to calculate body mass index, BMI) and concomitant drug use were also 
assessed at the pharmacokinetic sampling day. In addition, plasma protein albumin was 
measured, considering that 30 to 41% of protein-bound rifampicin is associated with 
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the serum albumin fraction (30). Informed consent was obtained from all subjects and 
the study was approved by the Independent Ethics Committee, Faculty of Medicine, 
University of Padjadjaran, Bandung, Indonesia.
Blood sampling, bio-analysis and pharmacokinetic data analysis
Patients refrained from the intake of any food or any drugs (other than study medication) 
starting from 11.00 p.m. on the day preceding the pharmacokinetic assessment, until 
four hours after the intake of study medication. TB drugs were taken with 230 mL of 
still water. Serial blood samples (10 mL) were collected from the antecubital vein just 
before, and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 and 12 h after observed TB drug intake. Plasma 
was immediately separated, frozen at -20°C and transferred to -80 °C within 72 h, until 
transport on dry ice to the Netherlands for bio-analysis. 
Bioanalysis 
The total (protein bound plus unbound) plasma concentrations of rifampicin were 
determined with a validated high-performance liquid chromatographic (HPLC) 
methods with ultraviolet (UV) detection as described previously (27). The lower limit of 
quantitation for this method was 0.28 mg/L.
In addition to total plasma concentrations, protein-unbound concentrations of 
rifampicin were measured in all obtained samples. Measurements were based on 
ultrafiltration to separate bound from unbound rifampicin, followed by HPLC. Briefly, 
0.5 mL of plasma was added into a Centrifree YM-30 tube (Millipore, Amsterdam, the 
Netherlands). Plasma was centrifuged for 15 min at 1,650 x g at 25 ºC with a Rotanta 
46 R, rotor 4445 (radius 164, <45°). The clear ultrafiltrate was placed in a thermostated 
autosampler (4°C) and fifty µl of this solution was injected in the HPLC system. The 
analytical column was an OmniSpher 5 C18 column (250 × 4.6 mm ID; particle size 
5 µm) protected by a Chromguard RP ss 10 x 3 mm column (Varian, Middelburg, The 
Netherlands). The mobile phase components were 30% acetonitrile and 70% 10 mM 
phosphate buffer with pH 5, run during a HPLC gradient with different flow rates. Total 
run time was 17 min. UV detection was set at 334 nm. The average accuracy of ultrafiltrate 
spiked with rifampicin was 107%. Intraday imprecision in measurement of rifampicin in 
ultrafiltrate varied from 1.4 to 2.4%, interday imprecision varied from 0% (i.e. there was 
no additional variation upon intraday imprecision as a result of performing the assay 
on different days) to 3.6%, and overall precision varied from 1.4 to 3.9%, dependent on 
the concentration measured. The range of the method for unbound rifampicin plasma 
concentrations was from 0.06 mg/L (lower limit of quantitation, LLOQ) to 13 mg/L.
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Pharmacokinetic analysis 
Pharmacokinetic parameters were assessed using standard noncompartmental 
methods in WinNonLin version 5.3 (Pharsight Corporation) as described before (27). 
Unbound fractions were calculated by dividing the unbound area under the plasma 
concentration-time curve up to 24h (unbound AUC0-24h) by total AUC0-24h in all study 
subjects.
Statistical analysis
Based on available data for the pharmacokinetics of rifampicin in Indonesian patients 
(27) it was calculated that a minimum of 15 patients per group were required to detect 
a difference of 25% in the AUC0-24h of total rifampicin with a significance level of 0.05 
and a power of 80% (two-sided test). 
Patients were firstly divided into three subgroups based on criteria for nutritional status 
as proposed by the World Health Organisation (31). Patients with a BMI <16.0 kg/
m2 were considered severely malnourished, patients with a BMI <18.5 kg/m2 were 
regarded malnourished and patients with a BMI  ≥18.5 kg/m2 were considered to have 
no malnutrition. Differences in pharmacokinetic parameters between malnourished 
patients as well as the severely malnourished subgroup versus well-nourished patients 
were assessed with independent-samples t-tests on logarithmically transformed 
pharmacokinetic parameters. Tmax values were not transformed and were compared 
using the Mann-Whitney U test. Apart from categorizing patients in groups with 
predefined BMI values, BMI was also evaluated as a continuous variable. AUC0-24h 
and Cmax values for both total and unbound rifampicin plasma concentrations were 
correlated with BMI using Spearman’s rho on the untransformed pharmacokinetic 
parameters.
To evaluate the confounding effect of other possible determinants of exposure to 
protein-unbound and total rifampicin, similar univariate analyses were performed to 
assess the effects of gender, weight, age, and plasma albumin concentration on the 
log-transformed AUC0-24h and Cmax values of the total and unbound concentrations 
of rifampicin. After the univariate analyses, a multiple linear regression analysis was 
performed to assess the variation in log-transformed AUC0-24h and Cmax attributable to 
the presence of those variables that emerged from the univariate analyses.
To assess the interindividual variability in pharmacokinetics as a secondary objective, all 
patients were combined in one group. First, the central tendency and spread in each 
pharmacokinetic parameter (protein-unbound and total rifampicin) were described 
with a geometric mean, geometric coefficient of variation (GCV; SD of ln-transformed 
191
Exposure to total and protein-unbound rifampicin is not affected by malnutrition
data*100%) and range, apart from Tmax, which was presented as median and range. The 
variability in average (arithmetic mean) percent unbound rifampicin (unbound AUC0-24h/
total AUC0-24h) was described with a CV (SD/mean*100%) determined over all individual 
pharmacokinetic curves. Second, the geometric mean total and protein-unbound 
plasma concentrations and average ratios of unbound to total rifampicin were 
calculated for all individual samples at each sampling time point. 
All statistical evaluations were performed with SPSS for Windows version 16.0 (SPSS 
Inc., Chicago, IL). P-values of less than 0.05 were considered statistically significant in 
all analyses. 
Table 1. Demographic, clinical, and laboratory characteristics of the study population.
Characteristic N=36
Age (yr) 35 (18-55)
Male sex (%) 39
Weight (kg) 44 (34-53)
Albumin (g/dL) 3.8 (2.6-4.2)
Hb (g/dL) 11.7 (8.9-14.4)
BMI (kg/m2) 
Severely malnourished (BMI <16 kg/m2; N=7) 
Malnourished (BMI 16-18.49 kg/m2; N=4) 
Normal BMI (BMI ≥18.5 kg/m2; N=25) 
19.0 (13.5-22.6)
15.3 (13.5-15.8)
16.3 (16.1-16.4)
19.6 (18.7-22.6)
Rifampicin dose (mg/kg) 10.3 (8.5-13.2)
Severely malnourished (BMI <16 kg/m2; N=7) 
Malnourished (BMI 16-18.49 kg/m2; N=4) 
Normal BMI (BMI ≥18.5 kg/m2; N=25)
12.4 (10.5-13.2)
11.4 (10.5-13.2)
9.6 (8.5-11.5)
Data are presented as median (minimum – maximum) unless stated otherwise
BMI, body mass index
Results
Patients 
Thirty-six patients with pulmonary TB were included in the study. Characteristics of 
the patients are presented in Table 1. The majority of the patients were female (61%). 
Twenty-five patients had a normal BMI (BMI ≥18.5 kg/m2), eleven patients were 
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malnourished (BMI <18.5 kg/m2), of which seven patients were severely malnourished 
(BMI <16.0 kg/m2). As all patients received a fixed dose of 450 mg of rifampicin, the 
dosage of rifampicin per kg body weight was somewhat higher among malnourished 
patients versus those with a normal BMI (11.6 mg/kg BW versus 9.7 mg/kg BW 
(geometric mean)). Albumin concentrations were within the normal range for severely 
malnourished, malnourished and well-nourished patients: 3.3, 3.4 and 3.8 g/dL 
(geometric mean), respectively. Albumin concentrations of severely malnourished and 
malnourished patients did not differ significantly when compared to well-nourished 
patients (p=0.12 and p=0.19, respectively).
Effect of malnutrition on the pharmacokinetics of rifampicin 
The geometric mean AUC0-24h of rifampicin did not differ between patients with 
malnutrition (BMI <18.5 kg/m2) and patients with a normal BMI, both for the total 
AUC0-24h (54.8 versus 54.6 mg/L*h; p=0.96) and the unbound plasma AUC0-24h (5.7 
versus 5.6 mg/L*h; p=0.95) (Table 2). Total and unbound geometric mean Cmax and 
other rifampicin pharmacokinetic parameters, especially the primary parameters 
clearance and volume of distribution, were similar in the two nutrition groups (Table 2). 
Severely malnourished patients (BMI <16.0 kg/m2) showed no differences in AUC0-24h 
compared to patients with a normal BMI either; geometric mean values for total and 
protein-unbound AUC0-24h were 56.7 and 6.1 mg/L*h among severely malnourished 
compared to 54.6 and 5.6 mg/L*h for patients with a normal BMI (p=0.73 and 0.53). 
Evaluation of Cmax values yielded similar results; geometric mean values for total and 
protein-unbound Cmax were 10.7 and 1.0 mg/L among severely malnourished compared 
to 10.9 and 1.1 mg/L in patients with a normal BMI (p=0.91 and p=0.65). Since patients 
who were severely malnourished or malnourished had a lower body weight while 
receiving the same fixed 450 mg dose of rifampicin, a similar AUC0-24h is explained by a 
trend towards a higher clearance per kg in both severely malnourished (0.21 L/(h*kg)) 
and malnourished (0.21 L/(h*kg)) patients versus well-nourished patients (0.18 L/(h*kg)) 
(p=0.09 and p=0.07, respectively). 
Apart from categorizing patients in groups with predefined BMI values, BMI was also 
evaluated as a continuous variable. There was no significant correlation between BMI 
and AUC0-24h for both total and unbound rifampicin plasma concentrations (Spearman’s 
rho, 0.035 and -0.055; p=0.84 and p=0.75), nor was there a significant correlation 
between BMI and Cmax for total and unbound rifampicin plasma levels (Spearman’s rho, 
0.000 and 0.095; p=1.0 and 0.58).
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Table 2. Steady-state pharmacokinetics of rifampicin – total and unbound concentrations – based 
on full pharmacokinetic curves of the total cohort (N=36).
Parameter in plasma
Total
(N=36)
BMI <18.5
(N=11) 
BMI ≥18.5
(N=25) 
P-value
Total rifampicin
AUC0-24h (mg/L*h)
54.7 
(32.6-88.8)
54.8 
(32.6-85.0)
54.6 
(35.0-88.8)
0.96a
Cmax (mg/L) 10.9 (6.4-16.6) 10.9 (6.4-16.6) 10.9 (7.1-16.3) 0.95a
Tmax (h) – median 2.0 (1.0-4.0) 2.5 (1.0-4.0) 1.5 (1.0-4.0) 0.17b
CL/F (l/h) 8.2 (5.1-13.8) 8.2 (5.3-13.8) 8.2 (5.1 -12.9) 0.96a
Vd/F (l)
24.1 
(15.1-57.4)
25.1 
(16.6-36.0)
23.7 
(15.1-57.4)
0.63a
Half-life (h) 2.0 (1.4-3.8) 2.1 (1.4-2.8) 2.0 (1.5-3.8) 0.47a
Unbound rifampicin
AUC0-24h (mg/L*h) 5.6 (2.9-9.8) 5.7 (2.9-8.7) 5.6 (3.2-9.8) 0.95a
Cmax (mg/L) 1.1 (0.7-2.2) 1.0 (0.7-2.0) 1.1 (0.7-2.2) 0.45a
Tmax (h) – median 2.0 (1.0-4.0) 2.5 (1.0-4.0) 1.5 (1.0-4.0) 0.06b
CL/F (l/h)
79.8 
(45.9-156)
79.3 
(51.9-156)
80.0 
(45.9-142)
0.95a
Vd/F(l) 320 (107-741) 337 (161-654) 313 (108-747) 0.65a
Half-life (h) 2.8 (1.2-6.8) 2.9 (2.0-4.0) 2.7 (1.2-6.8) 0.52a
Unbound fraction 
AUC ratio (%) – average1 10.5 (7.6-15.0) 10.5 (8.9-14.9) 10.5 (7.6-15.0) 0.99a
Data are presented as geometric mean (minimum – maximum) unless stated otherwise
1 The AUC-ratio was calculated by dividing unbound AUC0-24h by total AUC0-24h in all subjects
a By independent-samples t-test on log-transformed pharmacokinetic parameters between 
malnourished and well-nourished patients b By Mann-Whitney U test between malnourished and 
well-nourished patients
AUC0-24h, area under the plasma concentration-time curve from time point 0 to 24 hours; CL, clearance; 
Cmax, maximum plasma concentration; F, bioavailability; Tmax, time to maximum plasma concentration; 
Vd, volume of distribution
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Effects of other determinants on the pharmacokinetics of rifampicin
In univariate analyses, gender emerged as the only significant determinant of total and 
unbound plasma rifampicin pharmacokinetic parameters. Females were found to be 
exposed to higher concentrations of rifampicin compared to males, as indicated by a 
significantly higher total AUC0-24h (geometric mean 59.2 versus 48.2 mg/L*h; p=0.02) 
and higher unbound AUC0-24h (geometric mean 6.2 versus 4.8 mg/L*h; p=0.02). Total 
and unbound Cmax values did not differ significantly between the two groups (p=0.16 
and p=0.22), as was also the case for Tmax (p=0.23 and p=0.22). Univariate analyses did 
not show significant correlations for the determinants body weight and age (data not 
shown). 
As females were overrepresented in the group of patients with a normal BMI (68%) 
compared to patients with a BMI below 18.5 kg/m2 (45%; p=0.20), multiple linear 
regression analyses were performed to disentangle the effect of gender and BMI. 
These analyses showed that gender was a significant predictor of the AUC0-24h of total 
and protein-unbound rifampicin (p=0.02 and p=0.01), yet BMI was not (p=0.52 and 
0.35). Gender alone was explaining 15% of the variation (R2) in both the total and 
protein-unbound AUC0-24h. 
Variability in total and protein-unbound rifampicin concentrations
To assess the interindividual variability in pharmacokinetics, all patients were combined 
in one group. Both total and protein-unbound rifampicin concentrations showed 
considerable variation. The geometric mean total AUC0-24h of all 36 subjects was 54.7 
mg/L*h, with a GCV of 26% and a 2.4-fold inter-individual variation in total AUC0-24h, 
ranging from 32.6 to 88.8 mg/L*h (Table 2 and Figure 1). The geometric mean unbound 
AUC0-24h amounted to 5.6 mg/L*h, with a GCV of 32% and a 3.4-fold inter-individual 
variation in unbound AUC0-24h, ranging from 2.9 to 9.8 mg/L*h (Table 2 and Figure 1). 
Therefore, interpatient variability in AUC0-24h for total and unbound rifampicin were 
considered to be comparable. The same applied for Cmax, with a GCV of 27% and 30% 
for total and protein-unbound rifampicin, respectively. Overall, a significant correlation 
was found between total and unbound plasma rifampicin AUC0-24h (Spearman’s 
rho, 0.816; p<0.001) and between Cmax values (Spearman’s rho, 0.696; p<0.001). The 
arithmetic mean percent unbound AUC0-24h was found to be 10.5%, with a CV of 18% 
and a marked 2-fold interindividual variation in percent unbound rifampicin, ranging 
from 7.6 to 15.0%. 
Figure 2 shows the percent protein-unbound rifampicin (free fraction) at the various 
sampling time points and Table 3 summarizes the mean total and unbound rifampicin 
concentrations, unbound fractions and the interindividual variability at the various 
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sampling time points. The free fraction seemed to be slightly higher in samples taken 
later in the pharmacokinetic curve, with lower total concentrations (Figure 2 and Table 
3).
Figure 1. Total (triangles) and protein-unbound (circles) concentrations at various sampling time 
points post dose.
Concentrations are presented as median ± IQR 
Figure 2. Percent protein-unbound rifampicin (free fraction) at various sampling time points post 
dose.
Bars represent arithmetic mean ± SD 
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Table 3. Geometric mean total and unbound rifampicin concentrations, unbound fraction and 
inter-individual variability at each sampling time point.
Time post 
dose (h)
Protein-unbound 
concentration 
(mg/L)1
Total plasma 
concentration 
(mg/L)1
Protein-unbound 
fraction (%)2
N3
 0.5 0.3 (67%; 0.1-0.8) 2.7 (103%; 0.3-9.1) 8.1 (18%; 5.6-11.1) 18
1 0.7 (71%; 0.08-2.2) 6.5 (102%; 0.1-16.6) 9.5 (20%; 6.2-14.9) 33
1.5 0.8 (71%; 0.08-1.7) 6.8 (93%; 0.2-15.8) 10.3 (21%; 4.4-13.0) 34
2 0.8 (62%; 0.08-1.7) 7.3 (71%; 0.8-15.0) 10.3 (18%; 6.3-15.6) 35
2.5 0.9 (46%; 0.14-1.8) 8.5 (40%; 2.1-15.5) 10.2 (20%; 6.6-15.0) 36
3 0.8 (31%; 0.5-1.6) 8.9 (30%; 5.1-15.1) 9.8 (25%; 5.3-17.4) 36
4 0.7 (38%; 0.4-1.7) 8.7 (33%; 4.2-15.0) 8.7 (26%; 5.0-17.0) 36
6 0.5 (41%; 0.2-1.0) 3.9 (33%; 2.1-7.3) 12.4 (21%; 8.5-18.4) 36
8 0.3 (48%; 0.1-0.6) 2.4 (47%; 1.0 -6.0) 11.0 (21%; 6.4-14.7) 24
12 0.1 (43%; 0.06-0.2) 0.5 (68%; 0.1-1.5) 13.3 (23%; 7.8-20.6) 12
1 Includes concentrations > limit of quantitation, presented as geometric mean (GCV; range)
2 Includes concentrations > limit of quantitation, presented as arithmetic mean (CV; range)
3 N indicates number of patients for whom a protein-unbound fraction could be calculated based on 
quantifiable unbound and total rifampicin concentrations
Discussion 
To our knowledge, the present study is the first to obtain both total and protein-unbound 
full pharmacokinetic curves of rifampicin during the intensive phase of TB treatment in 
malnourished and well-nourished TB patients. The study shows comparable geometric 
mean total and protein-unbound AUC0-24h and Cmax values in patients who are severely 
malnourished (BMI <16.0 kg/m2), malnourished (BMI <18.5 kg/m2) and well-nourished 
(BMI ≥18.5 kg/m2). In addition, there was no significant correlation between BMI and 
AUC0-24h or Cmax for both total and unbound rifampicin plasma levels.
The absence of an effect of malnutrition on rifampicin exposure in this study is in contrast 
with the results by Polasa et al. (1984) (12). They found that the AUC of a single dose of 
rifampicin was 29% lower in undernourished (BMI <18 kg/m2) than in well-nourished 
healthy volunteers, with plasma peak concentrations in undernourished being 50% of 
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that observed in well-nourished individuals. In the study by Polasa et al., plasma protein 
binding was determined with equilibrium dialysis in peak samples only and a higher 
unbound fraction was found in undernourished volunteers. These data suggested that 
the decrease in total exposure was at least partly compensated by an increase in the 
free fraction. Polasa et al. also showed apparently lower rifampicin AUC and Cmax values 
in actual undernourished TB patients who had used rifampicin for 4 to 6 months, yet 
the comparison of steady-state AUC and Cmax with the single-dose data in healthy 
volunteers is not valid, considering that rifampicin decreases its own exposure upon 
repeated administration (auto-induction) (30). Nevertheless, average plasma protein 
binding for rifampicin was low in these patients as well (42.99%) (12), suggesting a shift 
in the equilibrium between total and protein-unbound concentrations.
Indeed we had anticipated that hypoalbuminemia (or a decrease in other proteins 
relevant to binding of drugs) might result in changes in the total rifampicin AUC but 
not in the protein-unbound free AUC in malnourished TB patients, as we considered 
that changes in plasma protein binding due to protein deficiency are very similar to 
the situation occurring with drug displacement interactions (24, 25). In this situation 
measuring the total concentrations would be mis-representative for the free, 
pharmacological active concentrations. Yet in our study there was even no trend 
for a decrease in exposure to total or protein-unbound rifampicin in malnourished 
or severely malnourished versus well-nourished TB patients. Furthermore, our study 
did not show a correlation between BMI and the steady-state protein-unbound and 
total rifampicin exposure in our cohort. An explanation for our findings might be that 
malnourished patients in our study had higher mean albumin levels compared to the 
individuals in the study of Polasa et al.: 3.8 g/dL (≥ 18.5 kg/m2), 3.4 g/dL (<18.5 kg/
m2) and 3.3 g/dL (<16.0 kg/m2) versus 3.6 (≥18.0 kg/m2) and 2.5 g/dL (<18.0 kg/m2), 
respectively. This indicates that the nutritional status of patients in our study may be 
better, suggesting that any effect of malnutrition mediated through altered binding to 
albumin was less likely to occur in our patient population. In contrast, it can also be 
argued that serum albumin is a suboptimal indicator of nutritional status, especially in 
marasmic populations, as albumin synthesis can be maintained in such states (32, 33).
Whereas malnutrition did not affect exposure to rifampicin, females showed 
significantly higher total and unbound AUC0-24h, also when corrected for BMI. In studies 
with predominantly Caucasian patients, higher serum rifampicin concentrations were 
found in females and this could not be explained by differences in body weight (30, 
34). In Indonesian patients, two of our previous studies found a relationship between 
gender and rifampicin pharmacokinetics (35, 36), but another study did not (11). In 
African subjects, female patients also showed higher exposures to rifampicin (15). An 
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explanation may be that females generally have a lower lean body mass than males. 
Thus, for drugs that are differentially distributed between water and fat, different drug 
concentrations can be found in subjects with the same weight (37). However, it should 
be noted here, that gender was only explaining 15% of the variation (R2) in both the 
total and protein-unbound AUC0-24h. Thus, other determinants are probably more 
important in causing the (high) variation in rifampicin exposures. 
With respect to interindividual variability, a marked 2-fold interindividual variation in the 
unbound rifampicin fraction (unbound AUC0–24h/total AUC0–24h), between 7.6 and 15.0%, 
was observed. In addition, the variation in free fraction at the various sampling time 
points was found to be considerably high (Figure 2), with CVs ranging from 18 till 26% 
(Table 3). This large interindividual variability in the free fraction shows that measurement 
of solely total concentrations could be mis-representative of the actual exposure. This 
suggests that protein-unbound rifampicin concentrations should be considered to 
evaluate along with total plasma concentrations for assessment of exposure-response 
relationships in clinical studies. The same may apply to individualization of rifampicin 
dosing based on plasma concentration measurements (Therapeutic Drug Monitoring) 
in those settings where this technique can be used in patient care. In light of this 
observed high interindividual variation, the slight increase in average unbound fraction 
of rifampicin found in the lower total concentrations later in the pharmacokinetic curve 
(Figure 2) might be less relevant, also when considering the relatively small number of 
included patients in this study. In addition, we cannot exclude that this small effect is an 
artifact related to ultrafiltration as a means to measure protein binding. 
In the current study, we measured free rifampicin concentrations using ultrafiltration 
performed at 25°C, as we also do for other drugs in routine patient care. In 
ultrafiltration, centrifugal forces are employed as the driving force for the passage of 
plasma water across a filter membrane (38). Besides ultrafiltration other methodologies 
are available to determine plasma protein binding of drugs, such as ultracentrifugation 
and equilibrium dialysis. For rifampicin all these techniques have been used. The review 
by Kenny and Strates (1981) states that in case of equilibrium dialysis, varying rifampicin 
binding values have been reported based on variable incubation temperatures, protein 
concentrations and dialysis times (30). However, the specific effect of temperature on 
the rifampicin-protein complex is not mentioned here or in literature. For other drugs, 
an increase in experimental ultrafiltration temperatures has been associated with an 
increase in free fraction (39-41), but as far as we know this has not been reported for 
rifampicin. Indeed, we found that measurement of free rifampicin at 37 oC resulted in a 
small increase in rifampicin free fraction (mean change in free fraction: +1.2%, median 
change +1.1%, range -0.7 to +3.5%, n=10 rifampicin concentrations measured, P=0.029, 
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paired-samples t-test) (unpublished data). This effect of temperature on rifampicin free 
fraction is small and is unlikely to have affected the findings in our study.       
This study has its limitations. First, the number of individuals included in the malnourished 
group seems somewhat low with 11 individuals, as a number of 15 individuals per group 
was calculated to be required to detect a difference of 25% in rifampicin AUC0-24h. 
However, with a number of 25 individuals included in the group with a normal BMI, 
it can be calculated that the present study could still detect a 24% difference in the 
AUC0-24h of total rifampicin with a significance level of 0.05 and a power of 80%. As 
a second limitation, it can be argued that the BMI of the well-nourished group was 
considerably low (19.6 kg/m2, 18.7-22.6 (median, range)), resulting in a relatively small 
difference with the malnourished group (16.3 kg/m2, 16.1-16.4). However, also when 
comparing the severely malnourished subgroup with well-nourished patients and 
when analyzing BMI as a continuous variable, nutritional status and BMI do not appear 
to have a major effect on total and protein-unbound pharmacokinetic parameters of 
rifampicin. Third, it should be considered that all participants were Indonesian and 
it cannot be excluded that the effect of malnutrition on rifampicin pharmacokinetics 
is different in people with another race or genetic background. A final limitation is 
that we did not include pharmacogenetic analyses. Pharmacogenetic polymorphisms 
are proposed to be an important factor in the high variability in rifampicin exposure. 
More specifically, polymorphisms of the SLCO1B1 gene have been associated with 
lower rifampicin exposure (16, 34, 42, 43). To our knowledge, the potential impact of 
such polymorphisms in Indonesian TB patients has not been investigated. According 
to Niemi et al. (2011) the c.463C<A polymorphism, that has been associated with 
decreased rifampicin exposures, is only present in 0 to 3% of the east Asian population 
(44). This indicates that at least this specific polymorphism is of minor importance in 
our study population and will not affect differences in rifampicin exposures between 
malnourished and well-nourished patients.
To summarize, severely malnourished, malnourished and well-nourished Indonesian 
TB patients showed no clear difference in total and protein-unbound pharmacokinetic 
parameters of rifampicin during the intensive phase of TB treatment. Similarly, BMI and 
rifampicin (total and unbound) pharmacokinetic parameters did not show any significant 
correlation. Significantly higher plasma concentrations (total and unbound) were found 
in females, also when corrected for BMI. Finally, a marked 2-fold interindividual variation 
in unbound rifampicin fraction was observed. This large interindividual variability in the 
free fraction of rifampicin shows that measurement of solely total concentrations could 
be mis-representative of the actual exposure, suggesting that it should be considered 
to evaluate protein-unbound rifampicin concentrations along with total plasma 
concentrations when studying exposure-response relationships for this pivotal TB drug. 
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Abstract
Introduction
We assessed the impact of chronic use of the pregnane X receptor (PXR) agonist 
rifampicin on steady-state metformin pharmacokinetics and on the glucose-lowering 
effect of metformin in Indonesian tuberculosis (TB) patients with diabetes mellitus (DM) 
type 2.
Methods
In a within-subject, 2-period (during and after TB treatment), fixed-order pharmacokinetic 
interaction study, performed in Bandung, Indonesia, the effect of rifampicin on metformin 
pharmacokinetics in TB-DM patients was assessed with two 8-hour pharmacokinetic 
curves measured in plasma and estimation of renal clearance and tubular secretion 
from urine collections. The glucose-lowering effect of metformin was evaluated with 
two blood glucose curves following ingestion of 75 grams of glucose. 
Results
Rifampicin increase metformin exposure: the metformin plasma AUC0-τ geometric 
mean ratio (GMR) (exposure during rifampicin treatment versus exposure after 
rifampicin treatment) was 1.30 (90% CI 1.07-1.59). Metformin Cmax GMR amounted to 
1.17 (90% CI 0.96-1.43) (n=11). Renal clearance and tubular secretion of metformin 
remained unaffected (p=0.881 and p=0.879, respectively). The glucose-lowering effect 
of metformin (maximum blood glucose concentrations (Gmax) and blood glucose AUC 
(G-AUC)) did not change significantly, even though there seemed a trend  for the 
Gmax to be minimally reduced under co-administration of rifampicin (-36 mg/dL or 
~10%, p=0.102) (n=8). Finally, 29% of these TB-DM patients using metformin had 
gastro-intestinal adverse effects.
Discussion
The AUC0-τ GMR suggests the occurrence of an interaction when co-administered 
with rifampicin, resulting in increased exposure of metformin. This effect was probably 
caused by increased absorption, because renal elimination of metformin remained 
unaffected and metformin is not a substrate for hepatic metabolism. The suggested 
pharmacokinetic interaction may require monitoring of metformin effectiveness during 
and after TB treatment. To prevent gastro-intestinal adverse effects, metformin and 
rifampicin should be taken with food, and preferably separated in time.
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Introduction
Tuberculosis (TB) remains a leading cause of morbidity and mortality in developing 
countries. In 2014 an estimated 9.0 million people developed active TB and approximately 
1.5 million patients died (1). At the same time an estimated 415 million people suffered 
from diabetes mellitus (DM). DM prevalence is growing rapidly, especially in low- and 
middle-income countries, where TB is endemic. Furthermore, DM increases the risk 
of developing active TB (2, 3). Overall, there is an increasing number of TB cases 
attributable to DM, namely 10% in 2010, and 15% in 2013 (4). 
Patients with concurrent TB and DM face a higher risk of TB treatment failure, relapse 
after cure, and death (5). DM management in TB patients is also problematic. The 
TB drug rifampicin possibly affects blood glucose concentrations and may induce 
hyperglycemia by augmenting intestinal absorption of glucose or reducing insulin 
sensitivity (6, 7). More importantly, rifampicin increases the metabolism of most oral 
antidiabetic drugs, that are commonly used in low- to middle-income countries (8, 9). 
For example, sulphonylureas are metabolized in the liver by cytochrome P450 (CYP) 
enzymes of which rifampicin is a very potent inducer (9, 10). 
To overcome the effects of rifampicin on treatment and maintenance of glycemic 
control, metformin has been proposed as a good alternative to other oral antidiabetics, 
as it is not hepatically metabolized. Moreover, metformin is the first choice antidiabetic 
according to recent type 2 DM treatment guidelines. Metformin is relatively cheap, 
widely available and leads to less weight gain  than for example sulphonylureas or 
insulin (11, 12). The drug lowers both basal and postprandial plasma glucose (13) by 
inhibiting the production of hepatic glucose, reducing intestinal glucose absorption, 
and improving glucose uptake and utilization (14). Interestingly, the search for novel 
host-targeted adjunct therapeutic strategies has unraveled metformin as a drug 
that inhibits the intracellular growth of Mycobacterium tuberculosis, restricts disease 
immunopathology and augments the efficacy of conventional TB drugs (15). The 
main disadvantage of metformin is the presumed risk for lactic acidosis and the high 
frequency of gastrointestinal adverse effects (16, 17). 
Metformin is eliminated unchanged in the urine with a half-life of approximately five 
hours (16). Its renal clearance is greater than that of creatinine, indicating that tubular 
secretion contributes to its elimination (18). The oral absorption, hepatic uptake and 
renal excretion of metformin are largely mediated by organic cation transporters 
(OCTs) and multidrug and toxin extrusion protein 1 and 2K (MATE1 and MATE2K), all 
members of the solute carrier (SLC) family (Figure 1) (16). Genetic polymorphisms in 
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these transporter genes explain at least some of the variability observed in metformin 
pharmacokinetics and drug responses (16, 19-21). 
There is very limited data on co-administration of metformin and rifampicin and the 
need for dose adjustments in TB-DM patients. Rifampicin is a pregnane X receptor (PXR) 
agonist, a transcription factor that upregulates a large number of genes involved in 
xenobiotic detoxification, including drug-metabolizing enzymes and drug transporters 
(22). In rats, the PXR agonist pregnenolone-16-carbonitrile upregulated the expression 
of OCT1 in the liver and OCT2 in the kidneys, which significantly reduced metformin 
plasma exposure (23). In healthy volunteers, rifampicin caused altered metformin 
absorption kinetics, leading to higher exposure levels and enhanced glucose-lowering 
action (24). Extrapolation of these results to complex TB-DM patients should be made 
cautiously, since disease status may alter transcriptional activator and transporter 
expression levels, and diabetic patients have altered glucose regulation compared to 
healthy volunteers. 
As the impact of rifampicin on metformin pharmacokinetics in TB patients with type 
2 DM and on the clinical response to the drug are unclear, the primary objective of 
this study was to assess the effect of rifampicin on the steady-state pharmacokinetic 
parameters of metformin in TB-DM patients. As a secondary objective we evaluated 
the effect of rifampicin on the glucose-lowering activity of metformin, to determine the 
clinical relevance of any pharmacokinetic interaction identified. 
Figure 1.  Schematic overview of the most important transporters involved in the absorption, 
hepatic uptake and excretion of metformin (16, 21, 25-28). The physiological significance of the 
transporters depicted in grey are still unclear (16).
MATE, multidrug and toxin extrusion protein; OCT, organic cation transporter; PMAT, plasma membrane 
monoamine transporter
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Methods
Subjects
Study subjects were Indonesian patients with pulmonary TB and DM type II that had 
been included as part of the TANDEM study (ClinicalTrials.gov: NCT02106039) at the 
University of Padjadjaran, Bandung, Indonesia. Eligibility of TB-DM patients for the 
present study was assessed when they were in the continuation phase of TB treatment. 
Patients were asked for informed consent if they were above 18 and below 65 years of 
age; were treated with metformin, irrespective of taking other blood glucose control 
drugs; were treated with the standard continuation phase TB regimen, containing 
rifampicin 450 or 600 mg and isoniazid 600 mg thrice weekly; and were not pregnant 
or lactating. 
Following informed consent, patients underwent a physical screen just prior to the 
first sampling session, to test adequate liver function (ALT <3x upper normal limit) and 
kidney function (estimated glomerular filtration rate (eGFR) >60 mL/min, calculated 
from plasma creatinine with The Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) formula (29, 30)); adequately controlled blood glucose concentrations 
(average of fasting blood glucose and 2-hour post-prandial glucose ≥300 mg/dL) and 
to perform a pregnancy test, to ensure all inclusion criteria and exclusion criteria were 
met. 
Study design
This was an open-label, 1-arm (within-subject), 2-period, fixed-order pharmacokinetic 
(PK) interaction study. Figure 2 shows the schematic overview of the study design in 
weeks. Sampling occurred in two sessions to enable the assessment of metformin 
exposure when patients were still taking rifampicin and isoniazid (at the end of the 
continuation phase), and after completion of TB treatment following a 1-month wash-
out period, after which any induction caused by rifampicin would have dissipated (9). 
Treating physician were informed not to change the dose of metformin in this period. 
All patients were switched from thrice weekly to daily intake of TB drugs for at least >7 
days prior to first PK sampling session, to match standard WHO guidelines (dashed lines, 
Figure 2). In between the two sessions, an intermediate screening visit was planned to 
assess patient status once more. The study was approved by the ethical review board 
of the Hasan Sadikin Hospital and Medical Faculty of Universitas Padjadjaran, Bandung, 
Indonesia.
The primary objective of this study was to evaluate the effect of rifampicin on the 
steady-state pharmacokinetic parameters of metformin. This was assessed with two 
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8-hour pharmacokinetic curves measured in plasma, together with 8- or 12-hour 
(depending on the metformin dosing interval) urine collections for estimation of renal 
clearance and tubular secretion. As a secondary objective we evaluated the effect of 
rifampicin on the glucose-lowering effect of metformin. This was evaluated by sampling 
two glucose curves (GC) following ingestion of 75 g of glucose on an empty stomach. 
With the use of the sample size nomograms by Diletti et al. (1991) for bioequivalence 
assessment by means of confidence intervals, it was determined that a number of 24 
participants would be needed to determine if metformin exposure remains the same 
after cessation of rifampicin (31).The current report forms an intermediate analysis and 
recruitment to reach the goal of 24 participants is still ongoing. 
Study drugs 
All patients received metformin (Glucophage) tablets of 500 or 850 mg (PT. Merck, 
Indonesia) for twice or thrice daily intake. TB drugs (rifampicin and isoniazid) were 
from PT. Kimia Farma (Bandung, Indonesia), formulated in separate tablets. The 
bioequivalence of the rifampicin tablets and an international reference standard has 
been established before (32). Metoclopramide (Metolon) 10 mg, was provided by PT 
Bernofarm.
Blood and urine collection
Both sampling sessions consisted of two days, one PK day and one GC day. For the 
first morning of each session, patients were ordered not to take breakfast and their 
study medication. After a drug adherence assessment, including pill count, physician 
assessment and patient diary check, metformin was administered together with a 
standardized breakfast, as recommended for this drug. 
To avoid the gastrointestinal adverse effects associated with metformin, patients were 
provided with oral metoclopramide (10 mg) 1 hour before taking metformin. Eight serial 
blood samples were drawn at 0 (pre dose), 1, 2, 3, 4, 5, 6 and 8 hours after witnessed 
metformin ingestion. Rifampicin and isoniazid were administered just after the 3 hour 
blood withdrawal and just prior a small standardized snack. Separate administration of 
the study drugs, as well as the intake of metoclopramide, were incorporated into the 
protocol after four out of the first six patients without these precautions had experienced 
nausea and vomiting during their first PK-GC session. 
During the PK day, cumulative urine of all subjects was collected for 8 or 12 hours 
in 2-hour periods. Patients taking metformin twice daily received a urine container 
to collect their urine at home between the 8-12 hour interval. Subjects received a 
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standardized snack/small lunch at a set time and extra blood was withdrawn to assess 
plasma creatinine concentrations for the estimation of creatinine clearance.
On the second morning of each session, glucose concentrations were measured just 
before and at ½, 1, 1½, 2, 2½ and 3 hour after the ingestion of 75 grams on empty 
stomach. Glucose ingestion occurred when metformin concentrations were expected 
to be at their maximum (Cmax), so 2.5 hours after metformin intake. One hour before 
the intake of metformin, metoclopramide was provided to the patients to prevent 
gastrointestinal side effects. 
Metformin concentration analysis
Urine and plasma concentration analyses were performed with validated ultra 
performance liquid chromatography assays. Extraction of metformin from plasma 
(200 μL) was performed with a 1-butanol-hexane (50:50, v/v) mixture under alkaline 
conditions followed by back-extraction into diluted phosphoric acid (0.1%). Extraction 
from urine samples followed the same procedure after dilution (1:10, v/v) in blank 
human plasma. Chromatography was carried out using an Acquity UPLC HSS T3 1,8 
um 2,1 x 100 mm analytical column (Waters, Milford, MA, USA), with an isocratic mobile 
phase of 100% phosphate buffer (0.02 M), alternated with a wash buffer (combination 
of phosphate buffer (0.02 M) and acetonitrile (50:50, v/v)) in between samples, 
pumped at an isocratic flow rate of 0.6 mL/min. The detection wavelength was set 
at 236 nm. Accuracy across five metformin quality control samples measured in three 
runs (n=15) ranged from 101-103% in plasma and 98-101% in urine. Intraday precision 
(n=5) ranged between 1.2-5.8% in plasma and 2.7-8.9% in urine. Interday precision 
(n=15) varied between 0-2.4% in plasma and 0-3.9% in urine. The lower and higher 
limit of quantitation (LLOQ and HLOQ) were 0.01 and 5.0 mg/L in the plasma assay, 
respectively, and 2.1 and 2091 mg/L in the urine assay, respectively. Finally, a stability 
analysis in plasma and urine confirmed that metformin was stable for a minimum of 7 
days at room temperature.
Pharmacokinetic evaluation
A non-compartmental pharmacokinetic analysis was applied to calculate the 
pharmacokinetic parameters of metformin using Phoenix WinNonlin v.6.3 (Pharsight 
Corp., Mountain View, California). The maximum concentration in plasma was defined 
as Cmax and the time to this maximum concentration as Tmax. Both parameters were 
directly derived from the plasma concentration-time data. The area under the 
concentration-time curve from 0 to 8 hours post dose (AUC0-8h) was calculated using 
the linear up-log down trapezoidal rule from 0 up to the last concentration. The 
half-life was calculated by 0.693/β, in which β (first-order elimination rate constant) 
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was derived with linear regression of the last three data points of the log-linear plasma 
concentration-time curve. Metformin plasma concentration were extrapolated until 12 
hours for patients on twice daily metformin with the equation C12h = C8h * e-β(t12-t8). The 
apparent clearance of the drug (CL/F) was calculated using the formula dose/AUC0–8h 
and the volume of distribution (Vd/F) was calculated by dividing CL/F by β. 
The cumulative amount of metformin excreted in urine during the dosing interval 
(Ae0-τ) was obtained by summing the amount excreted in each 2-hour time interval. 
Renal clearance of metformin was estimated using the formula Ae0-τ/AUC0-τ. The net 
tubular secretion of metformin was calculated by subtracting creatinine clearance from 
renal clearance of metformin. Creatinine clearance was based on eGFR, as calculated 
with the CKD-EPI formula (30). 
To assess changes in the glucose lowering effect of metformin, the maximum 
blood glucose concentration (Gmax) was determined directly from the glucose 
concentration-time curve, and the glucose area under the blood concentration-time 
curve until 3 hours (G-AUC0-3h) was calculated using the linear trapezoidal rule.
Statistical analysis
Patient characteristics were described for all included patients. Pharmacokinetic data 
and glucose handling data were presented descriptively for those patients that were 
sampled in both PK-GC sessions. 
A bioequivalence approach (Phoenix WinNonlin) was used to evaluate the 
metformin-rifampicin interaction (primary objective). This approach adequately 
controls the consumer risk (incorrect conclusion of lack of interaction with studies with 
low statistical power) and producer risk (incorrect conclusion of interaction with studies 
with high statistical power). The 90% confidence interval (CI) of the geometric mean 
ratios (GMR) AUC-session 1:AUC-session 2 and Cmax session 1:Cmax session 2 should be 
between 0.80 and 1.25 to conclude the absence of an interaction, or bioequivalence (31). 
Conclusions with regard to the presence of an interaction were drawn as described by 
Williams et al. (33), namely that bioequivalence (lack of an interaction) was suggested if 
the GMR fell within the limits of 0.80 to 1.25, but either the lower or the upper limit of the 
90% CI failed the limits of 0.80 to 1.25; bioinequivalence (an interaction) was concluded 
if the GMR and the 90% CI fell outside the limits of 0.80 to 1.25; and bioinequivalence 
was suggested if the GMR fell outside the range of 0.80 to 1.25, but one of the 90% CI 
limits fell within the limits of 0.80 to 1.25.
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To assess within-patient differences between sampling sessions Related-Samples 
Wilcoxon Signed Rank tests were performed. To assess the effect of rifampicin on 
metformin pharmacokinetic parameters and the effect of metformin, paired-samples 
t-test were performed on log-transformed plasma/blood parameters. All statistical 
analyses were performed with IBM SPSS Statistics 22 for Windows. P-values <0.05 were 
judged significant. 
Figure 2. Schematic overview of the study design in weeks from the start of TB treatment (wk 0). 
The period of TB treatment is colored grey. Daily intake of TB drugs (for >7 days) is indicated by 
dashed lines. 
ETH, ethambutol; IC, informed consent; INH, isoniazid; MTF, metformin; PK-GC, pharmacokinetic-glucose 
curve sampling session; PYR, pyrazinamide; RIF, rifampicin; wk, week
Results
Subjects
From the TANDEM cohort, 31 patients were found eligible and were asked for informed 
consent. Of these patients, 10 subjects did not participate in the study, because 
they either did not  meet the inclusion and exclusion criteria in the first screen or 
dropped out for other reasons. Of the included patients (n=21), 17 patients underwent 
pharmacokinetic sampling: 2 patients had vomited in the morning of pharmacokinetic 
sampling and another 2 had been non-compliant during the week prior the first PK 
session and were therefore excluded for pharmacokinetic assessment. Among these 
sampled patients, there were 10 females and 7 males. Thirteen patients were taking 500 
mg of metformin (test dose during PK day), of which 6 patients twice daily, 4 patients 
thrice daily and another 3 patients thrice daily in combination with 850 mg doses. Four 
patients were taking 850 mg of metformin (test dose during PK day), all thrice daily. 
Median fasting blood glucose during the first screen was 161 (range: 91-252) mg/dL, 
eGFR amounted to 101 (65-134) mL/min and ALT was 11 (6-21) U/L. Of these 17 patients, 
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only 14 subjects underwent GC sampling, because another 3 patients had vomited in 
the morning of GC sampling and were excluded for GC assessment. Weight and BMI 
remained comparable between the two sampling sessions, supporting comparability of 
the two situations within-subject (Table 1).
Drug adherence and adverse events
Patients’ adherence to metformin and TB drugs was good. Mean percentages drug 
adherence in the first session, according to the physician assessment, pill count, 
self-assessment, and diary, were 100%, 98%, 100% and 93%, respectively. These 
percentages were 100%, 93%, 100% and 83% in the second session, respectively. We 
expect any non-adherence to be of minor importance for our measurements, because 
we actively stimulated drug intake the final 3 days before pharmacokinetic sampling by 
personally contacting all patients individually. 
Of the 17 patients who underwent pharmacokinetic sampling, 8 patients (47%) 
experienced an adverse event during the follow-up period. More specifically, 5 patients 
experienced gastro-intestinal adverse effects (29%) and other adverse events were 
unlikely related to the study drugs. The number of gastro-intestinal adverse effects 
does not include the incidences of vomiting during the sampling days (Figure 3), which 
occurred mainly prior (4 out of the first 6 patients) the addition of metoclopramide to 
the protocol and the separation in time of metformin and TB drug intake. 
Effect of rifampicin on metformin pharmacokinetics
Steady-state metformin pharmacokinetics were assessed for subjects that underwent 
pharmacokinetic sampling in the first and second session (n=11) (Table 1). The metformin 
plasma AUC0-τ GMR (exposure during rifampicin treatment divided by exposure after 
rifampicin treatment) was 1.30 (90% CI 1.07-1.59). Metformin Cmax GMR amounted 
to 1.17 (90% CI 0.96-1.43). Furthermore, rifampicin exposure significantly altered the 
half-life (t1/2) (p=0.011) and the apparent clearance (p=0.006) of metformin (Table 1). 
While paired-samples t-tests demonstrated significant differences in AUC0-τ and Cmax, 
tubular secretion of metformin remained comparable after TB treatment (p=0.879) 
(Table 1 and Figure 3A-C). Creatinine clearance showed a trend for a small reduction 
(-5 ml/min) after rifampicin discontinuation (p=0.189), but this did not reach statistical 
significance (Table 1).
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Table 1. Comparison of steady-state metformin pharmacokinetic parameters with and without 
co-administration of rifampicin.
Parameter
With rifampicin
n=11
Without rifampicin
n=11
p-value or
GMR estimate 
(90% CI)
Age (years) 50 (33-62) 50 (33-62) 0.102a
Weight (kg) 54.9 (39.4-77.8) 57.1 (34.9-79.8) 0.168a
BMI (kg/m2) 22.7 (17.8-34.1) 23.9 (15.7-35.0) 0.155a
AUC0-τ (mg/L*h) 15.7 (7.8-32.8) 12.2 (8.1-21.6) 1.30 (1.07-1.59)b
Cmax (mg/L) 2.40 (1.25-5.22) 2.13 (1.24-3.86) 1.17 (0.96-1.43)
b
Tmax (h) - median 2 (1-4) 1 (0-3)
T1/2 (h) 6.3 (4.7-8.7) 4.9 (3.0-6.6) 0.011c
Vd/F (L) 337 (214-681) 336 (203-477) 0.980c
CL/F (L/h) 36.9 (22.7-66.2) 47.2 (34.5-72.6) 0.006c
CLcreatinine (mL/min) 113 (88-142) 108 (74-138) 0.189
c
CL0-8h,renal (mL/min)
* 324 (122-625) 319 (126-659) 0.881c
CL0-8h,secretion (mL/min)
* 198 (34-494) 203 (52-533) 0.879c
Metformin plasma concentration were extrapolated from 8 until 12 hours to calculate AUC0-τ for patients 
on twice daily metformin. Patient characteristics are presented as median (minimum-maximum). 
Pharmacokinetic data are expressed as geometric mean (minimum-maximum), unless stated 
otherwise. Significant differences are depicted in bold. 
a By related-Samples Wilcoxon Signed Rank tests, with and without co-administration of rifampicin 
b Evaluation of a pharmacokinetic interaction by means of the bioequivalence approach 
c By paired-samples t-test on log-transformed pharmacokinetic parameters
* due to miscollection of urine between the 8-12h interval at home, we calculated renal clearance based 
on observed urine collections up to 8h after metformin intake
AUC0-τ, area under the plasma concentration–time curve from time point 0 to the end of the dosing 
interval; CL, clearance; Cmax, maximum plasma concentration; F, bioavailability; t1/2, elimination half-life; 
Tmax, time to maximum plasma concentration; Vd, volume of distribution
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Figure 3. Individual changes in steady-state metformin pharmacokinetic parameters, AUC0-τ (A), 
Cmax (B) and tubular secretion (C), with and without co-administration of rifampicin.
Metformin plasma concentrations were extrapolated from 8 until 12 hours to calculate AUC0-τ for 
patients taking metformin twice daily. Tubular secretion was based on observed urine collections up 
to 8h after metformin intake. Data were assessed with paired-samples t-test on the log-transformed 
parameters (n=11).
AUC0-τ, area under the plasma concentration-time curve from time point 0 to the end of the dosing 
interval; Cmax, maximum plasma concentration
Effect of rifampicin on the glucose-lowering efficacy of metformin 
Blood glucose concentrations for both sessions are displayed in Figure 4. The glucose 
challenge was further analyzed for subjects that underwent GC sampling in the first and 
second session (n=8). Baseline or fasting blood glucose concentrations were similar 
before and after rifampicin cessation (p=0.770) (Table 2). The ability of metformin to 
reduce maximum blood glucose levels (Gmax) and the AUC of glucose were compared 
with and without co-administration of rifampicin treatment (Table 2 and Figure 5). 
Changes due to rifampicin exposure were not significant, even though there seemed 
A B
C
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a trend for a small reduction in maximum blood glucose concentrations under 
co-administration of rifampicin (p=0.102).
Table 2. The glucose-lowering effect of metformin with and without co-administration of rifampicin.
Parameter
With rifampicin
(n=8)
Without rifampicin
(n=8)
p-value
Baseline blood glucose (mg/dL) 117 (90-213) 119 (75-217) 0.770a
G-AUC (mg/dL*h) 717 (581-1212) 765 (621-1164) 0.213a
Gmax (mg/dL) 301 (229-491) 337 (265-487) 0.102a
Data are expressed as geometric mean (minimum-maximum)
a Paired-samples t-test on log-transformed blood glucose parameters 
G-AUC, area under the blood glucose concentration-time curve; Gmax, maximum blood glucose 
concentration
Figure 4. The blood glucose concentration-time curves following ingestion of 75 g of glucose, 2.5 
hours after metformin intake, during TB treatment (with rifampicin, n=14) and after cessation of 
treatment (without rifampicin, n=8). 
Data are presented as median ± interquartile range
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Figure 5. Individual changes in G-AUC (A) and Gmax (B), after a 75 gram glucose challenge, with 
and without co-administration of rifampicin.
Data were assessed with paired-samples t-test on log-transformed blood glucose parameters (n=8)
AUC, area under the blood concentration-time curve from; Gmax, maximum blood glucose concentration
Discussion
In this study, we evaluated the impact of rifampicin on metformin exposure by comparing 
metformin and glucose concentrations in Indonesian TB-DM patients with and without 
co-administration of rifampicin as part of their TB treatment. The AUC0-τ geometric 
mean ratio (GMR) of 1.30 (90% CI 1.07-1.59) suggests bioinequivalence of metformin 
(i.e. occurrence of an interaction) when co-administered with rifampicin, resulting in 
increased exposure of metformin (33). This pharmacokinetic interaction did not result 
in a statistically significant change in the glucose-lowering effect of metformin, even 
though there seemed a trend for a reduction in peak blood glucose concentrations 
(p=0.102) under co-administration of rifampicin. However, the effect was only small 
(-36 mg/dL or -10%) and its clinical importance can be debated. Presented data are 
the outcome of an intermediate analysis. Recruitment to reach the calculated goal of 
24 participants is still ongoing.
The higher metformin total and peak exposure observed in our study is probably the 
result of altered metformin absorption kinetics under influence of rifampicin exposure, 
because metformin urinary clearance and tubular secretion was not affected by 
rifampicin. In contrast, rifampicin exposure did significantly alter the apparent clearance 
and half-time in the non-compartmental analysis of plasma concentrations. This 
can be explained by the fact that apparent clearance is a derived parameter in the 
non-compartmental analysis, not corrected for bioavailability, and that half-life was 
A B
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calculated with an elimination rate constant (calculated from the last three data points; 
5, 6 and 8 hours post-dose) that was possibly not only depicting the elimination phase, 
but also absorption (up to 6-10 hours (16)) and distribution processes.
Metformin has relatively poor oral absorption with a bioavailability of 55% (16), leaving 
substantial space for absorption increases. Metformin displays nonlinear absorption 
kinetics, indicating the importance of (saturable) transport processes for drug uptake 
from the intestinal lumen (17, 34). OCT1, OCT3 and PMAT are the relevant metformin 
transporters in the small intestine, with PMAT being the most abundant (16, 35). 
Rifampicin-induced upregulation of these transporters is very likely responsible for the 
increased absorption assumed in our study. In agreement with this, rifampicin increased 
OCT1 expression in blood cells in healthy volunteers previously (24). Further study is 
needed to evaluate the inductive effect of rifampicin on the expression of metformin 
transporters at the site of the intestine, to confirm if this mechanism explains the 
rifampicin-metformin interaction. 
The increase in systemic exposure to metformin under influence of rifampicin is 
consistent with the findings of Cho et al. (2011) in healthy volunteers (24), even though 
the pharmacokinetic interaction in our study seems larger (14-18% compared to 17-30% 
in this study). This difference may be explained by the enhanced renal clearance and 
tubular secretion, mediated by OCT2, that was observed in the healthy volunteer study, 
lowering systemic metformin exposures under influence of rifampicin. Our study did 
not identify such an elimination effect. Disease status may have altered expression 
levels of transporters important for metformin elimination, such as OCT2, MATE1 or 
MATE2K. Information on the transcriptional regulation or inducibility of the MATE family 
is still mostly lacking. In a study performed in mice, mRNA levels of MATE1 and MATE2 
remained unchanged after treatment with prototypical drug-metabolizing enzyme and 
drug-transporter inducers (36). 
The present study did not identify a clear enhancement in the glucose-lowering effect 
of metformin to accompany the increase in metformin exposure. Several reasons can 
be brought forward to explain this discrepancy. First and foremost, presented data only 
contain glucose data (before and after) for eight individuals, as part of the intermediate 
analysis for this study. But also after completion of recruitment (aim 24 participants), 
our study would not be powered to assess (small) differences in the effect of metformin. 
Secondly, expression of OCT1 in the liver and OCT2 in the kidney could have been 
relatively less affected by rifampicin in this study compared to the expression of SLC 
transporters mediating metformin absorption. In humans, the liver has a central role in 
the regulation of systemic glucose, but also the kidneys contribute to glucose uptake, 
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gluconeogenesis and glucose utilization (37, 38). Theoretically, altered OCT1 and 
OCT2 expression influences local metformin exposure and thus overall drug efficacy. 
Unaffected expression would be in contrast with findings in rats, where the PXR agonist 
pregnenolone-16-carbonitrile upregulated the expression of both OCT1 in the liver 
and OCT2 in the kidneys (23). Thirdly, the pharmacological action of metformin could 
have been influenced by non-transporter related processes. For example, PXR itself is 
known to influence glucose homeostasis (39, 40), and rifampicin has been reported 
to induce early phase hyperglycemia possibly by enhancing glucose absorption (6). 
These parallel processes may have counteracted or dampened any pharmacodynamic 
interaction anticipated from OCT1 and OCT2 upregulation. Finally, while the paired 
glucose challenges are sufficient to detect changes in net glucose handling, it does not 
give information on alterations in the underlying severity of insulin resistance and beta 
cell function (41). 
Among the TB-DM patients there was a notably high prevalence of gastro-intestinal 
adverse effects during the study period (29%). Gastro-intestinal adverse effects, 
such as diarrhea, nausea and vomiting, are common to the intake of metformin and 
rifampicin. The severity of these adverse effects increased during the study days of the 
first six patients, because at that time study drugs were taken simultaneously without 
metoclopramide beforehand. This resulted in that 2/6 patients vomited during the PK 
days, and another 2/4 patients vomited during the GC days. Therefore, we adapted 
our study protocol and decided to separate the administration of study drugs in time, 
as well as to add the intake of metoclopramide, which is not expected to confound a 
rifampicin-metformin interaction. Overall, we feel that the high prevalence of these 
adverse effects should be taken into consideration in the treatment of all TB-DM 
patients. Normally rifampicin and other TB drugs are taken on an empty stomach, as 
food is known to limit the bioavailability of these drugs (42), but they can also be taken 
with food if gastro-intestinal side effects occur, such as when co-administered with 
metformin.
An important pitfall of this study is formed by its sequential design. Any clinically 
significant interaction might have lead to adaptation of the metformin dose by the 
physician in attendance. Indeed in three of the first seven cases who completed the 
second PK-GC session, the dosing interval of metformin had been changed after the 
first PK-GC session, resulting in an altered total daily dose. Two of these patients were 
switched to a dosing schedule that contained a lower daily dose of metformin. These 
patients were measured in a third session, after switching back to their dosing schedule 
of the first PK-GC session. A second limitation is formed by the fact that patients on 
twice daily metformin encountered difficulty with their urine collections between the 
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8-12h interval at home: 4/9 (44%) cases of 8-12hr urine collections failed. Therefore, we 
decided to calculate renal clearance based on the observed urine collections up to 8h 
after metformin intake. A third limitation is that rifampicin and isoniazid concentrations 
were not measured, which would have given information on the amount of rifampicin 
(and co-administered isoniazid) exposure resulting in altered metformin concentrations. 
A final limitation is the use of creatinine clearance (eGFR) as estimation for the fraction 
metformin eliminated from the body by glomerular filtration. It is well known that 
creatinine is freely filtered by the glomerulus, however active secretion by the proximal 
tubule also occurs. We know that OCT2 plays a role in the renal secretion of creatinine 
(43), and this may obscure our calculation of metformin clearance and secretion. This 
may also explain the very slight change in creatinine clearance after stopping rifampicin 
(-5 ml/min). Overall, the impact of this finding is probably minor; creatinine secretion 
is only a small contributor to creatinine clearance, namely approximately 10-20% of 
the GFR (44), whereas renal clearance of metformin can be up to 4-11 times as great 
as creatinine clearance, indicating a far more important role for tubular secretion for 
metformin. 
To summarize, we found that rifampicin exposure increased plasma metformin 
concentrations, without affecting the glucose lowering action of metformin in a similar 
magnitude. Increases in exposure are probably caused by enhanced absorption, 
as rifampicin did not affect the renal clearance or tubular secretion of metformin. 
Furthermore, there was a high prevalence of gastro-intestinal adverse effects amongst 
the studied TB-DM patients. Our findings should be taken into consideration when 
treating TB-DM patients who take rifampicin and metformin concurrently. This may 
include close monitoring of metformin effectiveness during and after TB treatment 
by performing additional fasting blood glucose and 2-hour post-prandial glucose 
assessments, and advising patients to take metformin and rifampicin with food, and 
possibly separated in time, to prevent gastro-intestinal adverse effects. 
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Abstract
Background
Recent data suggest that intensified antimicrobial treatment may improve outcome of 
tuberculous (TB) meningitis. Considering that drug exposure is the intermediate link 
between dose and effect, we examined the concentrations-response relationship for 
rifampicin and moxifloxacin in TB meningitis patients. 
Methods
In an open-label, phase 2 clinical trial performed in Indonesia (ClinicalTrials.gov 
NCT01158755), 60 TB meningitis patients were randomized to receive standard dose 
(450 mg oral) or high dose rifampicin (600 mg i.v.) plus either moxifloxacin (400 mg or 
800 mg) or ethambutol (750 mg). After 14 days all patients continued with standard 
tuberculosis (TB) treatment. Pharmacokinetic sampling was performed once in every 
patient during the first 3 critical days. Differences in exposure between patients who 
died or survived were tested with independent-samples t-tests. The relationship 
between drug exposure and mortality was examined using Cox regression. 
Results
Compared to patients who died during the 2 weeks of intensified treatment, surviving 
patients had significantly higher rifampicin plasma AUC0-6h, plasma Cmax and CSF Chighest. 
Additionally, patients had a 32-43% lower relative likelihood of dying with increasing 
interquartile range of rifampicin exposure. Moxifloxacin exposure did not show a clear 
relationship with survival. From exposure-response curves, a rifampicin plasma AUC0-6h 
of ca. 70 mg/L*h (AUC0-24h of ca. 116 mg/L*h) and a Cmax of ca. 22 mg/L were deduced 
as minimum target values for treatment. 
Conclusions
We found a strong concentration-effect relationship, with higher rifampicin exposure 
leading to better TB meningitis survival. The current treatment dose of rifampicin is 
suboptimal; higher doses of rifampicin should be evaluated. 
229
PK-PD analysis of an intensified regimen for tuberculous meningitis
Introduction
Tuberculous (TB) meningitis, the most severe manifestation of Mycobacterium 
tuberculosis (M. tuberculosis) infection, results in death or neurological disability in 
up to 50% of patients affected (1, 2). The treatment of TB meningitis patients follows 
the model for short-course chemotherapy in pulmonary tuberculosis (TB) patients, 
comprising an intensive and a continuation phase of treatment (3, 4). In addition, the 
same TB drugs and dosing guidelines are applied, even though it is known that the 
penetration of some first-line anti-TB drugs, especially rifampicin, into cerebrospinal 
fluid (CSF) is limited (5).
One way to improve the outcome of TB meningitis may be to intensify antimicrobial 
treatment. We have recently examined this in a phase 2 clinical trial among TB 
meningitis patients in Indonesia (6). Intensified treatment consisted of a 30% higher 
dose of intravenous (i.v.) rifampicin plus standard-dose or high-dose moxifloxacin 
orally, combined with oral isoniazid and pyrazinamide during the first 2 weeks. The 
higher dose of rifampicin was safe and led to a 3-fold higher drug exposure in plasma 
and CSF. In addition, high-dose i.v. rifampicin was associated with a strong reduction in 
6-month mortality compared with standard dose oral treatment (35% vs. 65%, adjusted 
hazard ratio (HR) 0.42 (95% CI 0.20-0.91)), although the study was not powered to 
detect differences in outcome. Moxifloxacin was not associated with a survival benefit. 
Previously, mortality and resolution of coma were related to the dose of rifampicin and 
moxifloxacin, not to individual concentrations of these drugs. However, administration 
of the studied rifampicin and moxifloxacin doses resulted in large interindividual 
variability in exposures, both in plasma and  CSF (6). Accumulating data suggest that 
exposure to TB drugs is relevant for outcome in pulmonary TB (7-12). Considering that 
concentrations of TB drugs are the intermediate link between the doses administered 
and their eventual effects, the current analysis examined the relationship between 
rifampicin and moxifloxacin (plasma and CSF) concentrations and mortality and 
resolution of coma in TB meningitis patients. The results of this analysis may reveal 
exposure thresholds predictive of good treatment response in TB meningitis. Such 
exposure thresholds help in the assessment of the optimal oral (rather than i.v.) dose 
of TB drugs needed to treat TB meningitis and aid in the design of pharmacokinetically 
optimized dosing regimens for TB meningitis in other populations (e.g. children).   
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Methods
Study design
The study evaluated an open-label, randomized, phase 2, clinical trial with a factorial 
design, performed at Hasan Sadikin Hospital (Bandung, Indonesia) (6). All patients 
older than 14 years with definite, probable, or possible TB meningitis were eligible 
for the study. Exclusion criteria were failure to perform a diagnostic lumbar puncture 
or evidence of bacterial or cryptococcal meningitis. Other exclusion criteria were 
treatment for tuberculosis for more than 7 days before admission, a history of TB 
meningitis, pregnancy, lactation, a known contraindication to moxifloxacin, alanine 
aminotransferase activity more than five times the upper limit of normal, known 
hypersensitivity or intolerance to rifampicin or moxifloxacin, rapid clinical deterioration 
during the screening process, and no informed consent. Written informed consent 
for participation in the trial and rapid HIV testing was obtained from patients or close 
relatives of patients who were unconscious.
Patients were randomized to receive a regimen with standard dose (450 mg once 
daily, ca. 10 mg/kg in Indonesian TB patients, orally) or high dose rifampicin (600 
mg once daily, ca, 13 mg/kg, i.v.), next plus either standard-dose moxifloxacin (400 
mg), high-dose moxifloxacin (800 mg) or oral ethambutol (750 mg) (6). All patients 
were given oral isoniazid (300 mg/day), pyrazinamide (1500 mg/day), and pyridoxine 
(50 mg/day). After 14 days, all patients continued taking the standard TB regimen, 
consisting of oral isoniazid 300 mg/day, rifampicin 450 mg/day, pyrazinamide 1500 
mg/day and ethambutol 750 mg/day for 2 months, with subsequent rifampicin 450 
mg/day and isoniazid 300 mg/day for four months in accordance with the Indonesian 
National Tuberculosis Program. All participants were given adjunctive corticosteroid 
treatment for the first 6 to 8 weeks according to international guidelines (13). Patients 
were followed up until 6 months after the start of treatment. The study was approved 
by the Ethical Review Board of Hasan Sadikin Hospital/Medical Faculty of Universitas 
Padjadjaran, Bandung, Indonesia. For specifics on randomization and masking, 
treatment and follow-up, we refer to our previously published work (6). 
Pharmacokinetic assessment
Pharmacokinetic sampling was performed in the first 3 days of drug administration 
as these days were considered to be critical for outcome. Serial blood sampling was 
done just before and at 1, 2, 4, 6, and 24h after dosing. Two CSF samples were taken, 
one on the same day as the blood samples (at 3 to 6h after dosing), and one on the 
next day (at 6 to 9h after dosing). The total (protein-bound plus unbound) plasma and 
CSF rifampicin and moxifloxacin concentrations were assessed at Radboud University 
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Medical Center, Nijmegen, The Netherlands, using validated high-performance liquid 
chromatography (HPLC) assays. For rifampicin, accuracy for standard concentrations 
was between  99.8% and 100.4% depending on the concentration. The intra-assay and 
inter-assay coefficients of variation were <4% for a concentration of 0.26-30 mg/L. The 
lower limit of quantification (LLOQ) was 0.26 mg/L. For moxifloxacin, accuracy was >95% 
at all standard concentrations. Intra-assay and inter-assay coefficients were from 1.4% 
to 5.4% and 0.2% to 3.9%, respectively. The lower LLOQ was 0.03 mg/L. Parameters 
for rifampicin and moxifloxacin in plasma were assessed non-compartmentally 
with WinNonLin Professional v5.0 as previously described (6). The highest plasma 
concentrations were defined as Cmax, with the corresponding times as Tmax. The area 
under the plasma concentration-time curve up to 6h and up to 24h after dosing 
(AUC0–6h and AUC0–24h, respectively) were calculated with the log-linear trapezoidal rule. 
Chighest in the CSF represents the highest concentration measured in the intervals of 
3–6h and 6–9h after dosing.
Statistical analysis
Descriptive statistics
First, patient characteristics, pharmacokinetic data and mortality data were presented 
descriptively for all patients included, irrespective of their study group. Correlation 
analyses using Spearman’s rank were performed between measures of rifampicin and 
moxifloxacin exposure: AUC in plasma versus Cmax in plasma, Cmax in plasma versus Chighest 
in CSF, and AUC in plasma versus Chighest in CSF. In addition, rifampicin and moxifloxacin 
Chighest CSF/Cmax plasma ratios were plotted against plasma Cmax. 
Categorizing data by exposure
Tertiles were formed based on the rifampicin and moxifloxacin exposure parameters 
(plasma AUC, plasma Cmax, CSF Chighest), which were designated groups with ‘low’, 
‘standard’ or ‘high’ exposure. Tertiles were chosen because with more than three groups 
the number of patients per group becomes too small. The use of tertiles also enabled 
us to check the presence of a U-shaped exposure-response relationship as reported by 
Thwaites et al. (2011) (14). Continuous characteristics or treatment outcomes per group 
were compared using one-way analysis of variance (ANOVA) with post-hoc Tukey’s test. 
Dichotomous measures were examined using Pearson’s χ2.
Comparing exposure per outcome value
Differences in exposure measures between patients who died and patients who 
survived, and between those with and without resolution of coma (Glasgow Coma Scale 
(GCS) score of 15) were tested with independent-samples t-tests on the logarithmically 
transformed values of plasma AUC, plasma Cmax and CSF Chighest. 
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Correlating exposure with outcome
Relationships between rifampicin and moxifloxacin exposure and the time-to-event 
outcome mortality were examined using Cox regression. Hazard ratios (HRs) were 
assessed for an interquartile  range (IQR) increase (IQ-HRs) in exposure, i.e. an 
increase in exposure from the 25th percentile to the 75th percentile, an approach used 
previously by Burhan et al. (2013) (15). Relationships between exposure measures and 
the dichotomous outcome ‘clearance of coma’ were examined using logistic regression. 
Multivariable analyses were conducted by means of ENTER all independent variables, 
including the exposure measures (plasma AUC, plasma Cmax and CSF Chighest), HIV-status, 
GCS at initiation of treatment and rifampicin dose (in the case of moxifloxacin exposure 
measures). 
Concentration-response curve analysis
A concentration-response curve was constructed to determine the exposure threshold 
above which relatively less survival benefit was to be expected. For this, classes of 20 
mg/L*h for AUC0-6h and 5 mg/l for Cmax were constructed and average survival within 
each class was calculated. All classes were designed to contain at least three patients. 
For this reason, the highest two rifampicin AUC exposure classes had to be combined. 
Survival after two months was used as response parameter, because the number of 
deceased patients in a shorter follow-up period was too small. Concentration-response 
curves were established by nonlinear regression fitting of a concentration-response 
stimulation curve with variable slope using GraphPad Prism v.5.03 (GraphPad Software). 
All statistical analyses were performed with SPSS v.18.0.2 for Windows (SPSS Inc., 
Chicago, IL). P-values <0.05 were considered significant.
Results
Descriptive statistics
Of the 60 TB meningitis, 52 patients had pharmacokinetic assessments of rifampicin 
and 35 patients had pharmacokinetic assessments of moxifloxacin. Seven patients 
died before pharmacokinetic sampling could be performed and one patient was 
excluded from pharmacokinetic assessments of rifampicin. Table 1 reports the patient 
characteristics at presentation and during follow-up. 
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Table 1. Patients’ characteristics and outcomes for the total study population and per AUC0-6h 
(rifampicin) and AUC0-24h (moxifloxacin) exposure categories.
Rifampicin 
(450 mg p.o. & 600 mg i.v.)1
Moxifloxacin 
(400 mg p.o. & 800 mg p.o.)1
All
(n=60)
Low 
(n=18)
Standard 
(n=17)
High 
(n=17)
Low
(n=8) 
Standard
(n=8)
High
(n=8)
P
re
se
n
ta
ti
o
n
 
Sex, male 
55% 
(33)
72% 
(13)
53% 
(9)
35% 
(6)
63% 
(5)
63% 
(5)
50% 
(4)
Age (years)
28 
(16-64)
29 
(18-57)
29 
(19-60)
27 
(16-49)
28 
(19-33)
27 
(18-50)
29 
(19-36)
Body weight 
(kg) 
48 
(34-75)
50 
(40-58)
50 
(42-75)
48 
(34-54)
49 
(40-60)
49 
(43-56)
55 
(40-75)
Body-mass 
index (kg/m3)
18 
(15-26)
18 
(15-23)
20 
(16-26)
18 
(15-22)
19 
(16-21)
18 
(17-20)a
20 
(17-26)a
HIV infection 
12% 
(7)
22% 
(4)
12% 
(2)
6% 
(1)
13% 
(1)
0% 
(0)
13% 
(1)
GCS <15 on 
presentation
77% 
(46)
83% 
(15)
77% 
(13)
59% 
(10)
75% 
(6)
75% 
(6)
75% 
(6)
Dose group, 
high 
0% 
(0)*
53% 
(9)*
100% 
(17)*
13% 
(1)*
38% 
(3)*
100% 
(8)*
Fo
llo
w
-u
p
AUC (mg/L*h)
19 
(1.5-41)b,c
55 
(43-67)b,d
90 
(69-136)c,d
25 
(18-30)e,f
37 
(30-49)e,g
78 
(53-120)f,g
Mortality until 
14 days
30% 
(42)
33% 
(6)*
24% 
(4)*
0% 
(0)*
25% 
(2)
38% 
(3)
13% 
(1)
Mortality until 
6 months
48% 
(29)
56% 
(10)
41% 
(7)
24% 
(4)
38% 
(3)
38% 
(3)
50% 
(4)
AUC0-6h is reported as a geometric mean (range), other data are presented as % (number) or median 
(range). Continuous variables across groups were compared using ANOVA with post-hoc Tukey’s test. 
Comparisons between AUCs were performed on log-transformed data. Dichotomous outcomes were 
examined by using Pearson’s χ2 tests for categorical independent variables.
1 Administered for the first 14 days of treatment; afterwards all patients received standard treatment 
a-g Pairs were found to be significantly different (p< 0.05) * Group was found to contain statistically 
significant differences (p<0.05)
AUC, area under the plasma concentration-time curve up to 6h (AUC0–6h) and up to 24h (AUC0–24h) after 
dosing; p.o., oral; i.v., intravenous; BMI, body mass index; HIV, human immunodeficiency virus; GCS, 
Glasgow Coma Scale
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Table 2. Patient characteristics and outcomes per plasma Cmax and CSF Chighest exposure 
categories.
Rifampicin 
(450 mg p.o. & 600 mg i.v.)
Moxifloxacin 
(400 mg p.o. & 800 mg p.o.)
Cmax in 
plasma
Low 
(n=18)
Standard 
(n=18)
High 
(n=16)
Low
(n=11) 
Standard
(n=13)
High
(n=11)
P
re
se
n
ta
ti
o
n HIV infection 
22% 
(4)
6% 
(1)
13% 
(2)
27% 
(3)
0% 
(0)
9% 
(1)
GCS <15 on 
presentation
83% 
(15)
67% 
(12)
69% 
(11)
82% 
(9)
69% 
(9)
82% 
(9)
Dose group, 
high 
0% 
(0)*
56% 
(10)*
100% 
(16)*
18% 
(2)*
39% 
(5)*
82% 
(9)*
Fo
llo
w
-u
p
Cmax (mg/L)
4.9 
(0.3-8.7)a,b
14 
(9-19)a,c
26 
(21-35)b,c
2.7 
(1.3-3.7)d,e
5.4 
(4.5-6.5)d,f
9.6 
(7.2-15.1)e,g
Mortality until 
14 days
33% 
(6)
17% 
(3)
6% 
(1)
36% 
(4)
15% 
(2)
9% 
(1)
Mortality until 
6 months
61% 
(11)*
39% 
(7)*
19% 
(3)*
64% 
(7)
23% 
(3)
55% 
(6)
Chighest in CSF
Low
(n=17)
Standard
(n=19)
High
(n=14)
Low
(n=12)
Standard
(n=9)
High
(n=11)
P
re
se
n
ta
ti
o
n HIV infection 
18% 
(3)
16% 
(3)
0% 
(0)
25% 
(3)
0% 
(0)
0% 
(0)
GCS <15 on 
presentation
88% 
(15)
68% 
(13)
57% 
(8)
75% 
(9)
78% 
(7)
73% 
(8)
Dose group, 
high 
6% 
(1)*
63% 
(12)*
86% 
(12)*
25% 
(3)*
33% 
(3)*
82% 
(9)*
Fo
llo
w
-u
p
 Chighest (mg/L)
0.13 
(0.13-0.13)h,i
0.42
(0.26-0.58)h,j
0.93
(0.59-2.3)i,j
1.1 
(0.66-1.6)k,l
1.9 
(1.5-2.1)k,m
3.2
(2.4-4.9)l,m
Mortality until 
14 days
35% 
(6)
16% 
(3)
7% 
(1)
25% 
(3)
22% 
(2)
9% 
(1)
Mortality until 
6 months
53% 
(9)
26% 
(5)
36% 
(5)
42% 
(5)
44% 
(4)
36% 
(4)
Cmax/Chighest are reported as geometric mean (range), other data are presented as % (number) or median 
(range). Continuous variables across groups were compared using ANOVA with post-hoc Tukey’s test. 
Cmax/Chighest were log-transformed. Dichotomous outcomes were examined with Pearson χ
2 tests. 
a-m Pairs were found to be statistically significant different (p< 0.05) * Group was found to contain 
statistically significant differences (p<0.05)
AUC0–24h could not be assessed in 41 patients in the case of rifampicin and in 11 patients 
in the case of moxifloxacin, because concentrations at C24h were below the LLOQ. 
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Estimation of the C24h based on the last measurable concentration and the elimination 
rate constant (extrapolation) was not possible in these patients either, because the 
elimination rate could not be assessed reliably with sampling at 2, 4 and 6h after dosing. 
Consequently, the measure for total rifampicin exposure was AUC0-6h (n=52) and for 
moxifloxacin exposure was AUC0-24h (n=24). Drug exposure in CSF was estimated as 
the highest concentration measured in the intervals of 3 to 6h and 6 to 9h after dose, 
with 24 hours between the first and second puncture. For the time-interval 3 to 6 
hours (first lumbar puncture), median rifampicin concentration in the CSF was 0.37 
mg/L (range 0.13-2.28 mg/L) and for the time interval 6 to 9 hours (second lumbar 
puncture) this amounted to 0.32 mg/L (range 0.13-1.35 mg/L). For moxifloxacin, median 
concentration at the first lumbar puncture was 1.95 mg/L (range 0.66-4.91 mg/L) and 
for the second lumbar puncture this was 1.28 mg/L (range 0.0-4.3 mg/L). 
Rifampicin AUC0-6h correlated significantly with plasma Cmax (Spearman’s rho, 0.978; 
p<0.001), as did plasma Cmax with Chighest in CSF (Spearman’s rho, 0.693; p<0.001). 
Similar correlations were found for moxifloxacin AUC0-24h and plasma Cmax (Spearman’s 
rho, 0.816; p<0.001) and plasma Cmax with Chighest in CSF (Spearman’s rho, 0.580; 
p<0.001). Rifampicin AUC0-6h correlated significantly with CSF Chighest (Spearman’s rho, 
0.720; p<0.001), as did moxifloxacin AUC0-24h with CSF Chighest (Spearman’s rho, 0.666; 
p<0.001). The ratio of rifampicin Chighest CSF/Cmax plasma stayed relatively constant with 
increasing concentrations of Cmax in plasma (Spearman’s rho, -0.073; p=0.62) (Figure 
1A). In contrast, the ratio of moxifloxacin Chighest CSF/ Cmax plasma decreased with higher 
plasma Cmax (Spearman’s rho, -0.326; p=0.07) (Figure 1B). 
Figure 1. Ratio CSF Chighest / plasma Cmax plotted against plasma Cmax for rifampicin (A) and for 
moxifloxacin (B).
CSF, cerebrospinal fluid; Chighest, highest concentration measured in the CSF in the intervals of 3 to 6h 
and 6 to 9h after dosing; Cmax, highest plasma concentration
A B
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Categorizing data by exposure 
Table 1 shows the patient characteristics per AUC exposure group (assessed in the 
first 3 days of drug administration) and reveals that the distribution (%) of deaths 
during the first 14 days of treatment is significantly different across the rifampicin AUC 
exposure categories (p=0.04). The percentage of deaths decreases with every higher 
exposure category. Mortality until 6 months shows a similar but not significant trend 
(p=0.16). Similar trends were found for rifampicin plasma Cmax and CSF Chighest (Table 2), 
whilst differences in moxifloxacin exposure (Table 1 and 2) did not show such a clear 
trend. Furthermore, from Table 1 and 2 it appears that patients with low rifampicin 
exposures were more likely to be male, HIV-positive, and have a low GCS. However, 
total exposure was not significantly different between males and females, HIV-positive 
and HIV-negative patients, and those with and without a decreased GCS (<15). Males 
had a geometric mean total rifampicin exposure (AUC0-6h) of 38.0 mg/L*h and females 
an exposure of 55.4 mg/L*h (p=0.09). HIV-positive patients (n=7) had a geometric 
mean total rifampicin exposure of 33.8 mg/L*h and HIV-negative patients (n=45) had a 
rifampicin exposure of 47.3 mg/L*h (p=0.31). Finally, patients with a GCS <15 (n=38) had 
a geometric mean total rifampicin exposure (AUC0-6h) of 43.0 mg/L*h and patients with 
the maximal GCS of 15 (n=14) had a rifampicin exposure of 51.9 mg/L*h (p=0.46). In a 
multivariable linear regression analysis including total rifampicin exposure as dependent 
variable and gender, HIV-status, GCS at baseline and rifampicin dose as covariates, only 
rifampicin dose was a significant predictor of rifampicin exposure (p<0.001).
Comparing exposure per outcome value
Figure 2 shows an overview of the median rifampicin and moxifloxacin AUC and Cmax 
in plasma and Chighest in CSF, measured in the first critical 3 days of drug administration. 
Medians are reported for patients who survived and who died during the study 
treatment period (first 2 weeks) and after 6 months. Patients who died in the first 2 
weeks had a significantly lower AUC0-6h, plasma Cmax and CSF Chighest for rifampicin, as 
measured in the first 3 days of drug administration, compared with surviving patients 
in the same period. The geometric mean AUC0-6h, plasma Cmax and CSF Chighest for 
rifampicin among the surviving patients was 51.3 mg/L*h, 13.3 mg/L and 0.40 mg/L, 
respectively. For the complete follow-up period of 6 months the difference in rifampicin 
exposure in the first days of drug treatment was not statistically significant (Figure 2). 
Moxifloxacin exposure did not show such a clear relationship with patient survival, 
although patients who died within 2 weeks appeared to have a slightly lower plasma 
Cmax (Figure 2). When performing a similar analysis for resolution of coma (yes versus 
no), rifampicin and moxifloxacin drug concentrations showed no relationship with this 
variable (data not shown). 
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Correlating exposure with outcome 
Table 3 shows the results of the multivariable Cox regression analyses. In these analyses, 
the effect of exposure was corrected for HIV-status, GCS at initiation of treatment and 
rifampicin dose (in the case of moxifloxacin exposure measures). Although males 
appeared to have lower exposure than females (Table 1), gender was not included in 
the multivariable analysis exposure, as this was not considered to be an independent 
predictor of mortality and was not found to confound the exposure-response relation 
when added to the multivariable Cox regression analyses (data not shown). For rifampicin 
a trend can be observed, in which patients with one IQR higher exposure have a 32-43% 
lower relative likelihood of dying at any given point, with IQ-HRs for AUC0-6h of 0.68 
(95% CI 0.46-1.01), for plasma Cmax 0.64 (95% CI 0.41-0.99) and CSF Chighest 0.57 (95% 
CI 0.23-1.42). For moxifloxacin such a trend was not observed and therefore, no target 
values for exposure were deduced. Logistic regression demonstrated that ‘resolution of 
coma’ did not have significant relationships with rifampicin and moxifloxacin exposure 
measures (data not shown). 
Concentration-response curve analysis
Figure 3A and B show rifampicin concentration-response curves obtained by non-linear 
regression fitting, suggesting that the highest desirable exposures were not yet reached. 
Examination of the fitted lines reveals that exceeding an AUC0-6h of ca. 70 mg/L*h and 
a Cmax of ca. 22 mg/L yields somewhat less survival benefit. The proposed threshold 
for rifampicin AUC0-6h was translated into a threshold expressed as AUC0-24h, based on 
a linear regression analysis among those patients in whom both AUC0-6h and AUC0-24h 
could be estimated. An AUC0-6h of ca. 70 mg/L*h corresponds to AUC0-24h of 116 mg/L*h. 
Of the 36 patients below the AUC0-6h threshold of 70 mg/L*h, 16 persons died (44%) 
and of the 16 patients above the threshold, 2 patients died (13%), resulting in a relative 
risk (RR) of 0.3 (95% CI 0.07-1.08). Of the 40 patients below the Cmax threshold of ca. 22 
mg/L, 17 persons died (43%) and of the 12 patients above the threshold, one patient 
died (8%), resulting in a RR of 0.2 (95% CI 0.03-1.32). 
238
Chapter 10
Figure 2. Median plasma AUC, plasma Cmax and CSF Chighest for rifampicin (RIF) and moxifloxacin 
(MXF) recorded in the first 3 days of drug administration according to treatment outcome (death/
survival) during 14 days and 6 months of treatment. 
Intensified treatment was administered during the first 14 days, thereafter all patients received standard 
treatment. Pharmacokinetic sampling was performed in the first three days of drug administration, as 
these days were considered to be critical for outcome.
* Independent-samples t-test demonstrated a significant difference (p<0.05) between means of the 
log-transformed pharmacokinetic parameters (geometric means).
AUC, area under the plasma concentration-time curve; Cmax, highest plasma concentration; Chighest, 
highest concentration measured in the cerebrospinal fluid (CSF); IQR, interquartile range
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Figure 3. Concentration-response curves to determine the effect of rifampicin plasma AUC0-6h (A) 
and Cmax (B) exposure on survival and to deduce threshold values.
For these concentration-response curves, classes of 20 mg/L*h for AUC0-6h and 5 mg/l for Cmax were 
constructed and percentage survival within each class was calculated (≥ n=3). Survival after 2 months 
was used as response parameter. The highest two rifampicin AUC exposure classes had to be 
combined to reach >n=3.
Table 3. Hazard ratios for an interquartile range increase in the exposure parameter (IQ-HRs).
Exposure parameter
Six month 
mortality
IQR in 
exposure
IQ-HR
(95% CI)
Rifampicin
AUC0-6h (mg/L*h) (n=52) 21/52 (40%) 32.4-75.3 0.68 (0.46-1.01)
Cmax in plasma (mg/L) (n=52) 21/52 (40%) 8.1-21.6 0.64 (0.41-0.99)
Chighest in CSF (mg/L) (n=50) 19/50 (38%) 0.13-0.61 0.57 (0.23-1.42)
Moxifloxacin
AUC0-24h (mg/L*h) (n=24) 10/24 (42%) 29.0-67.4 0.89 (0.31-2.57)
Cmax in plasma (mg/L) (n=35) 16/35 (46%) 3.4-7.3 0.50 (0.23-1.11)
Chighest in CSF (mg/L) (n=32) 13/32 (41%) 1.3-2.6 0.95 (0.36-2.51)
Interquartile Hazard Ratios (IQ-HRs) were calculated using Cox regression and were assessed for an 
IQR increase in exposure, i.e. an increase in exposure from the 25th percentile to the 75th percentile. 
IQ-HRs were corrected for HIV-status, GCS at initiation of treatment and rifampicin dose (in the case of 
moxifloxacin exposure measures) in a multivariable analysis.  
IQR, interquartile range; CI, confidence interval
A B
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Discussion
We previously described that a higher dose of i.v. rifampicin resulted in a reduction 
in 6-month mortality in patients with TB meningitis (6). In the current analysis, we 
studied the relationship between exposure and response, considering that exposure 
is the intermediate link between dose and response. For rifampicin, we found a strong 
concentration-effect relationship, with higher exposure leading to better survival. 
The aim of this study was to deduce rifampicin target exposure values that may be 
used, first, for assessment of optimal oral (rather than i.v.) administration of antibiotics. 
Oral administration of TB drugs would help implementation of intensified treatment 
for TB meningitis in settings where it is most needed, although it is unknown to what 
extent i.v. treatment contributes to response in these critically ill patients. Second, target 
exposure values can help to design pharmacokinetically-optimized dosing regimens 
in other populations, such as children. Doses in mg/kg applied in adults cannot be 
extrapolated to young children, as they differ in drug distribution and clearance. In fact, 
dosing guidelines for TB drugs in children have recently been changed, to help them 
achieve exposures that have proven to be efficacious in adults (16). 
In the present study, a rifampicin AUC0-6h of ca. 70 mg/L*h was deduced as target 
value for the first critical days of treatment of TB meningitis. This AUC0-6h translates 
into an AUC0-24h of ca. 116 mg/L*h, which is much higher than average (steady-state) 
exposures reported for rifampicin in the Indonesian population, even considering that 
auto-induction of rifampicin will lower the AUC0-24h beyond the first days of treatment 
(17). Furthermore, a rifampicin plasma concentration of ca. 22 mg/L was derived as Cmax 
target value. The common reference range for rifampicin Cmax (>8 mg/L or 8-24 mg/L) 
represents the ‘normal’ (population) concentration range that can be expected in adults 
administered with standard doses of TB drugs. Thus this range does not represent a 
clinically validated threshold value. 
Importantly, the concentration-response evaluation (Figure 3) shows some flattening 
off, but suggests that the highest desirable exposures have not been reached yet. This 
calls for evaluation of higher doses of rifampicin. In the treatment of TB meningitis, an 
important factor to consider is that TB drugs have to pass the blood-brain-barrier in 
order to enter the CSF. Only protein-unbound rifampicin can enter the CSF. In line with 
the concentration-response evaluation, we consider the rifampicin concentrations in 
CSF still to be relatively low. Fortunately our study showed that the ratio of rifampicin 
Chighest in CSF/Cmax in plasma was relatively constant with increasing rifampicin Cmax 
values in plasma, suggesting that there is no saturation in the transfer of rifampicin into 
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the CSF and that higher rifampicin doses and plasma concentrations may indeed result 
in higher exposures in CSF. 
In the search of higher, yet tolerable doses of rifampicin, several studies have been 
performed in the past. In vitro studies and studies in mouse models have suggested that 
higher doses of rifampicin are associated with better treatment results and treatment 
shortening in pulmonary TB (18-20). Clinical studies also suggested improved early 
bactericidal activity and better treatment results in pulmonary TB (21, 22). Meanwhile, 
in the field of TB meningitis, Alvarez-Uria et al. have administered 900 mg (ca. 20.5 mg/
kg) of oral rifampicin for a median of 7 days (23) and no safety issues were reported 
in this setting. The results of intensified treatment in an ongoing study in Vietnam 
using 15 mg/kg rifampicin for 2 months in 750 TB meningitis patients (24) will give 
additional information on the efficacy and tolerability of higher doses of rifampicin in 
TB meningitis. Most recently, much higher oral doses of rifampicin up to 35 mg/kg daily 
were administered for 14 days in African pulmonary TB patients (25), yielding strongly 
increased exposures in plasma and without causing major tolerability problems. This 
suggests that higher doses of rifampicin are feasible. Follow-up research may also 
examine a longer duration of intensified antibiotic treatment, as it appeared that the 
differential effect of rifampicin mainly occurred during the first 2 weeks of treatment 
during which the intensified TB treatment was administered.
In this study, moxifloxacin did not appear to have a significant effect on mortality, 
despite the fact that moxifloxacin has the best in vitro activity against Mycobacterium 
tuberculosis amongst the fluoroquinolones (26), moxifloxacin is known to penetrate the 
CSF well (27) (as we also demonstrated in our study (Figure 1B)) and moxifloxacin was 
dosed at the regular dose of 400 mg as well as at a higher dose of 800 mg daily to 
overcome the interaction with rifampicin. One explanation may be that the bacterial 
growth rate in CSF is low, hindering the sterilization of CSF in vivo as compared to killing 
bacteria in vitro (27). Furthermore, in this study there was no indication for an U-shaped 
concentration-response curve, different from what was reported in another study in 
Vietnam (14). More studies, with larger study populations are needed to confirm our 
findings on moxifloxacin. 
Our study suffers from limitations. Firstly, minimal inhibitory concentration (MIC) values 
for M. tuberculosis were not determined for rifampicin and moxifloxacin. As a result, 
although drug resistance was excluded, we were unable to calculate AUC/MIC, Cmax/
MIC and Chighest/MIC ratios. In literature, reported rifampicin MICs for susceptible strains 
range from 0.06 to 1 mg/L (28) and from 0.2 to 0.4 (29). Rifampicin Chighest (range 
0.13-2.28 mg/L) measured in CSF can therefore be considered to have reached MIC, 
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but not by much. This is in correspondence with a review on TB drug concentration 
in the CSF by Donald (2010) (5). Another limitation is that plasma samples (intensive 
pharmacokinetic sampling) and CSF samples (duplicate) were only obtained during the 
first critical days of treatment, and do not reflect the plasma and CSF drug concentration 
at steady-state or during the 6-month follow-up. 
To summarize, we found a clear concentration-effect relationship, with higher rifampicin 
exposure leading to better survival of TB meningitis. We can conclude that the current 
dose of rifampicin used for treating TB meningitis is suboptimal; higher doses should 
be evaluated. From exposure-response curves, an AUC0-6h of ca. 70 mg/L*h and Cmax of 
ca. 22 mg/L were deduced as target values during the first critical days of treatment of 
TB meningitis. These thresholds can aid in the design of pharmacokinetically-optimized 
dosing regimens for TB meningitis using oral (rather than i.v.) administration of drugs 
and applying high dose rifampicin in other populations. Preliminary data suggest that 
20 mg/kg oral rifampicin results in a similar average AUC0-24h compared to 600 mg i.v., 
but a comparable maximum concentration is not reached (30).
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Introduction
The overall objective of this thesis was to optimize therapeutic exposure of tuberculosis 
(TB) drugs and drugs used for TB-associated co-morbidities. The central principle 
underlying this work is that the efficacy and safety of these drugs is related to their 
plasma concentrations (Figure 2, chapter 1). We paid special attention to the role of 
drug transporters, as they enable the crossing of barriers in the body and therefore are 
a key determinant for systemic and intracellular drug concentrations (Figure 2, chapter 
1). 
In the first part of this thesis, we applied various in vitro transporter-overexpression 
techniques to evaluate the role of mycobacterial transporters in TB drug resistance 
(chapter 3), and to unravel transporter-mediated drug-drug interactions (DDIs) in TB 
treatment (chapter 4 and 5). Following the preclinical laboratory work, part two of this 
thesis described animal studies that aimed to identify human pharmacokinetic equivalent 
doses of linezolid (chapter 6) and moxifloxacin (chapter 7), as well as to evaluate 
‘dried blood spot’ (DBS) analyses for measuring drug concentrations in mice. The final 
part of this thesis include clinical pharmacology studies that investigated the impact of 
nutritional status on rifampicin pharmacokinetics and free drug concentrations (chapter 
8), the effect of rifampicin on metformin exposure in TB patients with diabetes mellitus 
(DM) (chapter 9), and rifampicin and moxifloxacin concentration-effect relationships 
in patients with TB meningitis (chapter 10); results that can be implemented in clinical 
practice directly. In Table 1, we summarized the aims, findings and implications of the 
individual chapters, together with the remaining challenges. 
Figure 1. Phases of drug development.
DDIs, drug-drug interactions; PK, pharmacokinetics; PD, pharmacodynamics 
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The different chapters of this thesis form a translational approach for TB treatment 
optimization, containing all stages of drug development: laboratory – animal – human 
(Figure 1), truly ‘crossing barriers’. The modern PK-PD paradigm that underlies this study 
sequence had not yet been established at the time most currently used TB drugs were 
brought onto the market (Figure 1, chapter 1). Antibiotic doses had not been optimized 
for the treatment of TB and did not undergo the various drug development phases for 
dose optimization. Substantial health benefits may be expected from going back and 
repeating the drug development steps, with modern understanding of molecular and 
clinical pharmacology. More specifically, optimum drug dosages and corresponding 
exposures, substantiated by the pharmacological and PK-PD characteristics of a drug, 
have the potential to greatly maximize efficacy of current TB medication (1). 
In this final chapter we will evaluate our contribution to TB drug therapy and identify 
remaining knowledge gaps that should be addressed in future research.
Table 1. The aims, findings and implications of the chapters in this thesis in light of the remaining 
challenges to be addressed in TB drug pharmacology
Aim
Main outcome and 
implication
Remaining challenges
In
tr
o
d
u
ct
io
n
C
ha
pt
er
 1
• Provide the background of 
this thesis 
• Evaluate the current 
situation and identify 
the importance of the 
proposed research
• State the research aim
Knowledge on the appropriate dose, plasma exposure 
and antimycobacterial efficacy are key components for 
adequate redevelopment and repurposing of TB drugs, and 
general TB therapy optimization. All studies in this thesis 
are interconnected by their shared aim to reach/maintain 
effective TB drug concentrations and together form a 
translational approach to optimize TB drug treatment.
C
ha
pt
er
 2
To review the promises and 
pitfalls of inhibition of human 
and mycobacterial efflux 
transporters:
• the role of transporters 
in TB drug PK and 
transporter-mediated DDIs
• the contribution of 
human efflux transporters 
to limiting TB drug 
penetration into sanctuary 
sites, such as brain and CSF 
• the role of macrophage 
and M. tuberculosis 
efflux transporters in 
the emergence of drug 
tolerance and resistance, 
respectively 
Efflux pump inhibition may 
provide a valuable tool to 
enhance the effectiveness of 
currently available TB drugs, 
however:
• drug transport can hardly 
be modulated specifically
• it is difficult to dose efflux 
pump inhibitors to reach 
full inhibition at safe 
plasma concentrations
• inter-species differences 
in substrate affinity, 
transporter abundance 
and transporter capacity 
hamper the extrapolation 
from animals to humans
• Human: at the pharma- 
cokinetic level it is largely 
unknown for which 
transporters TB drugs are 
substrates
• Mycobacterial: more data 
is necessary to support 
the relation between 
transporter upregulation 
and transporter-mediated 
resistance, next to 
identification of transporter 
substrates according to the 
standards set for human 
substrates
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Aim
Main outcome and 
implication
Remaining challenges
P
ar
t 
1:
 m
o
le
cu
la
r 
p
h
ar
m
ac
o
lo
gy
C
ha
pt
er
 3
To determine the ABC 
transporter proteins that are 
used to extrude TB drugs and 
establish an in vitro system 
that enables screening for 
efflux pump inhibition.
• M. tuberculosis efflux 
pumps were cloned and 
expressed in E. coli and 
HEK293 cells 
• The fluorescent molecule 
‘Fluo_P-gp’ (a human 
P-gp substrate) was 
associated with increased 
ATP-dependent uptake 
in Rv0194-overexpressing 
vesicles
• Uptake was diminished 
by known P-gp inhibitors 
(verapamil, SQ109, and 
thioridazine), but not 
by the MRP inhibitor 
probenecid
• Abundance of proteins 
expressed in the HEK293 
cell model needs to be 
further optimized to 
enable more detailed 
characterization of RV0194 
and test transport of TB 
drugs
• More efflux pumps from 
the ABC superfamilies, 
and other superfamilies, 
have been identified for M. 
tuberculosis
C
ha
pt
er
 4
To assess the in vitro 
inhibitory potential of 
currently used first and 
second-line TB drugs and 
of proposed mycobacterial 
efflux pump inhibitors on 
the major human ABC 
transporters relevant to drug 
transport, namely P-gp, 
BCRP, BSEP, and MRP1-5.
• Strong inhibition was 
observed for clofazimine 
(P-gp, BCRP and MRP1), 
thioridazine (BCRP), 
timcodar (P-gp, BSEP and 
MRP1) and SQ109 (P-gp 
and BCRP)
• Rifampicin inhibited all 
transporters, but less 
potently
• Co-administration of 
clofazimine, thioridazine, 
timcodar, SQ109, and 
rifampicin with drugs that 
are substrates for the 
mentioned transporters 
may lead to DDIs 
Considering the emphasis 
on development of TB drug 
regimens rather than single 
drugs and TB-associated 
polypharmacy, more 
preclinical pharmacological 
information should be 
derived. This would provide 
a mechanistic basis for 
prioritizing interaction 
studies and performing dose 
optimization studies and 
safety/tolerability studies 
for specific TB drugs or 
combinations.
C
ha
pt
er
 5
• To assess the in vitro 
inhibitory effects of TB 
drugs on metformin 
transport by OCTs and 
MATEs 
• To investigate whether TB 
drugs are also substrates of 
OCTs and MATEs, and thus 
can become a victim of 
transporter-mediated DDIs 
• Of all TB drugs, only 
moxifloxacin was a potent 
inhibitor of MATE1- and 
MATE2K-mediated 
metformin transport
• Only ethambutol appeared 
to be a substrate of OCTs 
and MATEs. Ethambutol 
uptake by MATE1 was 
inhibited strongly by 
moxifloxacin
• According to international 
guidelines, our findings 
warrant further in vivo 
interaction studies
PBPK models may help 
to predict DDIs based on 
in vitro data and simulate 
the impact of proposed 
perpetrator drugs on 
systemic and intracellular 
victim drug exposure. Data 
in this chapter can form 
valuable input for a PBPK 
model of TB-DM therapy.
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Main outcome and 
implication
Remaining challenges
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• To identify the human 
pharmacokinetic equi- 
valent dose of linezolid that 
can be used for efficacy 
testing in BALB/c mice 
• To evaluate DBS analysis 
for measuring linezolid 
concentrations in mouse 
blood spots to reduce 
the number of animals 
needed for future PK-PD 
assessments
• 50 mg/kg oral linezolid 
in BALB/c mice was 
the pharmacokinetic 
equivalent of a dose 
between 300 and 600 mg 
in humans 
• Concentrations in mouse 
blood spots were slightly 
lower than in plasma: 
Passing-Bablok regression 
showed a significant 
proportional bias with a 
slope of 0.81
• Nonlinear kinetics 
complicate deriving exact 
human pharmacokinetic 
equivalent doses in mice
• Specific drug plasma/blood 
partitioning characteristics 
may warrant the 
application of conversion 
factors to predict mouse 
plasma concentrations 
from DBS 
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• To identify the human 
pharmacokinetic 
equivalent dose of 
moxifloxacin 
• To evaluate DBS analysis 
for measuring moxifloxacin 
concentrations in mouse 
blood spots
• Passing-Bablok analysis 
showed a slight, but 
acceptable bias for the 
prediction of plasma 
concentrations from DBS 
• Bland-Altman analysis 
demonstrated good 
precision for plasma 
concentration predictions 
from DBS 
• A 200 mg/kg dose of 
moxifloxacin in mice would 
approximate a human 
equivalent exposure
Compound specific bio- 
analytical method vali- 
dation in DBS matrix is 
indispensable, as factors 
such as blood/plasma 
partition ratios and the 
impact of hematocrit may be 
drug specific, and can greatly 
complicate the comparison 
with plasma samples.
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• To assess the effect of 
malnutrition on the 
steady-state  pharmaco- 
kinetics of total and 
protein-unbound rifampi- 
cin in Indonesian TB 
patients
• To evaluate the inter- 
individual variability 
in exposure to pro- 
tein-unbound rifampicin 
• Nutritional status did 
not impact free or 
total rifampicin drug 
concentrations
• Females had higher total 
and unbound AUC0-24h 
• There was a marked 2-fold 
interindividual variation in 
free fraction
For highly protein-bound 
TB drugs with a low organ 
extraction ratio, such 
as rifampicin, free drug 
concentrations should be 
measured along with total 
plasma concentrations when 
studying exposure-response 
relationships. 
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Main outcome and 
implication
Remaining challenges
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To assess the effect of chronic 
rifampicin use via OCT 
upregulation on steady state 
metformin pharmacokinetics 
and on the glucose-lowering 
efficacy of metformin in 
Indonesian TB-DM patients.
• The AUC0-τ GMR sug- 
gests the occurrence 
of an interaction when 
co-administered with 
rifampicin, resulting in 
increased exposure of 
metformin 
• It may be required to 
closely monitor metformin 
efficacy during and after TB 
treatment 
The clinical impact of DDIs 
identified with small PK 
studies can be hard to 
interpret. In this context, 
incorporating PD endpoints 
in the study design may be 
useful for the generation of 
hypotheses.
C
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Considering that drug 
exposure is the intermediate 
link between dose and 
effect, we examined the 
concentration-response 
relationship for rifampicin 
and moxifloxacin in TB 
meningitis patients.
• Patients had a 32-43% 
lower relative likelihood 
of dying with increasing 
interquartile range of 
rifampicin exposure
• Moxifloxacin exposure did 
not show a clear relation 
with survival 
• From exposure-response 
curves, a rifampicin plasma 
AUC0-6h of ca. 70 mg/L.h 
(AUC0-24h of ca. 116 mg/L.h) 
was deduced as minimum 
target value for treatment 
The current dose of 
rifampicin used for treating 
TB meningitis is suboptimal; 
higher doses should be 
evaluated. In this context, 
thresholds for exposure can 
aid in deriving pharmacoki-
netically-optimized dosing 
regimens for TB meningitis. 
DBS, dried blood spots; DDIs, drug-drug interactions; GMR, geometric mean ratio; MATE, multidrug 
and toxin extrusion protein; OCT, organic cation transporter; PBPK modeling, physiologically-based 
pharmacokinetic modeling; PK, pharmacokinetics; PD, pharmacodynamics; TB-DM, 
tuberculosis-diabetes mellitus 
The drug development pipeline of TB drugs
The globally accepted standard treatment of drug-susceptible, active TB is a 6-month 
regimen using a combination of rifampicin, isoniazid, pyrazinamide and ethambutol for 
2 months, followed by rifampicin and isoniazid for 4 months (2). However, the lengthy 
treatment, poor patient adherence, large interpatient pharmacokinetic variability, 
emergence of drug resistance, presence of co-morbidities, and drug adverse effects 
complicate this therapy and fuel the necessity of new drugs and/or regimens (3-5).
The process of TB drug development is hampered by several hurdles. Box 1 gives an 
overview of the current challenges in TB treatment and drug development, suggesting 
enough reasons to invest time, people, and money in drug development. However, 
due to the relatively economically unattractive market for TB drugs and a perceived 
254
Chapter 11
lack of commercial return of investment, the pharmaceutical industry is not encouraged 
to sponsor large-scale TB drug development. Another challenge is the identification 
of new compounds that can effectively kill the complex M. tuberculosis bacterium. 
This is further complicated by the biologic difficulty of working with M. tuberculosis 
(slow culture, high biosafety level) (3, 5). Finally, because of the focus on TB drug 
combination regimens to prevent 
resistance, TB drug development is 
extremely lengthy and expensive. If 
new drugs would be added to the 
current regimen one at a time, it 
would take 20-30 years to develop a 
whole new regimen (5, 6). Alternative 
options are therefore needed to 
shorten the pathway to optimal drug 
combinations. This includes innovative 
designs for development and selection 
of regimens especially in phase 2 
of drug development (7, 8) and 
validated surrogate endpoints that can 
assess pharmacodynamic activity in 
preclinical models and in early clinical 
development. 
But hope is on the horizon. In 2000, the TB Alliance was conceived, including 
representatives from academia, industry, major government agencies, non-governmental 
organizations and donors. They gathered to discuss the problems of TB treatment, and 
released a blueprint, dedicated to closing the gaps in research and development (9). In 
addition, other research consortia, with abbreviations such as TBTC, ACTG, PanACEA, 
CPTR and PreDiCT-TB have started up preclinical and clinical research work. There 
have also been significant monetary contributions to pay for these efforts; from the 
non-private sector (including the Bill & Melinda Gates Foundation and the Rockefeller 
Foundation), and a number of governments that formed the European and Developing 
Countries Clinical Trials  Partnership (EDCTP) (6). Currently, there is a portfolio of novel 
TB drugs in preclinical and clinical development, representing the largest pipeline in 
history of TB drug development (10). Furthermore, for the first time in more than 50 
years, two new tuberculosis drugs, bedaquiline and delamanid, have been approved 
by the US (bedaquiline in 2012) and European (2014 and 2013, respectively) regulatory 
authorities for use against MDR-TB (11). 
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A range of novel and repurposed drugs are being investigated for their activity against 
TB: in phase 1 (safety, pharmacokinetics, and dose ranging in healthy volunteers), phase 
2 (early bactericidal activity, 2-months sputum culture conversion and pharmacokinetics 
in TB patients), and phase 3 (efficacy, relapse, and safety in TB patients) (5, 12) (Figure 1). 
The most rapid progress has been made by researchers repurposing or redosing known 
TB drugs such as rifamycins (rifampicin, rifapentine), fluoroquinolones (moxifloxacin, 
gatifloxacin) and riminophenazines (clofazimine), which have completed or are in 
advanced phase 2 or 3 studies (4). Other non-antibiotic drugs, such as efflux pump 
inhibitors (EPIs), are still in preclinical development (4), where they have demonstrated 
to increase antimycobacterial potency (13-18), although efficacy in animal models and 
humans remains to be established. 
The upcoming paragraphs will specifically discuss the advances and challenges in TB 
drug development in relation to pharmacology research from the molecule-animal-man 
perspective. Relevant topics addressed in the chapters of this thesis will also be 
highlighted.
The use of molecular pharmacological research for the 
optimization of TB therapy: focus on drug transporters
Since the development of the current 4-drug combination regimen, there have been 
many advances in laboratory assays relevant for lead optimization (19, 20), TB diagnosis, 
MDR-TB identification, and relapse assessment (21, 22). Many of these molecular 
techniques are beyond the scope of this thesis and will therefore not be discussed in 
this paragraph. Instead we will discuss examples that demonstrate the application of 
in vitro pharmacological assays focusing on drug transport to optimize TB treatment. 
Such insights contribute to ‘pharmacological optimization’ of new TB agents already 
before clinical testing (23, 24), contributing to shortening of the drug development 
timeline.
In general, drugs need to cross multiple cellular barriers in order to reach their site of 
action. Uptake and efflux via membrane transporters play a vital role in the passage 
across these barriers and, together with local drug metabolizing enzymes, they 
greatly affect the absorption, distribution, and excretion of drugs (chapter 2). In case 
of concurrent use of antimycobacterial, antiretroviral, and antidiabetic drugs, there is 
a high risk of DDIs at this level, which are generally clinically very relevant (25, 26). 
Considering the emphasis on development of TB drug regimens rather than single 
drugs and TB-associated polypharmacy, preclinical information on drug-transporter or 
drug-enzyme interactions can provide a mechanistic basis for prioritizing interaction 
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studies, and performing dose optimization studies and safety/tolerability studies for 
specific TB drugs or combinations. Therefore, in the drug development stage, the 
likelihood of new TB drug candidates to be involved in DDIs should be evaluated 
by assessing their potential to inhibit drug transporters and metabolizing enzymes 
(perpetrator), as well as whether they are a substrate for drug transporters and 
metabolizing enzymes (victim). Indeed, regulatory authorities support the investigation 
of pharmacokinetic interactions throughout drug development, as part of a general 
assessment of the drug’s safety and effectiveness (27, 28).
For many of the currently available TB drugs information on their interaction with drug 
transporters is lacking, probably because most TB drugs were discovered in the 1950s 
and 1960s (29). At that time the role of transporters in drug disposition was largely 
unknown, and their molecular identity and cellular distribution was yet to be discovered 
(30). Additional research is necessary to fill these knowledge gaps, a process which we 
started with the studies presented in chapters 4 and 5, with the use of transporter-over-
expressing membrane vesicles isolated from HEK293 cells (chapter 4) and transport-
er-overexpressing HEK293 cells (chapter 5). In drug development, overexpression 
models are recognized as appropriate in vitro assays to assess whether a drug is an 
in vivo transporter substrate or 
inhibitor (30). In chapter 4 we 
studied the interaction of TB drugs 
with relevant human ATP-binding 
cassette (ABC) drug efflux pumps. 
The vesicle model was selected 
as it has as major advantage that 
drugs can be directly applied to 
the cytoplasmic compartment 
and influx, rather than efflux, is 
measured. In contrast, in chapter 
5 we studied interactions with 
drug importers, for which the 
cellular overexpression model 
was best suited. Unfortunately, 
both overexpression systems 
are static and are not sensitive 
to the effect of protein inducers, 
such as rifampicin (31). Figure 2 
gives an overview of the cell and 
vesicle assay used in this thesis for 
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the identification of inhibitors and substrates of transporters. Box 2 summarizes the 
advantages and disadvantages of most well-known transport (efflux) models.
Figure 2. Schematic overview of the cellular and vesicular transport assay.
HEK293 cells can be manipulated to overexpress exporters, such as ABC transporters or MATE (A), 
as well as importers, such as OCT (B). Dashed arrows represent passive transport, whereas straight 
arrows indicate active transport. Membrane vesicles (C) are isolated from HEK293 cells overexpressing 
ABC transporters. Fifty percent of vesicles will be inside-out, and fifty percent will be right-side-out. 
Additional ATP should be added in substrate mix for vesicular transport studies to enable active 
transport via hydrolysis of ATP to AMP and phosphate (Pi). Because the substrate and ATP mix is 
offered on the outside of the vesicles, only membrane vesicles with the inside-out orientation will be 
able to display active transport. 
Drug transporters are not only relevant in the context of TB drug pharmacokinetics. 
There is increasing notion that insight into drug transport mechanisms is also relevant 
for the attainment of optimal therapeutic tissue concentrations and thus the efficacious 
treatment of TB. For example, efflux transporters protect human sanctuary sites such as 
the brain against drug entry, which can lead to insufficient drug exposure for patients 
suffering from TB meningitis (chapter 2). The macrophage can also be considered a 
pharmacological sanctuary site, as M. tuberculosis can reside and survive within this host 
cell. Efflux mechanisms located on the macrophage membrane may reduce intracellular 
drug concentrations and thereby reduce intracellular antibacterial activity (32) (chapter 
2). In this light, targeted inhibition of human transporters may be beneficial. For example, 
A
B
CCellular overexpression model Vesicular overexpression model
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transport inhibition at the macrophage level or at the blood-brain barrier may result 
in increased drug concentrations and thus more extensive mycobacterial killing locally. 
Administration of EPIs alongside available TB drugs may form an efficient strategy to 
improve current antibiotic efficacy and thereby circumventing the development of new 
antibiotics (Figure 3). 
Figure 3. Schematic representation of the effect of efflux pump inhibitors (EPIs) administered 
alongside available TB drugs as a treatment strategy to enhance drug passage across the 
blood-brain barrier (A), and increase drug concentrations in macrophages (B) and M. tuberculosis 
(C), by blocking drug efflux. 
EPIs, efflux pump inhibitors
We further investigated the concept of EPIs in chapter 3, in which we focused on 
mycobacterial transporters and aimed to identify the ABC transporters used by M. 
tuberculosis to extrude TB drugs and establish an in vitro system to screen for effective 
EPIs. For this we used our knowledge on human transporter overexpression systems 
(chapters 4 and 5), which enabled us to express TB transporters in HEK293 cells with 
a similar procedure. We identified a promising P-gp-like candidate (Rv0194) that was 
found to share common ancestry with human ABCB family members (chapter 2). 
Indeed vesicles overexpressing Rv0194 were associated with ATP-dependent uptake 
of a P-gp (ABCB1)-specific fluorescent model substrate, which could be inhibited with 
P-gp-specific inhibitors (chapter 3). This type of direct substrate identification (Box 
2) is to our knowledge the first for a TB transporter. Previous studies researching 
mycobacterial efflux pump inhibition consist mainly of in vitro screening for synergistic 
antimycobacterial activity of pump inhibitors combined with novel, first- or second-line 
TB drugs against M. tuberculosis bacterial isolates (cellular sensitivity assay in Box 2) 
that are either wild type, antibiotic resistant, knock-outs, or overexpressing transporters 
TB drug
Efflux pump inhibition
A
B
CEPIs
EPIs
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(chapter 2). Additional research on the function of Rv0194 as a drug transporter is 
necessary, including characterization of transport kinetics, efflux of TB drugs, and 
possibly knock-out of Rv0194 in M. tuberculosis itself. Nonetheless, the results of 
chapter 3 demonstrate the applicability of functional in vitro models in deriving novel 
drug targets from a mechanistic perspective. 
Studying pharmacokinetic-pharmacodynamic relation- 
ships in preclinical models
In vitro pharmacokinetic-pharmacodynamic (PK-PD) models can further stimulate 
efficient TB drug development by evaluating the direct interaction between the drug 
and the bacterium and enabling the selection of candidate compounds, alongside the 
optimization of their dosing regimens. 
The simplest bacteriological pharmacodynamic measure of activity, typically used in 
primary drug discovery screens, is the minimum inhibitory concentration (MIC), the 
drug concentration which arrests growth of 90 or 99% of colony-forming units in 
vitro under unrestricted growth conditions at a standardized density with static drug 
exposure (23, 33). An optimal clinical dose can be derived by comparing drug exposures 
in preclinical pharmacokinetic models with MICs of clinical isolates (34). As previously 
mentioned, the three most common PK-PD measures are the ratio of the area under 
the concentration time-curve from 0 up to 24h (TB drug dosing interval) to the MIC 
(AUC0-24h/MIC), the ratio of the maximal drug concentration to the MIC (Cmax/MIC), and 
the duration of time a drug concentration remains above the MIC (T>MIC) (33, 35-38). 
Static in vitro drug exposures cannot represent dynamic in vivo exposures, such 
AUC0-24h or T>MIC. For this purpose so-called hollow fiber systems are useful. These 
can mimic realistic pharmacokinetic patterns of drug exposure in vitro, including the 
half-life and dose schedules encountered in human patients, for the assessment of 
drug efficacy against M. tuberculosis (35, 39). With such a hollow-fiber model it could, 
for example, be demonstrated that pharmacokinetic variability is an important factor in 
the emergence of multidrug-resistant TB (MDR-TB) (40). 
Another method to measure drug efficacy in a concentration-dynamic environment is 
the ex vivo whole blood bactericidal assay. The approach benefits from the simplicity of 
whole blood culture and the presence of an intact intracellular immune system that can 
modulate drug effects (41, 42). The method has a recognized potential in assessing the 
sterilizing activity of new TB drugs against intracellular bacteria (41, 42). By collecting 
blood samples at various intervals before and after dosing, drug concentrations 
EPIs
260
Chapter 11
reflect those in the circulation (in plasma and within cells) at various time points of the 
drug concentration-time curve, linking pharmacokinetics to pharmacodynamics in a 
biologically representative manner. 
Pharmacokinetic data can also be linked to pharmacodynamic endpoints with an in 
silico approach. More specifically, a physiologically-based pharmacokinetic (PBPK) 
model can predict systemic and local (tissue and cellular) drug concentrations and 
couple them to pharmacodynamic break points. When linking in silico exposure data to 
pharmacodynamic parameters, inferences on drug dosing and corresponding efficacy 
can already be made in the preclinical stage. This is relevant for the development of 
new drugs, for dose optimization of repurposed or redeveloped drugs, and finally, for 
the design and prioritizing of drug interaction studies. Data on the inhibitory kinetics 
of relevant transporter/enzyme-substrate interactions and information on whether 
TB drugs are substrates of these proteins themselves (chapters 4 and 5) provide 
indispensable input for quantitative PBPK model predictions. 
The place of animal studies in developing new TB 
regimens
In general, in vivo testing in validated animal models follows in vitro assays. Such 
evaluations are important considering that drug-treated mice can display a very 
distinct phenotype due to host-pathogen specific interactions (43). Most investigators 
performing in vivo studies used a mouse model for TB (10). The mouse model gained 
popularity decades ago, as it was found to predict human clinical trial results of drug 
regimens based on isoniazid, rifampicin, and pyrazinamide very consistently. In addition, 
it predicted the sterilizing properties of drug regimens and duration of therapy needed 
to prevent relapse (10). Overall the mouse model is the most cost-effective and the best 
validated model (10, 44). Drug treatment in TB-infected mice even displays a biphasic 
killing curve (highly effective at start, less effective against the last 1% of bacteria), and 
intermittent therapy ultimately takes just as long as to cure a TB patient (10, 44).
The main limitation of the mouse model is that the most commonly used strains, 
such as Balb/c and C57BL/6, fail to develop lung pathology similar to that in humans, 
including caseating granulomas, cavitary disease, and fibrosis (10, 45). These specific 
environments may be required for the accurate assessment of sterilizing activity of 
novel TB drugs or new drug combinations. The Kramnik mouse was recently developed 
to exhibit a more human-like pathology, including the development of lesions with 
liquefactive necrosis (45). Such a model is especially valuable for testing drugs against 
bacteria that persist within necrotic lesions. In the past other animal models developing 
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TB-specific lesions have been used, of which the guinea pig model was probably 
the most cost-effective (45-47). Another limitation of the mouse model is the lack of 
comparability in pharmacokinetics and drug metabolism with humans, which hampers 
the investigation of PK-PD relations. As a consequence, interspecies extrapolation 
factors have to be calculated. In this context, rat TB models may also be of interest (48, 
49), as this species is considered the first-choice animal for pharmacokinetic testing. A 
final limitation of the mouse model is the troublesome validation of extrapulmonary TB, 
especially TB meningitis. For example, while hematogenous spread after pulmonary 
infection is key to the development of clinical TB meningitis, the meninges of a range 
of animal species could not be infected by hematogenous spread of bacteria, but 
required direct intracranial injection into the CNS in order to produce TB meningitis in 
these animals (50).
The steady improvements of the mouse model has formed the basis for current clinical 
experimentation in TB treatment. However, the disappointing recent failure of fluoro-
quinolone-containing regimens to shorten the duration of TB treatment in costly phase 
3 trials has raised serious questions about the reliability and application of the mouse 
model (51, 52). It was suggested that the most important reason for the failure of 
these regimens was the overly optimistic translation of the preclinical results into a 
presumed 2-month treatment-shortening effect (52). This underlines the importance 
of appropriate in vivo to human extrapolation, especially for relapse assessment and 
treatment duration.
Irrespective of the animal efficacy model selected or the pharmacodynamic endpoint 
under investigation, pharmacokinetic data are indispensable in preclinical assessments, 
because exposure is predictive for treatment outcome (the PK-PD paradigm). To 
improve clinical predictability from animal efficacy studies of novel TB drugs and drug 
combinations, it is important to know the effective exposure to strive for in patients 
(new drugs) or test drug doses that are pharmacokinetically equivalent to the dose 
used in humans (new combinations with repurposed drugs). In the second section of 
this thesis we addressed the importance of rational dose selection for linezolid (chapter 
6) and moxifloxacin (chapter 7) in BALB/c mice. These two drugs are currently under 
investigation for a new position in TB treatment, the first as building block for MDR-TB 
regimens and the second as a first-line agent for drug-sensitive TB. For both drugs 
we identified the dose resulting in exposures equivalent to those found in humans. 
Nonlinear kinetics were observed for linezolid (across the doses tested) and moxifloxacin 
(for the higher dose(s) tested), which complicated the translation to equivalent human 
pharmacokinetic doses. Compounds often exhibit nonlinear pharmacokinetics in 
experimental animals, the mechanism of which is probably species-dependent (53) 
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and/or administration-dependent (54, 55). This is an important notion to consider in 
future animal efficacy testing.
Pharmacokinetic analyses in mice would greatly benefit from measurement of 
analytes in small blood volumes using the DBS technique, because it allows for the 
assessment of multiple drug concentrations over time within a single mouse. This could 
significantly reduce the number of animals needed for pharmacokinetic assessment, 
as conventionally one animal is euthanized for collection of a single blood sample 
to ensure sufficient quantities of analytical sample. Figure 4 schematically shows the 
advantages of DBS sampling over classic pharmacokinetic sampling in animals.
Figure 4. Schematic overview of the advantages of DBS sampling over classic pharmacokinetic 
sampling in animal experiments. 
In the classic approach a single mouse is sacrificed to obtain one concentration in a pharmacokinetic 
curve, whereas blood spot sampling enables serial blood withdrawals within one mouse.
In chapters 6 and 7 we evaluated the application of DBS analyses for measuring drug 
concentrations in mouse blood spots. After cross-validation of mouse DBS samples 
with human DBS samples (analyzed with validated human DBS methods), we found an 
263
General discussion
overprediction of the linezolid (chapter 6) and moxifloxacin (chapter 7) concentration 
in mouse blood. The bias may be explained by measured differences in hematocrit 
concentrations in human and mice, 35% versus 55% (95% CI 44-67%), respectively. 
DBS sampling is hampered by variation in hematocrit due to differences in blood 
viscosity values, yielding a proportional analytical bias. Therefore, when considering 
the application of DBS sampling in animal models, we advise to handle the validation 
of the bio-analytical technique with great attention for the effect of hematocrit and 
blood spot volume (56, 57). After correction for this effect of hematocrit, we found a 
significant proportional bias for the prediction of plasma concentrations from DBS in 
case of linezolid (chapter 6), but not for moxifloxacin (chapter 7). Altogether these 
findings underline the importance of compound-specific validation in DBS matrix, as 
factors such as blood/plasma partition ratios and the impact of hematocrit may be 
drug specific, and can greatly complicate the comparison with plasma samples (58).
Factors influencing the clinical pharmacology of TB 
drugs
Pharmacokinetic variability is an important cause of subtherapeutic drug concentrations 
and subsequent therapy failure and drug resistance (40, 59). Such variability may be 
affected by various factors, including gender, co-morbidity (HIV/AIDS, diabetes mellitus 
and malnutrition), co-medication, drug formulation and genetic variation (60-65) 
(Figure 2, chapter 1). To be able to perform dose-exposure-response evaluations it is 
crucial to know the factors that contribute to the variation between dose and exposure. 
Co-morbidity occurs frequently among TB patients. Globally, 12% of the 9.6 million new 
TB cases in 2014 were HIV-positive (66). Furthermore, there is an increasing number 
of TB cases attributable to DM, namely 10% in 2010, and 15% in 2013 (67). Finally, 
malnutrition is observed frequently among TB patients. A case-control (n=121/n=371) 
study in Indonesia documented malnutrition in 87% and 33% of cases and controls, 
respectively (68). A bidirectional interaction exists between malnutrition and TB (69, 70). 
On the one hand, malnutrition impairs immune function and increases the susceptibility 
for development of active TB. At the same time, TB leads to severe abnormalities in 
protein metabolism, loss of lean tissues and fat reserves. It is known that nutritional 
status can have a profound impact on the pharmacokinetics of drugs (71, 72), yet few 
data are available for TB drugs. 
In chapter 8 we aimed to clarify the effect of malnutrition in Indonesian TB patients on 
the steady-state pharmacokinetics of total and protein-unbound rifampicin. Malnutrition 
and associated low concentrations of drug-binding plasma proteins may cause a change 
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in the equilibrium between protein-unbound and bound concentrations, rendering 
the total drug concentrations misleading for concentration-effect evaluations (73-75). 
Moreover, only protein-unbound drugs are pharmacologically active and diffuse or are 
being actively transported into tissues and to the sites of action (73, 76). For these reasons, 
free rather than total drug concentrations should be used in concentration-response 
evaluations (77). In a previous study among Indonesian TB patients (78), we confined 
to measurement of total concentrations of rifampicin and this may be one of several 
possible explanations for the absence of a concentration-response relationship in that 
study. 
In contrast to the hypothesis, chapter 8 explains why we could not demonstrate an 
effect of nutritional status on total or free rifampicin concentrations. Gender did impact 
drug exposure. Females showed significantly higher total and unbound AUC0-24h, also 
when corrected for BMI. In Indonesian patients, two of our previous studies identified 
a relationship between gender and rifampicin pharmacokinetics (79, 80), but another 
study did not (78). In African subjects, female patients also showed higher exposures to 
rifampicin (64). An explanation may be that females generally have a lower lean body 
mass than males. Thus, for drugs that are differentially distributed between water and 
fat, different drug concentrations can be found in subjects with the same weight (81). 
With respect to interindividual variability, a marked 2-fold interindividual variation in 
unbound rifampicin fraction between 7.6 and 15.0% was observed (chapter 8). This 
large interindividual variability in free fraction underlines that measurement of only total 
concentrations could be mis-representative of the actual exposure in individual cases. 
These findings support that protein-unbound rifampicin concentrations should be 
evaluated along with total plasma concentrations for assessment of exposure-response 
relationships in clinical studies. The same may apply to individualization of rifampicin 
dosing based on plasma concentration measurements (Therapeutic Drug Monitoring, 
TDM) in settings where this technique can be used in patient care.
Probably the main factors contributing to interindividual variation in drug 
pharmacokinetics are pharmacogenetic polymorphisms and interindividual differences 
in protein abundance of phase 1 (cytochromes P450, CYP450) and phase 2 metabolizing 
enzymes, and of drug transporters.  The most well-known example of relevant 
genetic polymorphisms in TB treatment is the genetic variation in isoniazid-induced 
hepatotoxicity, particularly polymorphisms in N-acetyl transferase 2 (NAT2), CYP2E1 
and glutathione-S-transferase (GST)(82). Another example are polymorphisms in the 
OATP1B1 (SLCO1B1) transporter. Rifampicin is a substrate of OATP1B1 and polymorphisms 
of this transporter have been associated with lower rifampicin exposure (65, 83-85). 
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As a result of OATP’s broad substrate spectrum and their wide tissue distribution, 
altered transport characteristics, or protein localization can contribute significantly to 
interindividual variations of drug effects (86). 
Pharmacokinetic and exposure-response evaluations may benefit from a broad 
knowledge on genetic variations in genes encoding transport proteins, contributing 
to a better understanding of interindividual differences in drug effects. Correlating 
a specific polymorphism with a certain phenotype can be challenging, because of 
the many unknown underlying genetic factors (multicausality). The development of 
high-throughput genetic platforms, such as those used in genome wide association 
studies (GWAS) and in genome/transcriptome deep sequencing approaches, allows 
for the simultaneous analysis and identification of intermediate frequency or rare 
polymorphisms, and changes in gene expression, which has resulted in more extensive 
exploration of the effects of genetic/expression variation on treatment response (87).
The application of DDI studies in TB therapy
As emphasized before in this thesis, DDIs can be an important cause of subtherapeutic 
or toxic drug concentrations. Considering the emphasis on development of TB drug 
regimens and TB-associated polypharmacy, there is a high likelihood of DDIs to occur 
in TB treatment. Therefore, it is important to evaluate whether TB drugs alter systemic 
or local disposition of co-administered compounds (perpetrator), as well as whether 
they can become a victim from the interaction with other drugs taken concurrently. The 
overall objective of DDI studies is to determine interactions that lead to clinically relevant 
drug concentration changes, which require dose adjustments, drug concentration 
monitoring (TDM), or a warning not to combine these drugs (contra-indication). After in 
vitro identification of a significant DDI, with free drug concentrations of the perpetrator 
and victim drug at relevant intracellular or systemic levels, human phase 2 studies can 
follow for the assessment of clinical significance in patients. For some drugs this path 
can also be reversed: unresolved toxicities or inefficacies of old drugs, without a well 
characterized molecular pharmacological profile, may be explained with mechanistic in 
vitro studies. 
The recommended design for pharmacokinetic DDI studies are cross-over or 
sequential designs, in which all subjects receive the potential victim drug alone (test), 
or in combination with the alleged perpetrator drug (reference) (28). The advantage of 
a cross-over or a sequential design is that it allows a within-subject comparison, with 
each subject serving as its own control, thereby reducing the amount of variation in 
the test and reference situation. This is in contrast with the parallel group design, which 
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is therefore statistically less efficient and requires more subjects. In a sequential design 
with fixed order, all subjects receive the test-reference treatment in a preset order, 
which can result in a period effect that confounds the interaction effect of interest. In a 
cross-over design, subjects are randomly assigned to receive a sequence of treatment, 
which enables the correction for period effect. In both situations, carry-over bias can 
occur, which confounds the DDI effect. Carry-over can be avoided by employing a 
sufficiently long “wash-out” period between treatments, based on pharmacokinetic and 
pharmacodynamic characteristics of the drug combination under investigation. 
Although the evaluation of DDIs 
is part of the drug development 
process (Figure 1), many 
questions/combinations remain 
unaddressed or cannot be 
anticipated beforehand. Especially 
for rifampicin, the cornerstone 
of TB treatment, a large number 
of DDIs have been reported and 
can be expected to be reported 
in the future, creating serious 
problems. Rifampicin is a known 
inducer of phase 1 (CYP450) and 
phase 2 metabolizing enzymes, as 
well as of drug transporters (31). 
The drug even induces its own 
elimination and thereby decreases 
its own exposure upon repeated administration (auto-induction) (88). Concomitant 
administration of rifampicin can result in the altered metabolism or transportation of the 
victim drug. In chapter 9, we addressed such a rifampicin-mediated DDI with metformin 
(via induction of organic cation transporters (OCTs)) in more detail. We performed an 
open-label, 1-arm (within-subject), 2-period, fixed-order pharmacokinetic interaction 
study. A fixed-order (sequential) design was chosen, as it enabled us to assess metformin 
exposure when patients were still taking rifampicin (reference treatment, at the end of 
the continuation phase), and after completion of TB treatment following a 1-month 
wash-out period (test treatment).
Chapter 9 reports a pharmacokinetic interaction between metformin and rifampicin 
(89, 90), assessed with the bioequivalence approach (Box 3). Renal clearance and tubular 
secretion of metformin remained unaffected, suggesting that the observed increase in 
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exposure was caused by enhanced absorption. The pharmacokinetic interaction did 
not affect the glucose-lowering efficacy of metformin, even though peak blood glucose 
concentrations did slightly increase after TB treatment was completed. Finally, there 
was a high prevalence of gastro-intestinal adverse effects amongst the studied TB-DM 
patients when taking both rifampicin and metformin. These results demonstrate that 
a simple study design (sequential and fixed-order), which does not require adaptation 
from clinical practice, can directly provide adequate measures to improve patient 
treatment. In this case, the advise includes to closely monitor metformin efficacy during 
and after TB treatment by performing additional fasting blood glucose and 2-hour 
post-prandial glucose assessments, and to take metformin and rifampicin with food, 
and preferably separated in time, to prevent gastro-intestinal adverse effects.
Studying concentration-effect relationships in humans 
Exposure-response information is indispensable for good assessment of drug safety 
and efficacy. A drug can be considered safe and effective only if the relationship of 
beneficial and adverse effects to a defined exposure is known. Ideally, the ‘right’ dose 
results in maximum efficacy, without any experienced adverse effects (Figure 5). For 
drugs with a narrow therapeutic window, clinical use is based on weighing the favorable 
and unfavorable effects at a particular dose (Figure 5). Dose-response or preferably 
exposure-response evaluations are part of the drug development process (Figure 1). 
However, for most TB drugs currently in use, historically far less attention has been paid 
to establishing the relationship between blood concentrations and pharmacodynamic 
responses for optimal dose-finding. Furthermore, there had been little interest for 
differences among disease-type subsets, such as TB meningitis. In general, the 
relationship between inadequate exposure and suboptimal clinical response has been 
relatively well described for TB drugs (38, 60, 91-94). Even though such a relation 
has not been demonstrated in all studies (78, 95, 96), the general paradigm is that 
inadequate exposure results in suboptimal clinical response. However, dose-response 
curves like those presented in Figure 5 are lacking for most TB drugs, especially when 
it comes to their sterilizing effect.  
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Figure 5. Exposure-response curves in relation to drug pharmacokinetics (PK) and 
pharmacodynamics (PD).
In chapter 10 we examined the concentrations-response relationship for rifampicin and 
moxifloxacin in TB meningitis patients, as part of a study on the effectiveness of higher 
doses of both drugs. TB meningitis, the most severe manifestation of M. tuberculosis 
infection, results in death or neurological disability in up to 50% of patients affected 
(97, 98). The treatment of TB meningitis patients follows the model for short-course 
chemotherapy in pulmonary TB patients (99, 100). The same TB drugs and dosing 
guidelines are applied, even though it is known that penetration into cerebrospinal 
fluid (CSF) of some first-line TB drugs is limited, especially of rifampicin (101). One way to 
improve the outcome of TB may be to intensify antimicrobial treatment, as for rifampicin 
it is generally assumed that more drug equals more effectiveness (102). Moreover, the 
current 600 mg dose is at the lower-end of the exposure-response curve, and indeed 
the selection of the 600 mg dose in the past had largely been based on the minimum 
effective dose that could be implemented at low enough costs (103). 
In an open-label phase 2 clinical trial performed in Indonesia (ClinicalTrials.gov 
NCT01158755), 60 TB meningitis patients were randomized to receive standard-dose 
(450 mg oral) or high-dose rifampicin (600 mg i.v) plus either moxifloxacin (400 mg 
or 800 mg) or standard ethambutol (750 mg) for the first 14 days of TB treatment. 
Pharmacokinetic sampling was performed once in every patient during the first three 
critical days. In a previous study, mortality and resolution of coma were related to the 
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dose and not to individual concentrations of rifampicin and moxifloxacin in Indonesian 
TB meningitis patients (104). However, administration of these doses resulted in large 
interindividual variability in exposures, both in plasma and CSF (104). Considering that 
concentrations of TB drugs are the intermediate link between the dose administered 
and the eventual effect, chapter 10 examined the relationship between rifampicin and 
moxifloxacin (plasma and CSF) concentrations and mortality and resolution of coma in 
TB meningitis patients. The analysis revealed a rifampicin exposure threshold of ca. 116 
mg/L.h (~AUC0-24h) and a Cmax of ca. 22 mg/L predictive of good treatment response 
in TB meningitis. These exposure thresholds help in the design of pharmacokinetically 
optimized dosing regimens for TB meningitis in other populations (e.g. children) or 
other type of administrations (oral rather than intravenous). In the study described 
in chapter 10, 38% of the patients receiving 13 mg/kg rifampicin i.v. still had drug 
exposures below the derived target exposure, implying that higher doses should be 
evaluated. In contrast, moxifloxacin exposure did not show such a clear relationship 
with survival, even though the standard-dose or high-dose moxifloxacin has better CSF 
penetration characteristics as the replaced drug ethambutol (105). 
Unfortunately, MIC values for M. tuberculosis were not determined for rifampicin and 
moxifloxacin. As a result, we were unable to calculate AUC/MIC, Cmax/MIC and Chighest/
MIC ratios. In literature, reported rifampicin MICs for susceptible strains range from 
0.06-1 mg/L (106) and from 0.2-0.4 mg/L (107), well below the derived Cmax threshold 
found to be effective in chapter 10. Another limitation of the study is that we did 
not measure free drug concentrations. Considering the high interindividual variation in 
rifampicin protein binding (chapter 8), free concentration may relate better to efficacy 
outcomes than total concentrations. 
In search of higher yet tolerable doses of rifampicin, several studies have been performed. 
In vitro studies and studies in mouse models have suggested that higher doses of 
rifampicin are associated with better results and shorter treatments in pulmonary TB 
(108-110). Clinical studies also suggested improved early bactericidal activity and better 
treatment results in pulmonary TB (111, 112). In the field of TB meningitis, Alvarez-Uria 
et al. have administered 900 mg (circa 20.5 mg/kg) of oral rifampicin for a median 
of 7 days (113) and no safety issues were reported in this setting. The results of an 
intensified treatment in a study in Vietnam using 15 mg/kg rifampicin for 8 weeks in 
817 TB meningitis patients did not show a survival benefit for higher doses of rifampicin 
(114). It was argued that these contrasting results can be explained by the dose of 
rifampicin that was administered (115). In the Vietnam study standard 10 mg/kg per day 
was compared with an increased dose of 15 mg/kg, whereas in our Indonesian study 
we evaluated 13 mg/kg i.v. (104), resulting in a 3-fold increase in rifampicin exposure in 
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blood and CSF. This suggests that the dose in the Vietnam study was not high enough, 
however, exposure data have not been reported yet. Recent trial data for pulmonary TB 
also support higher doses of rifampicin than that used in the Vietnam study. Regimens 
with less than 35 mg/kg of rifampicin did not reduce the time to culture conversion 
(116). 
The search for the ‘right’ high-dose of rifampicin is an explanatory example of how 
a better understanding of TB drug pharmacokinetics and pharmacodynamics could 
improve treatment regimens. More data are needed to expand our understanding, in 
which pharmacokinetic assessments are indispensable.
Future perspectives
The overall aim of this thesis was to optimize exposure of TB drugs and drugs used 
for TB-associated co-morbidities. The central paradigm is that the efficacy or toxicity of 
these drugs is related to their systemic or local plasma concentrations. We paid special 
attention to the role of drug transporters, as they are a key determinant for systemic 
and intracellular drug concentrations. In this chapter we will summarize the principal 
knowledge gaps identified in this thesis and propose future research for these topics. 
1. TB drug substrate identification of human and mycobacterial  
drug transporters
With the results obtained in chapters 2-5 we underlined the importance of drug 
transporters for current TB treatment as well as for posing a target for future drug 
development by means of efflux pump inhibition (Figure 3). The most important 
knowledge gap identified is the lack of insight into which TB drugs are substrates and 
for which transporter. In this context, both human and mycobacterial transporters are of 
interest, and substrate characteristics should be investigated according to established 
guidelines for in vitro testing (30). 
Firstly, after the identification of relevant substrate-TB transporter interactions (other than 
Rv0194), and subsequent characterization of transport kinetics, follow-up drug sensitivity 
assays and mouse drug efficacy testing should be performed with transporter knock-out 
M. tuberculosis. These studies will support the targets’ role in transporter-mediated 
drug resistance in more physiologically relevant models. Secondly, we have to derive 
in vitro pharmacokinetic parameters (e.g. affinities constants or Km) for the interaction 
of TB drugs with human transporters. Thirdly, after gathering aforementioned in vitro 
data, we have considerable input for a general PBPK TB model, which can perform 
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predictions on local drug concentrations at the site of infection and ultimately within 
the macrophage and bacterium itself. This may aid in optimum dose finding and help 
design and prioritize interaction studies by providing a mechanistic basis. 
In PBPK modeling, the various organs are represented by compartments, which are 
linked via blood flows. Within the model, mathematical equations describe the amounts 
of drug that are transported to the organs after administration (absorption and drug 
distribution) and the rate of elimination of the drug from relevant compartments, such 
as liver, intestine and kidney. Information on the physiology side can be incorporated 
by TB-specific disease parameters and abundances of metabolizing enzymes and 
drug transporters. After combining in vitro pharmacokinetic parameters and in vivo 
abundance information in an in silico PBPK model, uptake and efflux rates of TB drugs 
can be predicted for tissues/locations of interest, such as liver, kidney, brain, CSF 
and macrophages. Exposure can be simulated over time at various dose levels and 
drug combinations, which can help to understand which dosing regimen(s) will yield 
pharmacologically relevant concentrations of TB drugs, and concentrations that result 
in adverse effects and/or clinically significant drug interactions. Exposure information 
of TB drugs can be provided for compartments in which pharmacokinetic sampling is 
not possible. To validate the PBPK predictions of (local) exposure, predictions of plasma 
exposure can be compared with plasma concentrations measured in clinical samples. 
 
2. The road to TB drugs that cross barriers in TB meningitis
Multiple strategies are available to optimize TB meningitis treatment, all aiming to increase 
local drug exposures. These strategies include higher doses of current first-line drugs, 
administration of second-line drugs with good blood-brain barrier (BBB) penetration 
characteristics, and administration of EPIs to diminish any transporter-mediated TB 
drug efflux from the brain (Figure 3).
Before the applicability of these strategies can be assessed in TB meningitis treatment, 
we should have a good understanding of the relation between systemic drug exposure, 
brain/interstitial fluid (ISF) concentration, and CSF flow and concentration. When 
considering TB meningitis pathology, it seems eminent that optimal drug concentrations 
should be reached in the brain tissue and its ISF, as well as in the surrounding CSF and 
meninges. Most data on CNS entry of TB drugs only involve measurements in the 
CSF compartment. Little is known about how well these CSF concentrations correlate 
with concentrations in other CNS regions, also relevant for TB meningitis treatment. 
Inferences on exposure assessment from CSF should especially be made cautiously 
in case of transporter substrates, because of differences in transporter location and 
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function in the BBB compared to the blood-CSF barrier (BCSFB). We know that rifampicin 
and moxifloxacin are P-gp substrates, but other relevant TB drug-exporter interactions 
have not yet been reported and still need to be assessed (see previous point). In the 
following paragraphs we will discuss in vitro, in silico and in vivo approaches that will 
contribute to our understanding of the relation between TB drug systemic exposure, 
brain/ISF concentration, and CSF flow and concentration.
Different in vitro models are available to assess the BBB and BCSFB penetration 
characteristics of TB drugs and unravel factors that limit or enhance their membrane 
passage. After identification of all relevant substrate-transporter interactions at the BBB 
and BCSFB in overexpression models (topic 1), TB drug passage across the BBB can be 
investigated by studying transcellular transport in immortalized human brain capillary 
endothelial cell lines, such as the hBMEC, either in mono-culture or in co- culture with 
a human astrocyte cell line. Such a functional in vitro BBB model can also be used to 
study the effect of EPIs on TB drug penetration and inhibition of relevant efflux pumps. 
The type of EPI applied will depend on the drug-transporter interaction to be inhibited. 
Relevant EPIs to be considered for P-gp inhibition are the newest (third generation) 
inhibitors (e.g. elacridar, tariquidar, zosuquidar), which have been tested up to phase 
3 in humans.
PBPK modeling can be used to predict brain exposure of TB drugs for various dosing 
regimens and drug combinations. How a TB drug distributes in the body, how well 
it penetrates the brain, and how well it is cleared again from the brain, depends on 
properties of the drug as well as on properties of the biological system to which the 
drug is administered. These characteristics can all be combined in a PBPK model, as 
explained under topic 1. 
Most information on brain exposure and BBB transport inhibition originate from animal 
studies, which have been associated with difficulties in inter-species extrapolation, due 
to differences in substrate affinity, transporter abundance and transporter capacity. 
Positron emission tomography (PET) imaging in humans with radio-labeled P-gp 
substrates may circumvent this problem by enabling the direct study of brain exposure 
and transporter-mediated interactions. PET allows the characterization of whole-body 
distribution and pharmacokinetics of labeled drugs. Thereby it also enables a 
simultaneous assessment of the impact of transporter inhibition on the exposure of 
multiple organs, including kidney, liver, and ultimately, brain. Furthermore, PET imaging 
can be used to correlate CSF concentrations with brain exposure, which can give 
valuable information on the clinical use of drug concentrations determined with lumbar 
punctures and it provides scaling factors for extrapolation of rodent data to humans. 
Finally, data from PET imaging may be used to validate a PBPK model.
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Finally, we propose to evaluate the pharmacokinetic and BBB penetration characteristics 
of selected second-line TB drugs in TB meningitis patients, such as high-dose isoniazid, 
high-dose pyrazinamide, ethionamide, cycloserine, linezolid, and a TB drug with an 
EPI. Studies can be small-scale (8-10 adult patients), and drugs can be administered 
next to the standard TB meningitis regimen. Serial blood sampling should be 
performed, combined with repeated sampling of CSF with a lumbar drain. Total and 
protein-unbound concentrations of the drugs in plasma and CSF samples should be 
determined, especially in case of concentration-response evaluations.
3. The ‘right’ dosing of TB drugs 
Several important questions need to be answered to find the ‘right’ dose, especially in 
the context of the redevelopment and repurposing of TB drugs. What combination(s) of 
drugs will be most effective? At what dose(s) and according to what schedule(s) should 
each drug be administered? and What duration(s) of treatment will be efficacious (117)? 
The selection of the 600 mg dose of rifampicin is exemplary for how dose deriving has 
gone wrong in the past.
We propose a combination of in vitro, in vivo, and clinical studies to be employed to 
address these questions. Four preclinical ‘drug-development tools’ have been proposed 
to answer these questions: in vitro susceptibility tests, the TB hollow fiber model, mice, 
and guinea pigs (117). For the proper use of these models, special attention needs 
to be paid to standardization of nonclinical model experiments, evaluation of animal 
models with pathology more similar to that in humans (such as the Kramnik mouse 
and the guinea pig), assessment of human pharmacokinetic equivalent doses in the 
animal studies, and correlation of preclinical output with sterilizing effect in humans. 
With respect to the clinical phase of drug development, exposure-response evaluations 
are key for good drug safety and efficacy determination, and thus deriving of the ‘right’ 
dose. We propose that, if possible, thresholds for safe and effective use should be 
derived for TB drugs.
Subsequently, exposure thresholds can be used for individualizing TB treatment with 
TDM. TDM is the standard clinical technique for using plasma drug concentrations to 
determine doses for drugs that display high variation in pharmacokinetics (37). Thus, 
TDM can provide objective information for informed dosing decisions by clinicians, 
but only when exposure-response relationships and thresholds for adequate drug 
exposure have been established. The threshold for rifampicin exposure derived in this 
thesis can also be used as such. Furthermore, knowledge on the role of  polymorphisms 
in pharmacokinetic and exposure-response evaluations may contribute to a better 
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understanding of interindividual differences in drug effects and better personalization 
of TB treatment.
4. Use of smart method design and PK-PD statistical techniques  
for efficient drug development
A growing number of new drugs are in clinical development or are under investigation 
to be repurposed or redeveloped for TB treatment. Efficacy and safety confirming phase 
3 trials of these drugs are expensive and time-consuming. While preclinical studies 
provide guidance in the selection of regimens for clinical evaluation (see also topic 
3), most drug combinations will require phase 2 testing to ensure that only the best 
regimens advance to costly and lengthy phase 3 trials. Adaptive trial designs could be 
a practical solution to this problem. The multi-arm multi-stage (MAMS) trial design, as 
performed now by the Pan African Consortium for the Evaluation of Antituberculosis 
Antibiotics (PanACEA), is an example of a treatment selection-adaptive design, where 
multiple experimental arms are simultaneously compared with a single control arm, 
and interim analyses are used to eliminate poor-performing arms early in the study 
(8). Another example of innovative trial design is the Phase 2C Selection Trial with 
Extended Post-treatment follow-up (STEP) design (7), which proposes to investigate the 
new regimen for its intended (shorter than standard) duration, including a follow-up 
for a total of 12 months to collect data on the definitive clinical endpoint (a composite 
outcome of treatment failure and relapse). This composite outcome is the same as the 
one used in confirmatory phase 3 trials.
In the end these designs may require fewer patients, as a smaller number of patients 
are randomized to less effective regimens, and may even be performed in a shorter 
timeframe, especially if a hybrid phase 2/3 design is selected. After intermediate 
analyses in phase 2, new patients can be included and all patients are followed-up for 
the definitive endpoint (relapse or survival) on which the final analysis is based (7). Such 
design would also benefit from intermediate (surrogate endpoint) markers, that have 
good predictability of the ultimate endpoint, with low false-positive and false-negative 
prediction. M. tuberculosis cultures are slow, and thus not ideal in adaptive trial designs. 
More rapidly available and quantitative biomarkers are needed that predict treatment 
efficacy and cure of active TB. In this context, PCR-based methods for quantitation of 
viable mycobacteria may be promising (118).
Traditionally, pharmacokinetic data are analyzed with the standard two-stage approach, 
consisting of non-compartmental calculation of pharmacokinetic parameters after 
intensive (data-rich) sampling in the first stage, followed by statistical analysis of the 
275
General discussion
individual pharmacokinetic parameters in the second-stage. Population PK(-PD) 
modeling, with nonlinear mixed-effects analyses, may provide valuable additive 
information compared to two-stage analysis, as it enables more mechanistic 
understanding of the PK and it offers the possibility of assessing pharmacokinetics 
from relatively sparse data, or a combination of sparse and dense data (unbalanced 
designs). The advantage is that it enables the investigation of PK-PD relationships, as 
these types of studies are more easily combined with sparse pharmacokinetic sampling. 
Furthermore, with population PK modeling, variability in the pharmacokinetic behavior 
of a drug can be more easily explained by covariates and the magnitude of the 
unexplained variability in the patient population can be estimated (119). Estimation of 
variation is important, as larger variation in pharmacokinetics entails that a larger part 
of the population may be at risk for over- or under-treatment. This information is crucial 
for defining optimum dosing strategies. Furthermore, the variation of steady-state 
drug concentrations (within-subject and within-occasion) may vary due to inexplicable 
day-to-day or week-to-week individual variability and/or due to technical errors in 
concentration measurements. Estimates of variability may also adjust and improve the 
decision making process in TDM. Even though we do not expect different conclusions 
from this kind of modeling as compared to conventional statistics used in this thesis, 
more sophisticated covariate analyses could have resulted in a better explanation of 
variation and/or identification of additional contributing factors.
Concluding remarks 
Together, the chapters of this thesis truly form a translational approach (‘crossing barriers’) 
in the search for optimal exposures of drugs used in TB treatment and associated 
co-morbidities. Central themes were drug transporters, (free) drug concentrations 
and concentration-response evaluations. In this final chapter we identified remaining 
knowledge gaps in the context of this thesis, and proposed directions for future research.
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Summary
Background
Mankind has been confronted with tuberculosis (TB) since ancient times. Archaeological 
evidence of early TB has been found in for example Egyptian and Peruvian mummies, 
and was already described in classical Greece as phthisis. Nowadays, the disease 
burden of TB remains one of the world’s biggest threats. Globally, 10.4 million new 
TB cases arose in 2015, and a total of 1.8 million TB patients died. A third of the 
world’s population is estimated to be latently infected with the causative pathogen 
Mycobacterium tuberculosis (M. tuberculosis), forming an enormous reservoir for new 
cases of active TB. 
Antibiotic treatment against TB became successful for the first time in 1944 with the 
discovery of streptomycin. This drug revolutionized TB treatment, being the first 
bactericidal agent against M. tuberculosis. Use of this agent alone led to resistance, 
which was circumvented by combining multiple antibiotics. By the 1970s, the addition 
of rifampicin to a regimen of streptomycin, isoniazid, and ethambutol allowed a 
shortening of treatment of 12-18 months to 9-12 months. In the 1980s, the replacement 
of streptomycin with pyrazinamide yielded more rapid sterilization, allowing a further 
shortening of treatment to 6-8 months, even without optimal drug dose assessments 
for some of the drugs in the combination regimen.
Standard minimum treatment for TB, as recommended by the World Health 
Organization (WHO), still includes a combination of isoniazid, rifampicin, pyrazinamide, 
and ethambutol for six months. In an effort to improve treatment outcomes and 
shorten treatment duration, TB drug research has been aiming at redevelopment of 
existing first-line TB drugs (high dose rifamycins and pyrazinamide) and repurposing 
of available antibiotics (e.g. moxifloxacin, linezolid and clofazimine), alongside the 
development of new compounds (e.g. bedaquiline, delamanid and pretomanid). The 
advantage of redeveloping and repurposing existing antibiotics is that results can be 
obtained rapidly and safety data are already available. Knowledge on the appropriate 
dose, plasma exposure and antimycobacterial efficacy are key components for 
adequate redevelopment and repurposing of TB drugs, and thus general TB therapy 
optimization.  
In line with this, the overall objective of the studies in this thesis is to contribute to 
optimization of therapeutic exposure of TB drugs and drugs used for TB-associated 
co-morbidities. Optimum drug dosages, substantiated by the pharmacokinetic-phar-
macodynamic (PK-PD) characteristics of the drugs, have the potential to greatly 
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maximize efficacy of the current treatment. The central principle underlying the studies 
described in this thesis is that the efficacy and toxicity of these drugs is related to their 
plasma concentrations. We pay special attention to the role of drug transporters, as 
they are a key determinant for (systemic and intracellular) free drug concentrations.
The present thesis consists of 11 chapters, which are divided in three sections, representing 
all stages of drug development: in vitro, animal, and human pharmacological studies. 
Together they form a translational approach (‘crossing barriers’) to optimize TB drug 
treatment. 
Introduction and review of the literature
Chapter 1 provides the background and introduction to the thesis, as summarized 
above. It presents TB as a major public health problem, describes the evolution of TB 
treatment and the place of pharmacology in TB drug development and optimization, 
and explains the outline of the thesis. 
Chapter 2 reviews the role of drug transport mechanisms across human and 
mycobacterial membranes in reaching optimal systemic and local drug concentrations. 
We conclude that inhibition of human and/or mycobacterial efflux pumps may be 
valuable for enhancing the effectiveness of currently available TB drugs. Major hurdles 
are the inability to modulate drug transport specifically, and the difficulty to dose efflux 
pump inhibitors to reach full inhibition at safe plasma concentrations. To support the 
application of targeted efflux pump inhibition we should focus on elucidating the 
relation between mycobacterial transporter upregulation and transporter-mediated 
resistance, next to identification of TB drugs as transporter substrates for both human 
and mycobacterial efflux pumps. 
Part 1: Molecular pharmacology 
In chapter 3 we address the transport of drug out of the mycobacterium or (in 
relation to this) transporter-mediated drug resistance. The chapter describes the 
cloning and expression of three M. tuberculosis efflux pumps in E. coli and HEK293 
cells. Furthermore, it demonstrates that Rv0194-overexpressing vesicles are associated 
with increased ATP-dependent uptake of the fluorescent molecule ‘Fluo_P-gp’ (a 
human P-gp substrate). This uptake is diminished by known P-gp inhibitors (verapamil, 
SQ109, and thioridazine), but not by the MRP inhibitor probenecid, suggesting that we 
identified Rv0194 as a P-gp like drug efflux pump in M. tuberculosis. For future research 
we propose to optimize heterologous protein expression in the HEK293 cell model and 
investigate the expression of a larger variety of mycobacterial efflux pumps.
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Chapter 4 assesses the in vitro inhibitory potential of currently used first- and 
second-line TB drugs, as well as of proposed mycobacterial efflux pump inhibitors on 
human ATP-binding cassette (ABC) transporters most relevant to drug transport. Our 
results show strong inhibition for clofazimine (P-gp, BCRP and MRP1), thioridazine 
(BCRP), timcodar (P-gp, BSEP and MRP1) and SQ109 (P-gp and BCRP). Rifampicin 
inhibits all transporters, but less potently. We conclude that exposure to clofazimine, 
thioridazine, timcodar, SQ109, and rifampicin may lead to DDIs when co-administered 
with drugs that are substrates for the mentioned transporters. Presented preclinical 
pharmacological information provide a mechanistic basis for prioritizing interaction 
studies and performing dose optimization studies and safety/tolerability studies for 
specific TB drugs or combinations. 
Chapter 5 evaluates the in vitro inhibitory effects of TB drugs on metformin transport by 
organic cation transporters (OCTs) and multidrug and toxin extrusion proteins (MATEs). 
Furthermore, it investigates whether TB drugs are also substrates themselves of OCTs 
and MATEs. The results show that moxifloxacin is the only TB drug that acts as a potent 
inhibitor (DDI-index>0.1) of MATE1- and MATE2K-mediated metformin transport (IC50 
of 12 µM and 7.6 µM, respectively). Of all TB drugs studied, only ethambutol serves as 
a substrate to OCT1, OCT2, OCT3, MATE1 and MATE2K. MATE1-mediated ethambutol 
uptake is inhibited strongly (DDI-index >0.1) by moxifloxacin (IC50 of 12 µM). According 
to international guidelines, the observed in vitro interaction between ethambutol and 
moxifloxacin warrants further in vivo investigation, as the DDI-index (plasma Cmax/IC50) 
exceeds 0.1. 
Part 2: Animal studies 
In part 2 we identify human pharmacokinetic equivalent doses of linezolid (chapter 
6) and moxifloxacin (chapter 7) in BALB/c mice, and evaluate ‘dried blood spot’ (DBS) 
analyses for measuring DBS concentrations in mouse blood spots. Linezolid and 
moxifloxacin are promising agents for future drug-sensitive and/or MDR-TB regimens, 
to be evaluated in combination with existing and new TB drugs in the TB mouse model. 
To improve clinical predictability from animal efficacy studies, it is important to test a 
dose that is pharmacokinetically equivalent to the dose used in patients. Furthermore, 
pharmacokinetic analyses in mice benefit from measurement of analytes in small blood 
volumes using the DBS technique, because it allows for the assessment of multiple drug 
concentrations over time within a single mouse.
Chapter 6 and 7 report 50 mg/kg oral linezolid and 200 mg/kg oral moxifloxacin in 
BALB/c mice, respectively, as the pharmacokinetic equivalents of doses applied in 
humans. We recommend this dose for future TB regimen efficacy testing. With respect 
290
Chapter 12
to the application of the DBS technique, we propose a conversion factor of 1.2 to predict 
linezolid plasma concentrations from DBS to compensate for the differences in mouse 
plasma and blood. Such a correction factor is not necessary for moxifloxacin plasma 
predictions from DBS. Therefore, we conclude that compound specific (bio-analytical) 
method validation in DBS matrix is indispensable, as factors such as blood/plasma 
partition ratios and the impact of hematocrit may be drug specific, and can greatly 
complicate the comparison with plasma samples.
Part 3: Clinical pharmacology
In chapter 8 we investigate the impact of nutritional status on the steady-state 
pharmacokinetics of total and protein-unbound (free, active) concentrations of 
rifampicin. Malnutrition-associated low concentrations of drug-binding plasma proteins 
may cause a change in the equilibrium between unbound and bound concentrations, 
rendering total drug concentrations misleading. Results show that nutritional status 
does not impact free or total rifampicin drug concentrations, and females have 
higher total and unbound AUC0-24h compared to males. In this study we observe a 
marked 2-fold interindividual variation in free fraction. Thus, for highly protein-bound 
TB drugs with a low organ extraction ratio, such as rifampicin, we advise to measure 
free drug concentrations along with total plasma concentrations when studying 
exposure-response relationships.
Chapter 9 assesses the effect of rifampicin use on the steady-state pharmacokinetics 
of metformin and on the glucose-lowering effect of metformin in Indonesian TB 
patients with diabetes mellitus (DM) type 2. Rifampicin is a known inducer of drug 
handling enzymes, which may cause alterations in the expression of transporters that 
determine metformin pharmacokinetics and efficacy. The results of the interim-analysis 
suggest that rifampicin increases metformin exposure: the metformin plasma AUC0-τ 
geometric mean ratio (GMR) (exposure during rifampicin treatment versus exposure 
after rifampicin treatment) is 1.30 (90% CI 1.07-1.59). This effect is probably caused by 
an increase in absorption, because renal elimination of metformin remains unaffected 
and metformin is not a substrate for hepatic metabolism. The glucose-lowering efficacy 
of metformin is not affected in a similar magnitude by rifampicin, but with current 
results we cannot exclude it may be required to monitor metformin efficacy during and 
after TB treatment.  
The final chapter of part 3, chapter 10, examines the concentration-response 
relationship, systemically and locally (CSF), for rifampicin and moxifloxacin in TB 
meningitis patients. Moxifloxacin exposure does not show a clear relationship with 
survival, while TB meningitis patients have a 32-43% lower relative likelihood of dying 
291
Epilogue
with one interquartile range higher exposure to rifampicin in plasma and CSF. The 
chapter brings forward minimum target values for rifampicin exposure that aid in TB 
treatment, but also in the design of pharmacokinetically optimized dosing regimens in 
other populations. From exposure-response curves, a rifampicin plasma AUC0-6h of ca. 
70 mg/L.h corresponding to an AUC0-24h of ca. 116 mg/L.h and a Cmax of ca. 22 mg/L are 
deduced as minimum target values for treatment. From these values we can conclude 
that the current dose of rifampicin used for treating TB meningitis is suboptimal; higher 
doses should be evaluated. 
General discussion
The main findings of this thesis are summarized and discussed in chapter 11. In this 
chapter four TB research areas are identified that contain considerable knowledge gaps 
and are interesting for future research:
1. TB drug substrate identification of human and mycobacterial drug transporters 
There is a lack of insight into which TB drugs are substrates for human and/or 
mycobacterial drug transporters. Substrate characteristics should be investigated 
according to established guidelines for in vitro testing, which should include in 
vitro pharmacokinetic parameters, such as affinities constants. These data can 
serve as input for a general physiologically based pharmacokinetic (PBPK) TB 
model, which can perform predictions on local drug concentrations at the site of 
infection and ultimately within the macrophage and bacterium itself. 
2. The road to TB drugs that cross barriers in TB meningitis
Multiple strategies are available to optimize TB meningitis treatment, all aiming 
to increase local drug exposures. These strategies include higher doses of current 
first-line drugs, administration of second-line drugs with good blood-brain 
barrier (BBB) penetration characteristics, and administration of efflux pump 
inhibitors to diminish transporter-mediated TB drug efflux from the brain. Before 
these strategies can be implemented with correct dosing regimens, we should 
have a better understanding of the relation between systemic drug exposure, 
brain/interstitial fluid concentration, and CSF flow and concentration, all relevant 
to the development of optimized dosing strategies. 
3. The ‘right’ dosing of TB drugs
The implementation of the 600 mg dose of rifampicin decades ago is exemplary 
for how dose selection went wrong in the past. We propose a combination of in 
vitro, in vivo, and clinical studies to establish a broad evidence-base for the ‘right’ 
dose. Special attention needs to be paid to standardization of nonclinical model 
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experiments, evaluation of animal models with pathology more similar to that 
in humans, assessment of human pharmacokinetic equivalent doses in animal 
studies, and correlation of preclinical output with sterilizing effect in humans. 
With respect to the clinical phase of drug development, exposure-response 
evaluations are key for good drug safety and efficacy determination, and thus 
selection of the ‘right’ dose. 
4. Use of smart method design and PK-PD statistical techniques for efficient drug 
development
Efficacy and safety confirming phase 3 trials of new TB drugs are expensive 
and time-consuming. Adaptive trial designs could form a practical solution. 
These designs may require fewer patients, as a smaller number of patients 
are randomized to less effective regimens, and may even be performed in a 
shorter time-frame, especially if a hybrid phase 2/3 design is selected. Such 
designs would also benefit from intermediate (surrogate endpoint) markers, 
that have good predictability of the ultimate efficacy endpoint. As part of these 
studies, population PK(-PD) modeling provides the most effective means to 
estimate variation in pharmacokinetics. This is important, as large variation in 
pharmacokinetics can result in the over- or under-treatment of a significant part 
of the population may be at risk for over- or under-treatment, which is crucial 
for defining optimum dosing strategies. 
Together, the chapters of this thesis form a translational approach (‘crossing barriers’) 
in the search for optimal exposures of drugs used in TB treatment and associated 
co-morbidities.
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Samenvatting
Een oude én moderne plaag
Tuberculose (tbc) is een ernstige en besmettelijke infectieziekte, veroorzaakt door de 
bacterie Mycobacterium tuberculosis. De meest voorkomende vorm is longtuberculose, 
maar de bacterie kan ook op andere plaatsen in het lichaam ernstige ziekte veroorzaken. 
Het betreft een eeuwenoude ziekte. Sporen van tbc zijn onder meer aangetroffen 
in oude Egyptische en Peruaanse mummies. Tbc werd in het oude Griekenland ook 
wel phtisis genoemd: de tering. De ziekte gaat namelijk gepaard met een ernstig 
gewichtsverlies, waardoor patiënten als het ware ‘interen’. De naam tuberculose 
verwijst naar de kenmerkende ontwikkeling van tuberkels, een soort knobbeltjes, die 
ook wel granulomen worden genoemd. Granulomen zijn een opeenhoping van witte 
bloedcellen (macrofagen) en ontstaan als gevolg van een ontstekingsreactie van het 
lichaam met als doel de tbc-bacteriën op te ruimen. Echter, tbc-bacteriën kunnen 
overleven in deze macrofagen en vinden daar juist extra bescherming. 
Tbc komt in Nederland bij slechts circa 800 tot 900 mensen per jaar voor. Veel 
Nederlanders denken dan ook dat tbc niet meer bestaat. Niets is minder waar. 
Tegenwoordig vormt de ziektelast veroorzaakt door tbc één van de grootste 
bedreigingen voor de mens wereldwijd. In 2015 ontwikkelden namelijk 10,4 miljoen 
mensen actieve tbc en overleden er 1,8 miljoen patiënten aan de gevolgen van deze 
ziekte. Hiermee is het de meest dodelijke infectieziekte van dit moment, nog boven 
hiv/AIDS. Bovendien is een derde van de wereldbevolking latent geïnfecteerd met 
de bacterie, waarvan naar schatting 10 procent op enig moment in hun leven ook 
daadwerkelijk de actieve ziekte zal ontwikkelen.
Tuberculosebehandeling
Oudere mensen herinneren zich misschien nog wel de tijd dat tbc werd behandeld 
in sanatoria: frisse lucht, strikte bedrust en de juiste voeding waren toen de 
hoofdcomponenten van de eerstelijns behandeling. Echter, zonder antibiotische 
behandeling is het verloop van tbc ongunstig en kan tot de helft van de patiënten 
komen te overlijden. Met de ontdekking van streptomycine kwam de eerste 
succesvolle bacteriedodende therapie tegen tbc beschikbaar. Het gebruik van een 
enkel geneesmiddel leidde al snel tot resistentie, waarna werd overgestapt naar een 
combinatiekuur van meerdere antibiotica. Een volgende doorbraak kwam in de jaren 
‘70: het toevoegen van rifampicine aan een behandeling met streptomycine, isoniazide 
en ethambutol verkortte de behandeling van 12-18 maanden tot 9-12 maanden. Ten 
slotte werd in de jaren ‘80 streptomycine vervangen door pyrazinamide, waardoor een 
verdere verkorting van de behandeling naar 6-8 maanden kon worden bewerkstelligd. 
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Dit alles gebeurde toentertijd zonder onderzoek naar de juiste geneesmiddeldoseringen 
zoals dat tegenwoordig gebruikelijk is. Desondanks is de eerstelijns therapie sinds de 
jaren ’80 onveranderd gebleven.
De behandeling van tbc duurt in de regel zes maanden. Tijdens de eerste twee 
maanden is sprake van een intensieve fase en in de laatste vier maanden is sprake 
van een continueringsfase. Tijdens de eerste fase worden isoniazide, rifampicine, 
pyrazinamide en ethambutol voorgeschreven om de sneldelende bacteriën te doden 
(bactericide werking). In de laatste fase worden patiënten behandeld met isoniazide 
en rifampicine om ook de moeilijk te bereiken en/of minder actieve bacteriën te 
behandelen (steriliserende werking). Deze therapievolgorde is essentieel gebleken om 
resistentie en terugval te voorkomen. Wanneer de bacterie ongevoelig blijkt te zijn 
voor één van de gebruikelijke antibiotica (eerstelijns middelen) zal de behandeling 
langer voortgezet moeten worden met veelal een aangepast behandelingsschema. 
Onderzoek naar tuberculose en kennis over farmacokinetiek
In een poging om de behandelingsresultaten te verbeteren en de therapieduur te 
verkorten, is er de laatste jaren veel onderzoek gedaan naar het ‘herontwikkelen’ 
van bestaande eerstelijns tbc-geneesmiddelen (bijvoorbeeld hogere doseringen 
rifampicine en pyrazinamide) en het ‘herbestemmen’ van beschikbare antibiotica 
tegen andere infectieziekten (bijvoorbeeld moxifloxacine, linezolid en clofazimine). De 
ontwikkeling van nieuwe tbc-geneesmiddelen verloopt erg moeizaam, wat valt toe 
te schrijven aan de complexiteit van de behandeling en de beperkte interesse van 
de farmaceutische industrie. De arme landen waar tbc veel voorkomt, zijn immers 
financieel gezien geen aantrekkelijke markt. De laatste decennia zijn er slechts twee 
geneesmiddelen (bedaquiline en belamanid) nieuw op de markt gekomen. Het 
voordeel van het herontwikkelen en herbestemmen van bestaande antibiotica is dat 
er snel resultaten geboekt kunnen worden zonder dat er nieuwe geneesmiddelen 
‘ontdekt’ hoeven te worden. Kennis over de juiste dosis, geneesmiddelconcentraties 
in het bloed en antimycobacteriële werkzaamheid zijn belangrijke componenten voor 
een adequate herontwikkeling en herbestemming van tbc-geneesmiddelen en dus 
voor optimalisatie van de therapie.
Om werkzaam te zijn, moet een tbc-geneesmiddel een interactie kunnen aangaan 
met de tbc-bacterie. Dit wordt ook wel ‘farmacodynamiek’ (PD) genoemd: ‘wat het 
geneesmiddel doet met het lichaam’. Of in dit geval, ‘wat het geneesmiddel doet met de 
bacterie’. De hoeveelheid geneesmiddel ter plaatse van de werking bepaalt de sterkte 
waarmee het geneesmiddel werkzaam is. Deze concentratie wordt bepaald door de 
mate van absorptie uit de darmen, de verdeling over het lichaam, transport naar de 
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weefsels, afbraakprocessen in met name de lever en uitscheiding via bijvoorbeeld de 
nieren. Dit wordt ook wel de ‘farmacokinetiek’ (PK) van een geneesmiddel genoemd, 
oftewel: ‘wat het lichaam doet met het geneesmiddel’. De farmacokinetische en 
farmacodynamische processen bepalen samen het farmacologisch profiel van een 
medicijn. Zo zijn de werkzaamheid en de toxiciteit van tbc-geneesmiddelen gerelateerd 
aan de concentratie van deze middelen in het bloed. Een te hoge concentratie resulteert 
in bijwerkingen (toxiciteit) en een te lage concentratie in een suboptimale behandeling. 
Doelstelling van dit proefschrift
Het doel van dit proefschrift is het optimaliseren van de blootstelling (bloedconcentraties) 
van tbc-medicijnen en de blootstelling van geneesmiddelen gebruikt voor 
tbc-geassocieerde ziekten. Het verbeteren van de kennis over de farmacokinetische-far-
macodynamische (PK-PD) eigenschappen van tbc-geneesmiddelen vormt hierbij het 
centrale uitgangspunt. Daarnaast besteden we in dit proefschrift extra aandacht aan 
de rol van geneesmiddeltransporters, omdat zij het transport van medicijnen over 
cel/weefselbarrières verzorgen en daarmee sterk de absorptie, distributie, afbraak en 
excretie beïnvloeden. Kortom, transporters bepalen hoeveel geneesmiddel op een plek 
in het lichaam terechtkomt en zijn daarom essentieel in de farmacokinetiek. 
De resultaten van dit proefschrift vormen een relevante toevoeging aan de bestaande 
kennis over tbc-geneesmiddelen. Bij de ontwikkeling van de huidige eerstelijns 
middelen is namelijk weinig tot geen onderzoek naar farmacokinetiek gedaan. Kennis 
over de optimale dosering van een geneesmiddel, en de daarbij behorende PK-PD 
kenmerken, vormt de sleutel tot het optimaliseren van de huidige behandeling. 
Dit proefschrift is opgedeeld in drie secties, die alle stadia van de geneesmiddelontwikkeling 
vertegenwoordigen: in vitro onderzoek, dierproeven en klinische studies in de mens. 
Samen vormen ze een translationele benadering voor het optimaliseren van de 
medicamenteuze behandeling van tbc.
Deel 1: Moleculaire farmacologie
In dit deel onderzoeken we met behulp van laboratoriumtechnieken de interactie van 
geneesmiddelen met zowel humane als mycobacteriële transporter eiwitten (efflux 
pompen). Hiertoe produceren we deze eiwitten buiten het lichaam, namelijk in cellen 
of celmembranen die we in het lab kweken. Op deze wijze kunnen we de functionaliteit 
van de verschillende type transporters goed bestuderen. 
Allereerst bestuderen we in hoofdstuk 3 het transport van geneesmiddelen uit 
de mycobacterium. Wanneer veel geneesmiddel uit de bacterie wordt verwijderd 
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via deze efflux pompen, dan zal de bacterie minder gevoelig zijn voor de werking 
van het antibioticum. Dit noemen we in het proefschrift ‘transporter-gemedieerde 
resistentie’. In hoofdstuk 3 rapporteren we over ons onderzoek aan een specifieke 
Mycobacterium tuberculosis pomp, die transport laat zien van een molecuul waarvan 
we weten dat deze ook getransporteerd wordt door één van de belangrijkste 
humane geneesmiddeltransporters, namelijk de transporter P-glycoproteïne 
(P-gp). Deze bevinding ondersteunt het mogelijke belang van efflux pompen in 
transporter-gemedieerde resistentie. 
In hoofdstuk 4 en 5 kijken we specifiek naar de interactie van tbc-geneesmiddelen 
met humane transporters. Informatie hierover is belangrijk; als verschillende middelen 
getransporteerd worden door dezelfde transporter of als een geneesmiddel de 
activiteit van een transporter remt kan een zogenaamde ‘interactie’ (of ‘wisselwerking’) 
in de farmacokinetiek en farmacodynamiek van de gecombineerde geneesmiddelen 
optreden. Door dergelijke geneesmiddelinteracties kunnen bloedconcentraties of 
weefselconcentraties veranderen, wat weer gevolgen kan hebben voor de werking of 
toxiciteit van het medicijn. Het moleculair farmacologisch onderzoek uit hoofdstuk 4 
en 5 maakt het onder andere mogelijk om risicovolle combinaties van geneesmiddelen 
te voorspellen. Zo tonen we onder meer aan dat het tbc-geneesmiddel moxifloxacin 
het transport van het tbc-geneesmiddel ethambutol remt, alsmede het transport van 
het antidiabeticum metformine. Deze combinaties kunnen dus mogelijk risicovol zijn 
en zouden verder onderzocht moeten worden.
Deel 2: Dierproeven
In deel 2 van dit proefschrift bepalen we de juiste dosering van de tbc-geneesmiddelen 
linezolid en moxifloxacine in muizen. Beide antibiotica zijn veelbelovende middelen 
voor de behandeling van resistente en niet-resistente tbc. Ze zijn respectievelijk 
kandidaten voor ‘herbestemming’ en ‘herontwikkeling’, waardoor ze in de toekomst 
waarschijnlijk veelvuldig worden geëvalueerd in tbc- muizenmodellen. Om de klinische 
voorspelbaarheid van deze dierproeven te verbeteren, is het belangrijk om in de 
muis een  dosis te testen die resulteert in bloedconcentraties die vergelijkbaar zijn 
met bloedconcentraties bij de mens. Volgens dit principe tonen we in hoofdstuk 6 
(linezolid) en hoofdstuk 7 (moxifloxacine) aan dat 50 mg/kg oraal linezolid en 200 mg/
kg oraal moxifloxacine in BALB/c-muizen de doseringen zijn die in de toekomst moeten 
worden gebruikt om de werkzaamheid van deze geneesmiddelen in tbc-muizen te 
testen. Daarnaast laten we in deze hoofdstukken zien dat we de geneesmiddelcon-
centraties van linezolid en moxifloxacine in kleine druppeltjes muizenbloed kunnen 
bepalen, waardoor we over de tijd meerdere bloedmonsters van één muis kunnen 
afnemen. Met deze methode is het niet nodig een hele muis te offeren om voldoende 
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bloed te verzamelen voor één reguliere concentratiebepaling. Dit scheelt enorm in het 
aantal muizen dat nodig is om een goed beeld te krijgen van de geneesmiddelbloot-
stelling. 
Deel 3: Klinische farmacologie
In het derde deel van dit proefschrift presenteren we de uitkomsten van een reeks klinisch 
farmacologische studies uitgevoerd onder Indonesische tbc-patiënten. Hoofdstuk 
8 bestudeert de impact van ondervoeding op de farmacokinetiek van totaal- en 
eiwit-ongebonden (vrije, actieve) concentraties van rifampicine. Een groot gedeelte van 
de rifampicine moleculen bindt zich in het bloed aan eiwitcomponenten. Alleen de vrije 
concentratie is werkzaam en daarom wordt de ongebonden concentratie ook wel de 
actieve concentratie genoemd. We weten dat tbc geassocieerd is met ondervoeding, 
en dit laatste kan op haar beurt weer effect hebben op de aanwezigheid van eiwitten 
in het bloed die geneesmiddelen kunnen binden. De resultaten van hoofdstuk 8 tonen 
aan dat ondervoeding niet van invloed is op de gebonden en/of vrije concentratie 
rifampicine in het bloed. Wél vinden we een hoge mate van variatie tussen patiënten in 
de mate waarin rifampicine gebonden wordt aan deze eiwitten. Dit kan een verklaring 
vormen voor verschillen in de effectiviteit en toxiciteit in de behandeling tussen 
patiënten. 
In hoofdstuk 9 onderzoeken we het effect van rifampicine op de farmacokinetiek van 
metformine (diabetesmedicijn) in patiënten die gelijktijdig lijden aan tbc en diabetes. 
Van rifampicine weten we dat het de aanmaak stimuleert van geneesmiddelenzymen en 
transporters. Van metformine weten we dat het getransporteerd wordt door dezelfde 
transporters waarvan rifampicine de aanmaak beïnvloedt. Uit de resultaten van de 
interim-analyse blijkt dat rifampicine de bloedconcentraties van metformine verhoogt. 
Dit effect wordt waarschijnlijk veroorzaakt door een toename van de absorptie (meer 
opnametransport) van metformine uit de darmen. In de urine van deze patiënten wordt 
namelijk niet minder metformine teruggevonden (onveranderd eliminatietransport) en 
metformine wordt in het lichaam niet afgebroken. Hoewel het glucose-verlagende 
effect van metformine slechts in geringe mate en niet significant door rifampicine wordt 
verminderd, kunnen we op basis van deze gegevens niet uitsluiten dat rifampicine de 
werkzaamheid van metformine beïnvloedt.
In het laatste hoofdstuk van deel 3, hoofdstuk 10, onderzoeken we de 
concentratie-respons (PK-PD)-relatie van de tbc-geneesmiddelen rifampicine en 
moxifloxacine in patiënten met tbc-meningitis, de meest dodelijke vorm van tbc. De 
studie toont aan dat bij een hogere concentratie van rifampicine er minder sterfte 
ten gevolge van de meningitis optreedt. Bij een plasma piekspiegel (concentratie 
300
Chapter 12
in het bloed twee uur na inname) van circa 22 mg/L overlijdt nog maar ongeveer 
20% van de patiënten. We stellen deze rifampicineconcentratie dan ook voor als 
minimum streefwaarde voor behandeling. Echter, deze streefwaarde zal met de huidig 
geadviseerde dosis van 10 mg/kg door de meeste patiënten niet gehaald worden en 
we concluderen dan ook dat de huidige dosis rifampicine gebruikt voor de behandeling 
van tbc-meningitis suboptimaal is; hogere doses moeten worden geëvalueerd. Voor 
moxifloxacine kunnen we geen concentratie-effect relatie aantonen.
Discussie en toekomstperspectieven 
De belangrijkste bevindingen van dit proefschrift worden samengevat en geëvalueerd 
in hoofdstuk 11. Vier thema’s voor toekomstig onderzoek worden geïdentificeerd:
1. Het verkrijgen van inzicht in welke tbc-geneesmiddelen door humane en 
mycobacteriële efflux pompen worden getransporteerd (‘substraatidentificatie’):
Er is een gebrek aan inzicht in welke tbc-medicijnen substraten zijn voor humane 
en/of mycobacteriële geneesmiddeltransporters. Deze informatie is belangrijk 
voor het verklaren van bestaande geneesmiddelinteractie en voor het voorspellen 
van nieuwe interacties. Daarnaast vormt dit de sleutel voor het onderzoek naar 
de relevantie van transporter-gemedieerde geneesmiddelresistentie in de 
mycobacterie.
2. Het verbeteren van de lokale blootstelling in tbc-meningitis:
Tbc-meningitis blijft een lastig te behandelen en ernstige vorm van tbc. Er zijn 
diverse theoretische behandelstrategieën te bedenken die verder onderzocht 
dienen te worden. Deze behandelstrategieën zijn met name gericht op 
het verhogen van de lokale geneesmiddelconcentraties in het brein en de 
hersenvliezen, zoals het verhogen van de doseringen van de huidige eerstelijns 
geneesmiddelen, het toedienen van tweedelijnsgeneesmiddelen met gunstiger 
farmacologische eigenschappen voor wat betreft het bereiken van het brein, 
en het remmen van efflux pompen die tbc-geneesmiddelen uit het brein 
transporteren. 
3. Het vinden van de ‘juiste’ dosering van tbc-medicijnen:
Het kiezen van de 600 mg dosering rifampicine decennia geleden is exemplarisch 
voor de manier waarop dosisselectie in het verleden fout is gegaan. Bij de 
ontwikkeling van geneesmiddelen zouden concentratie-respons evaluaties, 
inclusief een afweging tussen optimale werkzaamheid en veiligheid, de basis 
moeten zijn voor dosisselectie. Deze basis ontbreekt echter nog bij een groot 
deel van de huidige eerste- en tweedelijns tbc middelen.
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4. Het toepassen van efficiënte onderzoeksdesigns:
Voordat een nieuw geneesmiddel op de markt komt, vindt normaliter uitgebreid 
geneesmiddelonderzoek plaats in drie fasen: fase 1 (dosisselectie in gezonde 
vrijwilligers), fase 2 (testen van farmacokinetiek en veiligheid in patiënten) en 
fase 3 (testen van effectiviteit in een grote patiëntenpopulatie). Aangezien tbc 
met een combinatie van geneesmiddelen behandeld wordt, zal het vinden van 
de optimale combinatietherapie volgens deze drie fasen duur en tijdrovend 
zijn. Zogenaamde flexibele onderzoeksdesigns vormen hiervoor een praktische 
oplossing. Voorbeelden zijn een hybride fase 2/3 design of een design 
waarbij meerdere combinaties parallel getest worden en minder presterende 
combinaties vervroegd uit het onderzoek gehaald kunnen worden. Dergelijke 
designs vereisen minder patiënten en minder tijd, en zijn daarom veelbelovend. 
De hoofdstukken uit dit proefschrift vormen een translationele benadering (‘crossing 
barriers’) om te komen tot een verbeterde blootstelling aan tbc-middelen, en aan 
middelen gegeven voor met tbc samenhangende ziekten.
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Curriculum Vitae
Lindsey te Brake werd op 21 april 1987 te Winterswijk geboren. In 2005 behaalde zij 
haar gymnasiumdiploma aan het RKSG Marianum te Groenlo. Aansluitend begon zij 
met de studie Biomedische wetenschappen aan de Radboud Universiteit te Nijmegen 
en in januari 2012 studeerde zij ‘bene meritum’ af in de richtingen ‘Arbeid, Milieu 
en Gezondheid’ en ‘Toxicologie’. Door haar onderzoeksstages aan de University of 
Adelaide in Australië (‘The effect of sunscreen, temperature variation, and fabric on 
percutaneous penetration of diazinon in human and pig in an in vitro model) en bij 
TNO in Zeist (‘Relative embryo-, developmental- and neurotoxicity of six organotins in 
a zebrafish embryo toxicity assay’) raakte Lindsey geïnteresseerd in de toepasbaarheid 
van in vitro resultaten en translationeel onderzoek. In augustus 2012 begon zij als 
promovenda aan het Radboud universitair medisch centrum onder begeleiding van dr. 
Rob Aarnoutse en prof. dr. David Burger van de afdeling Apotheek, en dr. Jan Koenderink 
en prof. dr. Frans Russel van de afdeling Farmacologie-Toxicologie. Het voorliggende 
proefschrift over de moleculaire en klinische farmacologie van tbc-geneesmiddelen is 
het resultaat van haar promotie-onderzoek. Tijdens haar promotie voltooide Lindsey 
tevens de postdoctorale opleiding tot toxicoloog van de Nederlandse Vereniging voor 
Toxicologie (NVT). In 2016 nam Lindsey deel aan de Radboud Da Vinci Challenge, een 
programma voor getalenteerde promovendi binnen het Radboud universitair medisch 
centrum.  
Lindsey was born on April 21st 1987 in Winterswijk, the Netherlands. In 2005 she 
completed her secondary school education at the RKSG Marianum in Groenlo, the 
Netherlands. She then studied Biomedical sciences at the Radboud university in 
Nijmegen, and graduated with majors in Occupational and Environmental Health and in 
Toxicology. During her research internships at the University of Adelaide, Australia (‘The 
effect of sunscreen, temperature variation, and fabric on percutaneous penetration of 
diazinon in human and pig in an in vitro model) and at the Netherlands Organisation for 
Applied Scientific Research (‘Relative embryo-, developmental- and neurotoxicity of six 
organotins in a zebrafish embryo toxicity assay’), Lindsey got involved in the application 
of in vitro techniques and translational research. In august 2012 she started her PhD 
at the Radboud university medical center, under supervision of dr. Rob Aarnoutse en 
prof. dr. David Burger of the Department of Pharmacy, and dr. Jan Koenderink and 
prof. dr. Frans Russel of the Department of Pharmacology-Toxicology. This thesis on 
the molecular and clinical pharmacology of tuberculosis drugs forms the final result of 
her PhD research. During her PhD Lindsey also completed the training required for the 
register of professional toxicologists by the Netherlands Society of Toxicology (NVT). In 
2016 Lindsey was part of the Radboud Da Vinci Challenge for talented PhD students. 
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RIMLS portfolio
Name PhD candidate: Lindsey H.M. te Brake
Department: Pharmacology and Toxicology
Graduate School: Radboud Institute for Molecular Life Sciences
PhD period: 01-08-2012 – 04-07-2016
Promotors:  
Prof. David Burger and Prof. Frans Russel
Co-promotors:  
Dr Rob Aarnoutse and Dr Jan Koenderink
Year(s) ECTS
TRAINING ACTIVITIES
Courses & Workshops
• Introduction day Radboudumc 
• RIMLS new frontiers symposium on advances in genomics
• Graduate School introductory course 
• RIMLS Phd retreat  
• Scientific Integrity course 
• RIMLS new frontiers symposium on synthetic life
• BROK course 
• RIMLS PhD retreat
• Biometrics course PAO Heyendael 
• Cell toxicology
• Molecular epidemiology
2012
2012
2013
2013
2013
2013
2014
2014
2014
2015
2015
0.5
1.0
2.0
1.0
1.0
1.0
1.5
1.0
3.75
1.5
2.0
Seminars & lectures
• Seventeen RIMLS lectures/seminars/spotlight sessions
• Technical forum: epigenetics
2012-2014
2013
1.7
0.2
Symposia & congresses
• Gordon Conference on Multi-drug efflux systems: attendance 
plus selected speaker
• 6th International Workshop on Clinical Pharmacology of TB 
Drugs, attendance plus selected speaker
• 7th International Workshop on Clinical Pharmacology of TB 
Drugs, attendance plus selected speaker 
• The UNION meeting Barcelona 2014, attendance
• NVT drug toxicology meeting plus participant at poster 
session (Amsterdam)
• NVT drug toxicology meeting (Nijmegen), attendance
2013
2013
2014
2014
2015
2016
1.75
0.75
0.75
1.0
0.75
0.25
Other
• Monthly journal club
• TANDEM meeting, Bandung, Indonesia, attendance and oral
• Radboud DaVinci Challenge: application and program
2012-2016
2015
2015-2016
1.0
1.25
4.25
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TEACHING ACTIVITIES
Lecturing
• Bachelor Biomedical Sciences and Medicine: supervising 
working groups on ‘farmacologische beïnvloeding van het 
autonome zenuwstelsel’
• Master medicine: aid in the design and supervision of the 
capita selecta on application of pharmacological studies in the 
field of TB treatment
2015
2015
0.5
0.5
Supervision of internships 
• Judith van de Sande, Bachelor thesis Molecular Life Sciences: 
‘ABC Transporters in Mycobacterium Tuberculosis’
• Daniëlle Verschoor, Bachelor thesis Molecular Life Sciences: 
‘Transporter Genes of Mycobacterium Tuberculosis: What is 
causing the multi-drug resistance of TB?
• Marjo de Bruijne, Bachelor thesis Medical Biology: 
‘The role of ABC transporters in Mycobacterium tuberculosis 
drug resistance’
• Lars Damen, Bachelor thesis Biomedical Sciences (Toxicology): 
‘Mycobacterium tuberculosis ABC transporter protein inhibition 
as a new treatment strategy against tuberculosis’ 
• Aaron Ohene Buaben, Master thesis Biomedical Sciences 
(Toxicology): ‘Drug-drug interactions: Metformin and 
anti-tuberculosis drugs’
• Roger Ottenheijm, Bachelor thesis Biomedical Sciences: 
‘Exploring the role of mitochondrial dysfunction in tuberculosis 
drugs-induced hepatotoxicity’
2013
2013
2013
2014
2015
2016
1.0
0.7
0.7
1.3
2.0
1.3
TOTAL 37.9
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Dankwoord
Hora est, het is tijd! Vrij vertaald, het zit erop! Wijze mensen zeggen wel eens: het 
gaat eigenlijk niet om het doel, maar om de reis ernaar toe. In augustus 2012 begon 
ik aan deze reis. Vol jeugdige onbevangenheid en nieuwsgierigheid ging ik aan de 
slag en betrad ik het pad dat verre van uitgestippeld bleek te zijn. Dit dankwoord gaat 
eigenlijk over die reis. Een woord van dank voor alle mensen die mij hebben gevormd, 
bijgestaan of simpelweg een glimlach op mijn gezicht hebben gebracht. Zij krijgen op 
deze manier een welverdiend plekje in dit werk. 
Allereerst wil ik mijn ‘promotieteam’ bedanken: prof. dr. Burger, prof. dr. Russel, dr. 
Aarnoutse en dr. Koenderink. Een hele mond vol, maar eigenlijk gewoon David, Frans, 
Rob en Jan. Om in sporttermen te blijven (speciaal voor David): wie wil nou niet begeleid 
worden door zo’n dreamteam? David en Rob van de afdeling Apotheek, en Frans 
en Jan van de Afdeling Farmacologie-Toxicologie: precies de juiste samenstelling van 
inventiviteit, nuchterheid, doelmatigheid en last but not least hart voor het onderzoek. 
Aan het begin van mijn promotietraject werd ik nog wel eens gewaarschuwd: het 
vormen van een brug tussen twee afdelingen valt niet te onderschatten. Maar eerlijk 
is eerlijk, jullie hebben me het niet moeilijk gemaakt. Rob, bij jou was er altijd een 
luisterend oor, een gebalanceerde oplossing voor iedereen (lees: de mediator), maar 
vooral ook heel veel rode correcties. Track changes als ik geluk had, anders moest 
ik je aantekeningen ontcijferen. Jouw feedback zorgde in ieder geval altijd voor de 
puntjes op de i. Jan, jij voorzag het geheel van de nodige creativiteit: offlabel gebruik 
van pipetten en apparaten uit de verfindustrie, jij bent out of the box! Frans, jou wil 
ik bedanken voor je heldere feedback tijdens de wekelijkse werkbesprekingen en de 
onderzoeksoverleggen: ik ken weinig mensen die zoveel weten als jij, en die zo weinig 
slapen. David, jou wil ik bedanken voor de manier waarop jij je hard maakt voor het 
onderzoek en je promovendi, en voor de kansen die jij mij geeft als niet-apotheker 
binnen de afdeling. Voor jou telt nog meer dan de prestatie, de weg ernaar toe, en 
de gezelligheid die ermee gepaard gaat. O ja, Vincent hoopt nog steeds dat je ons 
meeneemt naar NEC-Vitesse. 
Bij deze ook mijn dank aan Maarten en Cindy, mijn paranimfen, oftewel mijn 
reserveteam. Maarten, mijn vroegste herinnering in mijn PhD dateert terug naar mijn 
eerste ontmoeting met jou, en vooral je enthousiaste gezicht om een andere newbie 
te ontmoeten. Met hetzelfde enthousiasme leerde je me ook al jouw labskills. Het 
verbaasde me dan ook niets toen je me vertelde over je passie voor het onderwijs; 
het Science artikel zal nu wel echt begraven zijn. We werden een onafscheidelijk team 
en volgens mij worden we sindsdien in elke dankwoord als duo genoemd. Cindy, mijn 
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steun en toeverlaat buiten het werk. Altijd was je vol bewondering en interesse over 
mijn promotie. Regelmatig vroegen mensen wie die mooie brunette op de muur (!) van 
het promovendiparadijs was. Als paranimf mag je daarom niet ontbreken op deze dag: 
zeker omdat het ons een excuus geeft weer eens samen te shoppen. Stelling negen is 
speciaal voor ons.
 
De leden van de manuscriptcommissie, prof. dr. Mihai Netea, prof. dr. Roos Massereeuw 
en dr. Jan-Willem Alffenaar, de scheidsrechters in dit verhaal, wil ik bedanken voor het 
bestuderen en goedkeuren van mijn proefschrift. Alle drie zijn jullie op jullie eigen manier 
een voorbeeld voor jonge onderzoekers. De promotiecommissie wil ik bedanken voor 
het lezen van mijn proefschrift en voor hun deelname aan mijn oppositie. Bedankt, 
Saskia, Jakko, Martin en Reinout; hopelijk vind ik jullie na de verdediging ook nog 
aardig?!
Remco de Jong, afdelingshoofd van de Apotheek van het Radboudumc, wil ik bedanken 
voor het mogelijk maken van dit promotietraject binnen de afdeling en het inzien van 
de waarde van een onderzoekslijn naast de patiëntenzorg. Similarly, I would like to 
thank dr. Bachti, as head of the TB-HIV research center in Bandung, for giving me the 
opportunity to work with an inspiring team of enthusiastic doctors and researchers, and 
for getting me experienced with canoeing and camping in Indonesia.
Nu wordt het lastig. In de komende paragrafen wil ik graag al mijn collega’s bedanken, 
en dat zijn er nogal wat. Laten we beginnen bij het begin: mijn collega’s van het lab. 
Jullie hebben mij het verschil geleerd tussen normale en hufterproof protocollen, mij 
laten zien dat er geen grenzen zijn voor wat betreft kerst- en verjaardagversieringen en 
mij laten ervaren wat het belang is van koffiepauzes op een dakterras. Het torentuig van 
het eerste uur, Karl(pedia) (dank voor de honey badger beelden), Tom S (nog één die zo 
weinig slaapt), Jitske (motormuis/hoofd labdecoratie), Sanna ( jongleur van vele ballen), 
Esther (het zonnetje), Rick/Greup (nog één die zoveel weet), Martijn (Big Wilmer), 
Pedro, Julien, Rachel, Marieke en Elnaz hebben mij wegwijs gemaakt op het lab. En me 
getest door mij naar de verdunningsfactor van milli-Q te vragen en droogijsbommetjes 
in mijn prullenbak te dopeneren. Later kwamen daar ook (Razende) Ria, Tom N, Jelle, 
Michele en Milos bij. Ria is al gearriveerd, de laatste vier wens ik veel succes met het 
afronden van hun proefschrift. Stuk voor stuk getalenteerde en hard werkende jongens, 
jullie komen er wel! Ook mijn dank aan de pilaren van de toren, Janny en Jeroen. Janny, 
als u-genoot was je altijd een luisterend oor, mijn grootste hardloopfan en gaf je mijn 
bestellingen met veel liefde voorrang. Jeroen (partner in crime): bijna al mijn data heb 
ik met jou doorgenomen en we zitten dan meestal ook helemaal op één lijn. Ik hoop 
in de toekomst nog veel meer met jou samen te kunnen werken! Ten slotte wil ik hier 
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mijn studenten bedanken, Aaron, Roger, Lars, Judith, Daniëlle en Marjo. Ik heb het 
werken met jullie als zeer leerzaam ervaren. Jullie helpende hand heeft een belangrijke 
bijdrage geleverd aan Deel 1 van dit proefschrift, ontzettend bedankt! 
Gelukkig waren er ook gezette tijden dat we het lab op de zevende verdieping konden 
verlaten en op bezoek mochten bij de mensen uit de prekliniek. Ab: wat was ik altijd blij 
als ik op vrijdag mijn monsters weer in jouw kundige handen kon leggen, zeker als ik de 
tray níet ergens onderweg had gelanceerd. Dankzij jouw flexibiliteit en enthousiasme is 
het hoofdstuk over moxifloxacin en ethambutol tot zo’n mooi eind gekomen. Ook wil 
ik hier Petra, Jeanne, Danielle, Wendy, Robert, Bas, Lilibeth, Kees, Gerard en Suzanne 
bedanken: voor de vrolijke noot op alle borrels, soepafspraken, en het bijwonen van 
mijn jaarlijkse barbecue.  
Hier is dan een plekje vrij om mijn collega’s van de APO te bedanken. Allereerst de 
jonge honden. De eerste die ik goed leerde kennen was Vincent. De woensdagen waren 
een oase van rust na de chaotische dagen op het lab. Bij elkaar konden we lekker ons 
hart luchten over als het (op werk of thuis) tegenzat, maar ook hartelijk lachen om de 
onwaarschijnlijke dingen des levens. Je bent nu een bigshot in de Farma, maar houdt 
toch nog graag contact met de grijze muizen uit de wetenschap. Een loyale viervoeter! 
Ook bedankt alle mensen van het paradijs (This could be / Para-para-paradise / 
Para-para-paradise / Para-para-paradise), jullie waren mijn kers op de taart! Lisa, Stein, 
Elise, Mette, Krista, Paulien, en later kwamen daar Floor en Roeland bij. Ik zal jullie 
bijnamen maar achterwege laten. Lisa bekroonde ons met de titel ‘high potentials’, en 
ik denk echt dat jullie het waar gaan maken! Lisa, als ik me beter wil voelen kijk ik naar 
een presentatie van jou over kinderen en blood spots. Van dat enthousiasme knapt 
iedereen op. Stein wil ik bedanken voor zijn optimistische en zorgeloze blik: je trok me 
zo uit mijn promotiedip. Ik verheug me nu al op jouw promotie, want we hebben zoveel 
‘inspirerend’ beeldmateriaal van jou. Elise, de mater familias en keuze-vraagbaak. Als 
ik ergens mee zit, dan ben jij degene die ik het voorleg. Bedankt voor alle adviezen, 
je heldere kijk op zaken, én voor het extreem efficiënt shoppen in de Makro. Krista, de 
vreemde eend in de bijt, wil ik bedanken voor de vrolijke noot, de dienbladen thee 
en het laten zien dat er meer is dan onderzoek. Mette, ik ken niemand die zó uitkijkt 
naar haar onderzoekstijd, alles vind je leuk. Een collega als jij is als een cadeautje dat je 
niet moet uitpakken. Bedankt voor alle ‘haha’. Ik wens de huidige PhDs, Paulien, Floor, 
Roeland, Eline en Robert (de kapitein) veel succes met afronden van hun promotie, 
en Roeland daarnaast ook nog veel wijsheid bij het allometrisch schalen. Het komt 
vast goed met jullie, want (quote) de Apotheek lijkt te beschikken over een blik met 
oneindig veel talentvolle promovendi! 
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De senioren onderzoekers van de Apotheek, Roger, Nielka, Angela en Rob ter H, wil ik 
bedanken voor het opvoeden van het jonge gespuis. Zonder jullie geduld, kennis en 
gedrevenheid zouden de high potentials van de afdeling altijd slechts potentials blijven. 
Een speciaal woord van dank voor Angela, die iedereen van de Vakgroep ondersteunt 
waar zij dat kan. Angela, jij bent de spin in het web! Graag wil ik ook de analisten van 
het laboratorium van de Apotheek bedanken, met speciale dank voor Khalid, Noor, 
Léonie, Marga en Michel die mij hebben bijgestaan bij het opzetten, verwerken en 
meten van de Indonesische plasmamonsters. Alle ziekenhuisapothekers in opleiding 
wens ik veel succes met het voortzetten en/of afronden van hun opleiding. Ik heb jullie 
stuk voor stuk als talentvolle jonge mensen mogen leren kennen. Alle oud collega’s wil 
ik hier bedanken voor de bijdrage die zij aan de afdeling en/of de onderzoeksgroep 
hebben geleverd, jullie vormen de fundering van het huidige succes. 
Gerjo en Jurriaan van het Erasmus MC wil ik bedanken voor de prettige samenwerking 
in het kader van de ZonMW subsidie, de gezelligheid op de workshops en de prettig 
gestoorde feedback op mijn papers. Gerjo, ook voor jou is de eindstreep in zicht, 
succes! Jan-Willem en de analisten Kai en Remco van het UMCG ben ik dankbaar 
voor de bijdrage aan de blood spots analyses, zowel inhoudelijk als analytisch. Mijn 
collega’s van de afdeling Interne Geneeskunde wil ik hier bedanken voor de zeer 
prettige en leerzame samenwerking. Carolien, Ekta, Valerie en Arjan: de donderdagen 
over principal components, R-scripts en metabolomics waren niet altijd verhelderend, 
maar wel reuze interessant en gezellig. Reinout, bedankt voor al je feedback op 
mijn teksten, en vooral het knippen erin. Ook bedankt voor je openheid: jij vertelt 
zonder schroom de meest enthousiaste verhalen over het leven, familie, sport, en je 
spijkerjasje! Ik heb enorm veel bewondering voor wat je in Bandung samen met alle 
mensen daar hebt neergezet. Arjan en Suzanne wil ik verder bedanken voor alle gin 
tonics in hun tuin in Bandung. Het waren geweldig gezellige weken. John van het 
CMBI wil ik bedanken voor zijn geduld (Linux!) en hulp bij mijn fylogenetische boom. 
Deze hangt inmiddels als een oorkonde boven mijn computer. Rogier Donders van de 
afdeling Health Evidence ben ik dankbaar voor de statistische input, jij kan als geen 
ander een probleem helder uiteenzetten. Tenslotte wil ik alle mensen die ik via de 
Da Vinci Challenge heb ontmoet bedanken: Ellen, Machteld, Floor, Hanneke, Ramon, 
Geert, Saskia, Rob, Judith, Michiel, Loes, Ilse en Jimmie. Jullie hebben mij met jullie 
levenswijsheden van adviezen voorzien en een spiegel voor gehouden. Ik wil ook alle 
gasten van de Challenge bedanken, die mij met hun verhalen hebben geïnspireerd en 
verwarmd. Ook dank aan het Radboudumc voor het mogelijk maken van dit traject, 
waarin jonge, leergierige onderzoekers leren verder te kijken dan hun horizon. 
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In this paragraph I would like to thank my colleagues from Bandung, Indonesia. 
You learned me everything about the grateful, humble, and enthusiastic nature of 
Indonesian people. Plus the importance of always having a rice cooker. Dr. Nina, I 
would like to thank you for welcoming me so warmly in your team. For supporting 
and acknowledging me, and for making me feel a young chicken. Special thanks also 
to the METRICS people, Vycke, Resvi, dr Nanny and all other field doctors, nurses and 
technicians. Without you METRICS would not have been such a success, and more 
importantly, such a joyous experience. Resvi and Vycke, I would like to thank you for 
letting me be a part of your team, and I wish you all the best for your S3 (Vycke) and 
Masters (Resvi). The Bandung Pharmacokinetic Lab I am grateful for storage, analysis 
and ofcourse (!) transportation of all those samples. Furthermore, I would like to 
thank the Bandung Neurology research team, dr Rizal and dr Dian and all others that 
contributed to the TBM work and analyses. You are inspiring to work with, and your 
research has a great impact on all those suffering from TBM. Dian, I wish you all the best 
with finalizing your thesis. I also would like to thank all people of the TB-HIV research 
center in Bandung, Lydia, Lika, Alit, Sue (another welcoming hostess) and all others that 
are not mentioned here explicitly, but whom I would never forget in my mind. Finally, I 
would like to thank all Indonesian patients that agreed to take part of our studies and 
in this way contributed to better understanding of tuberculosis treatment and improved 
care of future patients. 
ZonMW en TANDEM wil ik bedanken voor hun financiële ondersteuning om de inhoud 
van dit boekje mogelijk te maken. Daarnaast ondersteunden de Afdeling Apotheek, 
Farmacologie/Toxicologie en Universitas Padjadjaran Bandung mijn persoonlijke 
ontwikkeling of analyses van monsters daar waar dat nodig was. Ook jullie bedankt!
Wat is een mens zonder vrienden? Als eerste wil ik mijn meisjes bedanken: Annemarie, 
Melanie, Liske en Fleur. Wij zijn samen opgegroeid en dragen dezelfde Achterhoekse 
normen en waarden met ons mee, soms tegen wil en dank. Ik hoop jullie nog vele jaren 
aan mijn zijde te hebben, want met niemand is het zo leuk theeleuten als met jullie. 
Melanie, jij ook bedankt voor je nakijkwerk van de Nederlands stukken, en alle broodjes 
die we samen zo bruin hebben gebakken. Annemarie, jou wens ik veel succes met het 
ingaan van je eigen promotietraject, geen promotiedip voor jou! Mijn (vriendinnen 
van) vriendinnen, Michelle, Britta en Christianne, uit de tijd van de Smetiusstraat wil 
ik bedanken voor alle dansjes, wijntjes en roddels. Mijn vrienden van de studie Lotte, 
Martine, Laura, Hedwig en Piet wil ik bedanken voor hun interesse in mijn onderzoek 
en voor de liters thee. Iedereen van AV Cifla wil ik bedanken voor het zorgen van 
de broodnodige afleiding en de gezellige rondjes over de atletiekbaan. Ik hoop jullie 
binnenkort weer meer te zien!
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Lieve papa en mama. Ook al staan jullie niet bovenaan in dit dankwoord, in mijn 
hoofd staan jullie daar zeker wel. Jullie hebben mij gevormd tot de persoon die ik nu 
geworden ben en daarom draag ik ook dit proefschrift aan jullie op. Alleen wij weten 
wat we samen als gezin hebben bereikt. Jullie waardering voor de kleine dingen des 
levens probeer ik altijd bij mij te dragen. Logischerwijs wil ik op deze plek ook mijn 
broers Marcel, Jurgen en Arno en mijn zus Monique bedanken. Ieder met een zeer 
eigen karakter, maar samen vormen we een eenheid. Wat een chaos was het vroeger 
in huis, maar ó zo gezellig. Ook jullie hebben bijgedragen aan dit proefschrift, meer 
dan jullie wellicht denken. Verder wil ik Ineke en Hennie bedanken voor het liefdevol 
opnemen van mij als onderdeel van de familie. Jullie staan altijd voor mij en vinc klaar, 
bedankt daarvoor.
Lieve Vincent, om voor het eerst in dit boekje in termen te spreken die jij als geen 
ander begrijpt: met jou heb ik gegokt en gewonnen. Jouw onvoorwaardelijke steun 
merkte ik vooral op het eind van mijn promotie, toen je me zonder morren mezelf liet 
opsluiten om aan dit proefschrift te werken, ik van je heiligdom mocht gebruik maken 
(de computer), en je het toestond dat er ‘monsters’ in onze vriezer lagen. Wij weten 
waar we aan toe zijn bij elkaar: ‘Cards are on the table, we’re both showing hearts’ – 
John Legend.
Liefs,
Lindsey


